{"PMC7264548": [["What is different in children? ::: INTRODUCTIONWhile all humans are at risk of being infected regardless of age, gender, or health, vulnerable populations at higher risk of developing a severe form of COVID\u201019 disease have been identified.", [["COVID", "DISEASE", 201, 206], ["children", "ORGANISM", 21, 29], ["humans", "ORGANISM", 57, 63], ["children", "SPECIES", 21, 29], ["humans", "SPECIES", 57, 63], ["humans", "SPECIES", 57, 63], ["COVID\u201019 disease", "PROBLEM", 201, 217], ["different", "OBSERVATION_MODIFIER", 8, 17], ["infected", "OBSERVATION", 85, 93], ["severe", "OBSERVATION_MODIFIER", 186, 192]]], ["Since the beginning of the pandemic, it has become rapidly apparent that children less often present symptoms and that these are less often severe.", [["children", "ORGANISM", 73, 81], ["children", "SPECIES", 73, 81], ["present symptoms", "PROBLEM", 93, 109], ["less often", "OBSERVATION_MODIFIER", 129, 139]]], ["The only systematic review bringing together data on children has been published recently and concluded that children account for 1%\u20106% of the diagnosed COVID\u201019 cases often have milder disease than adults, and mortality rates are extremely low.3However, with hundreds of papers published on COVID\u201019 in the past few months, the problem of reporting the same patients in different manuscripts was raised4; duplicate reporting may lead to inaccurate scientific record and thus potentially misleading results in any systematic review and meta\u2010analysis.", [["COVID", "DISEASE", 153, 158], ["children", "ORGANISM", 53, 61], ["children", "ORGANISM", 109, 117], ["patients", "ORGANISM", 359, 367], ["children", "SPECIES", 53, 61], ["children", "SPECIES", 109, 117], ["patients", "SPECIES", 359, 367], ["milder disease", "PROBLEM", 179, 193], ["mortality rates", "TEST", 211, 226], ["meta\u2010analysis", "TEST", 536, 549]]], ["The first reliable data came from more than 72.000 case reports reviewed by the Chinese Center for Disease Control and Prevention showing that less than 1% of cases were younger than 10 years of age.5Another recent report described in detail the clinical characteristics of 171 children treated for COVID\u201019 at the reference children's hospital in Wuhan.6The most common clinical signs included cough and pharyngeal erythema.", [["pharyngeal", "ANATOMY", 405, 415], ["COVID", "DISEASE", 299, 304], ["cough", "DISEASE", 395, 400], ["pharyngeal erythema", "DISEASE", 405, 424], ["children", "ORGANISM", 278, 286], ["children", "ORGANISM", 325, 333], ["pharyngeal erythema", "PATHOLOGICAL_FORMATION", 405, 424], ["children", "SPECIES", 278, 286], ["children", "SPECIES", 325, 333], ["Disease Control", "TREATMENT", 99, 114], ["cough", "PROBLEM", 395, 400], ["pharyngeal erythema", "PROBLEM", 405, 424], ["cough", "OBSERVATION", 395, 400], ["pharyngeal", "ANATOMY", 405, 415], ["erythema", "OBSERVATION", 416, 424]]], ["Fever was only observed in 41.5% of the children.", [["Fever", "DISEASE", 0, 5], ["children", "ORGANISM", 40, 48], ["children", "SPECIES", 40, 48], ["Fever", "PROBLEM", 0, 5]]], ["Interestingly, although 111/171 (64.9%) were diagnosed with pneumonia, 12 patients had radiologic signs of pneumonia without any symptoms of infection.", [["pneumonia", "DISEASE", 60, 69], ["pneumonia", "DISEASE", 107, 116], ["infection", "DISEASE", 141, 150], ["patients", "ORGANISM", 74, 82], ["patients", "SPECIES", 74, 82], ["pneumonia", "PROBLEM", 60, 69], ["pneumonia", "PROBLEM", 107, 116], ["any symptoms", "PROBLEM", 125, 137], ["infection", "PROBLEM", 141, 150], ["pneumonia", "OBSERVATION", 60, 69], ["pneumonia", "OBSERVATION", 107, 116], ["infection", "OBSERVATION", 141, 150]]], ["In the whole cohort, only 3 patients required hospitalization in an intensive care unit for invasive mechanical ventilation.", [["patients", "ORGANISM", 28, 36], ["patients", "SPECIES", 28, 36], ["invasive mechanical ventilation", "TREATMENT", 92, 123], ["mechanical ventilation", "OBSERVATION", 101, 123]]], ["All 3 patients had a pre\u2010existing medical condition (hydronephrosis, leukemia, or intussusception), and one of them, a 10\u2010month\u2010old infant, with intussusception had multi\u2010organ failure and died four weeks after admission to the hospital.", [["leukemia", "ANATOMY", 69, 77], ["hydronephrosis", "DISEASE", 53, 67], ["leukemia", "DISEASE", 69, 77], ["intussusception", "DISEASE", 82, 97], ["intussusception", "DISEASE", 145, 160], ["multi\u2010organ failure", "DISEASE", 165, 184], ["patients", "ORGANISM", 6, 14], ["leukemia", "CANCER", 69, 77], ["infant", "ORGANISM", 132, 138], ["patients", "SPECIES", 6, 14], ["infant", "SPECIES", 132, 138], ["a pre\u2010existing medical condition", "PROBLEM", 19, 51], ["hydronephrosis", "PROBLEM", 53, 67], ["leukemia", "PROBLEM", 69, 77], ["intussusception", "PROBLEM", 82, 97], ["intussusception", "PROBLEM", 145, 160], ["multi\u2010organ failure", "PROBLEM", 165, 184], ["hydronephrosis", "OBSERVATION", 53, 67], ["leukemia", "OBSERVATION", 69, 77], ["failure", "OBSERVATION", 177, 184]]], ["Asthma and allergies were not mentioned in this case series.", [["Asthma", "DISEASE", 0, 6], ["allergies", "DISEASE", 11, 20], ["Asthma", "PROBLEM", 0, 6], ["allergies", "PROBLEM", 11, 20]]], ["In another report, among children aged 1\u20107 years who were admitted to the hospital in Wuhan, all children including four with radiological evidence of pneumonia and one admitted to the intensive care unit have recovered.7", [["pneumonia", "DISEASE", 151, 160], ["children", "ORGANISM", 25, 33], ["children", "ORGANISM", 97, 105], ["children", "SPECIES", 25, 33], ["children", "SPECIES", 97, 105], ["pneumonia", "PROBLEM", 151, 160], ["pneumonia", "OBSERVATION", 151, 160]]]], "4591faf113bf68a0283ab338b77483e9da52cdeb": [["Ebola, severe acute respiratory syndrome coronavirus (SARS-CoV), and Middle East respiratory syndrome coronavirus (MERS-CoV), in part because the signs and symptoms can be non-specific, hospitalized patients with these infections may be particularly infectious, and health care personnel perform procedures that may aerosolize organisms.", [["Ebola", "DISEASE", 0, 5], ["acute respiratory syndrome coronavirus", "DISEASE", 14, 52], ["SARS-CoV)", "DISEASE", 54, 63], ["Middle East respiratory syndrome coronavirus", "DISEASE", 69, 113], ["infections", "DISEASE", 219, 229], ["Ebola", "ORGANISM", 0, 5], ["severe acute respiratory syndrome coronavirus", "ORGANISM", 7, 52], ["SARS-CoV", "ORGANISM", 54, 62], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 69, 113], ["MERS-CoV", "ORGANISM", 115, 123], ["patients", "ORGANISM", 199, 207], ["patients", "SPECIES", 199, 207], ["severe acute respiratory syndrome coronavirus", "SPECIES", 7, 52], ["SARS-CoV", "SPECIES", 54, 62], ["Middle East respiratory syndrome coronavirus", "SPECIES", 69, 113], ["MERS-CoV", "SPECIES", 115, 123], ["Ebola", "PROBLEM", 0, 5], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 7, 52], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 69, 113], ["the signs and symptoms", "PROBLEM", 142, 164], ["these infections", "PROBLEM", 213, 229], ["procedures", "TREATMENT", 296, 306], ["severe", "OBSERVATION_MODIFIER", 7, 13], ["acute", "OBSERVATION_MODIFIER", 14, 19], ["respiratory syndrome coronavirus", "OBSERVATION", 20, 52], ["Middle", "ANATOMY_MODIFIER", 69, 75], ["respiratory syndrome", "OBSERVATION", 81, 101]]]], "PMC7315324": [["Routes of Viral Transmission", [["Viral", "OBSERVATION", 10, 15]]]], "e934a10872f5faa1afbf2c088d37eb941b1d39b6": [["which can likely be delayed safely in the majority of individuals.INTRODUCTIONThe novel coronavirus disease 2019 caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has created an unprecedented challenge for healthcare delivery.", [["coronavirus disease", "DISEASE", 88, 107], ["acute respiratory syndrome coronavirus", "DISEASE", 134, 172], ["coronavirus", "ORGANISM", 88, 99], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 127, 174], ["SARS-CoV-2", "ORGANISM", 176, 186], ["coronavirus", "SPECIES", 88, 99], ["severe acute respiratory syndrome coronavirus", "SPECIES", 127, 172], ["SARS-CoV-2", "SPECIES", 176, 186], ["The novel coronavirus disease", "PROBLEM", 78, 107], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 123, 172], ["healthcare delivery", "TREATMENT", 231, 250], ["can likely be", "UNCERTAINTY", 6, 19], ["coronavirus disease", "OBSERVATION", 88, 107], ["severe", "OBSERVATION_MODIFIER", 127, 133], ["acute", "OBSERVATION_MODIFIER", 134, 139], ["respiratory syndrome", "OBSERVATION", 140, 160]]], ["The Centers for Disease Control and Prevention has recommended healthcare systems reduce face-to-face contact to promote physical distancing, slow disease transmission, and preserve supplies and personal protective equipment (PPE).", [["Disease Control", "TREATMENT", 16, 31], ["healthcare systems", "TREATMENT", 63, 81], ["slow disease transmission", "PROBLEM", 142, 167]]], ["[1] As the pandemic unfolded in March 2020, the American Academy of Otolaryngology-Head and Neck Surgery recommended otolaryngologists limit both inpatient and outpatient care to individuals with time-sensitive, urgent, and emergent medical conditions.[2]INTRODUCTIONAs a result, healthcare providers have adopted telehealth models to provide ongoing access to healthcare.", [["Head", "ANATOMY", 83, 87], ["Neck", "ANATOMY", 92, 96]]], ["[3] Technological advances enable patients to access medical services without the provider being in the same room, for both urgent and non-urgent complaints.", [["patients", "ORGANISM", 34, 42], ["patients", "SPECIES", 34, 42], ["non-urgent complaints", "PROBLEM", 135, 156]]], ["In general, telehealth improves patient care access and may improve compliance due to greater convenience of follow-up.", [["patient", "ORGANISM", 32, 39], ["patient", "SPECIES", 32, 39]]], ["[4] [5] [6] [7] However, telemedicine carries clear limitations related to the ability to conduct thorough physical exam and other investigations (e.g. laryngoscopy).", [["[4] [5] [6] [7", "SIMPLE_CHEMICAL", 0, 14], ["thorough physical exam", "TEST", 98, 120], ["other investigations", "TEST", 125, 145], ["laryngoscopy", "TEST", 152, 164]]], ["[7] [8] [9] [10] [11] There may be reduced personal connection between provider and patient.", [["[7] [8] [9] [10] [11]", "SIMPLE_CHEMICAL", 0, 21], ["patient", "ORGANISM", 84, 91], ["patient", "SPECIES", 84, 91]]], ["Technical challenges may limit access to care by the elderly or socioeconomically disadvantaged.INTRODUCTIONWhile televisits allow healthcare providers an opportunity to offer ongoing specialty care during this pandemic, there are challenges in translating a subspecialty care model from the office to the virtual realm.", [["ongoing specialty care", "TREATMENT", 176, 198]]], ["For laryngology, medical history can be accurately obtained through telehealth platforms, but the ability to complete a comprehensive head and neck exam, stroboscopy, instrumental swallow exam and acoustic/aerodynamic voice analyses is markedly limited.", [["head", "ANATOMY", 134, 138], ["neck", "ANATOMY", 143, 147], ["head", "ORGANISM_SUBDIVISION", 134, 138], ["neck", "ORGANISM_SUBDIVISION", 143, 147], ["a comprehensive head and neck exam", "TEST", 118, 152], ["stroboscopy", "TREATMENT", 154, 165], ["instrumental swallow exam", "TEST", 167, 192], ["acoustic/aerodynamic voice analyses", "TEST", 197, 232], ["neck", "ANATOMY", 143, 147]]], ["[9, 11] Furthermore, many laryngology centers employ a multidisciplinary assessment approach by including a speech-language pathologist (SLP) for most encounters.", [["a multidisciplinary assessment", "TEST", 53, 83]]], ["This model requires precise schedule coordination and may be more challenging to continue via telehealth in the COVID-19 era.INTRODUCTIONHerein, we reflect on our early experience of using telehealth to provide laryngology subspecialty care during the COVID-19 pandemic.", [["laryngology subspecialty care", "TREATMENT", 211, 240], ["the COVID", "TEST", 248, 257], ["pandemic", "PROBLEM", 261, 269]]], ["Collective knowledge and best practices surrounding COVID-19 continue to evolve rapidly.", [["COVID-19", "CHEMICAL", 52, 60], ["COVID", "TEST", 52, 57]]], ["We hope that the following information provides useful insight to other otolaryngology providers to maximize effectiveness of telehealth visits and optimize patient care through a new \"routine\" healthcare access model.MATERIALS AND METHODSIn preparation for this review, four laryngologists and a voice-specialized SLP engaged in a structured group consensus conference in early April 2020.", [["patient", "ORGANISM", 157, 164], ["patient", "SPECIES", 157, 164], ["telehealth visits", "TREATMENT", 126, 143], ["a new \"routine\" healthcare access model", "TREATMENT", 178, 217]]], ["All participants are routinely involved in the delivery of laryngology sub-specialty care at the UCSF Voice and Swallowing Center (VSC), a tertiary-care laryngology practice.", [["participants", "SPECIES", 4, 16]]], ["All participants actively contributed to sharing and discussing their experiences and practice patterns employed via tele-medicine (via telephone or video-communications) during the early COVID-19 era.", [["participants", "SPECIES", 4, 16]]], ["Barriers and challenges experienced to date were explored, and potential solutions for these difficulties proposed.MATERIALS AND METHODSOf note, the UCSF VSC has been offering video-telemedicine visits since June 2017, representing nearly three years of experience with the video-visit telemedicine model.", [["these difficulties", "PROBLEM", 87, 105]]], ["These visits were, however, limited to follow-up therapy sessions; all initial joint laryngologist-SLP patient visits and initial SLP therapy sessions were previously completed in-person.", [["patient", "ORGANISM", 103, 110], ["patient", "SPECIES", 103, 110], ["person", "SPECIES", 180, 186], ["therapy sessions", "TREATMENT", 49, 65], ["initial SLP therapy sessions", "TREATMENT", 122, 150], ["joint", "ANATOMY", 79, 84]]], ["Prior to March 2020 (i.e. COVID-19 era), laryngologists at the UCSF VSC did not offer telemedicine services.RESULTSBased on the input and discussion from UCSF VSC's telemedicine consensus conference, several key areas of consideration were identified for implementing and adopting telemedicine in a multi-disciplinary, tertiary-care laryngology practice.", [["telemedicine services", "TREATMENT", 86, 107]]], ["These key areas included (1) how to set up and structure a telemedicine visit and maintain patient confidentiality, (2) patient examination and treatment initiation, (3) optimization of the tele-visit, (4) limitations and recognition of when a tele-visit is insufficient for patient care needs, and (5) billing/reimbursement considerations.RESULTSThese topics are discussed individually in the following discussion.Setting Up a Telemedicine VisitTelemedicine video visits are provided through the Zoom for Healthcare platform (Zoom Video Communications, Inc., Version 4.6.10) at the UCSF Voice and Swallowing Center.", [["patient", "ORGANISM", 91, 98], ["patient", "ORGANISM", 120, 127], ["patient", "ORGANISM", 275, 282], ["patient", "SPECIES", 91, 98], ["patient", "SPECIES", 120, 127], ["patient", "SPECIES", 275, 282], ["patient examination", "TEST", 120, 139], ["treatment initiation", "TREATMENT", 144, 164]]], ["Other vendors that provide HIPAA-compliant video communication products include Skype for Business, Updox, VSee, Doxy.me and Google G Suite Hangouts meet [6] .", [["Doxy", "TREATMENT", 113, 117]]], ["In order for these platforms to meet HIPAA-compliance, several general requirements must be in place for video conferencing.", [["these platforms", "TREATMENT", 13, 28], ["HIPAA-compliance", "TREATMENT", 37, 53]]], ["Institutions and clinician providers should check with the specific vendors that allow video-communication to ensure the above HIPAA-compliance measures are met as well for the specifics on how the requirements are guaranteed.Setting Up a Telemedicine VisitPlatforms like Zoom offer virtual \"waiting rooms\" from which the clinician \"admits\" the patient; this safety measure protects patient privacy as the clinician controls who is allowed to enter the visit.", [["patient", "ORGANISM", 345, 352], ["patient", "ORGANISM", 383, 390], ["patient", "SPECIES", 345, 352], ["patient", "SPECIES", 383, 390], ["the above HIPAA-compliance measures", "TREATMENT", 117, 152]]], ["Multiple people can be admitted simultaneously (e.g. interpreters, additional family members, or scribes) as authorized by the clinician.Setting Up a Telemedicine VisitA flowchart to demonstrate our protocol at the UCSF VSC for arranging, preparing for, and conducting telemedicine visits is shown in Table 1 .", [["people", "ORGANISM", 9, 15], ["people", "SPECIES", 9, 15]]], ["Patients are contacted by telephone in advance to confirm their interest, willingness, and ability to participate in a telemedicine video visit.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["Patients are informed about the benefits and limitations of a telehealth visit.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8]]], ["Importantly, the patient is also notified that the video visit is a billable encounter, and thus insurance co-pay may be applied.", [["patient", "ORGANISM", 17, 24], ["patient", "SPECIES", 17, 24], ["insurance co-pay", "TREATMENT", 97, 113]]], ["A pre-visit check-in is performed by the clinical nursing team 1-3 days before the appointment.", [["A pre-visit check", "TEST", 0, 17]]], ["Medications, allergies, and personal information are reviewed, and relevant forms (e.g. review of system and patient reported outcome measure [PROM] questionnaires) are completed.", [["allergies", "DISEASE", 13, 22], ["patient", "ORGANISM", 109, 116], ["patient", "SPECIES", 109, 116], ["Medications", "TREATMENT", 0, 11]]], ["All patients at the UCSF VSC complete standard laryngology PROMs [e.g. VoiceSetting Up a Telemedicine VisitHandicap Index-10 (VHI-10) [13] , reflux symptom index (RSI) [14] , cough severity index (CSI) [15] , dyspnea index (DI) [16] , and eating assessment tool-10 (EAT-10) [17] ] prior to their clinic visit.", [["cough", "DISEASE", 175, 180], ["dyspnea", "DISEASE", 209, 216], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["a Telemedicine VisitHandicap Index", "TEST", 87, 121], ["VHI", "TEST", 126, 129], ["reflux symptom index", "TEST", 141, 161], ["cough severity index", "TEST", 175, 195], ["dyspnea index (DI)", "PROBLEM", 209, 227], ["eating assessment tool", "TEST", 239, 261]]], ["A Zoom for Healthcare link is provided electronically through the secure patient portal system or via email.", [["patient", "ORGANISM", 73, 80], ["patient", "SPECIES", 73, 80], ["portal", "ANATOMY", 81, 87]]], ["The clinical team confirms the patient is able to load and use the platform successfully before their scheduled visit.", [["patient", "ORGANISM", 31, 38], ["patient", "SPECIES", 31, 38]]], ["If possible, having the patient complete a \"trial run\" with the clinical staff team may enable early identification of technical issues and help the patient feel comfortable with the steps needed to connect to the virtual visit.Setting Up a Telemedicine VisitAt the start of the video-visit or telephone encounter, patient identity is verified; typically, name and date of birth can be sufficient.", [["patient", "ORGANISM", 24, 31], ["patient", "ORGANISM", 149, 156], ["patient", "ORGANISM", 315, 322], ["patient", "SPECIES", 24, 31], ["patient", "SPECIES", 149, 156], ["patient", "SPECIES", 315, 322]]], ["For video visits, the patient must connect to the virtual platform on their own accord, either by clicking on a provided link or by accessing a downloaded application.", [["patient", "ORGANISM", 22, 29], ["patient", "SPECIES", 22, 29], ["a downloaded application", "TREATMENT", 142, 166]]], ["Verbal consent to utilize telemedicine for the encounter is obtained by the provider and documented within the patient\"s clinical encounter note.", [["patient", "ORGANISM", 111, 118], ["patient", "SPECIES", 111, 118]]], ["If patients have any concerns about HIPAA-compliance or confidentiality, these questions are addressed by the clinician at this time.Setting Up a Telemedicine VisitUCSF institutional policy prohibits recording of the televisit.", [["patients", "ORGANISM", 3, 11], ["patients", "SPECIES", 3, 11]]], ["Patients verbally confirm their understanding of and agreement to abide by this policy, which further protects patient confidentiality.", [["Patients", "ORGANISM", 0, 8], ["patient", "ORGANISM", 111, 118], ["Patients", "SPECIES", 0, 8], ["patient", "SPECIES", 111, 118]]], ["The remainder of the telehealth visit should be conducted in the same manner as an in-person visit.Setting Up a Telemedicine VisitFor referring providers, good communication in the referral regarding patient complaint, duration of symptoms, and suspected urgency are especially important during this time for appropriate patient triage.", [["patient", "ORGANISM", 200, 207], ["patient", "ORGANISM", 321, 328], ["patient", "SPECIES", 200, 207], ["patient", "SPECIES", 321, 328], ["symptoms", "PROBLEM", 231, 239], ["urgency", "PROBLEM", 255, 262]]], ["A review of the referral and existing medical history can help clinicians anticipate patient\"s needs, and identify those who would especially benefit from SLP involvement.", [["patient", "ORGANISM", 85, 92], ["patient", "SPECIES", 85, 92]]], ["Patients with complex laryngologic complaints may be best served by a joint visit with both laryngologist and SLP.", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["complex laryngologic complaints", "PROBLEM", 14, 45], ["joint", "ANATOMY", 70, 75]]], ["A concurrent visit also allows for real-time discussion between the laryngologist and SLP, which facilitates efficiency and treatment decision-making.Setting Up a Telemedicine VisitVirtual joint laryngologist/SLP visits may be possible by logging into one meeting room with the patient.", [["patient", "ORGANISM", 278, 285], ["patient", "SPECIES", 278, 285]]], ["After joint initial patient evaluation, the laryngologist can maximize efficiency while the SLP spends time assessing the patient for therapy candidacy (i.e. stimulability [18, 19] ) by completing other patient-care related tasks.", [["patient", "ORGANISM", 20, 27], ["laryngologist", "ORGANISM", 44, 57], ["patient", "ORGANISM", 122, 129], ["patient", "ORGANISM", 203, 210], ["patient", "SPECIES", 20, 27], ["patient", "SPECIES", 122, 129], ["patient", "SPECIES", 203, 210], ["joint initial patient evaluation", "TEST", 6, 38], ["therapy candidacy", "TREATMENT", 134, 151], ["joint", "ANATOMY", 6, 11]]], ["This may include reviewing previous testing (e.g. pulmonary function testing, pH-impedance, manometry, or imaging), working on chart documentation, initiating referrals, or ordering medications or additional testing.Setting Up a Telemedicine VisitAfter initial evaluation, in the Zoom platform, the patient may be returned to the \"waiting room\" temporarily so that the laryngologist and SLP can discuss the patient\"s case privately, as providers might typically do outside of the patient\"s examination room.", [["pulmonary", "ANATOMY", 50, 59], ["pulmonary", "ORGAN", 50, 59], ["patient", "ORGANISM", 299, 306], ["patient", "ORGANISM", 407, 414], ["patient", "ORGANISM", 480, 487], ["patient", "SPECIES", 299, 306], ["patient", "SPECIES", 407, 414], ["patient", "SPECIES", 480, 487], ["reviewing previous testing", "TEST", 17, 43], ["pulmonary function testing", "TEST", 50, 76], ["pH", "TEST", 78, 80], ["manometry", "TEST", 92, 101], ["imaging", "TEST", 106, 113], ["ordering medications", "TREATMENT", 173, 193], ["additional testing", "TEST", 197, 215], ["initial evaluation", "TEST", 253, 271], ["pulmonary", "ANATOMY", 50, 59]]], ["Subsequently, the patient may be \"brought back in\" to the joint visit for discussion of suspected differential diagnosis and recommended next step(s) in evaluation or treatment.Setting Up a Telemedicine VisitNew patients present a particular challenge with respect to timing and coordination.", [["patient", "ORGANISM", 18, 25], ["patients", "ORGANISM", 212, 220], ["patient", "SPECIES", 18, 25], ["patients", "SPECIES", 212, 220], ["evaluation", "TEST", 153, 163], ["treatment", "TREATMENT", 167, 176], ["joint", "ANATOMY", 58, 63]]], ["A full SLP evaluation including voice stimulability testing [18, 19] , acoustic evaluation, and/or clinical swallow evaluation [20] requires adequate time allotment.", [["A full SLP evaluation", "TEST", 0, 21], ["voice stimulability testing", "TEST", 32, 59], ["acoustic evaluation", "TEST", 71, 90], ["clinical swallow evaluation", "TEST", 99, 126]]], ["During in-person visits, the laryngologist may go into another exam room with another patient during this time.", [["laryngologist", "ORGANISM", 29, 42], ["patient", "ORGANISM", 86, 93], ["person", "SPECIES", 10, 16], ["patient", "SPECIES", 86, 93]]], ["This may be most easily accomplished by the provider having more than one Zoom account or access to breakout rooms that can be utilized to run \"multiple rooms\" with multiple patients.", [["patients", "ORGANISM", 174, 182], ["patients", "SPECIES", 174, 182]]], ["Alternatively, it may be more advantageous for some new patients to be assessed independently by the laryngologist and SLP depending on the specific practice flow, patient complaint or anticipated patient needs.Setting Up a Telemedicine VisitFor follow-up visits, when care has already been established, a joint laryngologist/SLP session may be more feasible and efficient.", [["patients", "ORGANISM", 56, 64], ["patient", "ORGANISM", 164, 171], ["patient", "ORGANISM", 197, 204], ["patients", "SPECIES", 56, 64], ["patient", "SPECIES", 164, 171], ["patient", "SPECIES", 197, 204], ["a joint laryngologist/SLP session", "TREATMENT", 304, 337], ["joint", "ANATOMY", 306, 311]]], ["Such situations include patient progress updates, reevaluation after completion or plateau of voice/swallow therapy, evaluation of medication efficacy (e.g. allergy or reflux treatment), review of test results (e.g. modified barium swallow (MBSS)), and/or patient counseling.", [["allergy", "DISEASE", 157, 164], ["reflux", "DISEASE", 168, 174], ["patient", "ORGANISM", 24, 31], ["patient", "ORGANISM", 256, 263], ["patient", "SPECIES", 24, 31], ["patient", "SPECIES", 256, 263], ["voice/swallow therapy", "TREATMENT", 94, 115], ["evaluation", "TEST", 117, 127], ["medication efficacy", "TREATMENT", 131, 150], ["allergy", "PROBLEM", 157, 164], ["reflux treatment", "TREATMENT", 168, 184], ["test results", "TEST", 197, 209], ["modified barium swallow", "TREATMENT", 216, 239]]], ["A joint session to determine the role for additional therapy, addition of medications or surgical intervention, or review of trialed devices (such as an Expiratory Muscle Strength Trainer [EMST] or ProTrach) can be more easily accomplished.", [["A joint session", "TREATMENT", 0, 15], ["additional therapy", "TREATMENT", 42, 60], ["medications", "TREATMENT", 74, 85], ["surgical intervention", "TREATMENT", 89, 110], ["trialed devices", "TREATMENT", 125, 140], ["an Expiratory Muscle Strength Trainer", "TREATMENT", 150, 187], ["ProTrach", "TREATMENT", 198, 206], ["joint", "ANATOMY", 2, 7]]], ["The visit duration for follow-up is usually shorter which facilitates schedule coordination.Examination and TreatmentDespite advances in telehealth, otolaryngologists and SLPs depend highly on the oral/pharyngeal/laryngeal examination for diagnosis and treatment.", [["oral", "ANATOMY", 197, 201], ["pharyngeal", "ANATOMY", 202, 212], ["laryngeal", "ANATOMY", 213, 222], ["oral", "ORGANISM_SUBDIVISION", 197, 201], ["pharyngeal", "ORGAN", 202, 212], ["laryngeal", "ORGAN", 213, 222], ["Examination", "TEST", 92, 103], ["the oral/pharyngeal/laryngeal examination", "TEST", 193, 234], ["treatment", "TREATMENT", 253, 262], ["pharyngeal", "ANATOMY", 202, 212], ["laryngeal", "ANATOMY", 213, 222]]], ["A limited physical examination is possible via video visit.", [["A limited physical examination", "TEST", 0, 30]]], ["A cursory view of the oral cavity and oropharynx can be obtained with appropriate intra-oral lighting in some cooperative patients.", [["oral cavity", "ANATOMY", 22, 33], ["oropharynx", "ANATOMY", 38, 48], ["oral cavity", "MULTI-TISSUE_STRUCTURE", 22, 33], ["oropharynx", "ORGAN", 38, 48], ["patients", "ORGANISM", 122, 130], ["patients", "SPECIES", 122, 130], ["A cursory view", "TEST", 0, 14], ["oral cavity", "ANATOMY", 22, 33], ["oropharynx", "ANATOMY", 38, 48]]], ["While a telemedicine model of laryngoscopy-videostroboscopy has been described, where a remotely performed exam is relayed for review through either real-time or cloud-based (store and review) technologies, the reliance on an in-office visit with someone able to perform endoscopy remains.", [["laryngoscopy", "TEST", 30, 42], ["exam", "TEST", 107, 111], ["endoscopy", "TEST", 271, 280]]], ["[9, 11, 21] During the peak of the pandemic, avoidance of non-urgent inperson visits and aerosol-generating procedures were recommended.", [["non-urgent inperson visits", "TREATMENT", 58, 84], ["aerosol-generating procedures", "TREATMENT", 89, 118]]], ["[22, 23] Non-urgent laryngoscopy was therefore deferred.", [["Non-urgent laryngoscopy", "TEST", 9, 32]]], ["Of course, any urgent laryngoscopy should still be performed as deemed medically necessary.Examination and TreatmentIt is imperative that patients are counseled about the diagnostic and treatment limitations in the absence of an endoscopic laryngeal examination.", [["laryngeal", "ANATOMY", 240, 249], ["patients", "ORGANISM", 138, 146], ["laryngeal", "ORGAN", 240, 249], ["patients", "SPECIES", 138, 146], ["any urgent laryngoscopy", "TEST", 11, 34], ["Examination", "TEST", 91, 102], ["Treatment", "TREATMENT", 107, 116], ["an endoscopic laryngeal examination", "TEST", 226, 261], ["laryngeal", "ANATOMY", 240, 249]]], ["Furthermore, it must be emphasized to patients that such an examination is vital to complete as soon as it is deemed safe to do so.", [["patients", "ORGANISM", 38, 46], ["patients", "SPECIES", 38, 46], ["an examination", "TEST", 57, 71]]], ["However, proceeding with therapeutic intervention in the absence of the above comprehensive evaluations is nonetheless possible.", [["therapeutic intervention", "TREATMENT", 25, 49], ["the above comprehensive evaluations", "TEST", 68, 103]]], ["For example, in suspected laryngitis or vocal fold hemorrhage, a trial of voice rest could be considered, with reassessment for response in five to seven days.Examination and TreatmentAdditionally, there are many medical therapies that laryngologists can initiate with acceptable benefit-to-risk ratios without confirmatory laryngoscopy, including proton pump inhibitors, H2 blockers, alginates, steroids, antitussives, mucolytics, and antibiotics, based on appropriate history and suspected diagnosis.", [["vocal fold", "ANATOMY", 40, 50], ["laryngitis", "DISEASE", 26, 36], ["vocal fold hemorrhage", "DISEASE", 40, 61], ["alginates", "CHEMICAL", 385, 394], ["steroids", "CHEMICAL", 396, 404], ["alginates", "CHEMICAL", 385, 394], ["steroids", "CHEMICAL", 396, 404], ["laryngologists", "ORGANISM", 236, 250], ["proton pump inhibitors", "SIMPLE_CHEMICAL", 348, 370], ["H2 blockers", "SIMPLE_CHEMICAL", 372, 383], ["alginates", "SIMPLE_CHEMICAL", 385, 394], ["steroids", "SIMPLE_CHEMICAL", 396, 404], ["antitussives", "SIMPLE_CHEMICAL", 406, 418], ["mucolytics", "SIMPLE_CHEMICAL", 420, 430], ["suspected laryngitis", "PROBLEM", 16, 36], ["vocal fold hemorrhage", "PROBLEM", 40, 61], ["voice rest", "TREATMENT", 74, 84], ["Examination", "TEST", 159, 170], ["Treatment", "TREATMENT", 175, 184], ["many medical therapies", "TREATMENT", 208, 230], ["confirmatory laryngoscopy", "TEST", 311, 336], ["proton pump inhibitors", "TREATMENT", 348, 370], ["H2 blockers", "TREATMENT", 372, 383], ["alginates", "TREATMENT", 385, 394], ["steroids", "TREATMENT", 396, 404], ["antitussives", "TREATMENT", 406, 418], ["mucolytics", "TREATMENT", 420, 430], ["antibiotics", "TREATMENT", 436, 447], ["suspected", "OBSERVATION_MODIFIER", 16, 25], ["laryngitis", "OBSERVATION", 26, 36], ["vocal fold", "ANATOMY", 40, 50], ["hemorrhage", "OBSERVATION", 51, 61]]], ["Many clinical diagnoses are confirmed or supported by laryngoscopy, but may safely be treated with trials of medications.", [["laryngoscopy", "TEST", 54, 66], ["trials of medications", "TREATMENT", 99, 120]]], ["In these instances, laryngoscopy may be delayed without undue patient risk.", [["patient", "ORGANISM", 62, 69], ["patient", "SPECIES", 62, 69], ["laryngoscopy", "TEST", 20, 32], ["undue patient risk", "PROBLEM", 56, 74]]], ["For patients with known subglottic stenosis, use of a home peak flow meter to monitor airway symptoms may guide need for inperson visit or surgery.", [["subglottic", "ANATOMY", 24, 34], ["airway", "ANATOMY", 86, 92], ["subglottic stenosis", "DISEASE", 24, 43], ["patients", "ORGANISM", 4, 12], ["subglottic stenosis", "PATHOLOGICAL_FORMATION", 24, 43], ["airway", "MULTI-TISSUE_STRUCTURE", 86, 92], ["patients", "SPECIES", 4, 12], ["known subglottic stenosis", "PROBLEM", 18, 43], ["a home peak flow meter", "TREATMENT", 52, 74], ["airway symptoms", "PROBLEM", 86, 101], ["surgery", "TREATMENT", 139, 146], ["subglottic", "ANATOMY", 24, 34], ["stenosis", "OBSERVATION", 35, 43], ["airway", "ANATOMY", 86, 92]]], ["[24] [25] [26] Results may be relayed during tele-video visits, and if significant decline in values are noted, a prompt in-office visit should be considered.Examination and TreatmentAgain, providers should proceed with caution, carefully monitoring progress and ensuring completion of full evaluation when safely possible.", [["significant decline in values", "PROBLEM", 71, 100], ["Examination", "TEST", 158, 169], ["full evaluation", "TEST", 286, 301]]], ["Once clinics resume safe instrumental examination, timely completion should be accomplished.Optimizing the Success of the Video VisitMultiple steps can be taken on the part of both provider and patient in order to maximize telehealth efficiency and effectiveness.", [["patient", "ORGANISM", 194, 201], ["patient", "SPECIES", 194, 201], ["safe instrumental examination", "TEST", 20, 49]]], ["This can include a pre-visit call from office staff to ensure the patient is aware of and knows how to set up the video visit.", [["patient", "ORGANISM", 66, 73], ["patient", "SPECIES", 66, 73]]], ["Technical support or troubleshooting during this call can be helpful.Optimizing the Success of the Video VisitFor the provider, we recommend performing the telehealth visit in a quiet room and using headphones to hear the patient clearly.", [["patient", "ORGANISM", 222, 229], ["patient", "SPECIES", 222, 229], ["Technical support", "TREATMENT", 0, 17], ["headphones", "TREATMENT", 199, 209]]], ["Similarly, it is helpful for the patient to participate in a quiet room using headphones.", [["patient", "ORGANISM", 33, 40], ["patient", "SPECIES", 33, 40], ["headphones", "TREATMENT", 78, 88]]], ["In this way, both provider and patient can be heard without excessive vocal strain or effort.", [["patient", "ORGANISM", 31, 38], ["patient", "SPECIES", 31, 38], ["excessive vocal strain", "PROBLEM", 60, 82]]], ["For certain patients (e.g. elderly, hard of hearing, or those with disabilities), having family members or other care providers present for the video visit is anecdotally beneficial.Optimizing the Success of the Video VisitReliable internet connection is critical.", [["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20]]], ["Proximity to the router or being directly connected to ethernet can be helpful to avoid disruptions of video or audio feed.", [["ethernet", "CHEMICAL", 55, 63], ["ethernet", "CHEMICAL", 55, 63], ["ethernet", "SIMPLE_CHEMICAL", 55, 63]]], ["A readily accessible informational technology hotline number can help providers and patients troubleshoot technical issues.", [["patients", "ORGANISM", 84, 92], ["patients", "SPECIES", 84, 92]]], ["In the event a patient does not show on time for their visit, a simple phone call can help the provider understand the reason for that delay.", [["patient", "ORGANISM", 15, 22], ["patient", "SPECIES", 15, 22]]], ["If the patient is having difficulty with use of a downloaded application, a simple workaround may be use of the website via the internet (e.g. zoom.us) to join the meeting.", [["patient", "ORGANISM", 7, 14], ["patient", "SPECIES", 7, 14], ["a downloaded application", "TREATMENT", 48, 72]]], ["For the clinician, having your Personal Meeting Identification number (PMI) readily on hand to give to the patient to input manually on the website can expedite patient connection to the virtual meeting.Optimizing the Success of the Video VisitPatient reported outcome measures [e.g. Voice Handicap Index-10 (VHI-10) [13] , reflux symptom index (RSI) [14] , cough severity index (CSI) [15] , dyspnea index (DI) [16] , and eating assessment tool-10 (EAT-10) [17] ] can be completed by patients prior to the visit, and submitted by email or directly through the electronic medical record.", [["reflux", "DISEASE", 324, 330], ["cough", "DISEASE", 358, 363], ["dyspnea", "DISEASE", 392, 399], ["hand", "ORGANISM_SUBDIVISION", 87, 91], ["patient", "ORGANISM", 107, 114], ["patient", "ORGANISM", 161, 168], ["patients", "ORGANISM", 484, 492], ["patient", "SPECIES", 107, 114], ["patient", "SPECIES", 161, 168], ["patients", "SPECIES", 484, 492], ["outcome measures", "TEST", 261, 277], ["Voice Handicap Index", "TEST", 284, 304], ["VHI", "TEST", 309, 312], ["reflux symptom index", "TEST", 324, 344], ["cough severity index (CSI)", "PROBLEM", 358, 384], ["dyspnea index (DI)", "PROBLEM", 392, 410], ["eating assessment tool", "TEST", 422, 444]]], ["These results are then available to the providers prior to the visit for review.Optimizing the Success of the Video VisitIt is helpful to create a database of resources that can easily be shown during the video visit or sent to the patient via secure link for easy access.", [["patient", "ORGANISM", 232, 239], ["patient", "SPECIES", 232, 239]]], ["These resources serve as virtual replacement for the typical paper informational handouts given in the office.", [["virtual replacement", "TREATMENT", 25, 44]]], ["The Zoom for Healthcare platform allows the provider to share their screen.", [["their screen", "TEST", 62, 74]]], ["This feature facilitates reviewing results, imaging, previously archived endoscopic examinations, or diagrams for explaining proposed surgeries or procedures.Optimizing the Success of the Video VisitSound can sometimes be a challenge on a virtual visit.", [["imaging", "TEST", 44, 51], ["previously archived endoscopic examinations", "TEST", 53, 96], ["proposed surgeries", "TREATMENT", 125, 143], ["procedures", "TREATMENT", 147, 157]]], ["For example, sustained sounds during voice evaluation or voice therapy may be clipped on Zoom.", [["sustained sounds", "PROBLEM", 13, 29], ["voice evaluation", "TEST", 37, 53], ["voice therapy", "TREATMENT", 57, 70], ["sustained", "OBSERVATION_MODIFIER", 13, 22], ["sounds", "OBSERVATION", 23, 29]]], ["Providers may change settings to allow original sound; if the issue continues to persist, the patient can also be instructed to make these changes.", [["patient", "ORGANISM", 94, 101], ["patient", "SPECIES", 94, 101]]], ["(Table 2 )When is a Video Visit Not Enough?Some voice and swallowing complaints can be safely managed remotely.", [["Some voice", "PROBLEM", 43, 53], ["swallowing complaints", "PROBLEM", 58, 79]]], ["However, the majority of patients will ultimately require laryngoscopy for evaluation.", [["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33], ["laryngoscopy", "TEST", 58, 70], ["evaluation", "TEST", 75, 85]]], ["If on initial telehealth evaluation, the provider identifies medical complaints needing urgent evaluation, the patient should come in for an urgent office visit.", [["patient", "ORGANISM", 111, 118], ["patient", "SPECIES", 111, 118], ["initial telehealth evaluation", "TEST", 6, 35], ["medical complaints", "PROBLEM", 61, 79], ["urgent evaluation", "TEST", 88, 105]]], ["Within laryngology, urgent issues include suspected malignancy, symptomatic airway obstruction, aspiration, and severe dysphagia without alternative nutritional intake means (i.e. nasogastric or PEG tube).", [["airway", "ANATOMY", 76, 82], ["malignancy", "DISEASE", 52, 62], ["airway obstruction", "DISEASE", 76, 94], ["dysphagia", "DISEASE", 119, 128], ["PEG", "CHEMICAL", 195, 198], ["airway", "PATHOLOGICAL_FORMATION", 76, 82], ["suspected malignancy", "PROBLEM", 42, 62], ["symptomatic airway obstruction", "PROBLEM", 64, 94], ["aspiration", "PROBLEM", 96, 106], ["severe dysphagia", "PROBLEM", 112, 128], ["nasogastric or PEG tube", "TREATMENT", 180, 203], ["malignancy", "OBSERVATION", 52, 62], ["symptomatic", "OBSERVATION_MODIFIER", 64, 75], ["airway", "ANATOMY", 76, 82], ["obstruction", "OBSERVATION", 83, 94], ["aspiration", "OBSERVATION", 96, 106], ["severe", "OBSERVATION_MODIFIER", 112, 118], ["dysphagia", "OBSERVATION", 119, 128], ["PEG tube", "OBSERVATION", 195, 203]]], ["There are also situations when patients themselves are distressed and would be more reassured by in-person patient evaluation.", [["patients", "ORGANISM", 31, 39], ["patient", "ORGANISM", 107, 114], ["patients", "SPECIES", 31, 39], ["patient", "SPECIES", 107, 114], ["patient evaluation", "TEST", 107, 125]]], ["These cases should be addressed more urgently at the provider\"s discretion.When is a Video Visit Not Enough?In-person SLP evaluation with instrumentation including MBSS should be limited to urgent cases only during peak pandemic.", [["SLP evaluation", "TEST", 118, 132], ["instrumentation", "TREATMENT", 138, 153], ["MBSS", "TREATMENT", 164, 168], ["urgent cases", "TEST", 190, 202], ["peak pandemic", "PROBLEM", 215, 228]]], ["This includes patients with no means of nutrition and high risk of aspiration.", [["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22], ["aspiration", "PROBLEM", 67, 77], ["aspiration", "OBSERVATION", 67, 77]]], ["Alternatively, MBSS can be performed at a facility closer to home and then reviewed by the provider to determine urgency and in-office assessment needs.", [["MBSS", "TEST", 15, 19], ["urgency", "PROBLEM", 113, 120]]], ["In cases where urgent MBSS is required and the patient is unknown to the SLP, it is advantageous for the SLP to complete a video visit prior to the MBSS to obtain relevant history and complete a clinical swallow evaluation.", [["MBSS", "CANCER", 22, 26], ["patient", "ORGANISM", 47, 54], ["patient", "SPECIES", 47, 54], ["urgent MBSS", "TEST", 15, 26], ["the MBSS", "TEST", 144, 152], ["a clinical swallow evaluation", "TEST", 193, 222]]], ["Then, the in-person time in the fluoroscopy suite during the MBSS can be utilized most efficiently.", [["MBSS", "DNA", 61, 65], ["the MBSS", "TREATMENT", 57, 65]]], ["For patients with a tracheoesophageal voice prosthesis (TEP), in-person visit during peak pandemic may be necessary.", [["tracheoesophageal", "ANATOMY", 20, 37], ["patients", "ORGANISM", 4, 12], ["patients", "SPECIES", 4, 12], ["a tracheoesophageal voice prosthesis", "TREATMENT", 18, 54], ["tracheoesophageal", "ANATOMY", 20, 37], ["voice prosthesis", "OBSERVATION", 38, 54]]], ["However, video visits can be used for troubleshooting, as the patient may be able to apply a plug to the TEP or use other strategies to reduce urgency or even delay the need for in-person visit.Laryngology Tele-Health in the Post-COVID EraEven after the risks of COVID-19 have declined sufficiently to allow resumption of more routine clinical practice, telehealth will likely remain a useful tool for providers.", [["patient", "ORGANISM", 62, 69], ["patient", "SPECIES", 62, 69], ["a plug", "TREATMENT", 91, 97], ["the TEP", "TREATMENT", 101, 108], ["other strategies", "TREATMENT", 116, 132], ["urgency", "PROBLEM", 143, 150], ["COVID", "TEST", 263, 268]]], ["We envision that telehealth could be used as pre-screening for patients to identify needs and optimize resource utilization.", [["patients", "ORGANISM", 63, 71], ["patients", "SPECIES", 63, 71], ["resource utilization", "TREATMENT", 103, 123]]], ["For example, patients with swallowing complaints could be screened prior to coming into clinic for need for an instrumental swallow evaluation [i.e. flexible endoscopic evaluation of swallowing (FEES) or MBSS].", [["swallowing complaints", "DISEASE", 27, 48], ["patients", "ORGANISM", 13, 21], ["patients", "SPECIES", 13, 21], ["swallowing complaints", "PROBLEM", 27, 48], ["an instrumental swallow evaluation", "TEST", 108, 142], ["flexible endoscopic evaluation", "TEST", 149, 179]]], ["If deemed necessary, the instrumental swallow evaluation could be scheduled on the same day as an in-person office visit.", [["the instrumental swallow evaluation", "TEST", 21, 56]]], ["This would be especially advantageous for those patients coming from a long distance or in centers where the wait time to schedule MBSS may be prolonged.", [["patients", "ORGANISM", 48, 56], ["patients", "SPECIES", 48, 56]]], ["Determination of who would be best to do this screening and how to be reimbursed for this practice remains unknown.Laryngology Tele-Health in the Post-COVID EraRemote voice and swallow therapy have been performed for several years to increase patient access to care and have been shown to be cost-effective and efficient.", [["patient", "ORGANISM", 243, 250], ["patient", "SPECIES", 243, 250], ["this screening", "TEST", 41, 55], ["the Post-COVID EraRemote voice", "TREATMENT", 142, 172], ["swallow therapy", "TREATMENT", 177, 192]]], ["[27, 28] Patients benefit from both cost (e.g. gas, toll roads, parking, and public transportation) and time (e.g. driving, time off from work) savings with telehealth visits.", [["Patients", "ORGANISM", 9, 17], ["Patients", "SPECIES", 9, 17]]], ["However, not all patients are appropriate for nor desirous of remote therapy, and some patients may prefer or require hands-on, in-person work.", [["patients", "ORGANISM", 17, 25], ["patients", "ORGANISM", 87, 95], ["patients", "SPECIES", 17, 25], ["patients", "SPECIES", 87, 95], ["remote therapy", "TREATMENT", 62, 76]]], ["Patients who require manual therapies and certain voice patients with subtle sound variations or who are less stimulable for vocal change are better seen in person.Telemedicine Billing ConsiderationsRetroactive to January 27, 2020, the federal government has approved certain federal regulatory flexibilities and blanket waivers to expand access to telehealth for physicians.", [["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 56, 64], ["vocal", "ORGANISM_SUBDIVISION", 125, 130], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 56, 64], ["person", "SPECIES", 157, 163], ["manual therapies", "TREATMENT", 21, 37], ["subtle sound variations", "PROBLEM", 70, 93], ["vocal change", "PROBLEM", 125, 137]]], ["[29] It is important to be aware of potential state-to-state variability in these laws and regulations.Telemedicine Billing ConsiderationsFor example, in California, a pay parity law requires that if a service is covered in person, that service must be reimbursed at the same rate for a video visit.", [["person", "SPECIES", 224, 230]]], ["Criteria to meet various levels of billing for new and return patient video visits are similar to those for in-person visits, as specified by the American Medical Association.", [["patient", "ORGANISM", 62, 69], ["patient", "SPECIES", 62, 69]]], ["[30] Often, limitations of physical exam performance related to telehealth restricts the clinician\"s ability to bill above level 3.", [["physical exam", "TEST", 27, 40]]], ["In some situations (e.g. discussion of test results with a follow-up patients), time-based billing may be more appropriate.", [["patients", "ORGANISM", 69, 77], ["patients", "SPECIES", 69, 77]]], ["(Table 3 ) For patients requiring extensive record search and interpretation prior to or after the visit, use of the code 99358 may be appropriate for that time spent in addition to the actual visit.", [["patients", "ORGANISM", 15, 23], ["patients", "SPECIES", 15, 23]]], ["Under current guidelines, the telephone visit may be billed as shown in Table 4 .CONCLUSIONSCOVID-19 has presented unprecedented challenge to providing clinical care.", [["CONCLUSIONSCOVID", "TEST", 81, 97]]], ["Telehealth has been quickly adapted into both otolaryngology and subspecialty laryngology care.", [["subspecialty laryngology care", "TREATMENT", 65, 94]]], ["As with any new endeavor, there are challenges to adaptation; however, with appropriate planning and flexibility, the telehealth model can be optimized to provide high-quality, multi-disciplinary, Uncheck the box next to \"Automatically Adjust Microphone Volume Step 4 Click Advanced on the bottom right of the screen Step 5CONCLUSIONSCheck the box next to Show in-meeting option to \"Enable original sound\" Step 6CONCLUSIONSDisable Suppress Persistent Background Noise and Suppress Intermittent Background Noise are set to Step 7 Set Echo cancellation to Auto Step 8CONCLUSIONSClose out the box and return to your home zoom screen.CONCLUSIONSStep 9CONCLUSIONSClick \"Turn on Original Sound\" in the upper left-hand corner", [["left-hand", "ANATOMY", 702, 711], ["Microphone Volume Step 4 Click", "TREATMENT", 243, 273], ["Persistent Background Noise", "PROBLEM", 440, 467], ["Intermittent Background Noise", "PROBLEM", 481, 510], ["Echo cancellation", "TEST", 533, 550], ["your home zoom screen", "TEST", 608, 629], ["upper", "ANATOMY_MODIFIER", 696, 701], ["left", "ANATOMY_MODIFIER", 702, 706], ["hand corner", "ANATOMY", 707, 718]]]], "cabe4ebafa262c1d554491e812641c6e8a7d7d66": [["IntroductionInfection with SARS-CoV-2 can result in a spectrum of clinical phenotypes encompassed by COVID-19, from asymptomatic illness to a potentially lethal disease with hallmarks of acute respiratory distress syndrome (ARDS) (Yang et al., 2020) .", [["respiratory", "ANATOMY", 193, 204], ["SARS", "DISEASE", 27, 31], ["illness", "DISEASE", 129, 136], ["acute respiratory distress syndrome", "DISEASE", 187, 222], ["ARDS", "DISEASE", 224, 228], ["SARS-CoV-2", "ORGANISM", 27, 37], ["SARS-CoV", "SPECIES", 27, 35], ["clinical phenotypes", "PROBLEM", 66, 85], ["COVID", "TEST", 101, 106], ["asymptomatic illness", "PROBLEM", 116, 136], ["a potentially lethal disease", "PROBLEM", 140, 168], ["acute respiratory distress syndrome", "PROBLEM", 187, 222], ["ARDS", "PROBLEM", 224, 228], ["acute", "OBSERVATION_MODIFIER", 187, 192], ["respiratory distress", "OBSERVATION", 193, 213]]], ["While some clinical demographics have been associated with a more severe disease course (Guan et al., 2020) , the heterogeneity of clinical outcomes is otherwise poorly understood.IntroductionThe range of clinical outcomes may at least in part be related to patient-specific antiviral T cell responses.", [["T cell", "ANATOMY", 285, 291], ["patient", "ORGANISM", 258, 265], ["T cell", "CELL", 285, 291], ["patient", "SPECIES", 258, 265], ["a more severe disease course", "PROBLEM", 59, 87], ["severe", "OBSERVATION_MODIFIER", 66, 72], ["disease", "OBSERVATION", 73, 80]]], ["T cells are crucial for viral clearance and development of immunologic memory (Wherry and Ahmed, 2004) and are plausible contributors to immunopathology following viral infection (Channappanavar and Perlman, 2017) .", [["T cells", "ANATOMY", 0, 7], ["immunopathology", "DISEASE", 137, 152], ["viral infection", "DISEASE", 163, 178], ["T cells", "CELL", 0, 7], ["T cells", "CELL_TYPE", 0, 7], ["viral clearance", "PROBLEM", 24, 39], ["immunopathology", "PROBLEM", 137, 152], ["viral infection", "PROBLEM", 163, 178], ["viral", "OBSERVATION_MODIFIER", 163, 168], ["infection", "OBSERVATION", 169, 178]]], ["Both SARS-CoV-2 reactive CD4 and CD8 T cells have been detected in patients with COVID-19 (Chour et al., 2020; Grifoni et al., 2020a; Weiskopf et al., 2020a) , though early studies suggest the relationship between T cell responses and the severity of COVID-19 is complex (Mathew et al., 2020) .IntroductionThe heterogeneity in T cell responses to SARS-CoV-2 may be related to recognition of viral antigens in the context of class I and II human leukocyte antigen (HLA) proteins (Chour et al., 2020) .", [["CD8 T cells", "ANATOMY", 33, 44], ["T cell", "ANATOMY", 214, 220], ["T cell", "ANATOMY", 327, 333], ["SARS", "DISEASE", 347, 351], ["COVID-19", "CHEMICAL", 251, 259], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 5, 15], ["CD4", "GENE_OR_GENE_PRODUCT", 25, 28], ["CD8", "GENE_OR_GENE_PRODUCT", 33, 36], ["patients", "ORGANISM", 67, 75], ["T cell", "CELL", 214, 220], ["COVID-19", "GENE_OR_GENE_PRODUCT", 251, 259], ["T cell", "CELL", 327, 333], ["SARS-CoV-2", "ORGANISM", 347, 357], ["II human leukocyte antigen", "GENE_OR_GENE_PRODUCT", 436, 462], ["CD4 and CD8 T cells", "CELL_TYPE", 25, 44], ["viral antigens", "PROTEIN", 391, 405], ["class I and II human leukocyte antigen (HLA) proteins", "PROTEIN", 424, 477], ["patients", "SPECIES", 67, 75], ["human", "SPECIES", 439, 444], ["SARS-CoV", "SPECIES", 347, 355], ["class I", "SPECIES", 424, 431], ["human", "SPECIES", 439, 444], ["Both SARS", "TEST", 0, 9], ["CoV", "TEST", 10, 13], ["CD8 T cells", "PROBLEM", 33, 44], ["COVID", "TEST", 81, 86], ["The heterogeneity in T cell responses", "PROBLEM", 306, 343], ["SARS", "PROBLEM", 347, 351], ["CoV", "TEST", 352, 355], ["viral antigens", "PROBLEM", 391, 405], ["II human leukocyte antigen", "TEST", 436, 462], ["CoV", "ANATOMY", 10, 13], ["reactive CD4", "OBSERVATION", 16, 28], ["heterogeneity", "OBSERVATION_MODIFIER", 310, 323], ["T cell", "OBSERVATION", 327, 333], ["viral", "OBSERVATION", 391, 396]]], ["Indeed, genetic susceptibilities to viral infection have been tied to variation in the major histocompatibility complex (MHC) genes that encode HLA proteins (Dutta et al., 2018; Hill, 2001) .", [["viral infection", "DISEASE", 36, 51], ["major histocompatibility complex", "GENE_OR_GENE_PRODUCT", 87, 119], ["major histocompatibility complex (MHC) genes", "DNA", 87, 131], ["HLA proteins", "PROTEIN", 144, 156], ["viral infection", "PROBLEM", 36, 51], ["viral", "OBSERVATION_MODIFIER", 36, 41], ["infection", "OBSERVATION", 42, 51]]], ["Meanwhile, functional differences in viral antigen-specific T cell responses in symptomatic and asymptomatic patients may also contribute to the biology of at-risk populations (Mathew et al., 2020; Weiskopf et al., 2020a) .IntroductionFurther understanding of virus-specific T cell responses may aid in designing and monitoring the impact of preventative SARS-CoV-2 T cell vaccines.", [["T cell", "ANATOMY", 60, 66], ["T cell", "ANATOMY", 275, 281], ["T cell", "ANATOMY", 366, 372], ["T cell", "CELL", 60, 66], ["patients", "ORGANISM", 109, 117], ["T cell", "CELL", 275, 281], ["T cell", "CELL", 366, 372], ["viral antigen", "PROTEIN", 37, 50], ["patients", "SPECIES", 109, 117], ["functional differences", "PROBLEM", 11, 33], ["viral antigen", "TEST", 37, 50], ["virus", "PROBLEM", 260, 265], ["preventative SARS", "PROBLEM", 342, 359], ["CoV", "TEST", 360, 363], ["2 T cell vaccines", "TREATMENT", 364, 381], ["symptomatic", "OBSERVATION_MODIFIER", 80, 91]]], ["In contrast to SARS-CoV-2 vaccines focused on generating antibody responses against the surface spike glycoprotein that facilitates viral entry into the cell (Thanh Le et al., 2020) T cell vaccines have the capacity to generate immune responses against the entire viral proteome (Gilbert, 2012) .", [["surface", "ANATOMY", 88, 95], ["cell", "ANATOMY", 153, 157], ["T cell", "ANATOMY", 182, 188], ["SARS", "DISEASE", 15, 19], ["SARS-CoV-2", "ORGANISM", 15, 25], ["cell", "CELL", 153, 157], ["T cell", "CELL", 182, 188], ["surface spike glycoprotein", "PROTEIN", 88, 114], ["SARS-CoV", "SPECIES", 15, 23], ["SARS", "TEST", 15, 19], ["CoV-2 vaccines", "TREATMENT", 20, 34], ["generating antibody responses", "TREATMENT", 46, 75], ["the surface spike glycoprotein", "TREATMENT", 84, 114], ["T cell vaccines", "TREATMENT", 182, 197], ["the capacity", "PROBLEM", 203, 215]]], ["In fact, non-spike T cell responses may be associated with less severe COVID19 (Peng et al., 2020) .IntroductionTo evaluate patient-specific T cell responses, recent studies have used large pools of SARS-CoV-2 epitopes based on homology with SARS-CoV, or based on prediction of MHC class I-and class II-binding peptides across common HLA alleles in order to capture a broad population Smith et al., 2020) .", [["non-spike T cell", "ANATOMY", 9, 25], ["T cell", "ANATOMY", 141, 147], ["SARS", "DISEASE", 199, 203], ["non-spike T cell", "CELL", 9, 25], ["patient", "ORGANISM", 124, 131], ["T cell", "CELL", 141, 147], ["SARS-CoV", "ORGANISM", 242, 250], ["SARS-CoV-2 epitopes", "PROTEIN", 199, 218], ["MHC class I", "PROTEIN", 278, 289], ["HLA alleles", "DNA", 334, 345], ["patient", "SPECIES", 124, 131], ["SARS-CoV", "SPECIES", 242, 250], ["less severe COVID19", "PROBLEM", 59, 78], ["recent studies", "TEST", 159, 173], ["SARS", "PROBLEM", 199, 203]]], ["To facilitate a more comprehensive evaluation of anti-viral and vaccine-induced T cell responses, and to support region-specific and global vaccine design strategies, we generated a resource database with a corresponding user-friendly interface to facilitate exploration of predicted MHC-binding peptides across 9,360 and 8,445 class I and II HLA alleles, to account for the genetic diversity in the MHC gene complex across global populations.In silico predictions of SARS-CoV-2 antigensWe deployed binding predictions across the SARS-CoV-2 proteome (Figure 1) for 9,360 class I HLA alleles (2,987 HLA-A; 3,707 HLA-B; 2,666 HLA-C; 9-mers) and 8,445 class II HLA alleles (15-mers).", [["T cell", "ANATOMY", 80, 86], ["T cell", "CELL", 80, 86], ["HLA-C", "GENE_OR_GENE_PRODUCT", 624, 629], ["MHC", "PROTEIN", 284, 287], ["9,360 and 8,445 class I and II HLA alleles", "DNA", 312, 354], ["MHC gene complex", "PROTEIN", 400, 416], ["SARS-CoV-2 antigensWe", "DNA", 468, 489], ["SARS-CoV-2 proteome", "DNA", 530, 549], ["9,360 class I HLA alleles", "DNA", 565, 590], ["8,445 class II HLA alleles", "DNA", 643, 669], ["SARS-CoV", "SPECIES", 468, 476], ["SARS-CoV", "SPECIES", 530, 538], ["a more comprehensive evaluation", "TEST", 14, 45], ["anti-viral and vaccine", "TREATMENT", 49, 71], ["binding peptides", "TEST", 288, 304], ["II HLA alleles", "PROBLEM", 340, 354], ["SARS", "PROBLEM", 468, 472], ["CoV", "TEST", 473, 476], ["the SARS", "TEST", 526, 534], ["CoV", "TEST", 535, 538], ["HLA alleles", "TEST", 579, 590], ["HLA", "TEST", 598, 601], ["HLA", "TEST", 611, 614], ["B", "TEST", 615, 616], ["HLA", "TEST", 624, 627], ["C", "TEST", 628, 629], ["mers", "TEST", 633, 637], ["HLA alleles", "TEST", 658, 669], ["global", "OBSERVATION_MODIFIER", 424, 430], ["populations", "OBSERVATION_MODIFIER", 431, 442]]], ["The predicted binding affinity (in nanomolar [nM] ) between peptides and HLA proteins (pMHCs) were summarized by the median predicted binding affinity across all algorithms (Median Score).", [["HLA proteins", "GENE_OR_GENE_PRODUCT", 73, 85], ["HLA proteins", "PROTEIN", 73, 85], ["pMHCs", "PROTEIN", 87, 92], ["The predicted binding affinity", "PROBLEM", 0, 30], ["peptides and HLA proteins", "PROBLEM", 60, 85], ["binding affinity", "OBSERVATION", 14, 30]]], ["The Median Score values were filtered to those less than 500nM, a common filter used in peptide binding predictions for the purpose of identifying T cell epitopes (Rajasagi et al., 2014; Sidney et al., 1999) .", [["T cell", "ANATOMY", 147, 153], ["T cell", "CELL", 147, 153], ["T cell epitopes", "PROTEIN", 147, 162], ["The Median Score values", "TEST", 0, 23], ["a common filter", "TREATMENT", 64, 79]]], ["There were 368,145 unique combinations of peptides and HLA alleles (pMHCs) with a predicted binding affinity of less than 500nM (Table S2) , including 1,103 unique 9-mer and 2,547 15-mer peptides and 1,022 MHC class I and 3,481 MHC class II HLA proteins, respectively.", [["HLA alleles", "DNA", 55, 66], ["pMHCs", "DNA", 68, 73], ["MHC class I", "PROTEIN", 206, 217], ["MHC class II HLA proteins", "PROTEIN", 228, 253], ["HLA alleles", "TEST", 55, 66], ["a predicted binding affinity", "PROBLEM", 80, 108]]], ["Of note, 905 9-mers (82%) were nested within 1,789 15-mers (70%), indicating that a subset of peptides are predicted as both class I and II epitopes.In silico predictions of SARS-CoV-2 antigensIn order to better understand the predicted antigenic profile of SARS-CoV-2, we focused on the set of 368,145 pMHCs with predicted binding affinity of less than 500nM for the subsequent analyses.", [["SARS-CoV-2 antigens", "GENE_OR_GENE_PRODUCT", 174, 193], ["SARS-CoV-2", "ORGANISM", 258, 268], ["pMHCs", "CANCER", 303, 308], ["class I and II epitopes", "PROTEIN", 125, 148], ["SARS-CoV-2 antigens", "PROTEIN", 174, 193], ["368,145 pMHCs", "PROTEIN", 295, 308], ["SARS-CoV", "SPECIES", 174, 182], ["SARS-CoV", "SPECIES", 258, 266], ["a subset of peptides", "PROBLEM", 82, 102], ["SARS", "PROBLEM", 174, 178], ["CoV", "TEST", 179, 182], ["the subsequent analyses", "TEST", 364, 387]]], ["Both class I and class II antigens were predicted across 10 of the SARS-CoV-2 genes ( Figure 1B) , with the most derived from Orf1ab (n=690 9-mers; 1,589 15-mers), encoding the Orf1ab polyprotein.", [["class II antigens", "GENE_OR_GENE_PRODUCT", 17, 34], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 67, 77], ["Orf1ab", "GENE_OR_GENE_PRODUCT", 126, 132], ["15-mers", "GENE_OR_GENE_PRODUCT", 154, 161], ["Orf1ab", "GENE_OR_GENE_PRODUCT", 177, 183], ["class I and class II antigens", "PROTEIN", 5, 34], ["SARS-CoV-2 genes", "DNA", 67, 83], ["Orf1ab", "DNA", 126, 132], ["Orf1ab polyprotein", "DNA", 177, 195], ["SARS-CoV", "SPECIES", 67, 75], ["the SARS", "TEST", 63, 71], ["CoV", "TEST", 72, 75], ["the Orf1ab polyprotein", "TREATMENT", 173, 195]]], ["The number of peptides from each gene correlated with protein length (R 2 = 0.997, p=2.10e-11; Figure S1 ).Confirmation of predicted SARS-CoV-2 antigens in published datasetsIn order to assess the validity of the predictions in our dataset, we compared our predicted antigens to previously reported SARS-CoV-2 or SARS-CoV T cell epitopes.", [["T cell", "ANATOMY", 322, 328], ["SARS-CoV-2 antigens", "GENE_OR_GENE_PRODUCT", 133, 152], ["CoV-2", "ORGANISM", 304, 309], ["SARS-CoV-2 antigens", "PROTEIN", 133, 152], ["SARS-CoV-2 or SARS-CoV T cell epitopes", "PROTEIN", 299, 337], ["SARS-CoV", "SPECIES", 313, 321], ["protein length", "TEST", 54, 68], ["p", "TEST", 83, 84], ["predicted SARS", "PROBLEM", 123, 137], ["CoV", "TEST", 138, 141], ["SARS", "TEST", 299, 303], ["CoV", "TEST", 304, 307], ["SARS", "PROBLEM", 313, 317], ["CoV T cell epitopes", "PROBLEM", 318, 337], ["cell epitopes", "OBSERVATION", 324, 337]]], ["There were 9 nine-mer and 5 fifteen-mer peptides in our dataset that were previously validated experimentally as T cell epitopes and reported in IEDB from SARS (Table 1) .", [["T cell", "ANATOMY", 113, 119], ["SARS", "DISEASE", 155, 159], ["T cell", "CELL", 113, 119], ["T cell epitopes", "PROTEIN", 113, 128], ["T cell epitopes", "PROBLEM", 113, 128]]], ["Since our dataset was restricted to 9-mers and 15-mers, we expanded this search to include any IEDB epitopes that overlapped (i.e. either nested, or in overlapping positions) with our predicted peptides, which resulted in 81 additional epitopes ( Table S1 ).", [["IEDB epitopes", "PROTEIN", 95, 108], ["epitopes", "PROTEIN", 236, 244], ["S1", "PROTEIN", 253, 255], ["any IEDB epitopes", "PROBLEM", 91, 108]]], ["Four of these total 95 epitopes were specifically associated with HLA-A03:04, B11:01, and A) indicates that the peptide was not included in the pMHC profile of the United States.Figure 2.", [["HLA-A03:04", "GENE_OR_GENE_PRODUCT", 66, 76], ["HLA", "PROTEIN", 66, 69], ["B11:01", "PROTEIN", 78, 84], ["pMHC", "PROTEIN", 144, 148], ["HLA", "TEST", 66, 69], ["the peptide", "TEST", 108, 119]]], ["Peptide diversity in country pMHC profiles.", [["pMHC", "GENE_OR_GENE_PRODUCT", 29, 33], ["diversity", "OBSERVATION_MODIFIER", 8, 17]]], ["CC-BY-NC-ND 4.0 International license (which was not certified by peer review) is the author/funder.", [["CC", "CHEMICAL", 0, 2]]], ["It is made available under a The copyright holder for this preprint this version posted June 29, 2020. . https://doi.org/10.1101/2020.03.30.016931 doi: bioRxiv preprint The copyright holder for this preprint this version posted June 29, 2020 . . https://doi.org/10.1101 is colored by the number of SCSs (i.e. countries) within each global region (y-axis) corresponding to each peptide (x-axis).Figure 4.", [["https://doi.org/10.1101", "CHEMICAL", 246, 269], ["bioRxiv", "TREATMENT", 152, 159], ["colored", "OBSERVATION", 273, 280], ["number", "OBSERVATION_MODIFIER", 288, 294]]], ["The Smith et al. dataset was summarized across countries by previously reported epitopes and corresponding HLA types.", [["epitopes", "PROTEIN", 80, 88]]], ["The number of peptides included and the percent of the sample population covered by each SCS is shown, colored by each country's corresponding region.", [["the sample population", "TREATMENT", 51, 72]]], ["B. The peptides comprising the Smith SCS are shown (top panel), along with the number of SCSs (y-axis) associated with each peptide and the corresponding SARS-CoV-2 gene (color).", [["B", "GENE_OR_GENE_PRODUCT", 0, 1], ["SCSs", "GENE_OR_GENE_PRODUCT", 89, 93], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 154, 164], ["SARS-CoV-2 gene", "DNA", 154, 169], ["The peptides", "PROBLEM", 3, 15], ["top panel", "TEST", 52, 61], ["each peptide", "PROBLEM", 119, 131], ["the corresponding SARS", "TEST", 136, 158], ["CoV", "TEST", 159, 162]]], ["The HLA Alleles associated with these peptides is also shown (bottom), according to the number of pMHCs (i.e. peptides) predicted for the corresponding allele.", [["HLA", "GENE_OR_GENE_PRODUCT", 4, 7], ["pMHCs", "GENE_OR_GENE_PRODUCT", 98, 103], ["HLA Alleles", "DNA", 4, 15], ["pMHCs", "PROTEIN", 98, 103], ["allele", "DNA", 152, 158], ["these peptides", "PROBLEM", 32, 46]]], ["C. The percent of each simulated country (x-axis) population covered by their respective SCSs is shown; SCS from this work is shown in blue, and the SCS results from Smith et al. is shown in green.", [["green", "OBSERVATION", 191, 196]]], ["A 90% cutoff is denoted by the horizontal, dashed line.", [["horizontal, dashed line", "CELL_LINE", 31, 54], ["A 90% cutoff", "TEST", 0, 12], ["horizontal", "OBSERVATION_MODIFIER", 31, 41], ["dashed line", "OBSERVATION", 43, 54]]], ["CC-BY-NC-ND 4.0 International license (which was not certified by peer review) is the author/funder.", [["CC", "CHEMICAL", 0, 2]]], ["1101Lead ContactFurther information and requests for resources and reagents should be directed to and will be fulfilled by the Lead Contact, Katie Campbell (katiecampbell@mednet.ucla.edu).Data and Code AvailabilityThe results of this study are available in a public Google bucket through the following link: https://console.cloud.google.com/storage/browser/pici-covid19-data-resources (gs://pici-covid19-dataresources).", [["reagents", "TREATMENT", 67, 75], ["this study", "TEST", 229, 239]]], ["This bucket contains all of the unfiltered peptide binding predictions and the Supplemental Tables corresponding to this document.", [["all", "OBSERVATION_MODIFIER", 21, 24]]], ["The filtered peptide binding predictions and set cover solutions can be explored using the interactive Shiny app at https://rstudio-connect.parkerici.org/content/13/.", [["The filtered peptide binding predictions", "TREATMENT", 0, 40], ["set cover solutions", "TREATMENT", 45, 64]]], ["All filtered data can be exported from this web interface.", [["All filtered data", "TEST", 0, 17]]], ["The code for this manuscript and the Shiny App is available in the public github repository https://github.com/kcampbel/neocovid-app.Data acquisitionThe NCBI Virus resource (https://www.ncbi.nlm.nih.gov/labs/virus/vssi/) was used to obtain all annotated protein sequences for SARS-CoV-2 on March 15, 2020.", [["Virus", "ORGANISM", 158, 163], ["protein sequences", "DNA", 254, 271], ["NCBI", "SPECIES", 153, 157], ["SARS-CoV", "SPECIES", 276, 284], ["all annotated protein sequences", "TEST", 240, 271], ["SARS", "PROBLEM", 276, 280], ["CoV", "TEST", 281, 284]]], ["This dataset spanned 166 genotypes, but protein sequences were summarized by the corresponding UniProt annotation for the SARS-CoV-2 proteome (UP000464024).", [["SARS-CoV", "SPECIES", 122, 130], ["protein sequences", "TEST", 40, 57], ["the SARS", "TEST", 118, 126], ["CoV", "TEST", 127, 130]]], ["All possible 9-mer and 15-mer peptides were obtained from the entire viral proteome for Class I and Class II peptide binding predictions, respectively.Peptide-MHC binding predictionsPeptide binding predictions were performed using the pVACbind tool from pVACtools and executed using the griffithlab/pvactools:1.5.7 (https://hub.docker.com/r/griffithlab/pvactools/) Docker image.", [["Class I", "GENE_OR_GENE_PRODUCT", 88, 95], ["MHC", "PROTEIN", 159, 162], ["Peptide binding predictions", "PROBLEM", 182, 209], ["the griffithlab/pvactools", "TEST", 283, 308]]], ["Class I prediction algorithms included MHCflurry (v1.6.0) (O'Donnell et al., 2018) , MHCnuggets (v2.3) (Shao et al., 2020) , NetMHC (v4.0) (Andreatta and Nielsen, 2016) , PickPocket (v1.1) (Zhang et al., 2009) , SMM (v1.0) (Peters and Sette, 2005) , and SMMPMBEC (v1.0) (Kim et al., 2009) .", [["MHCflurry", "TEST", 39, 48], ["NetMHC", "TEST", 125, 131], ["PickPocket", "TEST", 171, 181], ["SMMPMBEC", "TEST", 254, 262]]], ["Class II prediction algorithms included NetMHCIIpan (v4.0) (Reynisson et al., 2020) , SMMalign (v1.1) (Nielsen et al., 2007) , NNalign (v2.3) (Nielsen and Andreatta, 2017) , and MHCnuggets (v2.3) (Shao et al., 2020) .Peptide-MHC binding predictionsHLA alleles were chosen by running the command and filtering out any non-expressed or null HLA alleles (those ending with the \"N\" suffix), resulting in 9,360 Class I HLA proteins and 8, Where ${fasta} was the protein sequence fasta containing the SARS-CoV-2 proteome, obtained at NCBI Virus.", [["MHC binding predictionsHLA alleles", "DNA", 225, 259], ["non-expressed or null HLA alleles", "DNA", 317, 350], ["Class I HLA proteins", "PROTEIN", 406, 426], ["SARS-CoV-2 proteome", "DNA", 495, 514], ["NCBI Virus", "SPECIES", 528, 538], ["NetMHCIIpan", "TEST", 40, 51], ["null HLA alleles", "PROBLEM", 334, 350], ["HLA proteins", "TEST", 414, 426], ["the protein sequence fasta", "TEST", 453, 479], ["the SARS", "TEST", 491, 499], ["CoV", "TEST", 500, 503]]], ["The pVACbind tool was performed individually across the union of HLA alleles available for all algorithms, and each allele was specified by the ${hla} input in the command.", [["HLA", "GENE_OR_GENE_PRODUCT", 65, 68], ["HLA alleles", "DNA", 65, 76], ["The pVACbind tool", "TEST", 0, 17]]], ["The filtered results, containing peptide-MHC complexes with predicted Median Score (nM) less than 500nM, were aggregated for the final dataset.Country PopulationsPopulation frequencies of HLA alleles were obtained from the Allele Frequency Net Database (Gonzalez-Galarza et al., 2020) .", [["MHC complexes", "PROTEIN", 41, 54], ["HLA alleles", "DNA", 188, 199], ["HLA alleles", "PROBLEM", 188, 199]]], ["The database contains HLA Frequency data for Class I and Class II alleles across 1,028 distinct populations.", [["Class I and Class II alleles", "DNA", 45, 73], ["distinct", "OBSERVATION_MODIFIER", 87, 95], ["populations", "OBSERVATION_MODIFIER", 96, 107]]], ["Populations whose net frequency data exceeded 1 at a given allele were excluded from this analysis, as well as populations that did not report frequencies for alleles with 2 or 3 fields.", [["net frequency data", "TEST", 18, 36], ["this analysis", "TEST", 85, 98]]], ["Because these populations are highly granular (i.e.", [["highly", "OBSERVATION_MODIFIER", 30, 36], ["granular", "OBSERVATION", 37, 45]]], ["\"USA San Francisco Caucasian\"), we aggregated them into 98 populations by country; 77 had data for Class I alleles.", [["Class I alleles", "DNA", 99, 114]]], ["This was done by (1) assigning each population to a country using the first word from each population name, (2) calculating the country \"sample size\" by summing the sample sizes of distinct populations, and (3) calculating HLA frequencies within each country population using Formula 1.Country Frequency = sum(*)/(Country Sample Size)Sample populations were generated from this country-frequency data for 77 countries.", [["distinct populations", "PROBLEM", 181, 201], ["calculating HLA frequencies", "TREATMENT", 211, 238], ["Sample populations", "TEST", 334, 352], ["distinct", "OBSERVATION_MODIFIER", 181, 189], ["populations", "OBSERVATION_MODIFIER", 190, 201]]], ["This was done by sampling 2n alleles from each country gene pool for each Class I allele with reported data, where n represents the number of simulated individuals in the sample population (n = 100,000).", [["2n alleles", "DNA", 26, 36], ["Class I allele", "DNA", 74, 88]]], ["The probability of selecting an allele for each sample population is equal to the frequency of that allele reported for each given country.", [["allele", "DNA", 32, 38], ["allele", "DNA", 100, 106], ["each sample population", "PROBLEM", 43, 65]]], ["The simulated populations used for analysis are available in the github repository (https://github.com/kcampbel/neocovid-app).", [["analysis", "TEST", 35, 43]]], ["These populations of simulated genotypes were then merged with our Class I predictions to create a pMHC profile for each country, based on each country's reported allele frequencies.Global PopulationA simulated \"global population\" was generated by first aggregating all 77 country sample populations, and then sampling from this pool 2n times to create a sample population of n individuals (n = 100,000).", [["pMHC", "PROTEIN", 99, 103], ["allele frequencies", "PROBLEM", 163, 181], ["Global PopulationA simulated \"global population", "PROBLEM", 182, 229]]], ["This ensured that each country would be represented in this global population with equal probability regardless of sample size, such that the global population was not further biased towards the United States and European countries.", [["size", "OBSERVATION_MODIFIER", 122, 126]]], ["It should be noted that consequently, this global population does not reflect true global HLA frequencies, which would require consideration of true country size.Set Cover SolutionsGiven a universal set of n elements (U), a collection of subsets of U (S), and the associated cost of each subset in S, the set cover problem is to identify I , the minimal subcollection of S, whose union equates to U and minimizes the total cost (Karp, 1972) .", [["U (S)", "GENE_OR_GENE_PRODUCT", 249, 254], ["true global HLA frequencies", "PROBLEM", 78, 105], ["the minimal subcollection of S", "PROBLEM", 342, 372], ["does not reflect", "UNCERTAINTY", 61, 77], ["true", "OBSERVATION_MODIFIER", 78, 82], ["global", "OBSERVATION_MODIFIER", 83, 89], ["HLA frequencies", "OBSERVATION", 90, 105], ["size", "OBSERVATION_MODIFIER", 157, 161], ["minimal", "OBSERVATION_MODIFIER", 346, 353], ["subcollection", "OBSERVATION", 354, 367]]], ["The greedy algorithm addresses this problem by iteratively adding elements of U to I until all subsets in S are covered (Vazirani, 2013) .", [["U to I", "TREATMENT", 78, 84]]], ["This problem is NP-hard, so a logN approximate solution was used.Set Cover SolutionsThat is, for a simulated population X, U = all individuals in X covered by at least one pMHC S_i = all individuals in X covered by the pMHC with Epitope i S = set of S_i whose union spans all individuals in U cost(S_i) = 1 for all Epitopes iSet Cover SolutionsThe solution (I) represents the smallest set of epitopes whose union covers the largest portion of population X.Quantification and Statistical AnalysisData analysis and visualization was performed in R using the tidyverse packages [REF] .", [["pMHC", "PROTEIN", 172, 176], ["pMHC", "PROTEIN", 219, 223], ["S_i", "PROTEIN", 250, 253], ["epitopes", "PROTEIN", 392, 400], ["a logN approximate solution", "TREATMENT", 28, 55], ["U cost(S_i)", "TREATMENT", 291, 302], ["all Epitopes iSet Cover SolutionsThe solution (I)", "TREATMENT", 311, 360], ["Statistical AnalysisData analysis", "TEST", 475, 508], ["visualization", "TEST", 513, 526], ["largest", "OBSERVATION_MODIFIER", 424, 431]]], ["The neoCOVID Explorer application was developed using the Shiny R package [REF] and deployed using RStudio-Connect.", [["The neoCOVID Explorer application", "TREATMENT", 0, 33], ["the Shiny R package [REF]", "TREATMENT", 54, 79], ["RStudio", "TREATMENT", 99, 106]]], ["Table REAGENT .", [["Table REAGENT", "TREATMENT", 0, 13]]], ["CC-BY-NC-ND 4.0 International license (which was not certified by peer review) is the author/funder.", [["CC", "CHEMICAL", 0, 2]]], ["It is made available under a The copyright holder for this preprint this version posted June 29, 2020. . https://doi.org/10.1101/2020.03.30.016931 doi: bioRxiv preprint", [["bioRxiv", "TREATMENT", 152, 159]]]], "2af1e014df4223c8e278de9b6ecf950bce2378be": [["RBP expression in tissuesTissue specificity was measured as the entropy deviation from a uniform distribution among all tissues as in 1 Most RBPs showed low specificity with broad expression across tissues ( Supplementary Fig. 1a) , with the 10 least specific including many ubiquitously expressed basic RNA processing factors (e.g. ribosomal proteins RPS11, RPS24, and RPL23A, translation machinery factors EIF4H and EEF2, and broad regulators of RNA processing including HNRNPC and HNRNPA2B1) ( Supplementary Fig. 1b, left) .", [["tissues", "ANATOMY", 18, 25], ["Tissue", "ANATOMY", 25, 31], ["tissues", "ANATOMY", 120, 127], ["tissues", "ANATOMY", 198, 205], ["RBP", "GENE_OR_GENE_PRODUCT", 0, 3], ["tissues", "TISSUE", 18, 25], ["Tissue", "TISSUE", 25, 31], ["tissues", "TISSUE", 120, 127], ["tissues", "TISSUE", 198, 205], ["RPS11", "GENE_OR_GENE_PRODUCT", 352, 357], ["RPS24", "GENE_OR_GENE_PRODUCT", 359, 364], ["RPL23A", "GENE_OR_GENE_PRODUCT", 370, 376], ["EIF4H", "GENE_OR_GENE_PRODUCT", 408, 413], ["EEF2", "GENE_OR_GENE_PRODUCT", 418, 422], ["HNRNPC", "GENE_OR_GENE_PRODUCT", 473, 479], ["HNRNPA2B1", "GENE_OR_GENE_PRODUCT", 484, 493], ["RBP", "PROTEIN", 0, 3], ["RBPs", "PROTEIN", 141, 145], ["basic RNA processing factors", "PROTEIN", 298, 326], ["ribosomal proteins", "PROTEIN", 333, 351], ["RPS11", "PROTEIN", 352, 357], ["RPS24", "PROTEIN", 359, 364], ["RPL23A", "PROTEIN", 370, 376], ["translation machinery factors", "PROTEIN", 378, 407], ["EIF4H", "PROTEIN", 408, 413], ["EEF2", "PROTEIN", 418, 422], ["HNRNPC", "PROTEIN", 473, 479], ["HNRNPA2B1", "PROTEIN", 484, 493], ["RBP expression in tissues", "PROBLEM", 0, 25], ["Tissue specificity", "TEST", 25, 43], ["the entropy deviation", "PROBLEM", 60, 81], ["Most RBPs", "TEST", 136, 145], ["low specificity", "PROBLEM", 153, 168], ["broad expression across tissues", "PROBLEM", 174, 205], ["basic RNA processing factors", "PROBLEM", 298, 326], ["ribosomal proteins", "TEST", 333, 351], ["RPS11", "TEST", 352, 357], ["RPS24", "TEST", 359, 364], ["EEF2", "TEST", 418, 422], ["RNA processing", "TREATMENT", 448, 462], ["HNRNPC", "TREATMENT", 473, 479], ["HNRNPA2B1", "TREATMENT", 484, 493], ["tissues", "ANATOMY", 18, 25], ["entropy deviation", "OBSERVATION", 64, 81], ["uniform", "OBSERVATION_MODIFIER", 89, 96], ["distribution", "OBSERVATION_MODIFIER", 97, 109], ["all tissues", "OBSERVATION", 116, 127], ["low specificity", "OBSERVATION_MODIFIER", 153, 168], ["left", "ANATOMY_MODIFIER", 520, 524]]], ["However, a small subset showed highly specific expression, including some with greatly increased expression in the K562 and HepG2 cancer Fig. 1b, right) .Identification of RBP-dependent gene expression and splicing changesFor analyses in this manuscript, each knockdown/RNA-seq dataset was compared against a non-target shRNA control infected and with library preparation performed within the same experimental batch to minimize potential batch effects in single-RBP comparisons.Single-RBP Gene Expression AnalysisSignificant gene expression changes were determined using DESeq and Cuffdiff as described inSingle-RBP Gene Expression AnalysisMethods, and yielded as few as 1 to as many as 5905 significantly altered genesSingle-RBP Alternative Splicing AnalysisSignificant alternative splicing changes were determined using rMATS as described in Methods, and yielded as few as 3 to as many as 35,000 (the RNA helicase and spliceosomal protein AQR 4 in K562 cells) significantly altered alternative splicing events (Supplementary Fig. 4Batch correction for global analysis of knockdown/RNA-seq datasetsSupplementary Information for Van Nostrand et al.Page S4As alterations in gene expression or splicing patterns due to experimental batches are a common problem in large-scale genomics efforts, to enable further integrated analyses we further performed the following batch correction methods to enable cross-RBP studies of the entire knockdown/RNA-seq data resource:Batch Correction for Gene Expression AnalysisGene expression batch effects were reduced with ComBat 5 .", [["K562", "ANATOMY", 115, 119], ["HepG2 cancer", "ANATOMY", 124, 136], ["K562 cells", "ANATOMY", 951, 961], ["K562", "CELL", 115, 119], ["HepG2 cancer Fig. 1b", "CELL", 124, 144], ["RBP", "GENE_OR_GENE_PRODUCT", 172, 175], ["RBP", "GENE_OR_GENE_PRODUCT", 463, 466], ["Single-RBP", "GENE_OR_GENE_PRODUCT", 720, 730], ["spliceosomal protein AQR 4", "GENE_OR_GENE_PRODUCT", 921, 947], ["K562 cells", "CELL", 951, 961], ["S4As", "GENE_OR_GENE_PRODUCT", 1154, 1158], ["K562", "CELL_LINE", 115, 119], ["RBP", "PROTEIN", 172, 175], ["DESeq", "DNA", 572, 577], ["5905 significantly altered genes", "DNA", 688, 720], ["rMATS", "DNA", 823, 828], ["RNA helicase", "PROTEIN", 904, 916], ["spliceosomal protein AQR 4", "PROTEIN", 921, 947], ["K562 cells", "CELL_LINE", 951, 961], ["a small subset", "PROBLEM", 9, 23], ["greatly increased expression in the K562", "PROBLEM", 79, 119], ["HepG2 cancer", "PROBLEM", 124, 136], ["RBP", "PROBLEM", 172, 175], ["dependent gene expression", "PROBLEM", 176, 201], ["splicing changes", "PROBLEM", 206, 222], ["a non-target shRNA control", "TREATMENT", 307, 333], ["library preparation", "TREATMENT", 352, 371], ["potential batch effects", "PROBLEM", 429, 452], ["single-RBP comparisons", "TEST", 456, 478], ["gene expression changes", "PROBLEM", 526, 549], ["DESeq and Cuffdiff", "TREATMENT", 572, 590], ["significantly altered genes", "PROBLEM", 693, 720], ["alternative splicing changes", "PROBLEM", 772, 800], ["the RNA helicase", "TEST", 900, 916], ["spliceosomal protein AQR", "TEST", 921, 945], ["K562 cells", "TEST", 951, 961], ["significantly altered alternative splicing events", "PROBLEM", 963, 1012], ["Supplementary Fig", "TREATMENT", 1014, 1031], ["4Batch correction", "TREATMENT", 1033, 1050], ["global analysis", "TEST", 1055, 1070], ["knockdown", "TEST", 1074, 1083], ["RNA", "TEST", 1084, 1087], ["splicing patterns", "PROBLEM", 1193, 1210], ["experimental batches", "PROBLEM", 1218, 1238], ["a common problem", "PROBLEM", 1243, 1259], ["RBP studies", "TEST", 1407, 1418], ["the entire knockdown", "TREATMENT", 1422, 1442], ["Gene Expression Analysis", "TEST", 1486, 1510], ["Gene expression batch effects", "TREATMENT", 1510, 1539], ["small", "OBSERVATION_MODIFIER", 11, 16], ["increased", "OBSERVATION_MODIFIER", 87, 96], ["expression", "OBSERVATION", 97, 107], ["K562", "ANATOMY", 115, 119], ["HepG2", "ANATOMY", 124, 129], ["cancer", "OBSERVATION", 130, 136], ["right", "ANATOMY_MODIFIER", 146, 151], ["RBP", "OBSERVATION", 172, 175], ["dependent", "OBSERVATION_MODIFIER", 176, 185], ["gene expression", "OBSERVATION", 186, 201], ["splicing changes", "OBSERVATION", 206, 222]]], ["The HepG2 and K562 samples were normalized separately.", [["HepG2", "ANATOMY", 4, 9], ["K562 samples", "ANATOMY", 14, 26], ["HepG2", "CELL", 4, 9], ["K562 samples", "CANCER", 14, 26], ["HepG2", "CELL_LINE", 4, 9], ["The HepG2", "TEST", 0, 9], ["K562 samples", "TEST", 14, 26], ["HepG2", "ANATOMY", 4, 9]]], ["Genes whose expected counts were 0 on more than 80% samples of the set were filtered out prior to normalization.", [["samples", "ANATOMY", 52, 59], ["expected counts", "TEST", 12, 27]]], ["After ComBat normalization and QuantileExperimental quality control of eCLIP experimentsLibrary complexity, defined as the number of unique molecules recovered during preparation of high-throughput sequencing library, is a critical measurement of experimental quality that effects many aspects of data quality and analysis, determines whether the resulting read density is quantitative, and whether PCR biases and other artifacts will be introduced.Experimental quality control of eCLIP experimentsAlthough library complexity is easily empirically calculated after sequencing and data processing, a quantitative metric for library complexity that can be applied prior to sequencing would enable rapid culling of poor quality experiments and could help guide a desired sequencing depth by estimating an upper bound on the number of recovered RNA fragments.Experimental quality control of eCLIP experimentsWe previously introduced the extrapolated CT (eCT) metric that estimates the number of PCR cycles needed to obtain sufficient material for sequencing.", [["RNA fragments", "RNA", 841, 854], ["ComBat normalization", "TREATMENT", 6, 26], ["QuantileExperimental quality control", "TREATMENT", 31, 67], ["eCLIP experiments", "TREATMENT", 71, 88], ["analysis", "TEST", 314, 322], ["PCR biases", "PROBLEM", 399, 409], ["other artifacts", "PROBLEM", 414, 429], ["eCLIP experiments", "TREATMENT", 481, 498], ["sequencing", "TEST", 565, 575], ["data processing", "TEST", 580, 595], ["library complexity", "TREATMENT", 623, 641], ["an upper bound", "PROBLEM", 799, 813], ["eCLIP experiments", "TREATMENT", 887, 904], ["the extrapolated CT", "TEST", 929, 948], ["PCR cycles", "TREATMENT", 991, 1001], ["density", "OBSERVATION", 362, 369], ["upper bound", "OBSERVATION_MODIFIER", 802, 813], ["RNA fragments", "OBSERVATION", 841, 854]]], ["This metric had appealing characteristics, as it was RBP-specific, showed high correlation with PCR duplication rate, and could be directly compared against eCLIP experiments performed with IgG isotype controls or antibodies in null cell lines 6, 7 .Experimental quality control of eCLIP experimentsHowever, although the initial eCT calculation assumed an idealized 2-fold amplification rate per PCR cycle, we observed that this rate is frequently lower in practice.", [["cell lines", "ANATOMY", 233, 243], ["RBP", "GENE_OR_GENE_PRODUCT", 53, 56], ["RBP", "PROTEIN", 53, 56], ["IgG isotype controls", "PROTEIN", 190, 210], ["antibodies", "PROTEIN", 214, 224], ["null cell lines", "CELL_LINE", 228, 243], ["RBP", "TEST", 53, 56], ["PCR duplication rate", "TEST", 96, 116], ["eCLIP experiments", "TEST", 157, 174], ["IgG isotype controls", "TREATMENT", 190, 210], ["antibodies in null cell lines", "PROBLEM", 214, 243], ["eCLIP experiments", "TREATMENT", 282, 299], ["the initial eCT calculation", "TEST", 317, 344], ["PCR cycle", "TEST", 396, 405], ["this rate", "TEST", 424, 433], ["null cell lines", "OBSERVATION", 228, 243]]], ["To properly estimate PCR efficiency during eCLIP, we noted that at our standard sequencing depths some experiments had saturated the discovery of unique fragments, which enabled us to accurately estimate the total number of pre-PCR unique fragments for these datasets.", [["fragments", "ANATOMY", 153, 162], ["eCLIP", "DNA", 43, 48], ["pre-PCR unique fragments", "DNA", 224, 248], ["PCR efficiency", "PROBLEM", 21, 35], ["unique fragments", "PROBLEM", 146, 162], ["PCR efficiency", "OBSERVATION", 21, 35], ["unique", "OBSERVATION_MODIFIER", 146, 152], ["fragments", "OBSERVATION", 153, 162], ["total", "OBSERVATION_MODIFIER", 208, 213], ["fragments", "OBSERVATION", 239, 248]]], ["Using 6 datasets with a PCR duplication rate of greater than 90%, we observed that the best fit between the number of observed unique fragments and the estimated number of unique fragments occurred at a PCR efficiency of 1.84 (Supplementary Fig. 8a -b).", [["fragments", "ANATOMY", 134, 143], ["fragments", "ANATOMY", 179, 188], ["a PCR duplication rate", "TEST", 22, 44], ["observed unique fragments", "PROBLEM", 118, 143], ["unique fragments", "PROBLEM", 172, 188], ["a PCR efficiency", "TEST", 201, 217], ["unique", "OBSERVATION_MODIFIER", 127, 133], ["fragments", "OBSERVATION", 134, 143], ["number", "OBSERVATION_MODIFIER", 162, 168], ["unique", "OBSERVATION_MODIFIER", 172, 178], ["fragments", "OBSERVATION", 179, 188]]], ["We therefore defined an accurate-eCT (a-eCT) as the eCT calculated with 1.84-fold amplification per cycle instead of 2-fold.Experimental quality control of eCLIP experimentsTo validate the a-eCT metric, we considered datasets that were beginning to saturate (PCR duplication rate greater than 60%).", [["eCT", "DNA", 52, 55], ["the eCT", "TEST", 48, 55], ["eCLIP experiments", "TREATMENT", 156, 173], ["PCR duplication rate", "TEST", 259, 279]]], ["We observed that a-eCT showed strong predictive power for the number of unique RNA fragments observed (R 2 = 0.46, p < 7.1 \u00d7 10 -38 ) ( Supplementary Fig. 8c ), an improvement on the prior eCT metric (MSE 0.19 versus 0.86),Experimental quality control of eCLIP experimentsconfirming that a-eCT provides a robust estimate of library complexity ( Supplementary Fig. 8d ).Experimental quality control of eCLIP experimentsThus, a-eCT enables prediction of unique fragments prior to sequencing and indicates that eCLIP of distinct RBPs can yield a range from hundreds of thousands to billions of unique fragments ( Supplementary Fig. 8e ).Experimental quality control of eCLIP experimentsNext, we compared a-eCT against a manual annotation of experiment quality.", [["fragments", "ANATOMY", 459, 468], ["fragments", "ANATOMY", 598, 607], ["a-eCT", "PROTEIN", 288, 293], ["a-eCT", "PROTEIN", 424, 429], ["eCLIP", "PROTEIN", 508, 513], ["RBPs", "PROTEIN", 526, 530], ["a-eCT", "TEST", 17, 22], ["unique RNA fragments", "PROBLEM", 72, 92], ["p", "TEST", 115, 116], ["MSE", "TEST", 201, 204], ["eCLIP experiments", "TREATMENT", 401, 418], ["unique fragments", "PROBLEM", 452, 468], ["sequencing", "TEST", 478, 488], ["distinct RBPs", "PROBLEM", 517, 530], ["unique fragments", "PROBLEM", 591, 607], ["eCLIP experiments", "TREATMENT", 666, 683], ["a-eCT", "TEST", 701, 706], ["RNA fragments", "OBSERVATION", 79, 92], ["improvement", "OBSERVATION_MODIFIER", 164, 175], ["fragments", "OBSERVATION", 459, 468], ["fragments", "OBSERVATION_MODIFIER", 598, 607]]], ["We observed that experiments that pass manual quality assessment had significantly lower a-eCT values than experiments that failed manual quality assessment with mean a-eCTs of 13.3 versus 14.4 respectively ( Supplementary Fig. 8f , students two-sided t-test; p < 10 -7 ).", [["manual quality assessment", "TEST", 39, 64], ["significantly lower a-eCT values", "PROBLEM", 69, 101], ["manual quality assessment", "TEST", 131, 156], ["mean a-eCTs", "TEST", 162, 173], ["sided t-test", "TEST", 246, 258]]], ["Low a-eCT (corresponding to a highly complex library) did not always indicate high-quality eCLIP datasets, with failures due to poor reproducibility, lack of significant binding signal, and other failure modes.", [["Low a-eCT", "PROTEIN", 0, 9], ["Low a-eCT", "PROBLEM", 0, 9], ["high-quality eCLIP datasets", "PROBLEM", 78, 105], ["failures", "PROBLEM", 112, 120], ["poor reproducibility", "PROBLEM", 128, 148], ["significant binding signal", "PROBLEM", 158, 184], ["other failure modes", "PROBLEM", 190, 209], ["significant", "OBSERVATION_MODIFIER", 158, 169], ["binding signal", "OBSERVATION", 170, 184], ["failure", "OBSERVATION", 196, 203]]], ["However, a high a-eCT value was a strong predictor of failure, typically due to a lack of the required number of unique fragments to produce reproducible peaks.", [["fragments", "ANATOMY", 120, 129], ["a high a-eCT value", "PROBLEM", 9, 27], ["failure", "PROBLEM", 54, 61], ["unique fragments", "PROBLEM", 113, 129], ["reproducible peaks", "PROBLEM", 141, 159], ["failure", "OBSERVATION", 54, 61], ["reproducible", "OBSERVATION_MODIFIER", 141, 153], ["peaks", "OBSERVATION", 154, 159]]], ["To establish a maximum a-eCT threshold beyond which data are unreliable, we observed that the mean a-eCT for IgG control eCLIP experiments (which only immunoprecipitate background RNA) was 19.6.Experimental quality control of eCLIP experimentsWith that threshold applied, 21 out of 24 datasets with an a-eCT > 19.6 also independently failed manual QC.", [["a maximum a-eCT threshold", "TEST", 13, 38], ["eCLIP experiments", "TREATMENT", 226, 243], ["an a-eCT", "TEST", 299, 307]]], ["In all datasets examined no successful experiment had an a-eCT > 20.7, while there were still 9 experiments that did not pass manual quality control that had a higher a-eCT ( Supplementary Fig. 8f ).Experimental quality control of eCLIP experimentsIn total, 331 out of 400 (83%) experiments had higher yield than this IgG-only value in both replicates, indicating successful immunoprecipitation of protein-bound RNA in the majority of experiments ( Supplementary Fig. 8g ).", [["IgG", "GENE_OR_GENE_PRODUCT", 318, 321], ["IgG", "PROTEIN", 318, 321], ["an a-eCT", "TEST", 54, 62], ["eCLIP experiments", "TREATMENT", 231, 248], ["this IgG", "TEST", 313, 321], ["protein-bound RNA", "TREATMENT", 398, 415], ["no", "UNCERTAINTY", 25, 27], ["bound RNA", "OBSERVATION", 406, 415]]], ["As we did observe a small number of high-quality datasets with a-eCT values above this cutoff (typically RBPs with high specificity for a single or small number of RNA transcripts, such as SLBP for histone RNAs), in later experiments we queried those with high a-eCT values with low-depth sequencing prior to full analysis and abandoned 36 such experiments which showed no observable binding specificity, leaving 349 datasets for analysis (Extended Data Fig. 1c ).eCLIP -data processing and peak identificationPrimary data analysis of eCLIP data (including adapter trimming, read mapping, cluster identification, and input normalization) was performed as previously published 6 step.", [["SLBP", "GENE_OR_GENE_PRODUCT", 189, 193], ["histone", "GENE_OR_GENE_PRODUCT", 198, 205], ["RBPs", "PROTEIN", 105, 109], ["RNA transcripts", "RNA", 164, 179], ["SLBP", "PROTEIN", 189, 193], ["histone RNAs", "RNA", 198, 210], ["a-eCT values", "PROBLEM", 63, 75], ["this cutoff", "PROBLEM", 82, 93], ["RNA transcripts", "TREATMENT", 164, 179], ["histone RNAs", "TREATMENT", 198, 210], ["high a-eCT values", "PROBLEM", 256, 273], ["low-depth sequencing", "PROBLEM", 279, 299], ["full analysis", "TEST", 309, 322], ["observable binding specificity", "PROBLEM", 373, 403], ["analysis", "TEST", 430, 438], ["peak identificationPrimary data analysis", "TEST", 491, 531], ["eCLIP data", "TEST", 535, 545], ["adapter trimming", "TREATMENT", 557, 573], ["read mapping", "TEST", 575, 587], ["cluster identification", "TEST", 589, 611], ["small", "OBSERVATION_MODIFIER", 20, 25], ["no observable", "UNCERTAINTY", 370, 383]]], ["Next, potential adapter sequences were removed using cutadapt (v1.8.1), performed in two steps to properly remove non-full length adapter sequences we observed to drive artifact peak identification.", [["non-full length adapter sequences", "DNA", 114, 147], ["potential adapter sequences", "TEST", 6, 33], ["non-full length adapter sequences", "TREATMENT", 114, 147]]], ["At this step, reads with less than 18 bases were removed from further analysis.", [["further analysis", "TEST", 62, 78]]], ["Next, we mapped reads using STAR (v2.4.0i) 8 against a database of repetitive elements (derived from RepBase (v18.05) 9 with the addition of elements including the 45S ribosomal RNA precursor), and removed reads with identified mapping (an independent method was derived to quantify mapping to repetitive elements, described in the next section).", [["ribosomal", "ANATOMY", 168, 177], ["45S", "CELLULAR_COMPONENT", 164, 167], ["ribosomal", "CELLULAR_COMPONENT", 168, 177], ["repetitive elements", "DNA", 67, 86], ["RepBase", "DNA", 101, 108], ["45S ribosomal RNA precursor", "RNA", 164, 191], ["repetitive elements", "DNA", 294, 313], ["STAR (v2.4.0i)", "TREATMENT", 28, 42], ["repetitive elements", "PROBLEM", 67, 86], ["RepBase", "TEST", 101, 108]]], ["Reads were then mapped against the human genome using STAR (v2.4.0i), requiring unique mapping (all analyses described in this manuscript used mapping to GRCh37 and GENCODE v19eCLIP -data processing and peak identificationannotations, but mapping to GRCh38 and GENCODE v24 annotations were also deposited at the ENCODE portal).", [["human", "ORGANISM", 35, 40], ["human genome", "DNA", 35, 47], ["STAR", "DNA", 54, 58], ["GRCh37", "DNA", 154, 160], ["GENCODE v19eCLIP", "DNA", 165, 181], ["GRCh38", "DNA", 250, 256], ["GENCODE v24 annotations", "DNA", 261, 284], ["human", "SPECIES", 35, 40], ["human", "SPECIES", 35, 40], ["unique mapping", "TEST", 80, 94], ["peak identificationannotations", "TEST", 203, 233], ["mapping", "TEST", 239, 246], ["portal", "ANATOMY", 319, 325]]], ["PCR duplicate reads were then identified as those with the same mapped start position and unique molecular identifier and were removed using custom scripts to obtain unique fragments.", [["fragments", "ANATOMY", 173, 182], ["start position", "DNA", 71, 85], ["PCR duplicate reads", "TEST", 0, 19], ["custom scripts", "TREATMENT", 141, 155], ["unique fragments", "PROBLEM", 166, 182], ["fragments", "OBSERVATION", 173, 182]]], ["Read clusters were identified using CLIPper 10 , which applies spine-fitting to identify clusters of enriched read density above local, transcript (both pre-mRNA and mRNA), and whole-genome background.", [["CLIPper 10", "DNA", 36, 46], ["pre-mRNA", "RNA", 153, 161], ["mRNA", "RNA", 166, 170], ["CLIPper", "TREATMENT", 36, 43], ["spine", "ANATOMY", 63, 68]]], ["Whole reads were used for this broad analysis of RBPs as the use of read 3\u2032 ends only can cause decreased signal-to-noise for the subset of RBPs that do not crosslink in close proximity to their RNA motif 11 .", [["RBPs", "DNA", 49, 53], ["RBPs", "PROTEIN", 140, 144], ["RNA motif 11", "DNA", 195, 207], ["this broad analysis", "TEST", 26, 45], ["decreased signal", "PROBLEM", 96, 112], ["the subset of RBPs", "PROBLEM", 126, 144]]], ["However, we note that future re-analyses restricting to only read 3\u2032 ends likely will provide increased resolution for motif and splicing regulatory map analyses for some RBPs.", [["RBPs", "PROTEIN", 171, 175], ["splicing regulatory map analyses", "TEST", 129, 161], ["some RBPs", "PROBLEM", 166, 175]]], ["Finally, clusters identified in IP samples were compared against paired size-matched input to obtain significantly enriched peaks using a To identify reproducible and significantly enriched peaks across biological replicates, we used a modified Irreproducible Discovery Rate (IDR) method ( Supplementary Fig. 9c ).", [["IP samples", "ANATOMY", 32, 42], ["IP samples", "CANCER", 32, 42], ["IP samples", "TEST", 32, 42], ["significantly enriched peaks", "PROBLEM", 101, 129], ["a modified Irreproducible Discovery Rate (IDR) method", "TREATMENT", 234, 287], ["size", "OBSERVATION_MODIFIER", 72, 76], ["peaks", "OBSERVATION_MODIFIER", 190, 195]]], ["IDR requires that peaks are ranked by an appropriate metric, but we found undesirable results ranking peaks by either significance (due to the dependence on underlying expression) or foldenrichment (due to the large variance of fold-enrichment when few reads are observed in input).eCLIP -data processing and peak identificationThus, we adapted relative entropy to better estimate the strength of binding in IP relative to input by defining the relative information content of a peak as , where p i and q i are the fraction of total reads in IP and input respectively that map to peak i.", [["foldenrichment", "PROBLEM", 183, 197], ["the large variance of fold", "PROBLEM", 206, 232], ["peak identification", "TEST", 309, 328], ["total reads in IP", "TREATMENT", 527, 544]]], ["To confirm that this clusters were reproducible when we ranked by information content (Supplementary Fig. 9d ).eCLIP -data processing and peak identificationGiven the increased number of reproducible clusters detected, we used information content to perform standard IDR analysis to identify reproducibly bound regions 12 .", [["peak identification", "TEST", 138, 157], ["reproducible clusters", "PROBLEM", 187, 208], ["standard IDR analysis", "TEST", 258, 279], ["increased", "OBSERVATION_MODIFIER", 167, 176], ["number", "OBSERVATION_MODIFIER", 177, 183], ["reproducible", "OBSERVATION_MODIFIER", 187, 199], ["clusters", "OBSERVATION_MODIFIER", 200, 208]]], ["We then identified the set of non-overlapping peaks from both replicates that maximized information content to define a final set of reproducibly enriched peaks that corresponded to CLIPper-identified regions ( Supplementary Fig. 9c ).", [["CLIPper", "PROTEIN", 182, 189], ["reproducibly enriched peaks", "PROBLEM", 133, 160], ["enriched peaks", "OBSERVATION", 146, 160]]], ["We defined reproducible and significant peaks to be the set of replicate-merged peaks that met an IDR cutoff of 0.01 as well as p-value \u2264 0.001 and foldenrichment \u2265 8 (using the geometric mean of log 2 (fold-enrichment) and the least significant pvalue between the two biological replicates).", [["significant peaks", "PROBLEM", 28, 45], ["an IDR cutoff", "TEST", 95, 108], ["foldenrichment", "TREATMENT", 148, 162], ["reproducible", "OBSERVATION_MODIFIER", 11, 23], ["significant", "OBSERVATION_MODIFIER", 28, 39], ["peaks", "OBSERVATION", 40, 45]]], ["This method revealed that an average of 53.1% of peaks identified as significantly enriched in individual replicates were significant and reproducible, indicating high reproducibility for most experiments (Extended Data Fig. 1g ).eCLIP -data processing and peak identificationFurthermore, the number of reproducible peaks identified upon profiling the same RBP in K562eCLIP -data processing and peak identificationand HepG2 cells was highly correlated, providing further validation that this approach reproducibly captures RBP-specific signal (Extended Data Fig. 1h ).Automated QC Metrics to verify data qualityWe next developed a set of metrics to assess the quality of ENCODE eCLIP experiments in an automated manner.", [["HepG2 cells", "ANATOMY", 418, 429], ["RBP", "GENE_OR_GENE_PRODUCT", 357, 360], ["HepG2 cells", "CELL", 418, 429], ["RBP", "GENE_OR_GENE_PRODUCT", 523, 526], ["RBP", "PROTEIN", 357, 360], ["K562eCLIP", "PROTEIN", 364, 373], ["HepG2 cells", "CELL_LINE", 418, 429], ["RBP", "PROTEIN", 523, 526], ["This method", "TEST", 0, 11], ["high reproducibility", "PROBLEM", 163, 183], ["reproducible peaks", "PROBLEM", 303, 321], ["data processing", "TEST", 375, 390], ["peak identificationand HepG2 cells", "PROBLEM", 395, 429], ["RBP", "TEST", 523, 526], ["significantly", "OBSERVATION_MODIFIER", 69, 82], ["enriched", "OBSERVATION_MODIFIER", 83, 91], ["significant", "OBSERVATION_MODIFIER", 122, 133], ["high reproducibility", "OBSERVATION", 163, 183], ["reproducible", "OBSERVATION_MODIFIER", 303, 315], ["peaks", "OBSERVATION", 316, 321]]], ["We ultimately arrived at two metrics for individual replicates (a minimal unique fragment cutoff, and a \"total information in peaks\" cutoff) as well as a third metric to assess reproducibility across the two biological replicates (Extended Data Fig. 1d ).", [["a minimal unique fragment cutoff", "PROBLEM", 64, 96], ["minimal", "OBSERVATION_MODIFIER", 66, 73], ["fragment cutoff", "OBSERVATION", 81, 96]]], ["To evaluate these metrics, we used manual quality assessment of datasets to define a reference set of highand low-quality eCLIP datasets.Automated QC Metrics to verify data qualityThe number of unique fragments per dataset varies widely, depending on library complexity and sequencing depth (as described above).", [["fragments", "ANATOMY", 201, 210], ["these metrics", "TEST", 12, 25], ["manual quality assessment", "TEST", 35, 60], ["unique fragments", "PROBLEM", 194, 210], ["sequencing depth", "TEST", 274, 290], ["number", "OBSERVATION_MODIFIER", 184, 190], ["unique", "OBSERVATION_MODIFIER", 194, 200], ["fragments", "OBSERVATION", 201, 210]]], ["We observed that a required number of 1.5M unique fragments maximized the predictive power for datasets passing manual quality assessment (f-score = 0.79) ( Supplementary Fig. 10a ).", [["1.5M unique fragments", "TREATMENT", 38, 59], ["manual quality assessment", "TEST", 112, 137]]], ["Page S9 more than 7-fold more likely to fail manual quality assessment ( Supplementary Fig. 10b ).Automated QC Metrics to verify data qualityConversely, 30 of 222 manually failed datasets do not meet the criteria (Supplementary Fig. 10c ).Automated QC Metrics to verify data qualityNext, we considered a metric based on whether the dataset contained significant binding signal.", [["manual quality assessment", "TEST", 45, 70], ["significant binding signal", "PROBLEM", 350, 376], ["significant", "OBSERVATION_MODIFIER", 350, 361], ["binding signal", "OBSERVATION", 362, 376]]], ["As described above, we observed that the relative information of a peak better captures the binding information of peaks across genes with widely varying expression levels.", [["widely varying expression levels", "PROBLEM", 139, 171]]], ["The information content model was more accurate (AUC = 0.71) ( Supplementary Fig. 10e , accurately classifying 63% of ENCODE datasets with 0.36 specificity and 0.93 sensitivity ( Supplementary Fig. 10f ).Automated QC Metrics to verify data qualityNext, we developed criteria to assay biological reproducibility, using two metrics based upon the Irreproducible Discovery Rate (IDR) approach that has previously been used to assay reproducibility of ChIP-seq peaks: reproducibility between real and pseudo-replicates (Rescue Ratio) and confirmation that the number of reproducible peaks between both replicates is similar (Self-Consistency Ratio) 16 .", [["AUC", "TEST", 49, 52], ["ENCODE datasets", "TEST", 118, 133], ["specificity", "TEST", 144, 155], ["ChIP", "TEST", 448, 452], ["reproducible peaks", "PROBLEM", 566, 584], ["reproducible", "OBSERVATION_MODIFIER", 566, 578], ["peaks", "OBSERVATION_MODIFIER", 579, 584]]], ["We found that cutoffs previously used for ChIP-seq data could be similarly applied to eCLIP 16 , and observed that 81.9% of experiments have a passing rescue ratio of <2 ( Supplementary Fig. 10g ) and 71.1% of experiments have a passing self-constancy ratio of <2 ( Supplementary Fig. 10h) .", [["eCLIP 16", "DNA", 86, 94], ["cutoffs", "TEST", 14, 21], ["ChIP-seq data", "TREATMENT", 42, 55], ["eCLIP", "TEST", 86, 91], ["a passing rescue ratio", "TEST", 141, 163]]], ["Notably, these IDR metrics have high specificity, as 151 out of 196 (77%) of experiments that meet unique fragment and total information content cutoffs and were manually judged to be high quality passed this IDR criteria.", [["these IDR metrics", "TEST", 9, 26], ["unique fragment", "PROBLEM", 99, 114], ["high", "OBSERVATION_MODIFIER", 32, 36], ["fragment", "OBSERVATION", 106, 114]]], ["In contrast, IDR detects potential false positives by correctly failing 9 out of 56 (16%) datasets that met read depth and information content metrics, but failed manual inspection ( Supplementary Fig. 10j ).Automated QC Metrics to verify data qualityFinally, we combined these metrics into one overall automated quality call requiring that each experiment passes minimum read and information content cutoffs as well as either being classified as passing or borderline based on IDR metrics ( Supplementary Fig. 10k ).", [["false positives", "PROBLEM", 35, 50], ["manual inspection", "TEST", 163, 180], ["IDR metrics", "TREATMENT", 478, 489], ["false positives", "OBSERVATION", 35, 50]]], ["Overall our model accurately classified 77% of eCLIP datasets with a sensitivity of 0.84 and a specificity of 0.62 (Extended Data Fig. 1e) , better than any individual classification scheme.Effect of sequencing depth on eCLIP peak identificationSupplementary Information for Van Nostrand et al.Effect of sequencing depth on eCLIP peak identificationPage S10Effect of sequencing depth on eCLIP peak identificationHow deeply to sequence a CLIP-seq dataset is a major consideration (particularly at large scale), as samples must be sequenced sufficiently to robustly detect true binding signals while balancing experimental cost.", [["samples", "ANATOMY", 513, 520], ["eCLIP", "DNA", 324, 329], ["eCLIP", "DNA", 387, 392], ["CLIP-seq dataset", "DNA", 437, 453], ["eCLIP datasets", "TEST", 47, 61], ["a sensitivity", "TEST", 67, 80], ["a specificity", "TEST", 93, 106], ["sequencing depth", "TEST", 200, 216], ["sequencing depth", "TEST", 304, 320], ["eCLIP", "TEST", 324, 329], ["sequencing depth", "TEST", 367, 383], ["eCLIP peak identification", "TEST", 387, 412], ["a CLIP", "TEST", 435, 441], ["true binding signals", "PROBLEM", 571, 591]]], ["To query whether the ENCODE eCLIP datasets were sequenced to sufficient depth, we considered two questions: first, how does sequencing depth affect identification of true binding sites, and second, how many reads are required to detect binding sites in any gene when accounting for variability in gene expression.Effect of sequencing depth on eCLIP peak identificationFirst, we asked whether peaks discovered at deeper sequencing depths were still likely to be biologically relevant.", [["ENCODE eCLIP datasets", "DNA", 21, 42], ["binding sites", "DNA", 236, 249], ["eCLIP", "DNA", 343, 348], ["the ENCODE eCLIP datasets", "PROBLEM", 17, 42], ["true binding sites", "PROBLEM", 166, 184], ["binding sites", "PROBLEM", 236, 249], ["sequencing depth", "TEST", 323, 339], ["eCLIP peak identificationFirst", "TEST", 343, 373], ["still likely to be", "UNCERTAINTY", 442, 460]]], ["To do this we looked at RBFOX2, which is known to bind to the GCAUG motif.", [["RBFOX2", "GENE_OR_GENE_PRODUCT", 24, 30], ["GCAUG", "GENE_OR_GENE_PRODUCT", 62, 67], ["RBFOX2", "PROTEIN", 24, 30], ["GCAUG motif", "DNA", 62, 73]]], ["Overall, we observed significant enrichment for RBFOX2 binding to its motif, with 36% of RBFOX2 peaks overlapping the motif versus a mean of 6% of peaks overlapping the motif in all other datasets ( Supplementary Fig. 11a ).", [["RBFOX2", "GENE_OR_GENE_PRODUCT", 48, 54], ["RBFOX2", "GENE_OR_GENE_PRODUCT", 89, 95], ["RBFOX2", "PROTEIN", 48, 54], ["RBFOX2", "PROTEIN", 89, 95], ["RBFOX2 binding", "PROBLEM", 48, 62], ["significant", "OBSERVATION_MODIFIER", 21, 32], ["enrichment", "OBSERVATION", 33, 43]]], ["We then down-sampled the unique genomic fragments, re-called peaks, and asked how many peaks discovered at each downsampling step overlapped the RBFOX2 motif.", [["fragments", "ANATOMY", 40, 49], ["RBFOX2", "GENE_OR_GENE_PRODUCT", 145, 151], ["genomic fragments", "DNA", 32, 49], ["RBFOX2 motif", "DNA", 145, 157], ["genomic fragments", "OBSERVATION", 32, 49]]], ["We observed that peaks discovered using only 10% of unique genomic fragments showed the highest motif overlap (38% on average), whereas peaks that were only discovered when going from 90% to 100% of unique genomic fragments were less likely to contain GCAUG (27% on average) ( Supplementary Fig. 11b ).Effect of sequencing depth on eCLIP peak identificationAlthough this suggests that signal to noise is highest among the most abundantly covered peaks, we note that later discovered peaks were still 3.0-to 7.4-fold enriched above non-RBFOX2 datasets, indicating they still contain true binding signal ( Supplementary Fig. 11b ).Effect of sequencing depth on eCLIP peak identificationSupporting this, we observed that conservation of later-discovered peaks was similar to those discovered earlier with a mean phastcons conservation score of 0.136 versus 0.132 ( Supplementary Fig. 11c ).", [["fragments", "ANATOMY", 67, 76], ["fragments", "ANATOMY", 214, 223], ["genomic fragments", "DNA", 59, 76], ["eCLIP", "DNA", 332, 337], ["non-RBFOX2 datasets", "DNA", 531, 550], ["eCLIP", "DNA", 659, 664], ["unique genomic fragments", "PROBLEM", 52, 76], ["the highest motif overlap", "PROBLEM", 84, 109], ["unique genomic fragments", "PROBLEM", 199, 223], ["GCAUG", "TEST", 252, 257], ["sequencing depth", "TEST", 312, 328], ["eCLIP peak identification", "TEST", 332, 357], ["signal to noise", "PROBLEM", 385, 400], ["true binding signal", "PROBLEM", 582, 601], ["sequencing depth", "TEST", 639, 655], ["eCLIP peak identification", "TEST", 659, 684], ["genomic fragments", "OBSERVATION", 206, 223]]], ["Considering an independent dataset, PRPF8, we observed similar results when testing its known association with the 5\u2032 splice site: although peaks discovered at low sequencing depth were less enriched for true signal, we continued to see true positive signal throughout the range of down-sampling, indicating that it is true that deeper sequencing allows for the continued discovery of high quality peaks ( Supplementary Fig. 11d-e) .Effect of sequencing depth on eCLIP peak identificationSecond, we considered the identification of peaks as a function of transcript abundance.Effect of sequencing depth on eCLIP peak identificationTo explore if there was a correlation between sequencing depth and the discovery of peaks in lowly expressed genes, we calculated the correlation between gene expression and the number of reads in each peak for RBFOX2.", [["PRPF8", "GENE_OR_GENE_PRODUCT", 36, 41], ["RBFOX2", "GENE_OR_GENE_PRODUCT", 842, 848], ["PRPF8", "PROTEIN", 36, 41], ["5\u2032 splice site", "DNA", 115, 129], ["eCLIP", "DNA", 463, 468], ["eCLIP", "DNA", 606, 611], ["RBFOX2", "PROTEIN", 842, 848], ["high quality peaks", "PROBLEM", 385, 403], ["sequencing depth", "TEST", 443, 459], ["eCLIP peak identificationSecond", "TEST", 463, 494], ["sequencing depth", "TEST", 586, 602], ["eCLIP peak identification", "TEST", 606, 631], ["sequencing depth", "TEST", 677, 693]]], ["We observed that lowly expressed genes had fewer reads per peak (as expected), whereas highly expressed genes displayed a large variation in the number of reads per peak, with only a weak correlation overall for both RBFOX2 (R 2 = 0.03) ( Supplementary Fig. 11f ).", [["RBFOX2", "PROTEIN", 217, 223], ["a large variation", "PROBLEM", 120, 137], ["both RBFOX2", "TEST", 212, 223], ["large", "OBSERVATION_MODIFIER", 122, 127], ["variation", "OBSERVATION_MODIFIER", 128, 137]]], ["All other RBPs showed a similar week correlation (mean R 2 = 0.13) ( Supplementary Fig. 11g ).", [["RBPs", "PROTEIN", 10, 14], ["All other RBPs", "TEST", 0, 14]]], ["Next, we asked whether peaks at lowly expressed genes could be Supplementary Information for Van Nostrand et al.Effect of sequencing depth on eCLIP peak identificationPage S11 detected at standard sequencing depths.", [["eCLIP peak identificationPage S11", "DNA", 142, 175], ["sequencing depth", "TEST", 122, 138], ["eCLIP", "TEST", 142, 147]]], ["Surprisingly, we found that lowly expressed genes (defined as those with TPM < 1) need on average only 670,000 unique genomic fragments to allow for detection of a peak in the gene, and this estimate was similar when varying the fraction of peaks required to be discovered or TPM thresholds ( Supplementary Fig. 11h-j) .", [["fragments", "ANATOMY", 126, 135], ["genomic fragments", "DNA", 118, 135], ["unique genomic fragments", "PROBLEM", 111, 135], ["TPM thresholds", "TEST", 276, 290]]], ["As ENCODE eCLIP datasets have a mean sequencing depth of over 4.3 million unique genomic fragments, these results suggest that an inability to detect peaks on lowly expressed genes is not a major concern in eCLIP data sequenced to standard depths.Effect of sequencing depth on eCLIP peak identificationOur analysis above indicates that continued sequencing until fragment saturation can recover true peaks even at extremely high read depths.", [["fragments", "ANATOMY", 89, 98], ["ENCODE eCLIP datasets", "DNA", 3, 24], ["genomic fragments", "DNA", 81, 98], ["eCLIP", "DNA", 277, 282], ["sequencing depth", "TEST", 257, 273], ["eCLIP peak identificationOur analysis", "TEST", 277, 314], ["fragment saturation", "TEST", 363, 382], ["true peaks", "PROBLEM", 395, 405]]], ["However, sequencing until fragment saturation is not typically economically reasonable.", [["fragment", "CELLULAR_COMPONENT", 26, 34], ["fragment saturation", "TEST", 26, 45]]], ["First, we developed a metric to quantify the diminishing returns of deeper sequencing in eCLIP datasets.", [["eCLIP datasets", "DNA", 89, 103], ["diminishing", "OBSERVATION_MODIFIER", 45, 56]]], ["Considering the discovery of significant peaks, we queried how many peaks were newly discovered when comparing peaks observed when 90% or 100% of fragments in a dataset were used to identify peaks.", [["fragments", "ANATOMY", 146, 155], ["significant peaks", "PROBLEM", 29, 46], ["significant", "OBSERVATION_MODIFIER", 29, 40], ["peaks", "OBSERVATION", 41, 46]]], ["We observed that 67% of experiments passing manual QC saturated the discovery of significant peaks (defined as the discovery of fewer than 5% new peaks in the above metric), suggesting that simple peak detection was saturating for most but not all high-quality datasets ( Supplementary Fig. 11k ).Effect of sequencing depth on eCLIP peak identificationNext, we considered whether binding information by total information content was saturating even when peak discovery was not.", [["eCLIP", "DNA", 327, 332], ["significant peaks", "PROBLEM", 81, 98], ["simple peak detection", "PROBLEM", 190, 211], ["sequencing depth", "TEST", 307, 323], ["eCLIP peak identification", "TEST", 327, 352], ["significant", "OBSERVATION_MODIFIER", 81, 92], ["peaks", "OBSERVATION", 93, 98], ["simple", "OBSERVATION_MODIFIER", 190, 196], ["peak detection", "OBSERVATION", 197, 211]]], ["Summing the total information content across all peaks, we observed that information recovered saturated for 97% of manually accepted datasets (using the same 5% or less discovery metric between 90% and 100% of fragments used to call peaks in a dataset) ( Supplementary Fig. 11k ).", [["fragments", "PROBLEM", 211, 220]]], ["Exploring downsampling experiments further, we found that 90% of all eCLIP datasets that passed manual quality assessment had saturated information discovery by 8.5M unique fragments (corresponding to 4.3M unique genomic fragments) ( Supplementary Fig. 11l-m) .", [["fragments", "ANATOMY", 221, 230], ["eCLIP datasets", "DNA", 69, 83], ["genomic fragments", "DNA", 213, 230], ["all eCLIP datasets", "PROBLEM", 65, 83], ["manual quality assessment", "TEST", 96, 121], ["8.5M unique fragments", "PROBLEM", 161, 182]]], ["Thus, these results suggest that although additional peaks can be identified, the majority of peak information content is already captured at current sequencing depths for the majority of eCLIP experiments described here.Transcriptome coverage of eCLIP and knockdown/RNA-seq eventsConsidering the total coverage of gene expression changes across all 472 knockdown/RNA-seq datasets, observed that 20,542 genes were differentially expressed in at least one knockdown experiment, including 92.1% of genes expressed in both cell types and 91.8% of those Page S12 expressed in at least one of the two (Extended Data Fig. 2g & Supplementary Fig. 12a-b) .Transcriptome coverage of eCLIP and knockdown/RNA-seq eventsSimilarly, 17,839 genes had a peak in at least one eCLIP dataset, including 84.2% of genes expressed in both cell types and 92.0% of those expressed in at least one.", [["cell", "ANATOMY", 520, 524], ["cell", "ANATOMY", 817, 821], ["eCLIP", "GENE_OR_GENE_PRODUCT", 247, 252], ["cell", "CELL", 520, 524], ["Page S12", "GENE_OR_GENE_PRODUCT", 550, 558], ["eCLIP", "GENE_OR_GENE_PRODUCT", 674, 679], ["cell", "CELL", 817, 821], ["eCLIP", "DNA", 247, 252], ["20,542 genes", "DNA", 396, 408], ["Page S12", "PROTEIN", 550, 558], ["eCLIP", "DNA", 674, 679], ["17,839 genes", "DNA", 719, 731], ["eCLIP dataset", "RNA", 759, 772], ["Transcriptome coverage of eCLIP", "TREATMENT", 221, 252], ["knockdown/RNA", "TREATMENT", 257, 270], ["gene expression changes", "PROBLEM", 315, 338], ["RNA-seq datasets", "TEST", 364, 380], ["Transcriptome coverage of eCLIP", "TREATMENT", 648, 679], ["knockdown/RNA", "TREATMENT", 684, 697], ["both cell types", "OBSERVATION", 812, 827]]], ["However, only 4,889 genes had eCLIP peaks from and were responsive to knockdown of the same RBP (Extended Fig. 2g) Fig. 2i & Supplementary Fig. 12d ).", [["RBP", "GENE_OR_GENE_PRODUCT", 92, 95], ["4,889 genes", "DNA", 14, 25], ["eCLIP peaks", "DNA", 30, 41], ["RBP", "PROTEIN", 92, 95], ["eCLIP peaks", "PROBLEM", 30, 41]]], ["While profiling a new RBP identified more novel sites than re-profiling the same RBP in the other (K562 or HepG2) cell type, re-profiling the same RBP in a more distinct cell type (H1 or H9 stem cells) yielded even greater increases, suggesting that many additional RBP binding sites remain to be detected (Supplementary Fig. 12e -g).", [["K562", "ANATOMY", 99, 103], ["HepG2) cell type", "ANATOMY", 107, 123], ["cell type", "ANATOMY", 170, 179], ["H9 stem cells", "ANATOMY", 187, 200], ["RBP", "GENE_OR_GENE_PRODUCT", 22, 25], ["RBP", "GENE_OR_GENE_PRODUCT", 81, 84], ["K562", "CELL", 99, 103], ["HepG2) cell type", "CELL", 107, 123], ["RBP", "GENE_OR_GENE_PRODUCT", 147, 150], ["cell type", "CELL", 170, 179], ["H1", "CELL", 181, 183], ["H9 stem cells", "CELL", 187, 200], ["RBP", "GENE_OR_GENE_PRODUCT", 266, 269], ["RBP", "PROTEIN", 22, 25], ["RBP", "PROTEIN", 81, 84], ["K562", "CELL_LINE", 99, 103], ["HepG2", "CELL_LINE", 107, 112], ["RBP", "PROTEIN", 147, 150], ["H1", "CELL_LINE", 181, 183], ["H9 stem cells", "CELL_LINE", 187, 200], ["RBP binding sites", "DNA", 266, 283], ["a new RBP", "PROBLEM", 16, 25], ["cell type", "TEST", 114, 123], ["the same RBP", "PROBLEM", 138, 150], ["H9 stem cells", "TEST", 187, 200], ["many additional RBP binding sites", "PROBLEM", 250, 283], ["more distinct", "OBSERVATION_MODIFIER", 156, 169], ["cell type", "OBSERVATION", 170, 179], ["greater", "OBSERVATION_MODIFIER", 215, 222], ["increases", "OBSERVATION_MODIFIER", 223, 232]]], ["While these results are consistent with previous work suggesting that RNAs are often densely coated by RBPs 17 , we note that many of the RBPs with large numbers of peaks include proteins that coat or transiently interact with RNAs as part of basic RNA processing functions, such as interaction of spliceosomal components (e.g. U2AF1/2, SF3B4) with the 5\u2032 and 3\u2032 splice sites, RNA Polymerase II component POLR2G with pre-mRNAs, ribosomal subunit RPS3 with translating RNAs, and various others, rather than likely marking alternative RNA processing regulatory sites.Analysis of eCLIP correlation with knockdown-perturbed splicing changes (splicing maps)Splicing maps depicting differential eCLIP enrichment at stereotypical positions relative to RBP knockdown-altered splicing changes were generated using the RBP-Maps methodology 11 .", [["U2AF1/2", "GENE_OR_GENE_PRODUCT", 328, 335], ["SF3B4", "GENE_OR_GENE_PRODUCT", 337, 342], ["5\u2032", "GENE_OR_GENE_PRODUCT", 353, 355], ["3", "GENE_OR_GENE_PRODUCT", 360, 361], ["RNA Polymerase II", "GENE_OR_GENE_PRODUCT", 377, 394], ["POLR2G", "GENE_OR_GENE_PRODUCT", 405, 411], ["ribosomal", "CELLULAR_COMPONENT", 428, 437], ["RPS3", "GENE_OR_GENE_PRODUCT", 446, 450], ["eCLIP", "GENE_OR_GENE_PRODUCT", 577, 582], ["eCLIP", "GENE_OR_GENE_PRODUCT", 689, 694], ["RBP", "GENE_OR_GENE_PRODUCT", 745, 748], ["RNAs", "RNA", 70, 74], ["RBPs 17", "PROTEIN", 103, 110], ["RBPs", "PROTEIN", 138, 142], ["RNAs", "RNA", 227, 231], ["spliceosomal components", "PROTEIN", 298, 321], ["U2AF1", "PROTEIN", 328, 333], ["SF3B4", "PROTEIN", 337, 342], ["5\u2032 and 3\u2032 splice sites", "DNA", 353, 375], ["RNA Polymerase II component", "PROTEIN", 377, 404], ["POLR2G", "PROTEIN", 405, 411], ["pre-mRNAs", "RNA", 417, 426], ["ribosomal subunit", "PROTEIN", 428, 445], ["RPS3", "PROTEIN", 446, 450], ["translating RNAs", "RNA", 456, 472], ["RNA processing regulatory sites", "DNA", 533, 564], ["eCLIP", "DNA", 577, 582], ["eCLIP", "DNA", 689, 694], ["RBP", "PROTEIN", 745, 748], ["RBP", "PROTEIN", 809, 812], ["RBPs", "TEST", 103, 107], ["the RBPs", "TEST", 134, 142], ["large numbers of peaks", "PROBLEM", 148, 170], ["RNAs", "TREATMENT", 227, 231], ["basic RNA processing functions", "PROBLEM", 243, 273], ["spliceosomal components", "PROBLEM", 298, 321], ["U2AF1", "TEST", 328, 333], ["3\u2032 splice sites", "TREATMENT", 360, 375], ["ribosomal subunit RPS3", "TREATMENT", 428, 450], ["translating RNAs", "TREATMENT", 456, 472], ["eCLIP correlation", "TEST", 577, 594], ["perturbed splicing changes", "PROBLEM", 610, 636], ["Splicing maps", "TREATMENT", 652, 665], ["RBP knockdown", "TEST", 745, 758], ["altered splicing changes", "PROBLEM", 759, 783], ["the RBP", "TEST", 805, 812], ["Maps methodology", "TEST", 813, 829], ["consistent with", "UNCERTAINTY", 24, 39], ["large", "OBSERVATION_MODIFIER", 148, 153], ["numbers", "OBSERVATION_MODIFIER", 154, 161], ["spliceosomal components", "OBSERVATION", 298, 321], ["subunit RPS3", "OBSERVATION", 438, 450], ["differential", "OBSERVATION_MODIFIER", 676, 688], ["eCLIP enrichment", "OBSERVATION", 689, 705], ["RBP knockdown", "OBSERVATION", 745, 758], ["altered splicing", "OBSERVATION", 759, 775]]], ["First, the set of differentially alternatively spliced events of the desired type (cassette/skipped exons (SE), alternative 5\u2032 splice site (A5SS), or alternative 3\u2032 splice site (A3SS) events were identified ( Supplementary Fig. 13a) Next, for each splicing event, per-position input probability densities were subtracted from IP probability densities to attain position-level enrichment or depletion, for regions extending 50nt into each exon and 300nt into each intron composing the event.", [["cassette", "DNA", 83, 91], ["exons", "DNA", 100, 105], ["SE", "DNA", 107, 109], ["alternative 5\u2032 splice site", "DNA", 112, 138], ["A5SS", "DNA", 140, 144], ["alternative 3\u2032 splice site", "DNA", 150, 176], ["A3SS", "DNA", 178, 182], ["exon", "DNA", 438, 442], ["intron", "DNA", 463, 469], ["cassette/skipped exons (SE)", "TREATMENT", 83, 110], ["alternative 5\u2032 splice site", "TREATMENT", 112, 138], ["each splicing event", "PROBLEM", 243, 262], ["per-position input probability densities", "PROBLEM", 264, 304], ["IP probability densities", "PROBLEM", 326, 350], ["level enrichment", "PROBLEM", 370, 386], ["depletion", "PROBLEM", 390, 399], ["position", "OBSERVATION_MODIFIER", 361, 369], ["enrichment", "OBSERVATION_MODIFIER", 376, 386], ["depletion", "OBSERVATION", 390, 399]]], ["Subtracted read densities were then normalized to sum to 1 across each event in order to equally weigh each event, creating tracks referred to as 'Normalized eCLIP enrichment' (Supplementary Fig. 13b ).", [["Subtracted read densities", "PROBLEM", 0, 25], ["densities", "OBSERVATION", 16, 25]]], ["To calculate significance, 1000 random samplings were performed from the native cassette exon set using the number of events in the knockdown-included (or excluded), andAnalysis of eCLIP correlation with knockdown-perturbed splicing changes (splicing maps)Supplementary Information for Van Nostrand et al.Analysis of eCLIP correlation with knockdown-perturbed splicing changes (splicing maps)Page S14Analysis of eCLIP correlation with knockdown-perturbed splicing changes (splicing maps)significance was set as being either lower than the 0.5 th or higher than the 99.5 th percentile for each position.Supplementary Data 1.", [["eCLIP", "GENE_OR_GENE_PRODUCT", 181, 186], ["eCLIP", "GENE_OR_GENE_PRODUCT", 317, 322], ["eCLIP", "GENE_OR_GENE_PRODUCT", 412, 417], ["eCLIP", "DNA", 181, 186], ["eCLIP", "DNA", 317, 322], ["eCLIP", "DNA", 412, 417], ["random samplings", "TEST", 32, 48], ["eCLIP correlation", "TEST", 181, 198], ["perturbed splicing changes", "PROBLEM", 214, 240], ["eCLIP correlation", "TEST", 317, 334], ["perturbed splicing changes", "PROBLEM", 350, 376], ["perturbed splicing changes", "PROBLEM", 445, 471]]], ["Data summary and manual annotation of RBP functions.", [["RBP", "GENE_OR_GENE_PRODUCT", 38, 41], ["RBP", "PROTEIN", 38, 41], ["manual annotation of RBP functions", "TEST", 17, 51]]], ["For eachRBP profiled by at least one assay in this study, ELAVL4 PABPN1L PCBP3 RBMS3 RBFOX3 KHDRBS2 PABPC3 HNRNPCL1 ESRP1 CPEB1 NOVA1 MSI1 TRIP6 RBM47 DDX51 CSTF2T DDX20 RBM45 SRFBP1 RBM23 TOE1 RC3H1 DDX28 DHX29 ZNF800 RBM15 DGCR8 WRN ATXN1 TRIM56 LSM11 POLK RBM24 CORO1A RBMS2 CNOT4 ZFC3H1 NKRF AGO2 AQR XRN1 YTHDC2 AKAP8 UPF2 RBM41 PHF6 TFIP11 NAA15 AGO1 DDX52 DHX33 RBM27 MAK16 MTPAP CSTF2 DNAJC17 ZC3H8 FXR2 GEMIN5 SRPK2 FASTKD1 CDC40 NOL12 TRNAU1AP AGGF1 NUFIP2 TROVE2 DDX59 RECQL RBM15B GRWD1 PRR3 DDX55 BUD13 MBNL1 PUS1 RRP9 NUPL2 ZNF106 ZNF326 ZFP36 MARK2 SCAF4 UTP3 NIPBL BOP1 WDR3 PRPF4 HLTF DROSHA RAVER1 SUPV3L1 GPKOW DEAF1 LIN28B RBMX2 RBM4B DNAJC2 DNAJC21 KHDRBS3 SRSF8 RTF1 NFX1 PCBP4 ATXN2 GOLGB1 NUP35 RBM22 CPEB4 CCDC124 PNPT1 RECQL5 LARP4 RBM14 STAU2 AATF FAM120A PSPC1 SUGP2 SMNDC1 ZNF622 SDAD1 ACO1 SAFB2 IGF2BP3 EXOSC5 EXOSC9 DDX6 DHX30 SART3 TNRC6A AUH FIP1L1 PARN UCHL5 XPO5 RBFOX2 ASCC1 KRR1 SLC4A1AP NSUN2 NXF1 EIF2S1 CELF1 ZRANB2 FTO UNK UPF1 RCC2 HNRNPLL FASTKD2 PRRC2C PTBP3 LARP7 SF3B4 CPSF7 CCDC86 TRA2A CCAR1 CEBPZ ABT1 CMTR1 FUBP3 NIP7 NUSAP1 SLBP SLTM PPIL4 PSIP1 ESF1 RBM34 IGF2BP1 PPP1R8 DDX27 SUPT6H ZCRB1 SRSF4 CASC3 SNRPA ADD1 DDX24 AKAP8L GTF2F1 MSI2 RBM25 DDX19B SF3A3 PES1 CSTF1 BCLAF1 HNRNPAB SMN1 SAFB DDX47 SYNCRIP UTP18 ZC3H11A ALYREF RBM5 FMR1 HNRNPH2 WDR43 XRCC5 PA2G4 SRSF11 U2AF1 FXR1 EWSR1 HNRNPF TIA1 SRSF9 HNRNPU SSB EIF3D HNRNPM EIF2S2 EIF3G SND1 ILF2 PTBP1 RALY TUFM EIF4H FUS CIRBP HNRNPDL HNRNPL PABPN1 MATR3 SF3B1 SERBP1 STAU1 XRCC6 ATP5C1 HDGF EIF4G2 HNRNPD HMGB1 NONO DDX5 SUB1 EIF3H PCBP1 HNRNPH1 HNRNPK SRSF5 EIF4B RBM39 EIF4A2 HNRNPC HNRNPA2B1 CALR PCBP2 PKM PABPC1 HSPD1 EEF2 NPM1 RPS5 HNRNPA1 RPL23A RACK1 RPS10 RPS2 RPLP0 RPS11 RPS19 RPS3A RPS3 RPS24 RBP expression in cell types RBP RBP HNRNPA2B1 TP5C1A EEF2 RPS24 RPS11 TUFM EIF4H RPL23A HMGB1 (h) Bars indicate the fraction of peaks observed for each RBP within sets of genes separated by their relative expression change between K562 and HepG2: unchanged (fold-difference \u2264 1.2), weakly (1.2 < fold-difference \u2264 2), moderately (2 < fold-difference \u2264 5) or strongly (folddifference > 5) differential, or cell-type specific genes (TPM < 0.1 in one cell type and TPM \u2265 1 in the other). n indicates the number of genes meeting each criteria.", [["cell", "ANATOMY", 1735, 1739], ["K562", "ANATOMY", 1949, 1953], ["HepG2", "ANATOMY", 1958, 1963], ["cell", "ANATOMY", 2123, 2127], ["cell", "ANATOMY", 2166, 2170], ["cell", "CELL", 1735, 1739], ["RBP", "GENE_OR_GENE_PRODUCT", 1746, 1749], ["RBP", "GENE_OR_GENE_PRODUCT", 1870, 1873], ["K562", "CELL", 1949, 1953], ["HepG2", "CELL", 1958, 1963], ["cell", "CELL", 2123, 2127], ["cell", "CELL", 2166, 2170], ["eachRBP", "DNA", 4, 11], ["ELAVL4 PABPN1L PCBP3 RBMS3 RBFOX3 KHDRBS2 PABPC3 HNRNPCL1 ESRP1 CPEB1 NOVA1 MSI1 TRIP6 RBM47 DDX51 CSTF2T DDX20 RBM45 SRFBP1 RBM23 TOE1 RC3H1 DDX28 DHX29 ZNF800 RBM15 DGCR8 WRN ATXN1 TRIM56 LSM11 POLK RBM24 CORO1A RBMS2 CNOT4 ZFC3H1 NKRF AGO2 AQR XRN1 YTHDC2 AKAP8 UPF2 RBM41 PHF6 TFIP11 NAA15 AGO1 DDX52 DHX33 RBM27 MAK16 MTPAP CSTF2 DNAJC17 ZC3H8 FXR2 GEMIN5 SRPK2 FASTKD1 CDC40 NOL12 TRNAU1AP AGGF1 NUFIP2 TROVE2 DDX59 RECQL RBM15B GRWD1 PRR3 DDX55 BUD13 MBNL1 PUS1 RRP9 NUPL2 ZNF106 ZNF326 ZFP36 MARK2 SCAF4 UTP3 NIPBL BOP1 WDR3 PRPF4 HLTF DROSHA RAVER1 SUPV3L1 GPKOW DEAF1 LIN28B RBMX2 RBM4B DNAJC2 DNAJC21 KHDRBS3 SRSF8 RTF1 NFX1 PCBP4 ATXN2 GOLGB1 NUP35 RBM22 CPEB4 CCDC124 PNPT1 RECQL5 LARP4 RBM14 STAU2 AATF FAM120A PSPC1 SUGP2 SMNDC1 ZNF622 SDAD1 ACO1 SAFB2 IGF2BP3 EXOSC5 EXOSC9 DDX6 DHX30 SART3 TNRC6A AUH FIP1L1 PARN UCHL5 XPO5 RBFOX2 ASCC1 KRR1 SLC4A1AP NSUN2 NXF1 EIF2S1 CELF1 ZRANB2 FTO UNK UPF1 RCC2 HNRNPLL FASTKD2 PRRC2C PTBP3 LARP7 SF3B4 CPSF7 CCDC86 TRA2A CCAR1 CEBPZ ABT1 CMTR1 FUBP3 NIP7 NUSAP1 SLBP SLTM PPIL4 PSIP1 ESF1 RBM34 IGF2BP1 PPP1R8 DDX27 SUPT6H ZCRB1 SRSF4 CASC3 SNRPA ADD1 DDX24 AKAP8L GTF2F1 MSI2 RBM25 DDX19B SF3A3 PES1 CSTF1 BCLAF1 HNRNPAB SMN1 SAFB DDX47 SYNCRIP UTP18 ZC3H11A ALYREF RBM5 FMR1 HNRNPH2 WDR43 XRCC5 PA2G4 SRSF11 U2AF1 FXR1 EWSR1 HNRNPF TIA1 SRSF9 HNRNPU SSB EIF3D HNRNPM EIF2S2 EIF3G SND1 ILF2 PTBP1 RALY TUFM EIF4H FUS CIRBP HNRNPDL HNRNPL PABPN1 MATR3 SF3B1 SERBP1 STAU1 XRCC6 ATP5C1 HDGF EIF4G2 HNRNPD HMGB1 NONO DDX5 SUB1 EIF3H PCBP1 HNRNPH1 HNRNPK SRSF5 EIF4B RBM39 EIF4A2 HNRNPC HNRNPA2B1 CALR PCBP2 PKM PABPC1 HSPD1 EEF2 NPM1 RPS5 HNRNPA1 RPL23A RACK1 RPS10 RPS2 RPLP0 RPS11 RPS19 RPS3A RPS3 RPS24 RBP", "PROTEIN", 58, 1720], ["RBP RBP HNRNPA2B1 TP5C1A EEF2 RPS24 RPS11 TUFM EIF4H RPL23A HMGB1 (h) Bars", "PROTEIN", 1746, 1820], ["RBP", "PROTEIN", 1870, 1873], ["K562", "CELL_LINE", 1949, 1953], ["HepG2", "CELL_LINE", 1958, 1963], ["this study", "TEST", 46, 56], ["ELAVL4", "TEST", 58, 64], ["PCBP3", "TEST", 73, 78], ["RBMS3", "TEST", 79, 84], ["RBFOX3", "TEST", 85, 91], ["KHDRBS2", "TEST", 92, 99], ["PABPC3", "TEST", 100, 106], ["HNRNPCL1", "TEST", 107, 115], ["ESRP1", "TEST", 116, 121], ["CPEB1", "TEST", 122, 127], ["NOVA1", "TEST", 128, 133], ["MSI1", "TEST", 134, 138], ["TRIP6", "TEST", 139, 144], ["RBM47", "TEST", 145, 150], ["DDX51", "TEST", 151, 156], ["CSTF2T", "TEST", 157, 163], ["DDX20", "TEST", 164, 169], ["RBM45", "TEST", 170, 175], ["SRFBP1", "TEST", 176, 182], ["RBM23", "TEST", 183, 188], ["TOE1", "TEST", 189, 193], ["RC3H1", "TEST", 194, 199], ["DDX28", "TEST", 200, 205], ["DHX29", "TEST", 206, 211], ["ZNF800", "TEST", 212, 218], ["DGCR8", "TEST", 225, 230], ["WRN", "TEST", 231, 234], ["ATXN1", "TEST", 235, 240], ["TRIM56", "TEST", 241, 247], ["LSM11", "TEST", 248, 253], ["POLK", "TEST", 254, 258], ["RBM24", "TEST", 259, 264], ["CORO1A", "TEST", 265, 271], ["RBMS2", "TEST", 272, 277], ["CNOT4", "TEST", 278, 283], ["ZFC3H1", "TEST", 284, 290], ["NKRF", "TEST", 291, 295], ["AGO2", "TEST", 296, 300], ["AQR", "TEST", 301, 304], ["YTHDC2", "TEST", 310, 316], ["AKAP8", "TEST", 317, 322], ["UPF2", "TEST", 323, 327], ["PHF6", "TEST", 334, 338], ["TFIP11", "TEST", 339, 345], ["AGO1", "TEST", 352, 356], ["DDX52", "TEST", 357, 362], ["DHX33", "TEST", 363, 368], ["RBM27", "TEST", 369, 374], ["MAK16", "TEST", 375, 380], ["MTPAP", "TEST", 381, 386], ["CSTF2", "TEST", 387, 392], ["DNAJC17", "TEST", 393, 400], ["ZC3H8", "TEST", 401, 406], ["FXR2", "TEST", 407, 411], ["GEMIN5", "TEST", 412, 418], ["SRPK2", "TEST", 419, 424], ["FASTKD1", "TEST", 425, 432], ["CDC40", "TEST", 433, 438], ["NOL12", "TEST", 439, 444], ["TRNAU1AP", "TEST", 445, 453], ["AGGF1", "TEST", 454, 459], ["NUFIP2", "TEST", 460, 466], ["TROVE2", "TEST", 467, 473], ["DDX59", "TEST", 474, 479], ["RECQL", "TEST", 480, 485], ["RBM15B", "TEST", 486, 492], ["GRWD1", "TEST", 493, 498], ["PRR3", "TEST", 499, 503], ["DDX55", "TEST", 504, 509], ["BUD13", "TEST", 510, 515], ["MBNL1", "TEST", 516, 521], ["PUS1", "TEST", 522, 526], ["RRP9", "TEST", 527, 531], ["NUPL2", "TEST", 532, 537], ["ZNF106", "TEST", 538, 544], ["ZNF326", "TEST", 545, 551], ["ZFP36", "TEST", 552, 557], ["MARK2", "TEST", 558, 563], ["SCAF4", "TEST", 564, 569], ["NIPBL", "TEST", 575, 580], ["RBMX2", "TEST", 643, 648], ["RBM4B", "TEST", 649, 654], ["DNAJC2", "TEST", 655, 661], ["KHDRBS3", "TEST", 670, 677], ["RTF1", "TEST", 684, 688], ["PCBP4", "TEST", 694, 699], ["GOLGB1", "TEST", 706, 712], ["CPEB4", "TEST", 725, 730], ["PNPT1", "TEST", 739, 744], ["RECQL5", "TEST", 745, 751], ["LARP4", "TEST", 752, 757], ["RBM14", "TEST", 758, 763], ["STAU2", "TEST", 764, 769], ["AATF", "TEST", 770, 774], ["FAM120A", "TEST", 775, 782], ["PSPC1", "TEST", 783, 788], ["SUGP2", "TEST", 789, 794], ["SMNDC1", "TEST", 795, 801], ["ZNF622", "TEST", 802, 808], ["SDAD1", "TEST", 809, 814], ["ACO1", "TEST", 815, 819], ["SAFB2", "TEST", 820, 825], ["IGF2BP3", "TEST", 826, 833], ["EXOSC5", "TEST", 834, 840], ["EXOSC9", "TEST", 841, 847], ["DDX6", "TEST", 848, 852], ["DHX30", "TEST", 853, 858], ["SART3", "TEST", 859, 864], ["TNRC6A", "TEST", 865, 871], ["AUH", "TEST", 872, 875], ["FIP1L1", "TEST", 876, 882], ["PARN", "TEST", 883, 887], ["UCHL5", "TEST", 888, 893], ["XPO5", "TEST", 894, 898], ["RBFOX2", "TEST", 899, 905], ["ASCC1", "TEST", 906, 911], ["KRR1", "TEST", 912, 916], ["SLC4A1AP", "TEST", 917, 925], ["NSUN2", "TEST", 926, 931], ["NXF1", "TEST", 932, 936], ["EIF2S1", "TEST", 937, 943], ["CELF1", "TEST", 944, 949], ["RCC2", "TEST", 970, 974], ["HNRNPLL", "TEST", 975, 982], ["FASTKD2", "TEST", 983, 990], ["PRRC2C", "TEST", 991, 997], ["LARP7", "TEST", 1004, 1009], ["TRA2A", "TEST", 1029, 1034], ["CEBPZ", "TEST", 1041, 1046], ["ABT1", "TEST", 1047, 1051], ["CMTR1", "TEST", 1052, 1057], ["FUBP3", "TEST", 1058, 1063], ["NIP7", "TEST", 1064, 1068], ["NUSAP1", "TEST", 1069, 1075], ["SLBP", "TEST", 1076, 1080], ["SLTM", "TEST", 1081, 1085], ["PPIL4", "TEST", 1086, 1091], ["PSIP1", "TEST", 1092, 1097], ["ESF1", "TEST", 1098, 1102], ["IGF2BP1", "TEST", 1109, 1116], ["DDX27", "TEST", 1124, 1129], ["ZCRB1", "TEST", 1137, 1142], ["SNRPA", "TEST", 1155, 1160], ["SAFB", "TEST", 1241, 1245], ["SYNCRIP", "TEST", 1252, 1259], ["EIF2S2", "TEST", 1383, 1389], ["EIF3G", "TEST", 1390, 1395], ["ILF2", "TEST", 1401, 1405], ["PTBP1", "TEST", 1406, 1411], ["CIRBP", "TEST", 1432, 1437], ["HNRNPDL", "TEST", 1438, 1445], ["SERBP1", "TEST", 1472, 1478], ["STAU1", "TEST", 1479, 1484], ["XRCC6", "TEST", 1485, 1490], ["ATP5C1", "TEST", 1491, 1497], ["HDGF", "TEST", 1498, 1502], ["EIF4G2", "TEST", 1503, 1509], ["HNRNPD", "TEST", 1510, 1516], ["HMGB1", "TEST", 1517, 1522], ["NONO", "TEST", 1523, 1527], ["DDX5", "TEST", 1528, 1532], ["SUB1", "TEST", 1533, 1537], ["EIF3H", "TEST", 1538, 1543], ["PCBP1", "TEST", 1544, 1549], ["HNRNPH1", "TEST", 1550, 1557], ["HNRNPK", "TEST", 1558, 1564], ["EIF4B", "TEST", 1571, 1576], ["EIF4A2", "TEST", 1583, 1589], ["HNRNPC", "TEST", 1590, 1596], ["HNRNPA2B1", "TEST", 1597, 1606], ["CALR", "TEST", 1607, 1611], ["PCBP2", "TEST", 1612, 1617], ["PKM", "TEST", 1618, 1621], ["PABPC1", "TEST", 1622, 1628], ["HSPD1", "TEST", 1629, 1634], ["EEF2", "TEST", 1635, 1639], ["NPM1", "TEST", 1640, 1644], ["RPS5", "TEST", 1645, 1649], ["HNRNPA1", "TEST", 1650, 1657], ["RPL23A", "TEST", 1658, 1664], ["RACK1", "TEST", 1665, 1670], ["RPS10", "TEST", 1671, 1676], ["RPS2", "TEST", 1677, 1681], ["RPLP0", "TEST", 1682, 1687], ["RPS11", "TEST", 1688, 1693], ["RPS19", "TEST", 1694, 1699], ["RPS3A", "TEST", 1700, 1705], ["RPS3", "TEST", 1706, 1710], ["RPS24", "TEST", 1711, 1716], ["RBP", "TEST", 1717, 1720], ["expression", "TEST", 1721, 1731], ["cell types", "TEST", 1735, 1745], ["RBP", "TEST", 1746, 1749], ["RBP", "TEST", 1750, 1753], ["HNRNPA2B1", "TEST", 1754, 1763], ["TP5C1A", "TEST", 1764, 1770], ["EEF2", "TEST", 1771, 1775], ["RPS24", "TEST", 1776, 1781], ["RPS11", "TEST", 1782, 1787], ["TUFM", "TEST", 1788, 1792], ["EIF4H", "TEST", 1793, 1798], ["HMGB1 (h)", "TREATMENT", 1806, 1815], ["each RBP", "PROBLEM", 1865, 1873], ["K562", "TEST", 1949, 1953], ["HepG2", "TEST", 1958, 1963], ["fold", "TEST", 1976, 1980], ["fold", "TEST", 2014, 2018], ["folddifference", "TEST", 2086, 2100], ["cell-type specific genes", "PROBLEM", 2123, 2147], ["TPM", "TEST", 2149, 2152], ["TPM", "TEST", 2180, 2183], ["unchanged", "OBSERVATION_MODIFIER", 1965, 1974], ["moderately", "OBSERVATION_MODIFIER", 2036, 2046]]], ["For each RBP, the resultsSupplementary Data 1.", [["RBP", "GENE_OR_GENE_PRODUCT", 9, 12], ["RBP", "PROTEIN", 9, 12], ["each RBP", "TEST", 4, 12]]], ["Data summary and manual annotation of RBP functions.", [["RBP", "GENE_OR_GENE_PRODUCT", 38, 41], ["RBP", "PROTEIN", 38, 41], ["manual annotation of RBP functions", "TEST", 17, 51]]], ["For eachshown are for the cell type with fewer total peaks.", [["cell", "ANATOMY", 26, 30], ["cell type", "CELL", 26, 35], ["the cell type", "TEST", 22, 35], ["fewer total peaks", "PROBLEM", 41, 58]]]], "e24f663ad6a4b885e355b38410695eff9ec8f632": [["IntroductionSince December 2019, a novel coronavirus outbreak occurred in wuhan, China [1, 2, 3] .", [["coronavirus", "DISEASE", 41, 52], ["coronavirus", "ORGANISM", 41, 52], ["a novel coronavirus outbreak", "PROBLEM", 33, 61]]], ["On February 12, 2020, the coronavirus panel of the international committee on the classification of viruses recommended that novel coronavirus be officially named \"SARS-CoV-2\".", [["SARS", "DISEASE", 164, 168], ["coronavirus", "ORGANISM", 26, 37], ["coronavirus", "ORGANISM", 131, 142], ["the coronavirus panel", "TEST", 22, 43], ["viruses", "PROBLEM", 100, 107], ["novel coronavirus", "PROBLEM", 125, 142], ["viruses", "OBSERVATION", 100, 107]]], ["On the same day, the World Health Organization (WHO) announced that the disease was officially named Coronavirus Disease 2019 (COVID-19) [4] .", [["the disease", "PROBLEM", 68, 79], ["Coronavirus Disease", "PROBLEM", 101, 120], ["COVID", "TEST", 127, 132], ["disease", "OBSERVATION", 72, 79], ["Coronavirus Disease", "OBSERVATION", 101, 120]]], ["As an acute respiratory infectious disease, COVID-19 has been incorporated into the law of the People's Republic of China on the prevention and treatment of infectious diseases.", [["respiratory infectious disease", "DISEASE", 12, 42], ["COVID-19", "CHEMICAL", 44, 52], ["infectious diseases", "DISEASE", 157, 176], ["COVID-19", "CHEMICAL", 44, 52], ["People", "SPECIES", 95, 101], ["an acute respiratory infectious disease", "PROBLEM", 3, 42], ["COVID", "TEST", 44, 49], ["the prevention", "TREATMENT", 125, 139], ["infectious diseases", "PROBLEM", 157, 176], ["acute", "OBSERVATION_MODIFIER", 6, 11], ["respiratory", "ANATOMY", 12, 23], ["infectious", "OBSERVATION", 24, 34], ["infectious", "OBSERVATION", 157, 167]]], ["On March 11, 2020 , WHO officially declared the novel coronavirus into a global pandemic.", [["coronavirus", "DISEASE", 54, 65], ["coronavirus", "ORGANISM", 54, 65], ["global", "OBSERVATION_MODIFIER", 73, 79], ["pandemic", "OBSERVATION", 80, 88]]], ["But the global number of confirmed and death cases is raising.", [["death", "DISEASE", 39, 44], ["global", "OBSERVATION_MODIFIER", 8, 14], ["number", "OBSERVATION_MODIFIER", 15, 21]]], ["By the end of April 24, 2020\uff0cthe cumulative number of infected cases was more than 2.8 million cases, and 197,003 deaths globally.IntroductionPrevious reports about the clinical characteristics of diagnosed patients in China alerted that the severity of COVID-19 became more serious in elder people and those with underlying medical condition(s) [5, 6] .", [["infected", "DISEASE", 54, 62], ["deaths", "DISEASE", 114, 120], ["patients", "ORGANISM", 207, 215], ["people", "ORGANISM", 292, 298], ["patients", "SPECIES", 207, 215], ["people", "SPECIES", 292, 298], ["COVID", "TEST", 254, 259], ["infected", "OBSERVATION", 54, 62]]], ["This current poses great challenges to HD patients.", [["patients", "ORGANISM", 42, 50], ["patients", "SPECIES", 42, 50], ["HD patients", "TREATMENT", 39, 50]]], ["On average, HD patients are elder and have a large numbers of comorbidities.", [["patients", "ORGANISM", 15, 23], ["patients", "SPECIES", 15, 23], ["HD", "TREATMENT", 12, 14], ["comorbidities", "PROBLEM", 62, 75], ["large", "OBSERVATION_MODIFIER", 45, 50]]], ["Most of them must travel to and from the hospital for hemodialysis two or three times a week.", [["hemodialysis", "TREATMENT", 54, 66]]], ["And simultaneously, patients in the dialysis centers are relatively dense and mobile.", [["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28], ["dialysis", "OBSERVATION", 36, 44], ["relatively", "OBSERVATION_MODIFIER", 57, 67], ["dense", "OBSERVATION", 68, 73], ["mobile", "OBSERVATION_MODIFIER", 78, 84]]], ["So it is urgently necessary to pay more attention to this group of people. so far, epidemiological data in patients on HD patients confirmed COVID-19 during SARS-CoV-2 outbreak is limited, except for some single cases reported.IntroductionIn our study, a comprehensive evaluation and comparison between HD patients confirmed with COVID-19 and the general HD patients were implemented.", [["COVID-19", "CHEMICAL", 141, 149], ["SARS", "DISEASE", 157, 161], ["people", "ORGANISM", 67, 73], ["patients", "ORGANISM", 107, 115], ["patients", "ORGANISM", 122, 130], ["SARS-CoV-2", "ORGANISM", 157, 167], ["patients", "ORGANISM", 306, 314], ["patients", "ORGANISM", 358, 366], ["people", "SPECIES", 67, 73], ["patients", "SPECIES", 107, 115], ["patients", "SPECIES", 122, 130], ["patients", "SPECIES", 306, 314], ["patients", "SPECIES", 358, 366], ["epidemiological data", "TEST", 83, 103], ["HD", "TREATMENT", 119, 121], ["COVID", "TEST", 141, 146], ["CoV", "TEST", 162, 165], ["our study", "TEST", 242, 251], ["a comprehensive evaluation", "TEST", 253, 279], ["HD patients", "TEST", 303, 314], ["COVID", "TEST", 330, 335], ["the general HD patients", "TREATMENT", 343, 366]]], ["We aimed to have a deeper understanding about the clinical features of HD patients after infected with SARS-CoV-2.Study design and patientsThis was a single-centre, retrospective, observational case-control study.", [["HD", "DISEASE", 71, 73], ["SARS", "DISEASE", 103, 107], ["patients", "ORGANISM", 74, 82], ["CoV-2", "ORGANISM", 108, 113], ["patients", "ORGANISM", 131, 139], ["patients", "SPECIES", 74, 82], ["patients", "SPECIES", 131, 139], ["SARS-CoV", "SPECIES", 103, 111], ["HD patients", "TREATMENT", 71, 82], ["CoV", "TEST", 108, 111], ["Study design", "TEST", 114, 126], ["observational case", "TEST", 180, 198], ["control study", "TEST", 199, 212]]], ["HD patients diagnosed with COVID-19 from Jan 10 to Mar 15, 2020, were admitted as confirmed group.", [["patients", "ORGANISM", 3, 11], ["patients", "SPECIES", 3, 11], ["HD", "TREATMENT", 0, 2], ["COVID", "TEST", 27, 32]]], ["We followed the clinical diagnosis criteria for COVID-19 in the New Coronavirus pneumonia Prevention and Control Program by the National Health Commission of China [1, 7, 8] .", [["pneumonia", "DISEASE", 80, 89], ["COVID", "TEST", 48, 53], ["the New Coronavirus pneumonia", "PROBLEM", 60, 89], ["Coronavirus", "OBSERVATION_MODIFIER", 68, 79], ["pneumonia", "OBSERVATION", 80, 89]]], ["At the same time, the ordinary HD patients who were not infected in our dialysis center at the hospital were chosen as control group.", [["patients", "ORGANISM", 34, 42], ["patients", "SPECIES", 34, 42]]], ["All of them received regular dialysis (3 times per week, 4 hours each time) in our dialysis center.", [["regular dialysis", "TREATMENT", 21, 37]]], ["Patients owning complete clinical data were selected in our research, and eliminated those infected of HBV, HCV, HIV, syphilis, and other pathogens.", [["HBV, HCV, HIV, syphilis", "DISEASE", 103, 126], ["Patients", "ORGANISM", 0, 8], ["HBV", "ORGANISM", 103, 106], ["HCV", "ORGANISM", 108, 111], ["HIV", "ORGANISM", 113, 116], ["Patients", "SPECIES", 0, 8], ["HIV", "SPECIES", 113, 116], ["HBV", "SPECIES", 103, 106], ["HCV", "SPECIES", 108, 111], ["HIV", "SPECIES", 113, 116], ["HBV", "PROBLEM", 103, 106], ["HCV", "PROBLEM", 108, 111], ["HIV", "PROBLEM", 113, 116], ["syphilis", "PROBLEM", 118, 126], ["other pathogens", "PROBLEM", 132, 147], ["HBV", "OBSERVATION", 103, 106]]], ["Finally the number of cases were determined: 43 cases in confirmed group and 99 cases in control group.Data collectionData of confirmed group was collected by consulting electronic medical records and asking patients themselves or their family members.", [["patients", "ORGANISM", 208, 216], ["patients", "SPECIES", 208, 216]]], ["Data of control group was obtained by logging into Chinese National Renal Data System (CNRD).", [["Renal", "ANATOMY", 68, 73]]], ["The basic information included: age, gender, height, weight, dialysis age, primary disease, underlying disease, the using of angiotensin converting enzyme inhibitor/ angiotensin receptor blockers ( ACEI/ ARB) in the past one month.", [["primary disease", "DISEASE", 75, 90], ["angiotensin", "CHEMICAL", 125, 136], ["angiotensin", "CHEMICAL", 166, 177], ["ACEI/ ARB", "CHEMICAL", 198, 207], ["angiotensin converting enzyme", "GENE_OR_GENE_PRODUCT", 125, 154], ["angiotensin receptor blockers", "SIMPLE_CHEMICAL", 166, 195], ["ACEI", "SIMPLE_CHEMICAL", 198, 202], ["dialysis", "TREATMENT", 61, 69], ["primary disease", "PROBLEM", 75, 90], ["underlying disease", "PROBLEM", 92, 110], ["angiotensin converting enzyme inhibitor", "TREATMENT", 125, 164], ["angiotensin receptor blockers", "TREATMENT", 166, 195], ["ACEI", "TREATMENT", 198, 202], ["ARB", "TREATMENT", 204, 207]]], ["Laboratory indicators included white blood cell count, hemoglobin, neutrophil count, neutrophil percentage, lymphocyte count, lymphocyte percentage, platelet count, neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), C-reactive protein, alanine transaminase, aspartate transaminase, total bilirubin, total protein, albumin, and alkaline phosphatase.", [["white blood cell", "ANATOMY", 31, 47], ["neutrophil", "ANATOMY", 67, 77], ["neutrophil", "ANATOMY", 85, 95], ["lymphocyte", "ANATOMY", 108, 118], ["lymphocyte", "ANATOMY", 126, 136], ["platelet", "ANATOMY", 149, 157], ["neutrophil", "ANATOMY", 165, 175], ["platelet", "ANATOMY", 203, 211], ["alanine", "CHEMICAL", 259, 266], ["aspartate", "CHEMICAL", 281, 290], ["bilirubin", "CHEMICAL", 311, 320], ["alanine", "CHEMICAL", 259, 266], ["aspartate", "CHEMICAL", 281, 290], ["bilirubin", "CHEMICAL", 311, 320], ["white blood cell", "CELL", 31, 47], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 55, 65], ["neutrophil", "CELL", 67, 77], ["neutrophil", "CELL", 85, 95], ["lymphocyte", "CELL", 108, 118], ["lymphocyte", "CELL", 126, 136], ["platelet", "CELL", 149, 157], ["neutrophil", "CELL", 165, 175], ["NLR", "GENE_OR_GENE_PRODUCT", 197, 200], ["platelet", "CELL", 203, 211], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 239, 257], ["alanine", "AMINO_ACID", 259, 266], ["transaminase", "GENE_OR_GENE_PRODUCT", 267, 279], ["aspartate transaminase", "GENE_OR_GENE_PRODUCT", 281, 303], ["bilirubin", "SIMPLE_CHEMICAL", 311, 320], ["albumin", "GENE_OR_GENE_PRODUCT", 337, 344], ["alkaline phosphatase", "GENE_OR_GENE_PRODUCT", 350, 370], ["hemoglobin", "PROTEIN", 55, 65], ["neutrophil", "CELL_TYPE", 85, 95], ["neutrophil", "CELL_TYPE", 165, 175], ["NLR", "PROTEIN", 197, 200], ["platelet", "PROTEIN", 203, 211], ["C-reactive protein", "PROTEIN", 239, 257], ["alanine transaminase", "PROTEIN", 259, 279], ["aspartate transaminase", "PROTEIN", 281, 303], ["total bilirubin", "PROTEIN", 305, 320], ["total protein", "PROTEIN", 322, 335], ["albumin", "PROTEIN", 337, 344], ["alkaline phosphatase", "PROTEIN", 350, 370], ["Laboratory indicators", "TEST", 0, 21], ["white blood cell count", "TEST", 31, 53], ["hemoglobin", "TEST", 55, 65], ["neutrophil count", "TEST", 67, 83], ["neutrophil percentage", "TEST", 85, 106], ["lymphocyte count", "TEST", 108, 124], ["lymphocyte percentage", "TEST", 126, 147], ["platelet count", "TEST", 149, 163], ["neutrophil", "TEST", 165, 175], ["lymphocyte ratio", "TEST", 179, 195], ["NLR", "TEST", 197, 200], ["platelet", "TEST", 203, 211], ["lymphocyte ratio", "TEST", 215, 231], ["PLR", "TEST", 233, 236], ["C-reactive protein", "TEST", 239, 257], ["alanine transaminase", "TEST", 259, 279], ["aspartate transaminase", "TEST", 281, 303], ["total bilirubin", "TEST", 305, 320], ["total protein", "TEST", 322, 335], ["albumin", "TEST", 337, 344], ["alkaline phosphatase", "TEST", 350, 370], ["neutrophil count", "OBSERVATION", 67, 83], ["neutrophil percentage", "OBSERVATION", 85, 106], ["lymphocyte count", "OBSERVATION", 108, 124], ["platelet count", "OBSERVATION", 149, 163]]], ["BMI is calculated by height and weight: weight (kg) / height 2 (m 2 ).", [["BMI", "TEST", 0, 3], ["height", "TEST", 21, 27], ["weight", "TEST", 32, 38], ["weight", "TEST", 40, 46], ["height", "TEST", 54, 60]]], ["In our study, we divided the patients into 3 categories according to the kinds of underlying disease: \u22641 ( one or less kind), and 2 (two kinds), \u22653(three or more kinds).Statistical analysisStatistical analyses were done using the SPSS software (version 25.0).", [["patients", "ORGANISM", 29, 37], ["patients", "SPECIES", 29, 37], ["our study", "TEST", 3, 12], ["underlying disease", "PROBLEM", 82, 100], ["Statistical analysisStatistical analyses", "TEST", 169, 209], ["the SPSS software", "TEST", 226, 243], ["version", "TEST", 245, 252], ["disease", "OBSERVATION", 93, 100]]], ["All statistical tests were conducted by bilateral test, with 95% confidence interval.", [["All statistical tests", "TEST", 0, 21], ["bilateral", "ANATOMY_MODIFIER", 40, 49]]], ["We present categorical variables as count (%), and continuous variables as mean \u00b1 SD if they were normally distributed or median (IQR) if they were not.", [["count", "TEST", 36, 41]]], ["We compared means for continuous variables by using independent group t tests when the data were normally distributed; otherwise, we used the Mann-Whitney U test.", [["independent group t tests", "TEST", 52, 77]]], ["Categorical variables were compared by the \uf063 2 test or Fisher's exact test.", [["Fisher's exact test", "TEST", 55, 74]]], ["A two-sided of less than 0.05 was considered statistically significant.General characteristics of confirmed HD patients and control patientsA total of 142 cases were admitted.", [["patients", "ORGANISM", 111, 119], ["patients", "ORGANISM", 132, 140], ["patients", "SPECIES", 111, 119], ["patients", "SPECIES", 132, 140], ["HD patients", "TREATMENT", 108, 119], ["sided", "ANATOMY_MODIFIER", 6, 11], ["significant", "OBSERVATION_MODIFIER", 59, 70]]], ["There were significant differences in BMI and underlying disease between the two groups.", [["significant differences in BMI", "PROBLEM", 11, 41], ["underlying disease between the two groups", "PROBLEM", 46, 87], ["significant", "OBSERVATION_MODIFIER", 11, 22], ["differences", "OBSERVATION_MODIFIER", 23, 34], ["disease", "OBSERVATION", 57, 64]]], ["In the confirmed group, BMI was slightly lower than that in control group (P=0.011).", [["BMI", "TEST", 24, 27], ["slightly lower", "PROBLEM", 32, 46], ["slightly", "OBSERVATION_MODIFIER", 32, 40], ["lower", "OBSERVATION_MODIFIER", 41, 46]]], ["The proportion of one or less underlying disease in confirmed group(51.16%) was higher than in control group(14.14%)( \uf063 2=21.71, P< 0.001), and the proportion of three or more underlying disease in confirmed group(11.63%) was lower than that in control group(52.53%)( \uf063 2=20.86, P< 0.001).", [["less underlying disease", "PROBLEM", 25, 48], ["P", "TEST", 129, 130], ["more underlying disease", "PROBLEM", 171, 194], ["P", "TEST", 279, 280], ["disease", "OBSERVATION", 41, 48], ["disease", "OBSERVATION", 187, 194]]], ["While the proportion of two underlying diseases between them was no difference (P= 0.655).General characteristics of confirmed HD patients and control patientsThe average age was 60.77 \u00b1 11.45 year and the median dialysis age was 33.00 (15.00-70.50) months.", [["patients", "ORGANISM", 130, 138], ["patients", "ORGANISM", 151, 159], ["patients", "SPECIES", 130, 138], ["patients", "SPECIES", 151, 159], ["two underlying diseases", "PROBLEM", 24, 47], ["P", "TEST", 80, 81], ["HD patients", "TREATMENT", 127, 138], ["two", "OBSERVATION_MODIFIER", 24, 27], ["underlying", "OBSERVATION_MODIFIER", 28, 38], ["diseases", "OBSERVATION", 39, 47], ["no", "UNCERTAINTY", 65, 67], ["difference", "OBSERVATION_MODIFIER", 68, 78]]], ["Male was more predominant in two groups, in which 29(67.44%) males confirmed and 69(69.7%) males control (P=0.975).", [["more predominant", "OBSERVATION_MODIFIER", 9, 25]]], ["Glomerulonephritis (56; 39.44%) was the most common primary disease, followed by hypertensive nephropathy (43; 30.28%), diabetic nephropathy (39; 27.46%), and others (as obstructive nephropathy, uric acid nephropathy, the polycystic kidney) (4; 2.82%).", [["kidney", "ANATOMY", 233, 239], ["Glomerulonephritis", "DISEASE", 0, 18], ["primary disease", "DISEASE", 52, 67], ["hypertensive nephropathy", "DISEASE", 81, 105], ["diabetic nephropathy", "DISEASE", 120, 140], ["obstructive nephropathy", "DISEASE", 170, 193], ["uric acid", "CHEMICAL", 195, 204], ["nephropathy", "DISEASE", 205, 216], ["polycystic kidney)", "DISEASE", 222, 240], ["uric acid", "CHEMICAL", 195, 204], ["uric acid", "SIMPLE_CHEMICAL", 195, 204], ["kidney", "ORGAN", 233, 239], ["Glomerulonephritis", "PROBLEM", 0, 18], ["common primary disease", "PROBLEM", 45, 67], ["hypertensive nephropathy", "PROBLEM", 81, 105], ["diabetic nephropathy", "PROBLEM", 120, 140], ["obstructive nephropathy", "PROBLEM", 170, 193], ["uric acid nephropathy", "PROBLEM", 195, 216], ["the polycystic kidney)", "PROBLEM", 218, 240], ["most common", "OBSERVATION_MODIFIER", 40, 51], ["primary disease", "OBSERVATION", 52, 67], ["hypertensive", "OBSERVATION_MODIFIER", 81, 93], ["nephropathy", "OBSERVATION", 94, 105], ["diabetic", "OBSERVATION_MODIFIER", 120, 128], ["nephropathy", "OBSERVATION", 129, 140], ["obstructive", "OBSERVATION_MODIFIER", 170, 181], ["nephropathy", "OBSERVATION", 182, 193], ["uric acid nephropathy", "OBSERVATION", 195, 216], ["polycystic", "OBSERVATION", 222, 232], ["kidney", "ANATOMY", 233, 239]]], ["17(39.53%) patients in confirmed group were taking the ACEI/ARB, and 37(37.37%) cases in control group, which expressed no difference.", [["ACEI", "CHEMICAL", 55, 59], ["ARB", "CHEMICAL", 60, 63], ["patients", "ORGANISM", 11, 19], ["patients", "SPECIES", 11, 19], ["the ACEI", "TREATMENT", 51, 59], ["ARB", "TREATMENT", 60, 63], ["no", "UNCERTAINTY", 120, 122]]], ["There was no statistically significant difference between the two groups in terms of age, gender, dialysis age, primary disease and the using of ACEI/ARB.", [["primary disease", "DISEASE", 112, 127], ["ACEI", "CHEMICAL", 145, 149], ["ARB", "CHEMICAL", 150, 153], ["ARB", "SIMPLE_CHEMICAL", 150, 153], ["primary disease", "PROBLEM", 112, 127], ["ACEI", "TREATMENT", 145, 149], ["ARB", "TREATMENT", 150, 153], ["no", "UNCERTAINTY", 10, 12], ["statistically", "OBSERVATION_MODIFIER", 13, 26], ["significant", "OBSERVATION_MODIFIER", 27, 38], ["difference", "OBSERVATION", 39, 49]]], ["No reuse allowed without permission.General characteristics of confirmed HD patients and control patients(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.General characteristics of confirmed HD patients and control patientsThe copyright holder for this preprint this version posted July 10, 2020. . https://doi.org/10.1101/2020.07.06.20147827 doi: medRxiv preprintLaboratory characteristics of confirmed group and control groupWe observed substantial differences in laboratory findings between confirmed group and control group (Table 2) .", [["patients", "ORGANISM", 76, 84], ["patients", "ORGANISM", 97, 105], ["patients", "ORGANISM", 280, 288], ["patients", "ORGANISM", 301, 309], ["patients", "SPECIES", 76, 84], ["patients", "SPECIES", 97, 105], ["patients", "SPECIES", 280, 288], ["patients", "SPECIES", 301, 309], ["HD patients", "TREATMENT", 73, 84], ["HD patients", "TREATMENT", 277, 288], ["The copyright holder", "TREATMENT", 309, 329], ["laboratory findings", "TEST", 552, 571], ["med", "ANATOMY", 184, 187], ["substantial", "OBSERVATION_MODIFIER", 525, 536]]], ["Patients in confirmed group exhibited significantly lower hemoglobin, lymphocyte count, and lymphocyte percentage, and higher neutrophil percentage, NLR, C-reactive protein, aspartate transaminase, and alkaline phosphatase.", [["lymphocyte", "ANATOMY", 70, 80], ["lymphocyte", "ANATOMY", 92, 102], ["neutrophil", "ANATOMY", 126, 136], ["aspartate", "CHEMICAL", 174, 183], ["aspartate", "CHEMICAL", 174, 183], ["Patients", "ORGANISM", 0, 8], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 58, 68], ["lymphocyte", "CELL", 70, 80], ["lymphocyte", "CELL", 92, 102], ["neutrophil", "CELL", 126, 136], ["NLR", "GENE_OR_GENE_PRODUCT", 149, 152], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 154, 172], ["aspartate transaminase", "GENE_OR_GENE_PRODUCT", 174, 196], ["alkaline phosphatase", "GENE_OR_GENE_PRODUCT", 202, 222], ["hemoglobin", "PROTEIN", 58, 68], ["neutrophil", "CELL_TYPE", 126, 136], ["NLR", "PROTEIN", 149, 152], ["C-reactive protein", "PROTEIN", 154, 172], ["aspartate transaminase", "PROTEIN", 174, 196], ["alkaline phosphatase", "PROTEIN", 202, 222], ["Patients", "SPECIES", 0, 8], ["significantly lower hemoglobin", "PROBLEM", 38, 68], ["lymphocyte count", "TEST", 70, 86], ["lymphocyte percentage", "TEST", 92, 113], ["neutrophil percentage", "TEST", 126, 147], ["NLR", "TEST", 149, 152], ["C", "TEST", 154, 155], ["reactive protein", "TEST", 156, 172], ["aspartate transaminase", "TEST", 174, 196], ["alkaline phosphatase", "TEST", 202, 222], ["lower", "OBSERVATION_MODIFIER", 52, 57], ["hemoglobin", "OBSERVATION", 58, 68], ["lymphocyte count", "OBSERVATION", 70, 86], ["lymphocyte percentage", "OBSERVATION", 92, 113], ["higher", "OBSERVATION_MODIFIER", 119, 125], ["neutrophil percentage", "OBSERVATION", 126, 147], ["reactive protein", "OBSERVATION", 156, 172], ["alkaline phosphatase", "OBSERVATION", 202, 222]]], ["Other indicators were not significantly different between the two groups.", [["significantly different", "OBSERVATION_MODIFIER", 26, 49]]], ["No reuse allowed without permission.Laboratory characteristics of confirmed group and control group(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Laboratory characteristics of confirmed group and control groupThe copyright holder for this preprint this version posted July 10, 2020. .", [["Laboratory characteristics", "TEST", 234, 260], ["The copyright holder", "TREATMENT", 297, 317], ["med", "ANATOMY", 178, 181]]], ["Abbreviations: NLR, neutrophil-to-lymphocyte ratio; PLR, platelet-to-lymphocyte ratio.Laboratory characteristics of confirmed group and control groupAll rights reserved.", [["neutrophil", "ANATOMY", 20, 30], ["lymphocyte", "ANATOMY", 34, 44], ["platelet", "ANATOMY", 57, 65], ["lymphocyte", "ANATOMY", 69, 79], ["NLR", "GENE_OR_GENE_PRODUCT", 15, 18], ["neutrophil", "CELL", 20, 30], ["lymphocyte", "CELL", 34, 44], ["platelet", "CELL", 57, 65], ["lymphocyte", "CELL", 69, 79], ["NLR", "PROTEIN", 15, 18], ["neutrophil", "CELL_TYPE", 20, 30], ["platelet", "CELL_TYPE", 57, 65], ["NLR", "TEST", 15, 18], ["neutrophil", "TEST", 20, 30], ["lymphocyte ratio", "TEST", 34, 50], ["PLR", "TEST", 52, 55], ["platelet", "TEST", 57, 65], ["lymphocyte ratio", "TEST", 69, 85], ["Laboratory characteristics", "TEST", 86, 112]]], ["No reuse allowed without permission.Laboratory characteristics of confirmed group and control group(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.Laboratory characteristics of confirmed group and control groupThe copyright holder for this preprint this version posted July 10, 2020. . https://doi.org/10.1101/2020.07.06.20147827 doi: medRxiv preprintDiscussionThis is the first retrospective case-control study to comprehensively compare clinical features between HD patients confirmed COVID-19 and those general HD patients.", [["HD", "DISEASE", 552, 554], ["HD", "DISEASE", 601, 603], ["patients", "ORGANISM", 555, 563], ["patients", "ORGANISM", 604, 612], ["patients", "SPECIES", 555, 563], ["patients", "SPECIES", 604, 612], ["Laboratory characteristics", "TEST", 234, 260], ["The copyright holder", "TREATMENT", 297, 317], ["control study", "TEST", 485, 498], ["COVID", "TEST", 574, 579], ["those general HD patients", "TREATMENT", 587, 612], ["med", "ANATOMY", 178, 181]]], ["In our study, there were indeed many differences in two groups, by the observation and comparison between 43 cases confirmed and 99 cases controlled.", [["our study", "TEST", 3, 12], ["the observation", "TEST", 67, 82], ["many", "OBSERVATION_MODIFIER", 32, 36], ["differences", "OBSERVATION_MODIFIER", 37, 48]]], ["These differences were distributed in general data and laboratory index.DiscussionAs we all known, the understanding of COVID-19 is gradually improved, and the diagnosis and treatment program is deepened from the 1st to the 7th.", [["laboratory index", "TEST", 55, 71], ["COVID", "TEST", 120, 125], ["treatment program", "TREATMENT", 174, 191]]], ["Due to low virus titers, sampling at late stage of illness, and inappropriate swabbing sites, false negative cases might be common for COVID-19 infection cases at special period [9] .", [["illness", "DISEASE", 51, 58], ["infection", "DISEASE", 144, 153], ["low virus titers", "PROBLEM", 7, 23], ["illness", "PROBLEM", 51, 58], ["inappropriate swabbing sites", "PROBLEM", 64, 92], ["COVID", "TEST", 135, 140], ["low virus", "OBSERVATION_MODIFIER", 7, 16]]], ["In order to reduce rate of misdiagnosis, clinical diagnosis was introduced in the 5th guidelines [7] .", [["misdiagnosis", "PROBLEM", 27, 39]]], ["Of 43 confirmed patients in our study, 19(44.19%) were with positive RT-PCR Tests for SARS-CoV-2, and 24 (55.81%) were diagnosed with COVID-19 through clinical diagnosis.", [["patients", "ORGANISM", 16, 24], ["patients", "SPECIES", 16, 24], ["SARS-CoV", "SPECIES", 86, 94], ["our study", "TEST", 28, 37], ["PCR Tests", "TEST", 72, 81], ["SARS", "TEST", 86, 90], ["CoV", "TEST", 91, 94], ["COVID", "TEST", 134, 139]]], ["These clinical diagnosis cases were mainly judged by epidemiological history, clinical manifestations and chest CT scan results, which could ensure their accuracy of diagnosis.DiscussionBMI is closely related to patients with Chronic Kidney Disease (CKD).", [["Kidney", "ANATOMY", 234, 240], ["Chronic Kidney Disease", "DISEASE", 226, 248], ["CKD", "DISEASE", 250, 253], ["patients", "ORGANISM", 212, 220], ["Kidney", "ORGAN", 234, 240], ["patients", "SPECIES", 212, 220], ["chest CT scan", "TEST", 106, 119], ["Chronic Kidney Disease", "PROBLEM", 226, 248], ["CKD", "PROBLEM", 250, 253], ["chest", "ANATOMY", 106, 111], ["Kidney", "ANATOMY", 234, 240], ["Disease", "OBSERVATION", 241, 248], ["CKD", "OBSERVATION", 250, 253]]], ["A prospective cohort study showed that maintaining a normal BMI can slow the development of CKD, while abnormal BMI can accelerate the progression of CKD to End-stage Renal Disease (ESRD) [10] .", [["Renal", "ANATOMY", 167, 172], ["CKD", "DISEASE", 92, 95], ["CKD", "DISEASE", 150, 153], ["End-stage Renal Disease", "DISEASE", 157, 180], ["ESRD", "DISEASE", 182, 186], ["Renal", "ORGAN", 167, 172], ["A prospective cohort study", "TEST", 0, 26], ["CKD", "PROBLEM", 92, 95], ["abnormal BMI", "PROBLEM", 103, 115], ["CKD", "PROBLEM", 150, 153], ["End-stage Renal Disease (ESRD)", "PROBLEM", 157, 187], ["normal", "OBSERVATION", 53, 59], ["CKD", "OBSERVATION", 92, 95], ["progression", "OBSERVATION_MODIFIER", 135, 146], ["CKD", "OBSERVATION", 150, 153], ["stage", "OBSERVATION_MODIFIER", 161, 166], ["Renal", "ANATOMY", 167, 172], ["Disease", "OBSERVATION", 173, 180]]], ["Similarly, in HD patients, together with hemoglobin and serum albumin, BMI usually represents the nutritional status of HD patients, which is one of the main factors affecting the prevalence of various diseases and the survival rate in HD patients.", [["serum", "ANATOMY", 56, 61], ["patients", "ORGANISM", 17, 25], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 41, 51], ["serum", "ORGANISM_SUBSTANCE", 56, 61], ["albumin", "GENE_OR_GENE_PRODUCT", 62, 69], ["patients", "ORGANISM", 123, 131], ["patients", "ORGANISM", 239, 247], ["hemoglobin", "PROTEIN", 41, 51], ["serum albumin", "PROTEIN", 56, 69], ["patients", "SPECIES", 17, 25], ["patients", "SPECIES", 123, 131], ["patients", "SPECIES", 239, 247], ["hemoglobin", "TEST", 41, 51], ["serum albumin", "TEST", 56, 69], ["BMI", "PROBLEM", 71, 74], ["HD patients", "TREATMENT", 120, 131], ["various diseases", "PROBLEM", 194, 210], ["the survival rate", "TREATMENT", 215, 232], ["HD patients", "TREATMENT", 236, 247]]], ["In our study, BMI of patients in confirmed group was significantly lower than that of control group (P=0.011).", [["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29], ["our study", "TEST", 3, 12], ["BMI", "TEST", 14, 17]]], ["Meanwhile, in confirmed group, hemoglobin and albumin were lower than that in control group.", [["hemoglobin", "GENE_OR_GENE_PRODUCT", 31, 41], ["albumin", "GENE_OR_GENE_PRODUCT", 46, 53], ["hemoglobin", "PROTEIN", 31, 41], ["albumin", "PROTEIN", 46, 53], ["hemoglobin", "TEST", 31, 41], ["albumin", "TEST", 46, 53]]], ["Therefor, we believe that HD patients with lower BMI and hemoglobin were more susceptible to be infected with SARS-CoV-2, which might be related to malnutrition.DiscussionThe differences in laboratory index between confirmed and control groups were obviously, including lymphocyte count, lymphocyte percentage, neutrophil percentage, NLR, C-reactive protein, aspartate transaminase, and alkaline phosphatase.", [["lymphocyte", "ANATOMY", 270, 280], ["lymphocyte", "ANATOMY", 288, 298], ["neutrophil", "ANATOMY", 311, 321], ["SARS", "DISEASE", 110, 114], ["malnutrition", "DISEASE", 148, 160], ["aspartate", "CHEMICAL", 359, 368], ["aspartate", "CHEMICAL", 359, 368], ["patients", "ORGANISM", 29, 37], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 57, 67], ["SARS-CoV-2", "ORGANISM", 110, 120], ["lymphocyte", "CELL", 270, 280], ["lymphocyte", "CELL", 288, 298], ["neutrophil", "CELL", 311, 321], ["NLR", "GENE_OR_GENE_PRODUCT", 334, 337], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 339, 357], ["aspartate transaminase", "GENE_OR_GENE_PRODUCT", 359, 381], ["alkaline phosphatase", "GENE_OR_GENE_PRODUCT", 387, 407], ["hemoglobin", "PROTEIN", 57, 67], ["neutrophil", "CELL_TYPE", 311, 321], ["NLR", "PROTEIN", 334, 337], ["C-reactive protein", "PROTEIN", 339, 357], ["aspartate transaminase", "PROTEIN", 359, 381], ["alkaline phosphatase", "PROTEIN", 387, 407], ["patients", "SPECIES", 29, 37], ["SARS-CoV", "SPECIES", 110, 118], ["HD", "TREATMENT", 26, 28], ["lower BMI", "PROBLEM", 43, 52], ["hemoglobin", "TEST", 57, 67], ["SARS", "PROBLEM", 110, 114], ["CoV", "TEST", 115, 118], ["malnutrition", "PROBLEM", 148, 160], ["laboratory index", "TEST", 190, 206], ["lymphocyte count", "TEST", 270, 286], ["lymphocyte percentage", "TEST", 288, 309], ["neutrophil percentage", "TEST", 311, 332], ["NLR", "TEST", 334, 337], ["C", "TEST", 339, 340], ["reactive protein", "TEST", 341, 357], ["aspartate transaminase", "TEST", 359, 381], ["alkaline phosphatase", "TEST", 387, 407], ["infected", "OBSERVATION", 96, 104], ["might be related to", "UNCERTAINTY", 128, 147], ["malnutrition", "OBSERVATION", 148, 160], ["lymphocyte count", "OBSERVATION", 270, 286], ["reactive protein", "OBSERVATION", 341, 357]]], ["Lymphocytopenia is a main feature of critical patients with coronavirus infection, such as SARS-CoV and MERS-CoV [11] [12] [13] .", [["Lymphocytopenia", "DISEASE", 0, 15], ["coronavirus infection", "DISEASE", 60, 81], ["SARS", "DISEASE", 91, 95], ["patients", "ORGANISM", 46, 54], ["coronavirus", "ORGANISM", 60, 71], ["SARS-CoV", "GENE_OR_GENE_PRODUCT", 91, 99], ["patients", "SPECIES", 46, 54], ["coronavirus", "SPECIES", 60, 71], ["SARS-CoV", "SPECIES", 91, 99], ["Lymphocytopenia", "PROBLEM", 0, 15], ["coronavirus infection", "PROBLEM", 60, 81], ["SARS", "PROBLEM", 91, 95], ["main feature", "OBSERVATION_MODIFIER", 21, 33], ["coronavirus", "OBSERVATION_MODIFIER", 60, 71], ["infection", "OBSERVATION", 72, 81]]], ["Elevated inflammatory biomarkers, like C-reactive protein, interleukin-1, interleukin-6 and ferritin, usually due to the hyperinflammatory response or secondary infection.", [["infection", "DISEASE", 161, 170], ["C-reactive protein", "GENE_OR_GENE_PRODUCT", 39, 57], ["interleukin-1", "GENE_OR_GENE_PRODUCT", 59, 72], ["interleukin-6", "GENE_OR_GENE_PRODUCT", 74, 87], ["ferritin", "GENE_OR_GENE_PRODUCT", 92, 100], ["C-reactive protein", "PROTEIN", 39, 57], ["interleukin-1", "PROTEIN", 59, 72], ["interleukin-6", "PROTEIN", 74, 87], ["ferritin", "PROTEIN", 92, 100], ["Elevated inflammatory biomarkers", "PROBLEM", 0, 32], ["C-reactive protein", "PROBLEM", 39, 57], ["interleukin", "TEST", 59, 70], ["interleukin", "TEST", 74, 85], ["ferritin", "TEST", 92, 100], ["the hyperinflammatory response", "PROBLEM", 117, 147], ["secondary infection", "PROBLEM", 151, 170], ["inflammatory", "OBSERVATION", 9, 21], ["reactive protein", "OBSERVATION", 41, 57], ["hyperinflammatory response", "OBSERVATION", 121, 147], ["secondary", "OBSERVATION_MODIFIER", 151, 160], ["infection", "OBSERVATION", 161, 170]]], ["Similar to the acute phase of SARS-CoV infection in humans, SARS-CoV-2 infection also have a hyperinflammatory response and \"cytokine storm\" in acute phase, which leads to acute respiratory distress syndrome, multiple organ failure, and was the leading cause of death [14] [15] [16] [17] .", [["respiratory", "ANATOMY", 178, 189], ["organ", "ANATOMY", 218, 223], ["SARS-CoV infection", "DISEASE", 30, 48], ["infection", "DISEASE", 71, 80], ["respiratory distress syndrome", "DISEASE", 178, 207], ["multiple organ failure", "DISEASE", 209, 231], ["death", "DISEASE", 262, 267], ["SARS-CoV", "ORGANISM", 30, 38], ["humans", "ORGANISM", 52, 58], ["SARS-CoV-2", "ORGANISM", 60, 70], ["organ", "ORGAN", 218, 223], ["[14] [15] [16] [17]", "SIMPLE_CHEMICAL", 268, 287], ["cytokine", "PROTEIN", 125, 133], ["humans", "SPECIES", 52, 58], ["SARS-CoV", "SPECIES", 30, 38], ["humans", "SPECIES", 52, 58], ["SARS-CoV-2", "SPECIES", 60, 70], ["SARS", "PROBLEM", 30, 34], ["CoV infection in humans", "PROBLEM", 35, 58], ["SARS", "PROBLEM", 60, 64], ["CoV-2 infection", "PROBLEM", 65, 80], ["a hyperinflammatory response", "PROBLEM", 91, 119], ["\"cytokine storm", "PROBLEM", 124, 139], ["acute respiratory distress syndrome", "PROBLEM", 172, 207], ["multiple organ failure", "PROBLEM", 209, 231], ["death", "PROBLEM", 262, 267], ["acute", "OBSERVATION_MODIFIER", 15, 20], ["phase", "OBSERVATION_MODIFIER", 21, 26], ["SARS", "OBSERVATION", 30, 34], ["CoV", "OBSERVATION_MODIFIER", 35, 38], ["infection", "OBSERVATION", 39, 48], ["hyperinflammatory response", "OBSERVATION", 93, 119], ["cytokine storm", "OBSERVATION", 125, 139], ["acute phase", "OBSERVATION_MODIFIER", 144, 155], ["acute", "OBSERVATION_MODIFIER", 172, 177], ["respiratory distress syndrome", "OBSERVATION", 178, 207], ["multiple", "OBSERVATION_MODIFIER", 209, 217], ["organ", "ANATOMY", 218, 223], ["failure", "OBSERVATION", 224, 231]]], ["This phenomenon also exists in HD patients.", [["patients", "ORGANISM", 34, 42], ["patients", "SPECIES", 34, 42], ["This phenomenon", "PROBLEM", 0, 15]]], ["In our study, contrasted with general HD patients, lymphocytes count (P = 0.005) and lymphocytes percentage (P < 0.001) were lower, and CRP (P < 0.001) higher in those confirmed after admission.", [["lymphocytes", "ANATOMY", 51, 62], ["lymphocytes", "ANATOMY", 85, 96], ["patients", "ORGANISM", 41, 49], ["lymphocytes", "CELL", 51, 62], ["lymphocytes", "CELL", 85, 96], ["CRP", "GENE_OR_GENE_PRODUCT", 136, 139], ["lymphocytes", "CELL_TYPE", 51, 62], ["lymphocytes", "CELL_TYPE", 85, 96], ["CRP", "PROTEIN", 136, 139], ["patients", "SPECIES", 41, 49], ["our study", "TEST", 3, 12], ["general HD patients", "TREATMENT", 30, 49], ["lymphocytes count", "TEST", 51, 68], ["P", "TEST", 70, 71], ["lymphocytes percentage", "TEST", 85, 107], ["P", "TEST", 109, 110], ["CRP", "TEST", 136, 139], ["P", "TEST", 141, 142]]], ["Previous studies have confirmed that, once patients infected with SARS-CoV-2, NLR was significantly increased and could be used as one of the intuitive indicators for clinical evaluation of the severity of COVID-19 [18] .", [["SARS", "DISEASE", 66, 70], ["COVID-19", "CHEMICAL", 206, 214], ["patients", "ORGANISM", 43, 51], ["SARS-CoV-2", "ORGANISM", 66, 76], ["NLR", "GENE_OR_GENE_PRODUCT", 78, 81], ["NLR", "PROTEIN", 78, 81], ["patients", "SPECIES", 43, 51], ["SARS-CoV", "SPECIES", 66, 74], ["Previous studies", "TEST", 0, 16], ["SARS", "TEST", 66, 70], ["CoV", "TEST", 71, 74], ["NLR", "TEST", 78, 81], ["clinical evaluation", "TEST", 167, 186], ["COVID", "TEST", 206, 211], ["increased", "OBSERVATION_MODIFIER", 100, 109]]], ["In our study, compared with control group, NLR was significantly increased in confirmed group(P = 0.01).", [["NLR", "GENE_OR_GENE_PRODUCT", 43, 46], ["NLR", "PROTEIN", 43, 46], ["our study", "TEST", 3, 12], ["NLR", "TEST", 43, 46], ["increased", "OBSERVATION_MODIFIER", 65, 74]]], ["Research suggests that the higher PLR of patients during treatment had longer average hospitalization days [19] .", [["patients", "ORGANISM", 41, 49], ["patients", "SPECIES", 41, 49], ["treatment", "TREATMENT", 57, 66], ["higher", "OBSERVATION_MODIFIER", 27, 33]]], ["However, there was no significant difference of PLR in HD patients, which may be related to thrombocytopenia in HD patients [20, 21] .DiscussionAt the same time, neutrophil percentage existed higher in confirmed group in our study.", [["neutrophil", "ANATOMY", 162, 172], ["HD", "DISEASE", 55, 57], ["thrombocytopenia", "DISEASE", 92, 108], ["HD", "DISEASE", 112, 114], ["patients", "ORGANISM", 58, 66], ["patients", "ORGANISM", 115, 123], ["neutrophil", "CELL", 162, 172], ["patients", "SPECIES", 58, 66], ["patients", "SPECIES", 115, 123], ["thrombocytopenia", "PROBLEM", 92, 108], ["neutrophil percentage", "TEST", 162, 183], ["our study", "TEST", 221, 230], ["no", "UNCERTAINTY", 19, 21], ["significant", "OBSERVATION_MODIFIER", 22, 33], ["may be related to", "UNCERTAINTY", 74, 91], ["thrombocytopenia", "OBSERVATION", 92, 108]]], ["This phenomenon may be caused by secondary bacterial infections [22] .", [["bacterial infections", "DISEASE", 43, 63], ["This phenomenon", "PROBLEM", 0, 15], ["secondary bacterial infections", "PROBLEM", 33, 63], ["may be caused", "UNCERTAINTY", 16, 29], ["secondary", "OBSERVATION_MODIFIER", 33, 42], ["bacterial", "OBSERVATION_MODIFIER", 43, 52], ["infections", "OBSERVATION", 53, 63]]], ["It has been recognized that patients of COVID-19 has been damaged with other organs such as liver, heart and kidney [23] .", [["organs", "ANATOMY", 77, 83], ["liver", "ANATOMY", 92, 97], ["heart", "ANATOMY", 99, 104], ["kidney", "ANATOMY", 109, 115], ["COVID-19", "CHEMICAL", 40, 48], ["patients", "ORGANISM", 28, 36], ["COVID-19", "CELL", 40, 48], ["organs", "ORGAN", 77, 83], ["liver", "ORGAN", 92, 97], ["heart", "ORGAN", 99, 104], ["kidney", "ORGAN", 109, 115], ["patients", "SPECIES", 28, 36], ["COVID", "TEST", 40, 45], ["liver", "ANATOMY", 92, 97], ["heart", "ANATOMY", 99, 104], ["kidney", "ANATOMY", 109, 115]]], ["In this study, we also found that AST and ALP were significantly higher than the control group, which may be related to other organ damage after SARS-CoV-2 infection.DiscussionSimilar to MERS-CoV, the risk of infection SARS-CoV-2 in elders and people with underlying conditions such as chronic obstructive pulmonary disease (COPD), diabetes, hypertension, and chronic cardiovascular disease (CVD) is increased [24] [25] [26] [27] .", [["organ", "ANATOMY", 126, 131], ["pulmonary", "ANATOMY", 306, 315], ["cardiovascular", "ANATOMY", 368, 382], ["organ damage", "DISEASE", 126, 138], ["infection", "DISEASE", 156, 165], ["infection", "DISEASE", 209, 218], ["chronic obstructive pulmonary disease", "DISEASE", 286, 323], ["COPD", "DISEASE", 325, 329], ["diabetes", "DISEASE", 332, 340], ["hypertension", "DISEASE", 342, 354], ["chronic cardiovascular disease", "DISEASE", 360, 390], ["CVD", "DISEASE", 392, 395], ["AST", "SIMPLE_CHEMICAL", 34, 37], ["ALP", "GENE_OR_GENE_PRODUCT", 42, 45], ["organ", "ORGAN", 126, 131], ["CoV-2", "ORGANISM", 150, 155], ["MERS-CoV", "GENE_OR_GENE_PRODUCT", 187, 195], ["people", "ORGANISM", 244, 250], ["pulmonary", "ORGAN", 306, 315], ["[24] [25] [26] [27]", "SIMPLE_CHEMICAL", 410, 429], ["AST", "PROTEIN", 34, 37], ["ALP", "PROTEIN", 42, 45], ["people", "SPECIES", 244, 250], ["MERS-CoV", "SPECIES", 187, 195], ["SARS-CoV", "SPECIES", 219, 227], ["this study", "TEST", 3, 13], ["AST", "TEST", 34, 37], ["ALP", "TEST", 42, 45], ["other organ damage", "PROBLEM", 120, 138], ["SARS", "PROBLEM", 145, 149], ["CoV-2 infection", "PROBLEM", 150, 165], ["infection SARS", "PROBLEM", 209, 223], ["underlying conditions", "PROBLEM", 256, 277], ["chronic obstructive pulmonary disease (COPD)", "PROBLEM", 286, 330], ["diabetes", "PROBLEM", 332, 340], ["hypertension", "PROBLEM", 342, 354], ["chronic cardiovascular disease (CVD)", "PROBLEM", 360, 396], ["may be related to", "UNCERTAINTY", 102, 119], ["organ", "ANATOMY", 126, 131], ["damage", "OBSERVATION", 132, 138], ["infection", "OBSERVATION", 156, 165], ["infection", "OBSERVATION", 209, 218], ["chronic", "OBSERVATION_MODIFIER", 286, 293], ["obstructive", "OBSERVATION_MODIFIER", 294, 305], ["pulmonary", "ANATOMY", 306, 315], ["disease", "OBSERVATION", 316, 323], ["COPD", "OBSERVATION", 325, 329], ["hypertension", "OBSERVATION", 342, 354], ["chronic", "OBSERVATION_MODIFIER", 360, 367], ["cardiovascular disease", "OBSERVATION", 368, 390], ["increased", "OBSERVATION_MODIFIER", 400, 409]]], ["In our study, there existed no significant in age difference between confirmed group and control group, so as to moderate and severe cases in confirmed group (data was not yet available).", [["our study", "TEST", 3, 12], ["moderate and severe cases", "PROBLEM", 113, 138], ["no", "UNCERTAINTY", 28, 30], ["significant", "OBSERVATION_MODIFIER", 31, 42], ["severe", "OBSERVATION_MODIFIER", 126, 132]]], ["This may be related to the age composition ratio of dialysis patients themselves.", [["patients", "ORGANISM", 61, 69], ["patients", "SPECIES", 61, 69], ["dialysis patients themselves", "TREATMENT", 52, 80], ["may be related to", "UNCERTAINTY", 5, 22]]], ["In our study, more underlying disease does not mean higher morbidity.", [["our study", "TEST", 3, 12], ["more underlying disease", "PROBLEM", 14, 37], ["mean higher morbidity", "PROBLEM", 47, 68], ["disease", "OBSERVATION", 30, 37], ["higher", "OBSERVATION_MODIFIER", 52, 58], ["morbidity", "OBSERVATION", 59, 68]]], ["We speculate that because of more attention from their family, organizations, and themselves, HD patients with more underlying diseases decrease their frequency of exposure to SARS-CoV-2, but that is not the case for HD patients with less underlying diseases.", [["SARS", "DISEASE", 176, 180], ["patients", "ORGANISM", 97, 105], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 176, 186], ["patients", "ORGANISM", 220, 228], ["patients", "SPECIES", 97, 105], ["patients", "SPECIES", 220, 228], ["SARS-CoV", "SPECIES", 176, 184], ["HD", "TREATMENT", 94, 96], ["more underlying diseases", "PROBLEM", 111, 135], ["HD", "TREATMENT", 217, 219], ["less underlying diseases", "PROBLEM", 234, 258], ["diseases", "OBSERVATION", 250, 258]]], ["While the percentage of male was higher in the two groups, there was no difference in sex ratio between the two groups (\uf063 2 =0.071, P=0.789).", [["P", "TEST", 132, 133], ["percentage", "OBSERVATION_MODIFIER", 10, 20], ["male", "OBSERVATION", 24, 28], ["higher", "OBSERVATION_MODIFIER", 33, 39], ["no", "UNCERTAINTY", 69, 71], ["difference", "OBSERVATION_MODIFIER", 72, 82]]], ["It has been previously reported that the risk of other diseases, such as pneumonia and tumor, increased with the extension of dialysis age in HD patients [28] , which is not obviously in the incidence of COVID-19 (P=0.074).", [["tumor", "ANATOMY", 87, 92], ["pneumonia", "DISEASE", 73, 82], ["tumor", "DISEASE", 87, 92], ["tumor", "CANCER", 87, 92], ["patients", "ORGANISM", 145, 153], ["patients", "SPECIES", 145, 153], ["other diseases", "PROBLEM", 49, 63], ["pneumonia", "PROBLEM", 73, 82], ["tumor", "PROBLEM", 87, 92], ["dialysis age", "TREATMENT", 126, 138], ["COVID", "TEST", 204, 209], ["diseases", "OBSERVATION", 55, 63], ["pneumonia", "OBSERVATION", 73, 82], ["tumor", "OBSERVATION", 87, 92], ["increased", "OBSERVATION_MODIFIER", 94, 103]]], ["As we known, SARS-CoV-2 is related to angiotensin-converting enzyme II (ACE2), which is widely distributed in multiple organs such as lung, heart, kidney and gastrointestinal tract [29, 30] .", [["organs", "ANATOMY", 119, 125], ["lung", "ANATOMY", 134, 138], ["heart", "ANATOMY", 140, 145], ["kidney", "ANATOMY", 147, 153], ["gastrointestinal tract", "ANATOMY", 158, 180], ["angiotensin", "CHEMICAL", 38, 49], ["SARS-CoV-2", "GENE_OR_GENE_PRODUCT", 13, 23], ["angiotensin-converting enzyme II", "GENE_OR_GENE_PRODUCT", 38, 70], ["ACE2", "GENE_OR_GENE_PRODUCT", 72, 76], ["organs", "ORGAN", 119, 125], ["lung", "ORGAN", 134, 138], ["heart", "ORGAN", 140, 145], ["kidney", "ORGAN", 147, 153], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 158, 180], ["angiotensin-converting enzyme II", "PROTEIN", 38, 70], ["ACE2", "PROTEIN", 72, 76], ["SARS-CoV", "SPECIES", 13, 21], ["SARS", "PROBLEM", 13, 17], ["angiotensin", "TEST", 38, 49], ["lung, heart, kidney and gastrointestinal tract", "PROBLEM", 134, 180], ["lung", "ANATOMY", 134, 138], ["heart", "ANATOMY", 140, 145], ["kidney", "ANATOMY", 147, 153], ["gastrointestinal tract", "ANATOMY", 158, 180]]], ["Upregulation of the ACE2-RAAS pathway is well-known to counter-regulate the proinflammatory and profibrotic effects of the ACE-Ang II-AT1 receptor axis in experimental models of HTN and CVD [31] [32] [33] [34] .", [["Ang", "CHEMICAL", 127, 130], ["HTN", "DISEASE", 178, 181], ["CVD", "DISEASE", 186, 189], ["ACE2", "GENE_OR_GENE_PRODUCT", 20, 24], ["RAAS", "GENE_OR_GENE_PRODUCT", 25, 29], ["ACE-Ang II-AT1 receptor", "GENE_OR_GENE_PRODUCT", 123, 146], ["CVD [31] [32] [33] [34]", "SIMPLE_CHEMICAL", 186, 209], ["ACE2", "PROTEIN", 20, 24], ["RAAS", "PROTEIN", 25, 29], ["ACE", "PROTEIN", 123, 126], ["Ang II", "PROTEIN", 127, 133], ["AT1 receptor", "PROTEIN", 134, 146], ["the ACE2-RAAS pathway", "TREATMENT", 16, 37], ["the ACE", "TEST", 119, 126], ["HTN", "PROBLEM", 178, 181], ["CVD", "TEST", 186, 189], ["profibrotic", "OBSERVATION", 96, 107]]], ["Therefore, it has been speculated that HD patients who have been or are currently using ACEI/ARB are more likely to be infected with SARS-CoV-2 and have a worse prognosis.", [["ACEI", "CHEMICAL", 88, 92], ["ARB", "CHEMICAL", 93, 96], ["SARS", "DISEASE", 133, 137], ["patients", "ORGANISM", 42, 50], ["ARB", "SIMPLE_CHEMICAL", 93, 96], ["SARS-CoV-2", "ORGANISM", 133, 143], ["patients", "SPECIES", 42, 50], ["SARS-CoV", "SPECIES", 133, 141], ["ACEI", "TREATMENT", 88, 92], ["ARB", "TREATMENT", 93, 96]]], ["However, in our study, ACEI/ARB did not significantly increase the incidence and mortality of COVID 19 in HD patient(\uf063 2 =0.059\uff0c P=0.857 ) .", [["ACEI", "CHEMICAL", 23, 27], ["ARB", "CHEMICAL", 28, 31], ["COVID", "DISEASE", 94, 99], ["ACEI", "SIMPLE_CHEMICAL", 23, 27], ["ARB", "SIMPLE_CHEMICAL", 28, 31], ["patient", "ORGANISM", 109, 116], ["patient", "SPECIES", 109, 116], ["our study", "TEST", 12, 21], ["ACEI", "TREATMENT", 23, 27], ["ARB", "TREATMENT", 28, 31], ["COVID", "TEST", 94, 99]]], ["Therefore, age, sex, comorbidity, dialysis age and the using of ACEI/ARB cannot be used as key indicators in assessing the COVID-19 susceptibility factors of HD patients in our study.DiscussionLast but not least, in order to avoid the interference of clinical symptoms and laboratory indicators, HD patients infected with other pathogen were specifically excluded.", [["ACEI", "CHEMICAL", 64, 68], ["ARB", "CHEMICAL", 69, 72], ["HD", "DISEASE", 158, 160], ["ARB", "SIMPLE_CHEMICAL", 69, 72], ["patients", "ORGANISM", 161, 169], ["patients", "ORGANISM", 299, 307], ["patients", "SPECIES", 161, 169], ["patients", "SPECIES", 299, 307], ["dialysis age", "TREATMENT", 34, 46], ["ACEI", "TREATMENT", 64, 68], ["ARB", "TREATMENT", 69, 72], ["the COVID", "TEST", 119, 128], ["HD patients", "TREATMENT", 158, 169], ["our study", "TEST", 173, 182], ["clinical symptoms", "PROBLEM", 251, 268], ["laboratory indicators", "TEST", 273, 294], ["HD", "TREATMENT", 296, 298], ["other pathogen", "PROBLEM", 322, 336]]], ["In fact, as a special population, the majority of them have a variety of complications, such as microinflammatory, heart failure, pulmonary edema, and lung infection [28, 35] , resulting in complicated clinical manifestations and variable chest CT findings.", [["heart", "ANATOMY", 115, 120], ["pulmonary", "ANATOMY", 130, 139], ["lung", "ANATOMY", 151, 155], ["chest", "ANATOMY", 239, 244], ["heart failure", "DISEASE", 115, 128], ["pulmonary edema", "DISEASE", 130, 145], ["lung infection", "DISEASE", 151, 165], ["heart", "ORGAN", 115, 120], ["pulmonary", "ORGAN", 130, 139], ["lung", "ORGAN", 151, 155], ["complications", "PROBLEM", 73, 86], ["microinflammatory, heart failure", "PROBLEM", 96, 128], ["pulmonary edema", "PROBLEM", 130, 145], ["lung infection", "PROBLEM", 151, 165], ["complicated clinical manifestations", "PROBLEM", 190, 225], ["variable chest CT findings", "TEST", 230, 256], ["variety", "OBSERVATION_MODIFIER", 62, 69], ["complications", "OBSERVATION", 73, 86], ["heart", "ANATOMY", 115, 120], ["failure", "OBSERVATION", 121, 128], ["pulmonary", "ANATOMY", 130, 139], ["edema", "OBSERVATION", 140, 145], ["lung", "ANATOMY", 151, 155], ["infection", "OBSERVATION", 156, 165], ["chest", "ANATOMY", 239, 244]]], ["This requires the medical staff in the dialysis center to master the basic data of all the patients in their own center.", [["patients", "ORGANISM", 91, 99], ["patients", "SPECIES", 91, 99]]], ["At the same time, under the premise of perfect protection, it is one of the necessary protective measures to take the screening of nucleic acid testing and chest CT scans for every hemodialysis patient in the dialysis center.DiscussionOur study is limited.", [["nucleic acid", "CHEMICAL", 131, 143], ["patient", "ORGANISM", 194, 201], ["patient", "SPECIES", 194, 201], ["the screening", "TEST", 114, 127], ["nucleic acid testing", "TEST", 131, 151], ["chest CT scans", "TEST", 156, 170], ["every hemodialysis", "TREATMENT", 175, 193], ["DiscussionOur study", "TEST", 225, 244], ["chest", "ANATOMY", 156, 161]]], ["Because this is a retrospective case-control study from one single center, and has a small sample, which could be subject to recall bias and selection bias.", [["a small sample", "PROBLEM", 83, 97], ["small", "OBSERVATION_MODIFIER", 85, 90]]], ["In conclusion, faced with SARS-CoV-2, HD patients with lower BMI and hemoglobin were more susceptible to be infected, which might be related to malnutrition.", [["SARS", "DISEASE", 26, 30], ["malnutrition", "DISEASE", 144, 156], ["SARS-CoV-2", "ORGANISM", 26, 36], ["HD", "ORGANISM", 38, 40], ["patients", "ORGANISM", 41, 49], ["hemoglobin", "GENE_OR_GENE_PRODUCT", 69, 79], ["hemoglobin", "PROTEIN", 69, 79], ["patients", "SPECIES", 41, 49], ["SARS-CoV", "SPECIES", 26, 34], ["SARS", "PROBLEM", 26, 30], ["CoV", "TEST", 31, 34], ["HD", "TREATMENT", 38, 40], ["lower BMI", "PROBLEM", 55, 64], ["hemoglobin", "TEST", 69, 79], ["malnutrition", "PROBLEM", 144, 156], ["infected", "OBSERVATION", 108, 116], ["might be related to", "UNCERTAINTY", 124, 143], ["malnutrition", "OBSERVATION", 144, 156]]], ["Once confirmed with COVID-19, HD patients expressed obviously dis-regulated of inflammation and immune.", [["inflammation", "DISEASE", 79, 91], ["patients", "ORGANISM", 33, 41], ["COVID-19", "DNA", 20, 28], ["patients", "SPECIES", 33, 41], ["COVID", "TEST", 20, 25], ["HD", "TREATMENT", 30, 32], ["inflammation", "PROBLEM", 79, 91], ["inflammation", "OBSERVATION", 79, 91]]], ["At the same time, we found that age, gender, comorbidities, dialysis age, and the using of ACEI/ARB could not be used as indicators of susceptibility to COVID-19 in HD patients.", [["ACEI", "CHEMICAL", 91, 95], ["ARB", "CHEMICAL", 96, 99], ["COVID-19", "CHEMICAL", 153, 161], ["COVID-19", "CHEMICAL", 153, 161], ["ACEI", "GENE_OR_GENE_PRODUCT", 91, 95], ["ARB", "SIMPLE_CHEMICAL", 96, 99], ["patients", "ORGANISM", 168, 176], ["patients", "SPECIES", 168, 176], ["comorbidities", "PROBLEM", 45, 58], ["dialysis", "TREATMENT", 60, 68], ["ACEI", "TREATMENT", 91, 95], ["ARB", "TREATMENT", 96, 99], ["COVID", "TEST", 153, 158]]], ["Expecting that our study could be helpful to regions currently suffering from the ravages of COVID-19.", [["COVID-19", "CHEMICAL", 93, 101], ["our study", "TEST", 15, 24], ["COVID", "TEST", 93, 98]]]], "PMC7462475": [["IntroductionOn December 31, 2019, several patients were admitted to the local hospitals of Wuhan, China, with symptoms of pneumonia linked to a common infection in the wholesale market in Wuhan.", [["pneumonia", "DISEASE", 122, 131], ["infection", "DISEASE", 151, 160], ["patients", "ORGANISM", 42, 50], ["patients", "SPECIES", 42, 50], ["symptoms", "PROBLEM", 110, 118], ["pneumonia", "PROBLEM", 122, 131], ["a common infection", "PROBLEM", 142, 160], ["pneumonia", "OBSERVATION", 122, 131], ["common", "OBSERVATION_MODIFIER", 144, 150], ["infection", "OBSERVATION", 151, 160]]], ["Alarmingly, the investigation reports indicated a new strain of coronavirus with unknown aetiology that had spread globally, which forced the World Health Organization to declare it a pandemic in March 2020, which was named coronavirus disease 2019 (COVID-19) (Bogoch et al. 2020; World Health Organization 2020f; Zhao et al., 2020, Lu et al., 2020).", [["coronavirus", "DISEASE", 64, 75], ["coronavirus disease", "DISEASE", 224, 243], ["coronavirus", "ORGANISM", 64, 75], ["the investigation", "TEST", 12, 29], ["a new strain of coronavirus", "PROBLEM", 48, 75], ["coronavirus disease", "PROBLEM", 224, 243], ["COVID", "TEST", 250, 255], ["coronavirus", "OBSERVATION", 64, 75], ["coronavirus disease", "OBSERVATION", 224, 243]]], ["Researchers have compared the current COVID-19 pandemic to the Spanish flu that occurred in 1918, which resulted in more than 50 million deaths around the world.", [["flu", "DISEASE", 71, 74], ["deaths", "DISEASE", 137, 143]]], ["In addition to that, the rapid transmission rate and the lack of vaccinations or any treatment option for the COVID-19 outbreak provoked the World Health Organisation (WHO) and the International Health Regulation (IHR) emergency committee to announce the case as a Public Health Emergency of International Concern (PHEIC) on January 30, 2020 (Centers for Disease Control and Prevention, 2019, Martini et al., 2019, Barry et al., 2020).IntroductionIn March 2020, Saudi Arabia reported the first case of COVID-19, and the disease started to spread increasingly throughout the whole country.", [["the rapid transmission rate", "TEST", 21, 48], ["vaccinations", "TREATMENT", 65, 77], ["any treatment option", "TREATMENT", 81, 101], ["the COVID", "TEST", 106, 115], ["Disease Control", "TREATMENT", 355, 370], ["COVID", "TEST", 502, 507], ["the disease", "PROBLEM", 516, 527], ["disease", "OBSERVATION", 520, 527]]], ["As a consequence, in order to prevent the rapid transmission of the infection, the Saudi government implemented multiple measures, including restrictions in the educational sectors and broad restrictions in the transportation sector (nationally and internationally).", [["infection", "DISEASE", 68, 77], ["the infection", "PROBLEM", 64, 77], ["multiple measures", "TREATMENT", 112, 129], ["infection", "OBSERVATION", 68, 77]]], ["Subsequently, a general curfew was placed on the residents and citizens of Saudi Arabia in an attempt to curtail the spread of the virus (Saudi Ministry of Health 2020; Saudi Center for Disease Prevention and Control 2020).", [["Disease Prevention", "TREATMENT", 186, 204]]], ["However, the transmission of the disease dramatically increased and reached more than 145,000 confirmed COVID-19 cases in the kingdom by the 18th of June (Saudi Ministry of Health 2020).IntroductionThe lack of treatment options for COVID-19 has raised many concerns among populations worldwide, which has led to many attempts to find alternative options to prevent the transmission of the disease or to alleviate the progression of the infection, including focusing more on preventive measures (to prevent transmission to other individuals) and the use of natural products and herbal extracts to increase immunity and decrease the probability of getting infected (Austin et al., 2007, Lake, 2020, World Health Organization, 2020a, World Health Organization, 2020c, Salathe et al., 2020).IntroductionHistorically, the use of natural products was known to be the only treatment method against many infections and diseases.", [["extracts", "ANATOMY", 584, 592], ["COVID-19", "CHEMICAL", 232, 240], ["infection", "DISEASE", 436, 445], ["infections", "DISEASE", 896, 906], ["the disease", "PROBLEM", 29, 40], ["treatment options", "TREATMENT", 210, 227], ["COVID", "TEST", 232, 237], ["alternative options", "TREATMENT", 334, 353], ["the disease", "PROBLEM", 385, 396], ["the infection", "PROBLEM", 432, 445], ["preventive measures", "TREATMENT", 474, 493], ["natural products", "TREATMENT", 556, 572], ["herbal extracts", "TREATMENT", 577, 592], ["natural products", "TREATMENT", 824, 840], ["treatment method", "TREATMENT", 866, 882], ["many infections", "PROBLEM", 891, 906], ["diseases", "PROBLEM", 911, 919], ["disease", "OBSERVATION", 33, 40], ["dramatically", "OBSERVATION_MODIFIER", 41, 53], ["increased", "OBSERVATION_MODIFIER", 54, 63], ["progression", "OBSERVATION_MODIFIER", 417, 428], ["infection", "OBSERVATION", 436, 445], ["infections", "OBSERVATION", 896, 906]]], ["Also, natural products were used to enhance the immune system and are still widely used nowadays, mainly without the need for a prescription [19, 20].", [["natural products", "TREATMENT", 6, 22]]], ["Regardless of the benefits of using herbal products, there is a significant disadvantage, namely the herbal-drug interaction.", [["herbal products", "TREATMENT", 36, 51], ["significant", "OBSERVATION_MODIFIER", 64, 75], ["disadvantage", "OBSERVATION", 76, 88]]], ["Posadzki et al. (2013) reported the possible interactions between herbal medicinal products and drugs, which they classified as minor, moderate, and severe.", [["herbal medicinal products", "TREATMENT", 66, 91], ["drugs", "TREATMENT", 96, 101], ["minor", "OBSERVATION_MODIFIER", 128, 133], ["moderate", "OBSERVATION_MODIFIER", 135, 143], ["severe", "OBSERVATION_MODIFIER", 149, 155]]], ["Their study showed that, in some cases, the combination of herbal medicine and drugs resulted in life-threatening conditions (Posadzki, Watson, and Ernst 2013).", [["Their study", "TEST", 0, 11], ["herbal medicine", "TREATMENT", 59, 74], ["drugs", "TREATMENT", 79, 84]]], ["Unfortunately, a recent report showed that about 80% of developed countries' populations still rely on herbal medicines without any control (Pathak and Das 2013).", [["herbal medicines", "TREATMENT", 103, 119]]], ["Regarding COVID-19, many studies have been conducted to investigate the ability of already-known antiviral herbal products to treat it.", [["COVID", "TEST", 10, 15], ["many studies", "TEST", 20, 32], ["antiviral herbal products", "TREATMENT", 97, 122]]], ["In addition, there has been a dramatic increase in the use of this kind of medicine among individuals who are afraid of contracting COVID-19, without taking into consideration the possible harmful effects of some products (Ekor 2014).", [["COVID-19", "CHEMICAL", 132, 140], ["COVID-19", "CHEMICAL", 132, 140], ["dramatic", "OBSERVATION_MODIFIER", 30, 38], ["increase", "OBSERVATION_MODIFIER", 39, 47]]], ["The objective of this study is to explore the knowledge of the population of the Kingdom of Saudi Arabia (KSA) about COVID-19 preventive measures and their belief about the consumption of herbal products for the prevention of COVID-19 infection.Study design and study population ::: MethodsA cross-sectional study using an online survey was conducted in Saudi Arabia between May 23rd and June 06th, 2020.", [["COVID-19", "CHEMICAL", 226, 234], ["infection", "DISEASE", 235, 244], ["COVID-19", "ORGANISM", 226, 234], ["COVID-19", "SPECIES", 226, 234], ["this study", "TEST", 17, 27], ["COVID", "TREATMENT", 117, 122], ["preventive measures", "TREATMENT", 126, 145], ["herbal products", "TREATMENT", 188, 203], ["COVID-19 infection", "PROBLEM", 226, 244], ["infection", "OBSERVATION", 235, 244]]], ["The survey instrument was developed based on extensive literature reviews on the COVID-19 pandemic, including its transmission and preventive measures and the use of traditional medicine (World Health Organization 2020e; Centers for Disease Control and Prevention 2020; Luo et al. 2020).", [["The survey instrument", "TEST", 0, 21], ["the COVID", "TEST", 77, 86], ["preventive measures", "TREATMENT", 131, 150], ["traditional medicine", "TREATMENT", 166, 186], ["Disease Control", "TREATMENT", 233, 248]]], ["The questionnaire tool was reviewed by three researchers to evaluate the appropriateness, relevancy, clarity, and adequacy of the questions.", [["The questionnaire tool", "TEST", 0, 22]]], ["The survey instrument included thirty-three questions, including socio-demographic characteristics, history of chronic diseases, respondents\u2019 adherence to the Ministry of Health (MOH) instructions on COVID-19 pandemic preventive measures and social distancing, and the use of herbal products and food supplements.", [["chronic diseases", "DISEASE", 111, 127], ["chronic diseases", "PROBLEM", 111, 127], ["COVID", "TREATMENT", 200, 205], ["pandemic preventive measures", "TREATMENT", 209, 237], ["herbal products", "TREATMENT", 276, 291], ["food supplements", "TREATMENT", 296, 312], ["chronic", "OBSERVATION_MODIFIER", 111, 118], ["diseases", "OBSERVATION", 119, 127]]], ["The survey was divided into five major sections.", [["sections", "ANATOMY", 39, 47]]], ["The second section included two questions about having a history of chronic diseases and whether the participant is currently/previously infected with COVID-19 (a yes-no question).", [["chronic diseases", "DISEASE", 68, 84], ["participant", "SPECIES", 101, 112], ["chronic diseases", "PROBLEM", 68, 84], ["COVID", "TEST", 151, 156], ["chronic", "OBSERVATION_MODIFIER", 68, 75], ["diseases", "OBSERVATION", 76, 84]]], ["The third section contained five questions on participants\u2019 knowledge about COVID-19 preventive measures (specifically handwashing and social distancing).", [["participants", "SPECIES", 46, 58], ["preventive measures", "TREATMENT", 85, 104]]], ["The higher the score, the better the knowledge about COVID-19 preventive measures.Study design and study population ::: MethodsThe knowledge section was followed by a question asking the participants whether they consider themselves committed to Saudi Ministry of Health recommendations regarding COVID-19 prevention and transmission.", [["participants", "SPECIES", 187, 199], ["COVID", "TEST", 53, 58], ["preventive measures", "TREATMENT", 62, 81], ["Methods", "TREATMENT", 120, 127], ["COVID-19 prevention", "TREATMENT", 297, 316], ["higher", "OBSERVATION_MODIFIER", 4, 10]]], ["The fourth section (17 questions) asked them about their beliefs about herbal products and food supplements in terms of: 1) usage, 2) the source of information about them and the source of supply, and 3) belief in the protective effects of herbal products and food supplements as effective protection against COVID-19.Sampling strategy ::: MethodsA convenient sample of eligible participants was invited to participate in the study through social media (Facebook, Twitter, Snapchat, Instagram and WhatsApp).", [["participants", "ORGANISM", 379, 391], ["participants", "SPECIES", 379, 391], ["herbal products", "TREATMENT", 71, 86], ["herbal products", "TREATMENT", 240, 255], ["food supplements", "TREATMENT", 260, 276], ["COVID", "TEST", 309, 314]]], ["All participants voluntarily participated in the study and were thus considered exempt from written informed consent.", [["participants", "SPECIES", 4, 16], ["the study", "TEST", 45, 54]]], ["The study aims and objectives were clearly explained at the beginning of the survey.Sampling strategy ::: MethodsThe inclusion criteria were: a) participants aged 18 years and above and currently living in Saudi Arabia.", [["participants", "SPECIES", 145, 157], ["The study", "TEST", 0, 9], ["Methods", "TREATMENT", 106, 113]]], ["Participants were excluded if they were: a) below 18 years of age; and b) unable to understand the Arabic language.Sample size ::: MethodsUsing a confidence interval of 95%, a standard deviation of 0.5, and a margin of error of 5%, the required sample size was 385 participants.Statistical analysis ::: MethodsData were analysed using SPSS software, version 25 (IBM Corp, Armonk, NY, USA).", [["Participants", "SPECIES", 0, 12], ["participants", "SPECIES", 265, 277], ["a standard deviation", "TEST", 174, 194], ["SPSS software", "TEST", 335, 348], ["size", "OBSERVATION_MODIFIER", 122, 126], ["margin", "OBSERVATION_MODIFIER", 209, 215], ["size", "OBSERVATION_MODIFIER", 252, 256]]], ["The Kolmogorov\u2013Smirnov and Shapiro Wilk tests were used to check the normality of the data.", [["The Kolmogorov\u2013Smirnov", "TREATMENT", 0, 22], ["Shapiro Wilk tests", "TEST", 27, 45]]], ["Participants' knowledge scores were interpreted as a continuous scale based on the scale midpoint, where scores above the midpoint represented better knowledge about COVID-19 preventive measures.", [["Participants", "SPECIES", 0, 12], ["a continuous scale", "TEST", 51, 69], ["preventive measures", "TREATMENT", 175, 194]]], ["Student t-test and one-way ANOVA test were used to compare the mean knowledge scores between different demographic groups respectively.", [["Student t-test", "TEST", 0, 14], ["ANOVA test", "TEST", 27, 37]]], ["Tukey\u2019s HSD post-hoc test was conducted to identify the source of significant variation within each group.", [["HSD post-hoc test", "TEST", 8, 25], ["significant", "OBSERVATION_MODIFIER", 66, 77], ["variation", "OBSERVATION", 78, 87]]], ["Additionally, significant predictors of better knowledge were determined using multiple linear regression analysis.", [["multiple linear regression analysis", "TEST", 79, 114], ["significant", "OBSERVATION_MODIFIER", 14, 25]]], ["A confidence interval of 95% (p<0.05) was applied to represent the statistical significance of the results, and the level of significance was predetermined as 5%.Ethical considerations ::: MethodsThis study was approved by the general directorate of health affairs \u2013 Al-Qassem Region, Ministry of Health, Saudi Arabia, registration No H-04-Q-001.", [["H-04-Q-001", "CHEMICAL", 335, 345], ["A confidence interval", "TEST", 0, 21], ["Methods", "TREATMENT", 189, 196], ["This study", "TEST", 196, 206]]], ["As participation in the study was voluntary, the research ethics committee approved the consent waiver.Characteristics of study participants ::: ResultsA total of 5,258 individuals participated in this study.", [["individuals", "ORGANISM", 169, 180], ["participants", "SPECIES", 128, 140], ["the study", "TEST", 20, 29], ["this study", "TEST", 197, 207]]], ["Around 41.0% (n= 2,155) of the participants were aged 25 to 39 years.", [["participants", "ORGANISM", 31, 43], ["participants", "SPECIES", 31, 43]]], ["The majority were married (60.3%, n= 3,169), Saudi (96.5%, n= 5,076), and living in central provinces (58.0%, n= 3,048) of the Kingdom.", [["Saudi", "TEST", 45, 50], ["central", "ANATOMY_MODIFIER", 84, 91]]], ["More than half of them (60.0%, n= 3,155) were bachelor degree holders, 45.4% (n= 2,387) were employed, and 34.3% (n= 1,803) have a family member working in the healthcare provision sector.", [["bachelor degree holders", "TEST", 46, 69]]], ["Around 14.5% (n= 760) of them reported that they have a history of chronic disease and 0.6% (n= 30) reported that they had been or were currently infected with COVID-19.", [["chronic disease", "DISEASE", 67, 82], ["COVID-19", "CHEMICAL", 160, 168], ["chronic disease", "PROBLEM", 67, 82], ["COVID", "TEST", 160, 165], ["chronic", "OBSERVATION_MODIFIER", 67, 74], ["disease", "OBSERVATION", 75, 82]]], ["When the participants were asked whether they consider themselves committed to the Ministry of Health instructions regarding the COVID-19 pandemic, 43.0% (n= 2,262) reported that they are completely committed and 32.0% (n= 1,685) reported that they are committed most of the time except in emergency cases, refer to (Table 1).Participants\u2019 demographics and their knowledge about COVID-19 preventive measures. ::: Participants\u2019 knowledge about COVID-19 preventive measures ::: Results", [["participants", "ORGANISM", 9, 21], ["participants", "SPECIES", 9, 21], ["Participants", "SPECIES", 326, 338], ["Participants", "SPECIES", 413, 425], ["the COVID", "TEST", 125, 134], ["COVID-19 preventive measures", "TREATMENT", 379, 407]]]], "PMC7406961": [["IntroductionIn December 2019, a novel viral pathogen, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), was discovered in Wuhan, Hubei province, China, with its disease named Coronavirus Disease 2019 (COVID-19) [1, 2].", [["viral pathogen", "DISEASE", 38, 52], ["acute respiratory syndrome coronavirus", "DISEASE", 65, 103], ["Coronavirus Disease", "DISEASE", 191, 210], ["severe acute respiratory syndrome coronavirus 2", "ORGANISM", 58, 105], ["SARS-CoV-2", "ORGANISM", 107, 117], ["severe acute respiratory syndrome coronavirus", "SPECIES", 58, 103], ["SARS-CoV-2", "SPECIES", 107, 117], ["a novel viral pathogen", "PROBLEM", 30, 52], ["the severe acute respiratory syndrome coronavirus", "PROBLEM", 54, 103], ["SARS-CoV", "TEST", 107, 115], ["its disease named Coronavirus Disease", "PROBLEM", 173, 210], ["COVID", "TEST", 217, 222], ["severe", "OBSERVATION_MODIFIER", 58, 64], ["acute", "OBSERVATION_MODIFIER", 65, 70], ["respiratory syndrome", "OBSERVATION", 71, 91], ["Coronavirus Disease", "OBSERVATION", 191, 210]]], ["The COVID-19 global pandemic has rapidly escalated, requiring widespread critical care level management of patients to include mechanical ventilation [3, 4].", [["patients", "ORGANISM", 107, 115], ["patients", "SPECIES", 107, 115], ["The COVID", "TEST", 0, 9], ["widespread critical care level management", "TREATMENT", 62, 103], ["mechanical ventilation", "TREATMENT", 127, 149]]], ["The demand for invasive mechanical ventilation has surpassed the supply of ventilators in many locations and has placed the USA in a public health emergency as the trajectory of cases continues to rise [5, 6].IntroductionThe Federal Drug Administration (FDA) has provided emergency guidance during the crisis caused by the COVID-19 pandemic in an effort to increase immediate access to ventilators, with special mention regarding potential utilization of devices typically used for treatment of obstructive sleep apnea at home, to include noninvasive positive pressure ventilation (NIPPV) devices such as continuous positive airway pressure (CPAP) and bilevel positive airway pressure (bilevel PAP) [5].", [["airway", "ANATOMY", 625, 631], ["airway", "ANATOMY", 669, 675], ["obstructive sleep apnea", "DISEASE", 495, 518], ["airway", "MULTI-TISSUE_STRUCTURE", 625, 631], ["airway", "MULTI-TISSUE_STRUCTURE", 669, 675], ["invasive mechanical ventilation", "TREATMENT", 15, 46], ["ventilators", "TREATMENT", 75, 86], ["The Federal Drug Administration", "TREATMENT", 221, 252], ["ventilators", "TREATMENT", 386, 397], ["potential utilization of devices", "TREATMENT", 430, 462], ["obstructive sleep apnea", "PROBLEM", 495, 518], ["noninvasive positive pressure ventilation", "TREATMENT", 539, 580], ["NIPPV) devices", "TREATMENT", 582, 596], ["continuous positive airway pressure (CPAP", "TREATMENT", 605, 646], ["bilevel positive airway pressure (bilevel PAP)", "TREATMENT", 652, 698], ["invasive", "OBSERVATION_MODIFIER", 15, 23], ["mechanical ventilation", "OBSERVATION", 24, 46], ["obstructive sleep apnea", "OBSERVATION", 495, 518], ["pressure ventilation", "OBSERVATION", 560, 580], ["airway pressure", "OBSERVATION", 625, 640], ["airway pressure", "OBSERVATION", 669, 684]]], ["The FDA also cautioned that design modifications are to minimize the risk of aerosolization, as SARS-CoV-2 has demonstrated viability in the aerosolized form for up to 3 h, and thus poses a risk for infection to health care workers [5, 7].", [["SARS", "DISEASE", 96, 100], ["infection", "DISEASE", 199, 208], ["design modifications", "TREATMENT", 28, 48], ["aerosolization", "PROBLEM", 77, 91], ["viability", "PROBLEM", 124, 133], ["infection", "PROBLEM", 199, 208], ["aerosolization", "OBSERVATION", 77, 91]]], ["Unlike conventional mechanical ventilators, home NIPPV devices use a single limb passive breathing circuit with a calibrated intentional leak incorporated into the system, usually on the mask itself, to prevent rebreathing [8].", [["limb", "ANATOMY", 76, 80], ["limb", "ORGANISM_SUBDIVISION", 76, 80], ["conventional mechanical ventilators", "TREATMENT", 7, 42], ["home NIPPV devices", "TREATMENT", 44, 62], ["a single limb passive breathing circuit", "TREATMENT", 67, 106], ["a calibrated intentional leak", "PROBLEM", 112, 141], ["the mask", "TREATMENT", 183, 191], ["mechanical ventilators", "OBSERVATION", 20, 42], ["leak", "OBSERVATION", 137, 141]]], ["The intentional leak design of NIPPV devices could potentially lead to aerosolization of the virus and expose healthcare workers to pathogens [9].", [["The intentional leak", "PROBLEM", 0, 20], ["NIPPV devices", "TREATMENT", 31, 44], ["aerosolization", "TREATMENT", 71, 85], ["the virus", "PROBLEM", 89, 98], ["leak", "OBSERVATION", 16, 20]]], ["Even with a non-vented mask and a bacterial/viral filter placed on an expiratory port to mitigate this, unintentional leak may still occur in the patient-mask interface.", [["patient", "ORGANISM", 146, 153], ["patient", "SPECIES", 146, 153], ["a non-vented mask", "TREATMENT", 10, 27], ["a bacterial/viral filter", "TREATMENT", 32, 56], ["an expiratory port", "TREATMENT", 67, 85], ["unintentional leak", "PROBLEM", 104, 122], ["viral filter", "OBSERVATION", 44, 56], ["leak", "OBSERVATION", 118, 122]]], ["Therefore, guidelines have cautioned against using traditional NIPPV modalities with a face mask on critically ill patients with COVID-19 [10].IntroductionBilevel PAP devices with back-up respiratory rates [spontaneous/timed mode (ST)] are commonly used at home to treat many conditions including obstructive sleep apnea, and chronic respiratory failure secondary to chronic obstructive pulmonary disease, obesity hypoventilation syndrome, and neuromuscular disease [11\u201314].", [["respiratory", "ANATOMY", 188, 199], ["respiratory", "ANATOMY", 334, 345], ["pulmonary", "ANATOMY", 387, 396], ["neuromuscular", "ANATOMY", 444, 457], ["critically ill", "DISEASE", 100, 114], ["obstructive sleep apnea", "DISEASE", 297, 320], ["chronic respiratory failure", "DISEASE", 326, 353], ["chronic obstructive pulmonary disease", "DISEASE", 367, 404], ["obesity hypoventilation syndrome", "DISEASE", 406, 438], ["neuromuscular disease", "DISEASE", 444, 465], ["COVID-19", "CHEMICAL", 129, 137], ["patients", "ORGANISM", 115, 123], ["pulmonary", "ORGAN", 387, 396], ["patients", "SPECIES", 115, 123], ["traditional NIPPV modalities", "TREATMENT", 51, 79], ["a face mask", "TREATMENT", 85, 96], ["COVID", "TEST", 129, 134], ["IntroductionBilevel PAP devices", "TREATMENT", 143, 174], ["back-up respiratory rates", "TREATMENT", 180, 205], ["spontaneous/timed mode", "TREATMENT", 207, 229], ["many conditions", "PROBLEM", 271, 286], ["obstructive sleep apnea", "PROBLEM", 297, 320], ["chronic respiratory failure", "PROBLEM", 326, 353], ["chronic obstructive pulmonary disease", "PROBLEM", 367, 404], ["obesity hypoventilation syndrome", "PROBLEM", 406, 438], ["neuromuscular disease", "PROBLEM", 444, 465], ["obstructive sleep apnea", "OBSERVATION", 297, 320], ["chronic", "OBSERVATION_MODIFIER", 326, 333], ["respiratory failure", "OBSERVATION", 334, 353], ["chronic", "OBSERVATION_MODIFIER", 367, 374], ["obstructive", "OBSERVATION_MODIFIER", 375, 386], ["pulmonary", "ANATOMY", 387, 396], ["disease", "OBSERVATION", 397, 404], ["obesity", "OBSERVATION_MODIFIER", 406, 413], ["hypoventilation syndrome", "OBSERVATION", 414, 438], ["neuromuscular", "ANATOMY", 444, 457]]], ["These devices are only approved for NIPPV with the use of a mask interface, and their use for invasive ventilation has not been reported except by one small study [15].IntroductionThe impending predicted shortage of mechanical ventilators lead us to investigate whether or not bilevel PAP ST devices, designed for noninvasive use at home and the sleep laboratory, could provide invasive ventilation.", [["These devices", "TREATMENT", 0, 13], ["NIPPV", "TREATMENT", 36, 41], ["a mask interface", "TREATMENT", 58, 74], ["invasive ventilation", "TREATMENT", 94, 114], ["mechanical ventilators", "TREATMENT", 216, 238], ["bilevel PAP ST devices", "TREATMENT", 277, 299], ["invasive ventilation", "TREATMENT", 378, 398]]], ["The objective of this study was to demonstrate the feasibility and effectiveness of using bilevel PAP ST with a single limb filtered respiratory circuit to maintain adequate ventilation and oxygenation in an intubated healthy swine model.Respiratory circuit concept and design ::: Materials and methodsWe designed two single limb respiratory circuits using resources commonly available in a sleep laboratory and respiratory therapy department, with proximal and distal filtration to prevent aerosolization of the virus.", [["limb", "ANATOMY", 119, 123], ["limb", "ANATOMY", 325, 329], ["limb", "ORGANISM_SUBDIVISION", 119, 123], ["limb", "ORGANISM_SUBDIVISION", 325, 329], ["swine", "SPECIES", 226, 231], ["swine", "SPECIES", 226, 231], ["this study", "TEST", 17, 27], ["bilevel PAP ST", "TREATMENT", 90, 104], ["a single limb filtered respiratory circuit", "TREATMENT", 110, 152], ["an intubated healthy swine model", "TREATMENT", 205, 237], ["proximal and distal filtration", "TREATMENT", 449, 479], ["the virus", "PROBLEM", 509, 518], ["respiratory circuit", "OBSERVATION", 133, 152], ["adequate ventilation", "OBSERVATION", 165, 185], ["oxygenation", "OBSERVATION_MODIFIER", 190, 201], ["respiratory circuits", "OBSERVATION", 330, 350], ["distal filtration", "OBSERVATION", 462, 479], ["aerosolization", "OBSERVATION", 491, 505], ["virus", "OBSERVATION", 513, 518]]], ["The circuits differed in regard to the type of passive exhalation valve used to prevent CO2 retention and rebreathing.", [["CO2", "CHEMICAL", 88, 91], ["CO2", "CHEMICAL", 88, 91], ["CO2", "SIMPLE_CHEMICAL", 88, 91], ["The circuits", "TREATMENT", 0, 12], ["passive exhalation valve", "TREATMENT", 47, 71], ["CO2 retention", "PROBLEM", 88, 101], ["exhalation valve", "OBSERVATION", 55, 71], ["CO2 retention", "OBSERVATION", 88, 101]]], ["The first circuit (see Fig. 1) includes in order of connectivity from device to patient: one bacterial/viral filter (Teleflex Inc., Wayne, Pennsylvania, USA), 6-ft corrugated tubing, one Hudson RCI Pressure Line Adapter (Teleflex Inc., Wayne, Pennsylvania, USA) for an oxygen (O2) supply port, an exhaust collector and positive end-expiratory pressure (PEEP) valve (Smith Medical, London, UK), and a second bacterial/viral filter (Teleflex Inc., Wayne, Pennsylvania, USA), which then connects to the endotracheal tube.Respiratory circuit concept and design ::: Materials and methodsThe second circuit (see Fig. 2) includes in order of connectivity from device to patient: one bacterial/viral filter (Teleflex Inc., Wayne, Pennsylvania, USA), 6-ft corrugated tubing, a SyncVent\u00ae passive exhalation adaptor (Dr\u00e4ger Medical, L\u00fcbeck, Germany), one Hudson RCI Pressure Line Adapter (Teleflex Inc., Wayne, Pennsylvania, USA) for O2 supply port, and a second bacterial/viral filter (Teleflex Inc., Wayne, Pennsylvania, USA), which then connects to the endotracheal tube.Test lung ::: Materials and methodsThese proof-of-concept circuits were originally tested on a 1 L test-lung using two commercially available bilevel PAP ST devices designed for NIPPV in the home and sleep laboratory settings.", [["endotracheal tube", "ANATOMY", 500, 517], ["endotracheal tube", "ANATOMY", 1045, 1062], ["lung", "ANATOMY", 1068, 1072], ["lung", "ANATOMY", 1167, 1171], ["oxygen", "CHEMICAL", 269, 275], ["O2", "CHEMICAL", 277, 279], ["oxygen", "CHEMICAL", 269, 275], ["O2", "CHEMICAL", 277, 279], ["O2", "CHEMICAL", 923, 925], ["patient", "ORGANISM", 80, 87], ["oxygen", "SIMPLE_CHEMICAL", 269, 275], ["O2", "SIMPLE_CHEMICAL", 277, 279], ["endotracheal tube", "TISSUE", 500, 517], ["patient", "ORGANISM", 663, 670], ["endotracheal tube", "MULTI-TISSUE_STRUCTURE", 1045, 1062], ["lung", "ORGAN", 1068, 1072], ["lung", "ORGAN", 1167, 1171], ["patient", "SPECIES", 80, 87], ["patient", "SPECIES", 663, 670], ["The first circuit", "TREATMENT", 0, 17], ["one bacterial/viral filter", "TREATMENT", 89, 115], ["6-ft corrugated tubing", "TREATMENT", 159, 181], ["an oxygen (O2) supply port", "TREATMENT", 266, 292], ["an exhaust collector", "TEST", 294, 314], ["a second bacterial/viral filter", "TREATMENT", 398, 429], ["the endotracheal tube", "TREATMENT", 496, 517], ["The second circuit", "TREATMENT", 582, 600], ["one bacterial/viral filter", "TREATMENT", 672, 698], ["6-ft corrugated tubing", "TREATMENT", 742, 764], ["a SyncVent\u00ae passive exhalation adaptor", "TREATMENT", 766, 804], ["O2 supply port", "TREATMENT", 923, 937], ["a second bacterial/viral filter", "TREATMENT", 943, 974], ["the endotracheal tube", "TREATMENT", 1041, 1062], ["a 1 L test", "TEST", 1156, 1166], ["bilevel PAP ST devices", "TREATMENT", 1205, 1227], ["NIPPV", "TREATMENT", 1241, 1246], ["viral filter", "OBSERVATION", 103, 115], ["Pressure Line", "OBSERVATION", 198, 211], ["expiratory pressure", "OBSERVATION", 332, 351], ["viral filter", "OBSERVATION", 417, 429], ["endotracheal tube", "OBSERVATION", 500, 517], ["viral filter", "OBSERVATION", 686, 698], ["viral filter", "OBSERVATION", 962, 974], ["endotracheal tube", "OBSERVATION", 1045, 1062], ["lung", "ANATOMY", 1068, 1072], ["lung", "ANATOMY", 1167, 1171]]], ["These devices produce an inspiratory positive airway pressure (IPAP) and expiratory positive airway pressure (EPAP), with a timed back-up respiratory rate (RR).", [["airway", "ANATOMY", 46, 52], ["airway", "ANATOMY", 93, 99], ["airway", "MULTI-TISSUE_STRUCTURE", 46, 52], ["airway", "MULTI-TISSUE_STRUCTURE", 93, 99], ["These devices", "TREATMENT", 0, 13], ["an inspiratory positive airway pressure (IPAP)", "TREATMENT", 22, 68], ["expiratory positive airway pressure", "TREATMENT", 73, 108], ["RR", "TEST", 156, 158], ["inspiratory positive", "OBSERVATION", 25, 45], ["airway pressure", "OBSERVATION", 46, 61], ["airway pressure", "OBSERVATION", 93, 108]]], ["Both circuits and devices generated consistent and regular delivery of pressures to the test lung.Animal preparation and testing ::: Materials and methodsThe Institutional Animal Care and Use Committee at the Uniformed Service University of the Health Sciences approved the animal protocol.", [["lung", "ANATOMY", 93, 97], ["lung", "ORGAN", 93, 97], ["Both circuits and devices", "TREATMENT", 0, 25], ["regular delivery of pressures", "TREATMENT", 51, 80], ["the animal protocol", "TREATMENT", 270, 289], ["pressures", "OBSERVATION_MODIFIER", 71, 80], ["lung", "ANATOMY", 93, 97]]], ["Four Yorkshire-cross swine (Sus scrofa domesticus), 63\u201399 kg, were sedated with tiletamine (6 mg/kg) intramuscularly to allow ear vein cannulation.", [["ear vein", "ANATOMY", 126, 134], ["tiletamine", "CHEMICAL", 80, 90], ["tiletamine", "CHEMICAL", 80, 90], ["swine", "ORGANISM", 21, 26], ["Sus scrofa domesticus", "ORGANISM", 28, 49], ["tiletamine", "SIMPLE_CHEMICAL", 80, 90], ["ear vein", "MULTI-TISSUE_STRUCTURE", 126, 134], ["swine", "SPECIES", 21, 26], ["Sus scrofa", "SPECIES", 28, 38], ["domesticus", "SPECIES", 39, 49], ["swine", "SPECIES", 21, 26], ["Sus scrofa domesticus", "SPECIES", 28, 49], ["tiletamine", "TREATMENT", 80, 90], ["ear vein cannulation", "TREATMENT", 126, 146], ["ear vein", "ANATOMY", 126, 134], ["cannulation", "OBSERVATION", 135, 146]]], ["Following isoflurane induction and endotracheal intubation, surgical anesthesia was initially provided with isoflurane 1\u20132% in 50% O2.", [["endotracheal", "ANATOMY", 35, 47], ["isoflurane", "CHEMICAL", 10, 20], ["isoflurane", "CHEMICAL", 108, 118], ["O2", "CHEMICAL", 131, 133], ["isoflurane", "CHEMICAL", 10, 20], ["isoflurane", "CHEMICAL", 108, 118], ["O2", "CHEMICAL", 131, 133], ["isoflurane", "SIMPLE_CHEMICAL", 10, 20], ["isoflurane", "SIMPLE_CHEMICAL", 108, 118], ["O2", "SIMPLE_CHEMICAL", 131, 133], ["isoflurane induction", "TREATMENT", 10, 30], ["endotracheal intubation", "TREATMENT", 35, 58], ["surgical anesthesia", "TREATMENT", 60, 79], ["isoflurane", "TREATMENT", 108, 118], ["50% O2", "TREATMENT", 127, 133], ["endotracheal intubation", "OBSERVATION", 35, 58]]], ["During ventilator testing, anesthesia was transitioned to total intravenous anesthesia by continuous infusion of propofol 2\u20134.4 mg/kg/h, combined with midazolam 1\u20134 mg/kg/h and vecuronium 0.1 mg/kg.Animal preparation and testing ::: Materials and methodsThe Apollo\u00ae anesthesia workstation (Dr\u00e4ger Medical, L\u00fcbeck, Germany) is a full feature anesthesia workstation and E-Vent plus servo controlled high-speed piston ventilator.", [["intravenous", "ANATOMY", 64, 75], ["propofol", "CHEMICAL", 113, 121], ["midazolam", "CHEMICAL", 151, 160], ["vecuronium", "CHEMICAL", 177, 187], ["propofol", "CHEMICAL", 113, 121], ["midazolam", "CHEMICAL", 151, 160], ["vecuronium", "CHEMICAL", 177, 187], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 64, 75], ["propofol", "SIMPLE_CHEMICAL", 113, 121], ["midazolam", "SIMPLE_CHEMICAL", 151, 160], ["vecuronium", "SIMPLE_CHEMICAL", 177, 187], ["ventilator testing", "TEST", 7, 25], ["anesthesia", "TREATMENT", 27, 37], ["total intravenous anesthesia", "TREATMENT", 58, 86], ["propofol", "TREATMENT", 113, 121], ["midazolam", "TREATMENT", 151, 160], ["vecuronium", "TREATMENT", 177, 187], ["Vent", "TREATMENT", 370, 374], ["servo controlled high-speed piston ventilator", "TREATMENT", 380, 425], ["piston ventilator", "OBSERVATION", 408, 425]]], ["The animals were mechanically ventilated with this machine in the supine position while establishing venous access.", [["venous", "ANATOMY", 101, 107], ["animals", "ORGANISM", 4, 11], ["venous", "MULTI-TISSUE_STRUCTURE", 101, 107], ["this machine", "TREATMENT", 46, 58], ["establishing venous access", "TREATMENT", 88, 114], ["mechanically", "OBSERVATION_MODIFIER", 17, 29], ["ventilated", "OBSERVATION", 30, 40], ["venous", "ANATOMY", 101, 107]]], ["Assist control (A/C) volume ventilation was adjusted to achieve a tidal volume (VT) of 6\u201310 ml/kg measured body weight; PEEP 5 cm H2O was applied, and RR was adjusted to achieve an end-tidal CO2 (ETCO2) of 40 mmHg during instrumentation.", [["body", "ANATOMY", 107, 111], ["H2O", "CHEMICAL", 130, 133], ["H2O", "CHEMICAL", 130, 133], ["CO2", "CHEMICAL", 191, 194], ["body", "ORGANISM_SUBDIVISION", 107, 111], ["A/C) volume ventilation", "TREATMENT", 16, 39], ["a tidal volume", "TEST", 64, 78], ["VT", "TEST", 80, 82], ["body weight", "TEST", 107, 118], ["PEEP", "TREATMENT", 120, 124], ["RR", "TEST", 151, 153], ["an end-tidal CO2", "TEST", 178, 194], ["ETCO2", "TEST", 196, 201], ["instrumentation", "TREATMENT", 221, 236]]], ["Isotonic sodium chloride solution was administered at a rate of 500 ml/h to overcome insensible losses.", [["sodium chloride", "CHEMICAL", 9, 24], ["sodium chloride", "CHEMICAL", 9, 24], ["Isotonic sodium chloride", "SIMPLE_CHEMICAL", 0, 24], ["Isotonic sodium chloride solution", "TREATMENT", 0, 33], ["insensible losses", "PROBLEM", 85, 102]]], ["An underbody warmer was set at 39 \u00b0C and adjusted as needed to maintain body temperature (36.7\u201339.1 \u00b0C).Physiological measurements ::: Materials and methodsA 20 g femoral artery catheter (Cook Medical, Inc., Bloomington, Indiana, USA) was placed percutaneously for blood pressure measurement and arterial blood gas (ABG) sampling.", [["body", "ANATOMY", 72, 76], ["femoral artery", "ANATOMY", 163, 177], ["blood", "ANATOMY", 265, 270], ["arterial blood", "ANATOMY", 296, 310], ["body", "ORGANISM_SUBDIVISION", 72, 76], ["femoral artery", "MULTI-TISSUE_STRUCTURE", 163, 177], ["blood", "ORGANISM_SUBSTANCE", 265, 270], ["arterial", "MULTI-TISSUE_STRUCTURE", 296, 304], ["blood", "ORGANISM_SUBSTANCE", 305, 310], ["An underbody warmer", "TREATMENT", 0, 19], ["body temperature", "TEST", 72, 88], ["Materials", "TREATMENT", 135, 144], ["methodsA 20 g femoral artery catheter", "TREATMENT", 149, 186], ["blood pressure measurement", "TEST", 265, 291], ["arterial blood gas", "TEST", 296, 314], ["ABG", "TEST", 316, 319], ["femoral artery", "ANATOMY", 163, 177], ["catheter", "OBSERVATION", 178, 186]]], ["A secondary venous catheter was placed percutaneously in the right hind leg for fluid and drug administration.", [["venous", "ANATOMY", 12, 18], ["right hind leg", "ANATOMY", 61, 75], ["venous catheter", "MULTI-TISSUE_STRUCTURE", 12, 27], ["hind leg", "ORGANISM_SUBDIVISION", 67, 75], ["fluid", "ORGANISM_SUBSTANCE", 80, 85], ["A secondary venous catheter", "TREATMENT", 0, 27], ["fluid and drug administration", "TREATMENT", 80, 109], ["secondary", "OBSERVATION_MODIFIER", 2, 11], ["venous", "ANATOMY", 12, 18], ["catheter", "OBSERVATION", 19, 27], ["right", "ANATOMY_MODIFIER", 61, 66], ["hind leg", "ANATOMY", 67, 75], ["fluid", "OBSERVATION", 80, 85]]], ["Solid-state pressure transducer catheters (Transonic Systems Inc., Ithaca, New York, USA) were placed in the esophagus to continuously measure esophageal pressure (Peso) as a surrogate for pleural pressure and through the endotracheal tube into the trachea to measure peak airway pressure.Physiological measurements ::: Materials and methodsVT and flow-volume loops were monitored continuously with an in-line 1 L/min flowhead spirometer (ADInstruments Inc. Colorado Springs, Colorado, USA).", [["esophagus", "ANATOMY", 109, 118], ["esophageal", "ANATOMY", 143, 153], ["pleural", "ANATOMY", 189, 196], ["endotracheal tube", "ANATOMY", 222, 239], ["trachea", "ANATOMY", 249, 256], ["airway", "ANATOMY", 273, 279], ["esophagus", "ORGAN", 109, 118], ["esophageal", "ORGAN", 143, 153], ["pleural", "MULTI-TISSUE_STRUCTURE", 189, 196], ["endotracheal tube", "MULTI-TISSUE_STRUCTURE", 222, 239], ["trachea", "ORGAN", 249, 256], ["airway", "MULTI-TISSUE_STRUCTURE", 273, 279], ["Solid-state pressure transducer catheters", "TREATMENT", 0, 41], ["esophageal pressure (Peso)", "TREATMENT", 143, 169], ["pleural pressure", "TREATMENT", 189, 205], ["the endotracheal tube", "TREATMENT", 218, 239], ["peak airway pressure", "TEST", 268, 288], ["methodsVT", "TEST", 334, 343], ["an in-line", "TREATMENT", 399, 409], ["pressure", "OBSERVATION_MODIFIER", 12, 20], ["transducer", "OBSERVATION_MODIFIER", 21, 31], ["catheters", "OBSERVATION", 32, 41], ["esophagus", "ANATOMY", 109, 118], ["esophageal", "ANATOMY", 143, 153], ["pressure", "OBSERVATION", 154, 162], ["pleural", "ANATOMY", 189, 196], ["pressure", "OBSERVATION", 197, 205], ["endotracheal tube", "OBSERVATION", 222, 239], ["trachea", "ANATOMY", 249, 256], ["peak airway pressure", "OBSERVATION", 268, 288], ["volume loops", "OBSERVATION", 353, 365]]], ["Arterial blood pressure (ABP), Peso, airway pressure, RR, heart rate, fraction of inspired O2 (FiO2), and exhaled ETCO2 concentrations were continuously monitored and digitally recorded using Powerlab data acquisition system (ADInstruments Inc., Colorado Springs, Colorado, USA).", [["Arterial", "ANATOMY", 0, 8], ["blood", "ANATOMY", 9, 14], ["airway", "ANATOMY", 37, 43], ["heart", "ANATOMY", 58, 63], ["O2", "CHEMICAL", 91, 93], ["O2", "CHEMICAL", 91, 93], ["FiO2", "CHEMICAL", 95, 99], ["ETCO2", "CHEMICAL", 114, 119], ["Arterial blood", "MULTI-TISSUE_STRUCTURE", 0, 14], ["airway", "MULTI-TISSUE_STRUCTURE", 37, 43], ["heart", "ORGAN", 58, 63], ["O2", "SIMPLE_CHEMICAL", 91, 93], ["FiO2", "SIMPLE_CHEMICAL", 95, 99], ["Arterial blood pressure", "TEST", 0, 23], ["ABP", "TEST", 25, 28], ["Peso", "TEST", 31, 35], ["airway pressure", "TEST", 37, 52], ["RR", "TEST", 54, 56], ["heart rate", "TEST", 58, 68], ["inspired O2 (FiO2", "TREATMENT", 82, 99], ["exhaled ETCO2 concentrations", "TEST", 106, 134], ["pressure", "OBSERVATION_MODIFIER", 15, 23], ["airway", "ANATOMY", 37, 43], ["pressure", "OBSERVATION_MODIFIER", 44, 52], ["heart", "ANATOMY", 58, 63]]], ["ABGs were obtained 20 min following each ventilator change and were analyzed with an i-STAT\u00ae Handheld Blood Analyzer (Abbott Point of Care Inc., Princeton, New Jersey, USA).", [["Blood", "ANATOMY", 102, 107], ["ABGs", "SIMPLE_CHEMICAL", 0, 4], ["STAT", "GENE_OR_GENE_PRODUCT", 87, 91], ["Blood", "ORGANISM_SUBSTANCE", 102, 107], ["STAT", "PROTEIN", 87, 91], ["ABGs", "TEST", 0, 4], ["each ventilator change", "TREATMENT", 36, 58], ["Handheld Blood Analyzer", "TEST", 93, 116]]], ["All physiologic parameters were measured at baseline after a 20-min stabilization period and 20 min after each experimental condition.Bilevel PAP ST devices ::: Materials and methodsThe first bilevel PAP ST device (device 1), an OMNILab Advanced +\u00ae (Phillips Respironics, Murrysville, Pennsylvania, USA), has multiple modes designed for sleep laboratory use.", [["All physiologic parameters", "TEST", 0, 26], ["Bilevel PAP ST devices", "TREATMENT", 134, 156], ["The first bilevel PAP ST device (device", "TREATMENT", 182, 221], ["bilevel", "OBSERVATION_MODIFIER", 192, 199], ["PAP", "OBSERVATION", 200, 203]]], ["This device offers enhanced features designed to perform sleep laboratory titration studies with several advanced modes.", [["sleep laboratory titration studies", "TEST", 57, 91], ["several advanced modes", "TREATMENT", 97, 119]]], ["For this study, the bilevel PAP ST mode was utilized, which has pressure ranges EPAP 4 to 25 cm H2O and IPAP 4 to 30 cm H2O, and RR 0\u201330 breaths/min.", [["H2O", "CHEMICAL", 96, 99], ["H2O", "CHEMICAL", 120, 123], ["H2O", "CHEMICAL", 96, 99], ["H2O", "CHEMICAL", 120, 123], ["this study", "TEST", 4, 14], ["the bilevel PAP ST mode", "TREATMENT", 16, 39], ["pressure ranges EPAP", "TREATMENT", 64, 84], ["IPAP", "TREATMENT", 104, 108], ["RR", "TEST", 129, 131], ["pressure", "OBSERVATION_MODIFIER", 64, 72], ["ranges", "OBSERVATION_MODIFIER", 73, 79]]], ["The second bilevel PAP ST (device 2), a RemStar BiPAP S/T\u00ae (Philips Respironics, Murrysville, Pennsylvania, USA), is designed for home use.", [["The second bilevel PAP ST (device", "TREATMENT", 0, 33], ["a RemStar BiPAP S", "TREATMENT", 38, 55]]], ["It provides bilevel PAP ST also with EPAP 4 to 25 cm H2O and IPAP 4 to 30 cm H2O and RR 0\u201330 breaths/min.", [["H2O", "CHEMICAL", 53, 56], ["H2O", "CHEMICAL", 77, 80], ["H2O", "CHEMICAL", 53, 56], ["H2O", "CHEMICAL", 77, 80], ["bilevel PAP ST", "TREATMENT", 12, 26], ["EPAP", "TEST", 37, 41], ["IPAP", "TEST", 61, 65], ["RR", "TEST", 85, 87], ["25 cm", "OBSERVATION_MODIFIER", 47, 52]]], ["The inspiratory time was set at 1 s with rise time of 3 for both devices.Experimental protocol ::: Materials and methodsOn preliminary testing, there was no difference in the performance observed between the two single limb respiratory circuits in the animal model, and the second circuit (see Fig. 2) was chosen for the full testing protocol due to its simpler design.", [["limb", "ANATOMY", 219, 223], ["limb", "ORGANISM_SUBDIVISION", 219, 223], ["both devices", "TREATMENT", 60, 72], ["preliminary testing", "TEST", 123, 142], ["the second circuit", "TREATMENT", 270, 288], ["the full testing protocol", "TEST", 317, 342], ["respiratory circuits", "OBSERVATION", 224, 244]]], ["Following baseline data acquisition, each device was tested sequentially to characterize the in vivo respiratory mechanics of the two bilevel PAP ST devices as well as the anesthesia ventilator.", [["respiratory", "ANATOMY", 101, 112], ["baseline data acquisition", "TEST", 10, 35], ["each device", "TREATMENT", 37, 48], ["the two bilevel PAP ST devices", "TREATMENT", 126, 156], ["the anesthesia ventilator", "TREATMENT", 168, 193], ["respiratory mechanics", "OBSERVATION", 101, 122]]], ["Each device was set at various IPAP pressures ranging from 15 to 30 cm H2O with various EPAP settings (5, 10, 15, 20 cm H2O) and a RR of 20 breaths/min.", [["H2O", "CHEMICAL", 71, 74], ["H2O", "CHEMICAL", 71, 74], ["H2O", "CHEMICAL", 120, 123], ["Each device", "TREATMENT", 0, 11], ["various IPAP pressures", "TEST", 23, 45], ["various EPAP settings", "TREATMENT", 80, 101], ["a RR", "TEST", 129, 133], ["pressures", "OBSERVATION_MODIFIER", 36, 45]]], ["Initially and prior to each change in EPAP, a recruitment breath was delivered to recruit as many alveoli as possible.", [["alveoli", "ANATOMY", 98, 105], ["alveoli", "MULTI-TISSUE_STRUCTURE", 98, 105], ["EPAP", "TREATMENT", 38, 42], ["a recruitment breath", "TREATMENT", 44, 64]]], ["At the end of the recruitment breath, the devices were transitioned to the next higher EPAP setting.", [["the recruitment breath", "TREATMENT", 14, 36], ["the devices", "TREATMENT", 38, 49], ["the next higher EPAP setting", "TREATMENT", 71, 99]]], ["At each setting, flow-volume loops, peak airway pressures, mean airway pressures, and compliance data were acquired.Experimental protocol ::: Materials and methodsFollowing characterization of respiratory mechanics, the ability of the bilevel PAP ST devices to deliver a specified minute ventilation (VE) was evaluated.", [["airway", "ANATOMY", 41, 47], ["airway", "ANATOMY", 64, 70], ["respiratory", "ANATOMY", 193, 204], ["airway", "MULTI-TISSUE_STRUCTURE", 41, 47], ["airway", "MULTI-TISSUE_STRUCTURE", 64, 70], ["flow-volume loops", "TEST", 17, 34], ["peak airway pressures", "TEST", 36, 57], ["mean airway pressures", "TEST", 59, 80], ["compliance data", "TEST", 86, 101], ["respiratory mechanics", "TEST", 193, 214], ["the bilevel PAP ST devices", "TREATMENT", 231, 257], ["a specified minute ventilation", "TREATMENT", 269, 299], ["flow", "OBSERVATION", 17, 21], ["volume loops", "OBSERVATION", 22, 34], ["peak airway pressures", "OBSERVATION", 36, 57], ["airway pressures", "OBSERVATION", 64, 80], ["respiratory mechanics", "OBSERVATION", 193, 214]]], ["The IPAP/EPAP was adjusted to achieve a VT of 6 ml/kg.", [["IPAP", "CHEMICAL", 4, 8], ["IPAP", "SIMPLE_CHEMICAL", 4, 8], ["EPAP", "SIMPLE_CHEMICAL", 9, 13], ["The IPAP/EPAP", "TREATMENT", 0, 13]]], ["The devices were subjected to three scenarios based on different VE levels resulting in respiratory acidosis, normocapnia, and respiratory alkalosis.ResultsBoth bilevel PAP ST devices were tested to characterize the respiratory mechanics at varying IPAP and EPAP levels (see Table 1).", [["respiratory", "ANATOMY", 88, 99], ["respiratory", "ANATOMY", 127, 138], ["respiratory", "ANATOMY", 216, 227], ["respiratory acidosis", "DISEASE", 88, 108], ["respiratory alkalosis", "DISEASE", 127, 148], ["The devices", "TREATMENT", 0, 11], ["different VE levels", "TEST", 55, 74], ["respiratory acidosis", "PROBLEM", 88, 108], ["normocapnia", "PROBLEM", 110, 121], ["respiratory alkalosis", "PROBLEM", 127, 148], ["Both bilevel PAP ST devices", "TREATMENT", 156, 183], ["the respiratory mechanics", "TEST", 212, 237], ["varying IPAP", "TREATMENT", 241, 253], ["EPAP levels", "TEST", 258, 269], ["respiratory acidosis", "OBSERVATION", 88, 108], ["normocapnia", "OBSERVATION", 110, 121], ["respiratory alkalosis", "OBSERVATION", 127, 148], ["respiratory mechanics", "OBSERVATION", 216, 237]]], ["When compared to an anesthesia ventilator, both tested devices generated lower VT at various settings.", [["an anesthesia ventilator", "TREATMENT", 17, 41], ["both tested devices", "TREATMENT", 43, 62], ["lower", "OBSERVATION_MODIFIER", 73, 78], ["VT", "OBSERVATION", 79, 81]]], ["Device 1 approximated VT closer to the anesthesia ventilator than device 2.", [["Device", "TREATMENT", 0, 6], ["the anesthesia ventilator", "TREATMENT", 35, 60]]], ["Device 1 provided a slightly higher measured VT compared to the anesthesia ventilator only at the IPAP/EPAP 30/20 cm H2O setting.", [["H2O", "CHEMICAL", 117, 120], ["H2O", "CHEMICAL", 117, 120], ["a slightly higher measured VT", "PROBLEM", 18, 47], ["the anesthesia ventilator", "TREATMENT", 60, 85], ["the IPAP/EPAP", "TREATMENT", 94, 107]]], ["Measured peak inspiratory and expiratory flow rates were generally equal and consistent at equivalent IPAP/EPAP levels.", [["EPAP", "SIMPLE_CHEMICAL", 107, 111], ["EPAP", "PROTEIN", 107, 111], ["Measured peak inspiratory", "TEST", 0, 25], ["expiratory flow rates", "TEST", 30, 51], ["peak", "OBSERVATION_MODIFIER", 9, 13], ["inspiratory", "OBSERVATION_MODIFIER", 14, 25], ["expiratory flow", "OBSERVATION", 30, 45]]], ["Using 5 L/min and 10 L/min of oxygen, a FiO2 of 0.50 and 0.85, respectively, were achieved using the pressure line adaptor in the single limb respiratory circuit.ResultsIn the evaluation of the VE, the test devices\u2019 pressure settings and RR were manipulated targeting a VT of 6 ml/kg to generate three acid-base balance conditions: respiratory acidosis, normocapnia, and respiratory alkalosis.", [["limb", "ANATOMY", 137, 141], ["respiratory", "ANATOMY", 332, 343], ["respiratory", "ANATOMY", 371, 382], ["oxygen", "CHEMICAL", 30, 36], ["respiratory acidosis", "DISEASE", 332, 352], ["respiratory alkalosis", "DISEASE", 371, 392], ["oxygen", "CHEMICAL", 30, 36], ["FiO2", "CHEMICAL", 40, 44], ["oxygen", "SIMPLE_CHEMICAL", 30, 36], ["limb", "ORGANISM_SUBDIVISION", 137, 141], ["oxygen", "TREATMENT", 30, 36], ["a FiO2", "TREATMENT", 38, 44], ["the pressure line adaptor", "TREATMENT", 97, 122], ["the single limb respiratory circuit", "TREATMENT", 126, 161], ["the evaluation", "TEST", 172, 186], ["the VE", "TEST", 190, 196], ["the test devices", "TEST", 198, 214], ["pressure settings", "TREATMENT", 216, 233], ["RR", "TEST", 238, 240], ["three acid-base balance conditions", "PROBLEM", 296, 330], ["respiratory acidosis", "PROBLEM", 332, 352], ["normocapnia", "PROBLEM", 354, 365], ["respiratory alkalosis", "PROBLEM", 371, 392], ["pressure line", "OBSERVATION", 101, 114], ["limb", "ANATOMY", 137, 141], ["respiratory circuit", "OBSERVATION", 142, 161], ["respiratory acidosis", "OBSERVATION", 332, 352], ["normocapnia", "OBSERVATION", 354, 365], ["respiratory alkalosis", "OBSERVATION", 371, 392]]], ["These scenarios were performed in three separate trials, one using device 1 and two using device 2 (see Table 2).ResultsIn trial 1, device 1 was programmed to deliver an IPAP of 23 cm H2O and an EPAP of 10 cm H2O.", [["H2O", "CHEMICAL", 184, 187], ["H2O", "CHEMICAL", 209, 212], ["H2O", "CHEMICAL", 184, 187], ["H2O", "CHEMICAL", 209, 212], ["device", "TREATMENT", 67, 73], ["an IPAP", "TREATMENT", 167, 174], ["an EPAP", "TEST", 192, 199], ["10 cm", "OBSERVATION_MODIFIER", 203, 208]]], ["These pressures were maintained throughout all three scenarios.", [["These pressures", "TEST", 0, 15], ["pressures", "OBSERVATION_MODIFIER", 6, 15]]], ["To induce respiratory acidosis, the RR was programmed to 10 breaths/min and an ABG revealed respiratory acidosis, with pH 7.31, and PaCO2 of 61.9 mmHg with ETCO2 of 65 mmHg.", [["respiratory", "ANATOMY", 10, 21], ["respiratory", "ANATOMY", 92, 103], ["respiratory acidosis", "DISEASE", 10, 30], ["respiratory acidosis", "DISEASE", 92, 112], ["respiratory acidosis", "PROBLEM", 10, 30], ["the RR", "TEST", 32, 38], ["an ABG", "TEST", 76, 82], ["respiratory acidosis", "PROBLEM", 92, 112], ["pH", "TEST", 119, 121], ["PaCO2", "TEST", 132, 137], ["ETCO2", "TEST", 156, 161], ["respiratory acidosis", "OBSERVATION", 10, 30], ["respiratory acidosis", "OBSERVATION", 92, 112]]], ["Next, the RR was increased to 20 breath/min in an effort to reach eucapnia.", [["eucapnia", "DISEASE", 66, 74], ["the RR", "TEST", 6, 12]]], ["ABG revealed a pH 7.43, and a PaCO2 45 mmHg with ETCO2 at 43 mmHg.", [["ABG", "CHEMICAL", 0, 3], ["ABG", "TEST", 0, 3], ["a pH", "TEST", 13, 17], ["a PaCO2", "TEST", 28, 35], ["ETCO2", "TEST", 49, 54]]], ["Next, the RR was increased to 25 breaths/min to induce respiratory alkalosis, and an ABG revealed a pH 7.45, and a PaCO2 44.7 mmHg with ETCO2 38 mmHg.ResultsIn trial 2, device 2 was programmed to deliver an IPAP of 20 cm H2O and an EPAP of 10 cm H2O.", [["respiratory", "ANATOMY", 55, 66], ["respiratory alkalosis", "DISEASE", 55, 76], ["H2O", "CHEMICAL", 221, 224], ["H2O", "CHEMICAL", 246, 249], ["H2O", "CHEMICAL", 221, 224], ["H2O", "CHEMICAL", 246, 249], ["the RR", "TEST", 6, 12], ["respiratory alkalosis", "PROBLEM", 55, 76], ["an ABG", "TEST", 82, 88], ["a pH", "TEST", 98, 102], ["a PaCO2", "TEST", 113, 120], ["ETCO2", "TEST", 136, 141], ["an IPAP", "TREATMENT", 204, 211], ["an EPAP", "TEST", 229, 236], ["respiratory alkalosis", "OBSERVATION", 55, 76], ["10 cm", "OBSERVATION_MODIFIER", 240, 245]]], ["To induce respiratory acidosis, the RR was programmed to 15 breaths/min and an ABG was obtained.", [["respiratory", "ANATOMY", 10, 21], ["respiratory acidosis", "DISEASE", 10, 30], ["ABG", "CHEMICAL", 79, 82], ["respiratory acidosis", "PROBLEM", 10, 30], ["the RR", "TEST", 32, 38], ["an ABG", "TEST", 76, 82], ["respiratory acidosis", "OBSERVATION", 10, 30]]], ["This caused a respiratory acidosis with a pH 7.38, and PaCO2 51.9 mmHg with ETCO2 51 mmHg.", [["respiratory", "ANATOMY", 14, 25], ["acidosis", "DISEASE", 26, 34], ["a respiratory acidosis", "PROBLEM", 12, 34], ["a pH", "TEST", 40, 44], ["PaCO2", "TEST", 55, 60], ["mmHg", "TEST", 66, 70], ["ETCO2", "TEST", 76, 81], ["respiratory acidosis", "OBSERVATION", 14, 34]]], ["Next, the IPAP was decreased to 18 cm H2O and the RR was increased to 20 breaths/min in an effort to reach eucapnia.", [["H2O", "CHEMICAL", 38, 41], ["eucapnia", "DISEASE", 107, 115], ["H2O", "CHEMICAL", 38, 41], ["IPAP", "SIMPLE_CHEMICAL", 10, 14], ["the IPAP", "TEST", 6, 14], ["the RR", "TEST", 46, 52], ["18 cm", "OBSERVATION_MODIFIER", 32, 37]]], ["An ABG revealed a pH 7.41, and a PaCO2 47.9 mmHg with ETCO2 51 mmHg.", [["ABG", "CHEMICAL", 3, 6], ["An ABG", "TEST", 0, 6], ["a pH", "TEST", 16, 20], ["a PaCO2", "TEST", 31, 38], ["ETCO2", "TEST", 54, 59]]], ["Next, the IPAP was increased to 25 cm H2O and the RR was increased to 30 breaths/min to induce respiratory alkalosis, and an ABG revealed a pH 7.53, and a PaCO2 34.9 mmHg with an ETCO2 30 mmHg.ResultsIn trial 3, device 2 was programmed to deliver an IPAP of 23 cm H2O and an EPAP of 10 cm H2O.", [["respiratory", "ANATOMY", 95, 106], ["H2O", "CHEMICAL", 38, 41], ["respiratory alkalosis", "DISEASE", 95, 116], ["H2O", "CHEMICAL", 264, 267], ["H2O", "CHEMICAL", 289, 292], ["H2O", "CHEMICAL", 38, 41], ["ABG", "CHEMICAL", 125, 128], ["H2O", "CHEMICAL", 264, 267], ["H2O", "CHEMICAL", 289, 292], ["IPAP", "SIMPLE_CHEMICAL", 10, 14], ["the IPAP", "TEST", 6, 14], ["the RR", "TEST", 46, 52], ["respiratory alkalosis", "PROBLEM", 95, 116], ["an ABG", "TEST", 122, 128], ["a pH", "TEST", 138, 142], ["a PaCO2", "TEST", 153, 160], ["an ETCO2", "TEST", 176, 184], ["an IPAP", "TREATMENT", 247, 254], ["an EPAP", "TEST", 272, 279], ["25 cm", "OBSERVATION_MODIFIER", 32, 37], ["respiratory alkalosis", "OBSERVATION", 95, 116], ["10 cm", "OBSERVATION_MODIFIER", 283, 288]]], ["To induce respiratory acidosis, the RR was programmed to 10 breaths/min and an ABG revealed a respiratory acidosis with a pH 7.35, and a PaCO2 of 55.1 mmHg with ETCO2 55 mmHg.", [["respiratory", "ANATOMY", 10, 21], ["respiratory", "ANATOMY", 94, 105], ["respiratory acidosis", "DISEASE", 10, 30], ["respiratory acidosis", "DISEASE", 94, 114], ["respiratory acidosis", "PROBLEM", 10, 30], ["the RR", "TEST", 32, 38], ["an ABG", "TEST", 76, 82], ["a respiratory acidosis", "PROBLEM", 92, 114], ["a pH", "TEST", 120, 124], ["a PaCO2", "TEST", 135, 142], ["ETCO2", "TEST", 161, 166], ["respiratory acidosis", "OBSERVATION", 10, 30], ["respiratory acidosis", "OBSERVATION", 94, 114]]], ["Next, the RR was increased to 20 breath/min in an effort to reach eucapnia.", [["eucapnia", "DISEASE", 66, 74], ["the RR", "TEST", 6, 12]]], ["An ABG revealed a pH 7.43 and a PaCO2 44.8 mmHg with ETCO2 44 mmHg.", [["ABG", "CHEMICAL", 3, 6], ["An ABG", "TEST", 0, 6], ["a pH", "TEST", 16, 20], ["a PaCO2", "TEST", 30, 37], ["mmHg", "TEST", 43, 47], ["ETCO2", "TEST", 53, 58]]], ["Next, the IPAP was increased to 25 cm H2O and the RR was increased to 22 breaths/min to induce respiratory alkalosis, and an ABG revealed a pH 7.45 and a PaCO2 42.4 mmHg with an ETCO2 42 mmHg.DiscussionIn the current study, we demonstrated the feasibility of noninvasive home and sleep laboratory bilevel PAP ST devices to provide invasive ventilation with two different single limb passive breathing circuits with an intentional leak.", [["respiratory", "ANATOMY", 95, 106], ["limb", "ANATOMY", 378, 382], ["H2O", "CHEMICAL", 38, 41], ["respiratory alkalosis", "DISEASE", 95, 116], ["H2O", "CHEMICAL", 38, 41], ["IPAP", "SIMPLE_CHEMICAL", 10, 14], ["limb", "ORGANISM_SUBDIVISION", 378, 382], ["the IPAP", "TEST", 6, 14], ["the RR", "TEST", 46, 52], ["respiratory alkalosis", "PROBLEM", 95, 116], ["an ABG", "TEST", 122, 128], ["a pH", "TEST", 138, 142], ["a PaCO2", "TEST", 152, 159], ["an ETCO2", "TEST", 175, 183], ["sleep laboratory bilevel PAP ST devices", "TREATMENT", 280, 319], ["invasive ventilation", "TREATMENT", 331, 351], ["two different single limb passive breathing circuits", "TREATMENT", 357, 409], ["an intentional leak", "PROBLEM", 415, 434], ["25 cm", "OBSERVATION_MODIFIER", 32, 37], ["respiratory alkalosis", "OBSERVATION", 95, 116], ["passive breathing circuits", "OBSERVATION", 383, 409], ["intentional leak", "OBSERVATION", 418, 434]]], ["These devices were able to maintain both adequate ventilation and oxygenation.", [["These devices", "TREATMENT", 0, 13], ["adequate", "OBSERVATION_MODIFIER", 41, 49], ["ventilation", "OBSERVATION", 50, 61], ["oxygenation", "OBSERVATION_MODIFIER", 66, 77]]], ["Furthermore, both devices were able to induce respiratory alkalosis.", [["respiratory", "ANATOMY", 46, 57], ["respiratory alkalosis", "DISEASE", 46, 67], ["both devices", "TREATMENT", 13, 25], ["respiratory alkalosis", "PROBLEM", 46, 67], ["respiratory alkalosis", "OBSERVATION", 46, 67]]], ["This is the first study using an animal model to evaluate the ability of NIPPV home and sleep laboratory devices to provide invasive ventilation in the context of the current COVID-19 pandemic.DiscussionMechanical ventilators are complex and expensive medical devices that require specialized training for safe and effective use.", [["the first study", "TEST", 8, 23], ["NIPPV home", "TREATMENT", 73, 83], ["sleep laboratory devices", "TREATMENT", 88, 112], ["invasive ventilation", "TREATMENT", 124, 144], ["the current COVID", "TEST", 163, 180], ["pandemic", "PROBLEM", 184, 192], ["Mechanical ventilators", "TREATMENT", 203, 225], ["expensive medical devices", "TREATMENT", 242, 267], ["specialized training", "TREATMENT", 281, 301]]], ["Positive pressure is delivered via a respiratory circuit that connects ventilator tubing to either an endotracheal tube or a noninvasive mask interface.", [["respiratory", "ANATOMY", 37, 48], ["endotracheal", "ANATOMY", 102, 114], ["a respiratory circuit", "TREATMENT", 35, 56], ["ventilator tubing", "TREATMENT", 71, 88], ["an endotracheal tube", "TREATMENT", 99, 119], ["a noninvasive mask interface", "TREATMENT", 123, 151], ["pressure", "OBSERVATION_MODIFIER", 9, 17], ["respiratory circuit", "OBSERVATION", 37, 56], ["ventilator tubing", "OBSERVATION", 71, 88], ["endotracheal tube", "OBSERVATION", 102, 119]]], ["Most conventional mechanical ventilators use a double-limb respiratory circuit, composed of inspiratory and expiratory limbs.", [["limb", "ANATOMY", 54, 58], ["limbs", "ANATOMY", 119, 124], ["limb", "ORGANISM_SUBDIVISION", 54, 58], ["limbs", "ORGANISM_SUBDIVISION", 119, 124], ["Most conventional mechanical ventilators", "TREATMENT", 0, 40], ["a double-limb respiratory circuit", "TREATMENT", 45, 78], ["mechanical ventilators", "OBSERVATION", 18, 40], ["limb", "ANATOMY", 54, 58], ["respiratory circuit", "OBSERVATION", 59, 78], ["inspiratory", "ANATOMY", 92, 103], ["expiratory limbs", "ANATOMY", 108, 124]]], ["The limbs attach to a ventilator and contain one-way valves that prevent rebreathing and CO2 retention.", [["limbs", "ANATOMY", 4, 9], ["CO2", "CHEMICAL", 89, 92], ["CO2", "CHEMICAL", 89, 92], ["limbs", "ORGANISM_SUBDIVISION", 4, 9], ["CO2", "SIMPLE_CHEMICAL", 89, 92], ["a ventilator", "TREATMENT", 20, 32], ["one-way valves", "TREATMENT", 45, 59], ["CO2 retention", "PROBLEM", 89, 102], ["limbs", "ANATOMY", 4, 9], ["valves", "OBSERVATION", 53, 59], ["CO2 retention", "OBSERVATION", 89, 102]]], ["These limbs meet at a Y-connector distally that then connects to an endotracheal tube.", [["limbs", "ANATOMY", 6, 11], ["endotracheal tube", "ANATOMY", 68, 85], ["limbs", "ORGAN", 6, 11], ["endotracheal tube", "TISSUE", 68, 85], ["an endotracheal tube", "TREATMENT", 65, 85], ["limbs", "ANATOMY", 6, 11], ["endotracheal tube", "OBSERVATION", 68, 85]]], ["Humidification and filtration can be connected within the circuit at various locations [8, 16].", [["Humidification", "TREATMENT", 0, 14], ["filtration", "TREATMENT", 19, 29]]], ["A critical shortage of medical resources is projected during the COVID-19 pandemic [6].", [["the COVID", "TEST", 61, 70]]], ["When ventilators are unavailable, bilevel PAP ST devices could be used with endotracheal intubation, but it must be understood that they were not approved to be used in this way and would be used under a special FDA exception during this crisis situation [5].DiscussionOne potential concern for using bilevel PAP ST devices invasively is that these devices were not designed to overcome the resistance of an endotracheal tube.", [["endotracheal", "ANATOMY", 76, 88], ["endotracheal tube", "ANATOMY", 408, 425], ["endotracheal tube", "MULTI-TISSUE_STRUCTURE", 408, 425], ["ventilators", "TREATMENT", 5, 16], ["bilevel PAP ST devices", "TREATMENT", 34, 56], ["endotracheal intubation", "TREATMENT", 76, 99], ["bilevel PAP ST devices invasively", "TREATMENT", 301, 334], ["these devices", "TREATMENT", 343, 356], ["an endotracheal tube", "TREATMENT", 405, 425], ["endotracheal tube", "OBSERVATION", 408, 425]]], ["In this study, we found that the intratracheal pressures were fairly consistent with the use of the bilevel PAP ST devices and were comparable to those obtained with an anesthesia ventilator, so the added resistance of an endotracheal tube compared to a mask interface did not affect significantly the functionality of these devices.", [["endotracheal tube", "ANATOMY", 222, 239], ["endotracheal tube", "MULTI-TISSUE_STRUCTURE", 222, 239], ["this study", "TEST", 3, 13], ["the intratracheal pressures", "TEST", 29, 56], ["the bilevel PAP ST devices", "TREATMENT", 96, 122], ["an anesthesia ventilator", "TREATMENT", 166, 190], ["an endotracheal tube", "TREATMENT", 219, 239], ["a mask interface", "TREATMENT", 252, 268], ["intratracheal pressures", "OBSERVATION", 33, 56], ["endotracheal tube", "OBSERVATION", 222, 239]]], ["There was also concern that the FiO2 that could be achieved with bleed-in O2 adaptors would be severely limited.", [["FiO2", "CHEMICAL", 32, 36], ["O2", "CHEMICAL", 74, 76], ["O2", "SIMPLE_CHEMICAL", 74, 76], ["the FiO2", "TREATMENT", 28, 36], ["bleed", "PROBLEM", 65, 70], ["O2 adaptors", "TREATMENT", 74, 85]]], ["However, the bilevel PAP ST devices were able to maintain a FiO2 of 0.5 and 0.85 with an O2 bleed-in rate of 5 L/min and 10 L/min, respectively, and thus, oxygenation does not appear to be a severe limitation of these circuits and devices.DiscussionInterestingly, device 1 achieved higher VTs than device 2 at various pressure settings.", [["O2", "CHEMICAL", 89, 91], ["O2", "SIMPLE_CHEMICAL", 89, 91], ["the bilevel PAP ST devices", "TREATMENT", 9, 35], ["a FiO2", "TEST", 58, 64], ["an O2 bleed", "PROBLEM", 86, 97], ["a severe limitation of these circuits", "PROBLEM", 189, 226], ["various pressure settings", "TREATMENT", 310, 335], ["bleed", "OBSERVATION", 92, 97], ["severe", "OBSERVATION_MODIFIER", 191, 197]]], ["Device 1 is a newer, multi-function device designed for sleep laboratories, and device 2 is a simpler bilevel PAP ST designed for home use.", [["a newer, multi-function device", "TREATMENT", 12, 42], ["sleep laboratories", "TEST", 56, 74], ["device", "TREATMENT", 80, 86], ["a simpler bilevel PAP ST", "TREATMENT", 92, 116]]], ["In the VE challenge, tachypnea was needed to achieve eucapnia.", [["tachypnea", "DISEASE", 21, 30], ["eucapnia", "DISEASE", 53, 61], ["tachypnea", "PROBLEM", 21, 30], ["eucapnia", "PROBLEM", 53, 61]]], ["This is clinically relevant, as higher RRs may be required to maintain adequate VE, and as we identified, different devices may perform differently at the same pressure and rate settings.DiscussionBecause these devices would only be considered for invasive use in resource-constrained situations, there is an implication that during use, one or more parts of the respiratory circuit will be unavailable.", [["respiratory", "ANATOMY", 363, 374], ["these devices", "TREATMENT", 205, 218], ["the respiratory circuit", "TREATMENT", 359, 382], ["respiratory circuit", "OBSERVATION", 363, 382]]], ["The single limb circuits used in this study were constructed from parts that are usually readily available commercially and were not especially manufactured for the study.", [["limb", "ANATOMY", 11, 15], ["limb", "ORGANISM_SUBDIVISION", 11, 15], ["The single limb circuits", "TREATMENT", 0, 24], ["this study", "TEST", 33, 43], ["the study", "TEST", 161, 170], ["limb circuits", "ANATOMY", 11, 24]]], ["Potentially, adequate replacements for the circuit components could be rapidly manufactured as needed.", [["adequate replacements", "TREATMENT", 13, 34], ["the circuit components", "TREATMENT", 39, 61], ["adequate replacements", "OBSERVATION", 13, 34]]], ["Both tested circuits performed well, but we felt that the SyncVent passive exhalation adapter was simpler to use.", [["the SyncVent passive exhalation adapter", "TREATMENT", 54, 93]]], ["The exhaust collector and PEEP valve assembly had to be adjusted with changes in the EPAP setting, whereas the SyncVent passive exhalation adapter did not need any additional adjustments.DiscussionTo our knowledge, only one study has reported the use of a bilevel PAP ST device designed exclusively for NIPPV for invasive ventilation.", [["The exhaust collector", "TREATMENT", 0, 21], ["PEEP valve", "TREATMENT", 26, 36], ["the SyncVent passive exhalation adapter", "TREATMENT", 107, 146], ["any additional adjustments", "TREATMENT", 160, 186], ["a bilevel PAP ST device", "TREATMENT", 254, 277], ["NIPPV", "TREATMENT", 303, 308], ["invasive ventilation", "TREATMENT", 313, 333], ["exhaust collector", "OBSERVATION", 4, 21], ["PEEP valve", "OBSERVATION", 26, 36]]], ["In an observational study performed in India, 20 patients with COPD exacerbation and reduced level of consciousness, who could not afford the use of a standard mechanical ventilator, were intubated and placed on a bilevel PAP ST (BiPAP S/T) [15].", [["COPD", "DISEASE", 63, 67], ["reduced level of consciousness", "DISEASE", 85, 115], ["patients", "ORGANISM", 49, 57], ["patients", "SPECIES", 49, 57], ["an observational study", "TEST", 3, 25], ["COPD exacerbation", "PROBLEM", 63, 80], ["reduced level of consciousness", "PROBLEM", 85, 115], ["a standard mechanical ventilator", "TREATMENT", 149, 181], ["intubated", "TREATMENT", 188, 197], ["a bilevel PAP ST", "TREATMENT", 212, 228], ["COPD", "OBSERVATION", 63, 67]]], ["Therapy was successful in 85% of the patients, defined as gaining full consciousness and being discharged home.", [["patients", "ORGANISM", 37, 45], ["patients", "SPECIES", 37, 45], ["Therapy", "TREATMENT", 0, 7]]], ["All responders had improvement at 2 h of therapy, compared to the non-responders, who did not.", [["therapy", "TREATMENT", 41, 48], ["improvement", "OBSERVATION_MODIFIER", 19, 30]]], ["The duration of ventilation for responders was 3.8 (2.7 to 5.0) days, while length of hospitalization was 8 (5 to 15) days.DiscussionA similar study was conducted in Pakistan with endotracheal intubation utilizing a Stellar 150 device (ResMed, San Diego, California, USA) (personal communication, author), a more advanced device compared to a bilevel PAP ST [17].", [["endotracheal", "ANATOMY", 180, 192], ["ventilation", "TREATMENT", 16, 27], ["responders", "TEST", 32, 42], ["similar study", "TEST", 135, 148], ["endotracheal intubation", "TREATMENT", 180, 203], ["a Stellar 150 device", "TREATMENT", 214, 234], ["a more advanced device", "TREATMENT", 306, 328], ["a bilevel PAP ST", "TEST", 341, 357]]], ["This device is approved for noninvasive and invasive use at home and in healthcare settings.", [["This device", "TREATMENT", 0, 11]]], ["This study described 44 consecutive patients with severe COPD exacerbation with reduced level of consciousness.", [["COPD", "DISEASE", 57, 61], ["reduced level of consciousness", "DISEASE", 80, 110], ["patients", "ORGANISM", 36, 44], ["patients", "SPECIES", 36, 44], ["This study", "TEST", 0, 10], ["severe COPD exacerbation", "PROBLEM", 50, 74], ["reduced level of consciousness", "PROBLEM", 80, 110], ["severe", "OBSERVATION_MODIFIER", 50, 56], ["COPD", "OBSERVATION", 57, 61], ["reduced", "OBSERVATION_MODIFIER", 80, 87]]], ["Thirty-one (70.5%) patients responded to therapy.", [["patients", "ORGANISM", 19, 27], ["patients", "SPECIES", 19, 27], ["therapy", "TREATMENT", 41, 48]]], ["All responders had improvement at 2 h of therapy, compared to the non-responders, who did not [17].DiscussionWhile bilevel PAP ST devices cannot generate peak pressures higher than 30 cm H2O, they appear to be capable of maintaining and manipulating VE in this model.", [["H2O", "CHEMICAL", 187, 190], ["H2O", "CHEMICAL", 187, 190], ["therapy", "TREATMENT", 41, 48], ["bilevel PAP ST devices", "TREATMENT", 115, 137], ["peak pressures", "TEST", 154, 168], ["pressures", "OBSERVATION_MODIFIER", 159, 168], ["higher", "OBSERVATION_MODIFIER", 169, 175]]], ["These devices could be used to ventilate patients invasively prior to the onset of severe ARDS.", [["ARDS", "DISEASE", 90, 94], ["patients", "ORGANISM", 41, 49], ["patients", "SPECIES", 41, 49], ["These devices", "TREATMENT", 0, 13], ["severe ARDS", "PROBLEM", 83, 94], ["severe", "OBSERVATION_MODIFIER", 83, 89], ["ARDS", "OBSERVATION", 90, 94]]], ["It is worth noting that hypoxemic respiratory failure associated with COVID-19 is a heterogeneous process [18].", [["respiratory", "ANATOMY", 34, 45], ["hypoxemic respiratory failure", "DISEASE", 24, 53], ["COVID-19", "CHEMICAL", 70, 78], ["COVID-19", "CHEMICAL", 70, 78], ["hypoxemic respiratory failure", "PROBLEM", 24, 53], ["COVID", "TEST", 70, 75], ["a heterogeneous process", "PROBLEM", 82, 105], ["hypoxemic", "OBSERVATION_MODIFIER", 24, 33], ["respiratory failure", "OBSERVATION", 34, 53], ["heterogeneous", "OBSERVATION_MODIFIER", 84, 97]]], ["Therefore, it may be premature to dismiss using NIPPV devices generating lower pressures as there may be a greater role for these devices as our understanding of COVID-19 physiology evolves.", [["NIPPV devices", "TREATMENT", 48, 61], ["lower pressures", "TREATMENT", 73, 88], ["these devices", "TREATMENT", 124, 137], ["COVID", "TEST", 162, 167], ["may be", "UNCERTAINTY", 14, 20]]], ["Unusually, long periods of ventilation in COVID-19 patients have been reported, and bilevel PAP ST devices could also be utilized invasively in a post-ARDS setting when attempting to wean from the ventilator to allow conventional ventilators to be allocated to more severe and critically ill ARDS cases [19].DiscussionOther single limb circuit designs could potentially be used other than the ones that we tested.", [["limb", "ANATOMY", 331, 335], ["ARDS", "DISEASE", 151, 155], ["critically ill", "DISEASE", 277, 291], ["ARDS", "DISEASE", 292, 296], ["patients", "ORGANISM", 51, 59], ["limb", "ORGANISM_SUBDIVISION", 331, 335], ["patients", "SPECIES", 51, 59], ["ventilation", "TREATMENT", 27, 38], ["bilevel PAP ST devices", "TREATMENT", 84, 106], ["a post-ARDS setting", "TREATMENT", 144, 163], ["the ventilator", "TREATMENT", 193, 207], ["conventional ventilators", "TREATMENT", 217, 241], ["critically ill ARDS cases", "PROBLEM", 277, 302], ["single limb circuit designs", "TREATMENT", 324, 351], ["long", "OBSERVATION_MODIFIER", 11, 15]]], ["If required in a resource-poor condition, the key principles to consider when constructing these circuits are that all exhaled air must be filtered and the exhalation port or valve leak must be adequate to prevent rebreathing of CO2.DiscussionThis was a proof-of-concept design that was intended to show the feasibility of using bilevel PAP ST devices for invasive ventilation in an animal model.", [["valve", "ANATOMY", 175, 180], ["CO2", "CHEMICAL", 229, 232], ["CO2", "CHEMICAL", 229, 232], ["valve", "MULTI-TISSUE_STRUCTURE", 175, 180], ["CO2", "SIMPLE_CHEMICAL", 229, 232], ["all exhaled air", "PROBLEM", 115, 130], ["the exhalation port", "TREATMENT", 152, 171], ["valve leak", "PROBLEM", 175, 185], ["rebreathing of CO2", "PROBLEM", 214, 232], ["bilevel PAP ST devices", "TREATMENT", 329, 351], ["invasive ventilation", "TREATMENT", 356, 376], ["valve", "ANATOMY", 175, 180], ["leak", "OBSERVATION", 181, 185], ["invasive ventilation", "OBSERVATION", 356, 376]]], ["There are limitations to both this study design and to the practical application.", [["this study", "TEST", 30, 40], ["the practical application", "TREATMENT", 55, 80]]], ["Regarding the study design limitations, we used a healthy swine model.", [["swine", "ORGANISM", 58, 63], ["swine", "SPECIES", 58, 63], ["swine", "SPECIES", 58, 63], ["the study", "TEST", 10, 19], ["a healthy swine model", "TREATMENT", 48, 69]]], ["It is unknown if the performance of the bilevel PAP ST devices would be comparable in a swine model or human with ARDS, which limits the generalizability of these findings.", [["ARDS", "DISEASE", 114, 118], ["human", "ORGANISM", 103, 108], ["swine", "SPECIES", 88, 93], ["human", "SPECIES", 103, 108], ["swine", "SPECIES", 88, 93], ["human", "SPECIES", 103, 108], ["the bilevel PAP ST devices", "TREATMENT", 36, 62], ["ARDS", "PROBLEM", 114, 118], ["ARDS", "OBSERVATION", 114, 118]]], ["A future study of bilevel PAP ST in a diseased/ARDS model is warranted.DiscussionThere are four important limitations to the practical application that clinicians should consider when using bilevel PAP ST devices as standard ventilators.", [["ARDS", "DISEASE", 47, 51], ["A future study", "TEST", 0, 14], ["bilevel PAP ST", "PROBLEM", 18, 32], ["a diseased/ARDS model", "PROBLEM", 36, 57], ["bilevel PAP ST devices", "TREATMENT", 190, 212], ["standard ventilators", "TREATMENT", 216, 236], ["ARDS", "OBSERVATION", 47, 51]]], ["First, these devices do not usually have an internal battery, and an uninterrupted power supply is recommended as back-up.", [["these devices", "TREATMENT", 7, 20], ["an internal battery", "TEST", 41, 60], ["an uninterrupted power supply", "TREATMENT", 66, 95]]], ["It is not well known how the devices will perform when used continuously for many days or how long they will function without needing replacement when used under those conditions.", [["replacement", "TREATMENT", 134, 145]]], ["Third, alarms are usually not included on these devices, requiring closer monitoring of these patients.", [["patients", "ORGANISM", 94, 102], ["patients", "SPECIES", 94, 102], ["these devices", "TREATMENT", 42, 55], ["closer monitoring", "TEST", 67, 84]]], ["Use of continuous pulse oximetry, telemetry, ETCO2 monitoring, and airway pressure monitoring would provide an extra layer of safety.", [["airway", "ANATOMY", 67, 73], ["airway", "MULTI-TISSUE_STRUCTURE", 67, 73], ["continuous pulse oximetry", "TREATMENT", 7, 32], ["telemetry", "TEST", 34, 43], ["ETCO2 monitoring", "TEST", 45, 61], ["airway pressure monitoring", "TEST", 67, 93], ["airway", "ANATOMY", 67, 73]]], ["A flow sensor in the circuit, adjacent to the patient, could provide a source for an alarm.", [["patient", "ORGANISM", 46, 53], ["patient", "SPECIES", 46, 53], ["A flow sensor in the circuit", "TREATMENT", 0, 28], ["flow sensor", "OBSERVATION", 2, 13]]], ["Fourth, VT cannot be measured directly, unlike conventional mechanical ventilators, unless an external measuring device is used.DiscussionThe proposed circuit has shown feasibility in an animal model and may be considered as an alternative method of providing adequate ventilation and oxygenation if all conventional ventilator options have been exhausted.", [["conventional mechanical ventilators", "TREATMENT", 47, 82], ["an external measuring device", "TREATMENT", 91, 119], ["The proposed circuit", "TREATMENT", 138, 158], ["adequate ventilation", "TREATMENT", 260, 280], ["all conventional ventilator options", "TREATMENT", 300, 335], ["mechanical ventilators", "OBSERVATION", 60, 82]]], ["Further studies in animal models of ARDS and in humans would provide more information of the utility of these devices in the current COVID-19 pandemic and beyond.", [["ARDS", "DISEASE", 36, 40], ["humans", "ORGANISM", 48, 54], ["humans", "SPECIES", 48, 54], ["humans", "SPECIES", 48, 54], ["Further studies", "TEST", 0, 15], ["ARDS", "PROBLEM", 36, 40], ["these devices", "TREATMENT", 104, 117], ["the current COVID", "TEST", 121, 138], ["ARDS", "OBSERVATION", 36, 40]]], ["Given the FDA emergency use authorization and the scarcity of ventilator options during the COVID-19 pandemic, we felt it necessary to provide these early findings to the medical community.", [["ventilator options", "TREATMENT", 62, 80], ["the COVID", "TEST", 88, 97]]]], "b4da943c4da0e6fb285fd6b1283f2813ced6f080": [], "13f8fe9cd4b06843fce134699ecc8b89cf6a2353": [["INTRODUCTIONDiphtheria, a bacterial disease caused by Corynebacterium diphtheriae, is a vaccinepreventable disease.", [["bacterial disease", "DISEASE", 26, 43], ["Corynebacterium diphtheriae", "DISEASE", 54, 81], ["Corynebacterium diphtheriae", "ORGANISM", 54, 81], ["Corynebacterium diphtheriae", "SPECIES", 54, 81], ["Corynebacterium diphtheriae", "SPECIES", 54, 81], ["a bacterial disease", "PROBLEM", 24, 43], ["Corynebacterium diphtheriae", "PROBLEM", 54, 81], ["a vaccinepreventable disease", "PROBLEM", 86, 114], ["bacterial disease", "OBSERVATION", 26, 43], ["Corynebacterium diphtheriae", "OBSERVATION", 54, 81]]], ["Symptomatic patients initially complain sore throat and fever.", [["sore throat", "DISEASE", 40, 51], ["fever", "DISEASE", 56, 61], ["patients", "ORGANISM", 12, 20], ["patients", "SPECIES", 12, 20], ["sore throat", "PROBLEM", 40, 51], ["fever", "PROBLEM", 56, 61], ["throat", "ANATOMY", 45, 51], ["fever", "OBSERVATION", 56, 61]]], ["Additionally, a gray or white patch causes the \"croup,\" blocking the airway and causing a barking cough.", [["airway", "ANATOMY", 69, 75], ["croup", "DISEASE", 48, 53], ["cough", "DISEASE", 98, 103], ["airway", "MULTI-TISSUE_STRUCTURE", 69, 75], ["white patch", "TREATMENT", 24, 35], ["the \"croup", "PROBLEM", 43, 53], ["a barking cough", "PROBLEM", 88, 103], ["croup", "OBSERVATION", 48, 53], ["airway", "ANATOMY", 69, 75], ["barking", "OBSERVATION_MODIFIER", 90, 97], ["cough", "OBSERVATION", 98, 103]]], ["Due to widespread use of diphtheria-tetanus-pertussis (DTP) vaccine globally, the incidence has steadily declined over time, and thus, diphtheria is commonly perceived as a disease of pre-vaccination era.", [["diphtheria-tetanus-pertussis", "CHEMICAL", 25, 53], ["DTP", "CHEMICAL", 55, 58], ["diphtheria", "DISEASE", 135, 145], ["diphtheria-tetanus-pertussis", "ORGANISM", 25, 53], ["DTP", "SIMPLE_CHEMICAL", 55, 58], ["diphtheria-tetanus-pertussis", "SPECIES", 25, 53], ["diphtheria-tetanus-pertussis", "SPECIES", 25, 53], ["diphtheria", "PROBLEM", 25, 35], ["tetanus-pertussis (DTP) vaccine", "TREATMENT", 36, 67], ["diphtheria", "PROBLEM", 135, 145], ["pre-vaccination era", "TREATMENT", 184, 203]]], ["Nevertheless, sporadic cases and even epidemics of the disease have been yet reported especially in politically unstable areas, and many cases have been considered as arising from susceptible pockets of the vulnerable population (Rusmil et al., 2015; Hosseinpoor et al., 2016; Sangal et al., 2017) .INTRODUCTIONIn 2017, multiple diphtheria outbreaks were reported in refugee camps, including those in Yemen and Bangladesh (World Health Organization (WHO), 2017a).", [["diphtheria outbreaks", "DISEASE", 329, 349], ["sporadic cases", "PROBLEM", 14, 28], ["the disease", "PROBLEM", 51, 62], ["multiple diphtheria outbreaks", "PROBLEM", 320, 349], ["vulnerable", "OBSERVATION_MODIFIER", 207, 217]]], ["Of these, a Rohingya refugee camp in Bangladesh, which is temporarily located in Cox's Bazar, experienced a large-scale diphtheria epidemic.", [["diphtheria", "DISEASE", 120, 130], ["a large-scale diphtheria epidemic", "PROBLEM", 106, 139], ["large", "OBSERVATION_MODIFIER", 108, 113]]], ["As of December 26, 2017, the cumulative number of 2,526 cases and 27 deaths were reported (World Health Organization (WHO), 2017a).", [["deaths", "DISEASE", 69, 75]]], ["To interrupt chains of transmission, emergency vaccination has been conducted among children since December 12, 2017, achieving the overall coverage greater than 90% by the end of 2017 (World Health Organization (WHO), 2018).", [["children", "ORGANISM", 84, 92], ["children", "SPECIES", 84, 92], ["emergency vaccination", "TREATMENT", 37, 58]]], ["Due to vaccination effort and other countermeasures, including contact tracing and hospital admission of cases, the epidemic has been brought under control, with incidence beginning to decline by the end of December 2017 (World Health Organization (WHO), 2017a).INTRODUCTIONConsidering that diphtheria has become a rare disease in industrialized countries, epidemiological information on model parameters that govern the transmission dynamics has become very limited, and thus, it is valuable to assess how transmissible diphtheria would be through the analysis of the recent outbreak data.", [["diphtheria", "DISEASE", 291, 301], ["diphtheria", "DISEASE", 521, 531], ["vaccination effort", "TREATMENT", 7, 25], ["contact tracing", "TEST", 63, 78], ["diphtheria", "PROBLEM", 291, 301], ["a rare disease", "PROBLEM", 313, 327], ["transmissible diphtheria", "PROBLEM", 507, 531], ["rare", "OBSERVATION_MODIFIER", 315, 319], ["disease", "OBSERVATION", 320, 327]]], ["To date, an explicit epidemiological estimate of R 0 for diphtheria has been reported only by Anderson & May (1982) : using a static modeling approach to age-dependent incidence data with an assumption of the endemic equilibrium, R 0 was estimated as 6.6 in Pennsylvania, 1910s and 6.4 in Virginia and New York from 1934 to 1947.", [["diphtheria", "DISEASE", 57, 67], ["R 0", "GENE_OR_GENE_PRODUCT", 49, 52], ["diphtheria", "PROBLEM", 57, 67], ["a static modeling approach", "TREATMENT", 124, 150], ["the endemic equilibrium", "TEST", 205, 228]]], ["Subsequently, a few additional modeling studies of diphtheria took place (Kolibo & Romaniuk, 2001; Sornbundit, Triampo & Modchang, 2017; Torrea, Ortega & Torera, 2017) , but none of these offered an empirical estimate of R 0 .INTRODUCTIONHere we analyze the epidemiological dataset of diphtheria in Rohingya refugee camp, 2017, aiming to estimate R 0 in this particular epidemic setting.", [["diphtheria", "DISEASE", 51, 61], ["diphtheria", "DISEASE", 285, 295], ["diphtheria", "ORGANISM", 51, 61], ["diphtheria", "PROBLEM", 51, 61], ["diphtheria", "PROBLEM", 285, 295]]], ["Given that the epidemic occurred among refugees, we explicitly account for uncertainties associated with unknown background information, including the fraction of previously immune individuals and ascertainment rate of cases.Epidemiological dataThe latest epidemic curve was extracted from the report of the World Health Organization (WHO) Regional Office for South East Asia (SEARO) (World Health Organization (WHO), 2017a).", [["Epidemiological data", "TEST", 225, 245]]], ["Cases consist of (i) confirmed cases: cases reported as positive for C. diphtheriae by multiplex assay, (ii) probable cases: cases with upper respiratory tract illness with laryngitis or nasopharyngitis or tonsillitis AND sore throat or difficulty swallowing and an adherent membrane (pseudomembrane) OR gross cervical lymphadenopathy, and (iii) suspected cases: any case with a clinical suspicion of diphtheria, including cases that are unclassified due to missing values (World Health Organization (WHO), 2017b).", [["upper respiratory tract", "ANATOMY", 136, 159], ["throat", "ANATOMY", 227, 233], ["membrane", "ANATOMY", 275, 283], ["pseudomembrane", "ANATOMY", 285, 299], ["cervical", "ANATOMY", 310, 318], ["C. diphtheriae", "DISEASE", 69, 83], ["respiratory tract illness", "DISEASE", 142, 167], ["laryngitis", "DISEASE", 173, 183], ["nasopharyngitis", "DISEASE", 187, 202], ["tonsillitis", "DISEASE", 206, 217], ["sore throat", "DISEASE", 222, 233], ["cervical lymphadenopathy", "DISEASE", 310, 334], ["diphtheria", "DISEASE", 401, 411], ["upper", "ORGANISM_SUBDIVISION", 136, 141], ["respiratory tract", "ORGANISM_SUBDIVISION", 142, 159], ["membrane", "CELLULAR_COMPONENT", 275, 283], ["cervical", "ORGAN", 310, 318], ["C. diphtheriae", "SPECIES", 69, 83], ["C. diphtheriae", "SPECIES", 69, 83], ["C. diphtheriae", "PROBLEM", 69, 83], ["upper respiratory tract illness", "PROBLEM", 136, 167], ["laryngitis", "PROBLEM", 173, 183], ["nasopharyngitis", "PROBLEM", 187, 202], ["tonsillitis", "PROBLEM", 206, 217], ["sore throat", "PROBLEM", 222, 233], ["difficulty swallowing", "PROBLEM", 237, 258], ["an adherent membrane (pseudomembrane)", "PROBLEM", 263, 300], ["gross cervical lymphadenopathy", "PROBLEM", 304, 334], ["diphtheria", "PROBLEM", 401, 411], ["missing values", "PROBLEM", 458, 472], ["upper", "ANATOMY_MODIFIER", 136, 141], ["respiratory tract", "ANATOMY", 142, 159], ["laryngitis", "OBSERVATION", 173, 183], ["nasopharyngitis", "OBSERVATION", 187, 202], ["tonsillitis", "OBSERVATION", 206, 217], ["adherent membrane", "OBSERVATION", 266, 283], ["cervical", "ANATOMY", 310, 318], ["lymphadenopathy", "OBSERVATION", 319, 334]]], ["The definition was improved on and after December 12 (World Health Organization (WHO), 2017c), enforcing to count mainly probable cases, while not restricting the reporting of suspected cases.", [["improved", "OBSERVATION_MODIFIER", 19, 27]]], ["Mass child vaccination started on December 12, and according to the administrative coverage, greater than 90% vaccination coverage was achieved by December 30 (World Health Organization (WHO), 2018).", [["Mass child vaccination", "PROBLEM", 0, 22], ["the administrative coverage", "TREATMENT", 64, 91], ["90% vaccination coverage", "TREATMENT", 106, 130]]], ["Vaccine-induced immunity requires at least 7-14 days to become effective, and moreover, the reporting delay was assumed to be about four days (based on additional analyses; results not shown).", [["Vaccine", "TREATMENT", 0, 7], ["additional analyses", "TEST", 152, 171]]], ["For these reasons, the dataset from December 23-26 was discarded as the number of cases may be influenced by emergency vaccination and also biased by the reporting delay.Modeling methodsTo formulate the epidemiological model, here we mathematically capture the epidemiological process of secondary transmission using R 0 and the serial interval, i.e., the time from illness onset in the primary case to illness onset in the secondary case.", [["illness", "DISEASE", 366, 373], ["illness", "DISEASE", 403, 410], ["the dataset", "TEST", 19, 30]]], ["We assume that secondary transmission does not take place before illness onset.", [["illness", "DISEASE", 65, 72]]], ["According to a classical study by Stocks (1930) in the United Kingdom (UK), the time interval from first to second diphtheria cases in the household revealed a bimodal shape.", [["diphtheria", "DISEASE", 115, 125], ["a classical study", "TEST", 13, 30], ["bimodal shape", "OBSERVATION", 160, 173]]], ["Following Klinkenberg & Nishiura (2011) , the first peak corresponds to an independent infection in the community and the second peak reflects within-household transmission.", [["infection", "DISEASE", 87, 96], ["an independent infection", "PROBLEM", 72, 96], ["independent", "OBSERVATION_MODIFIER", 75, 86], ["infection", "OBSERVATION", 87, 96]]], ["As one of peak time-lags in the observed time interval was observed on day 8, we assumed that the mean serial interval was eight days, and we imposed an assumption that the coefficient of variation (CV) of the serial interval distribution was 50%, and later varied it from 25% to 75% as part of the sensitivity analysis.Modeling methodsTo capture the epidemiological phenomena of reproduction, it has been shown that the renewal process can capture the serial stochastic dependence structure (Nishiura, 2010) .", [["the sensitivity analysis", "TEST", 295, 319]]], ["Let i t be the number of new cases on day t. g t represents the distribution of the serial interval.", [["Let i", "GENE_OR_GENE_PRODUCT", 0, 5]]], ["To describe the time-dependent incidence i t on day t, we haveModeling methods(1)Modeling methodswhere s t represents the fraction of susceptible individuals on day t.", [["susceptible individuals", "PROBLEM", 134, 157]]], ["The renewal process of this type is not original to the present study and has been applied to other settings including real-time epidemic modeling studies (Asai & Nishiura, 2017; Dinh et al., 2016; Ejima & Nishiura, 2018; Endo & Nishiura, 2015; Nishiura et al., 2010 Nishiura et al., , 2016 Tsuzuki et al., 2017) .", [["the present study", "TEST", 52, 69]]], ["It should be noted that the incidence i t includes both symptomatic and asymptomatic cases.", [["both symptomatic and asymptomatic cases", "PROBLEM", 51, 90], ["symptomatic", "OBSERVATION_MODIFIER", 56, 67]]], ["Let c t be the reported number of cases on calendar day t.", [["Let c", "GENE_OR_GENE_PRODUCT", 0, 5]]], ["Supposing that only the fraction a t among the total number of infections are diagnosed and reported, c t satisfiesModeling methodswhere a t is modeled as a function of t.", [["infections", "DISEASE", 63, 73], ["infections", "PROBLEM", 63, 73], ["total", "OBSERVATION_MODIFIER", 47, 52], ["number", "OBSERVATION_MODIFIER", 53, 59], ["infections", "OBSERVATION", 63, 73]]], ["Because the case definition was improved from December 12, 2017 onward, the ascertainment rate likely varied around that time.", [["the ascertainment rate", "TEST", 72, 94]]], ["We assumed that only the ascertainment rate changed as a function of time, and also that R 0 and depletion of susceptible individuals were unaffected by time.Modeling methodsWe model the fraction susceptible s t on day t in the following way.", [["the ascertainment rate", "PROBLEM", 21, 43], ["susceptible individuals", "PROBLEM", 110, 133], ["fraction", "OBSERVATION_MODIFIER", 187, 195], ["susceptible", "OBSERVATION_MODIFIER", 196, 207]]], ["Let n represent the previously immunized fraction so that only fraction (1 -n) of the population is susceptible at the beginning of the epidemic.", [["Let n", "GENE_OR_GENE_PRODUCT", 0, 5], ["the previously immunized fraction", "PROBLEM", 16, 49], ["the population", "PROBLEM", 82, 96]]], ["In addition to the previously immune fraction, s t decreases when natural infection takes place.", [["infection", "DISEASE", 74, 83], ["the previously immune fraction", "PROBLEM", 15, 45], ["natural infection", "PROBLEM", 66, 83], ["infection", "OBSERVATION", 74, 83]]], ["Suppose that the total population size was N, s t is written asModeling methodsWe assume that N is equal to the population size of epidemic area within Rohingya refugee camp as 579,384 persons (Banerji & Ahmed, 2017) .", [["persons", "SPECIES", 185, 192], ["size", "OBSERVATION_MODIFIER", 34, 38], ["size", "OBSERVATION_MODIFIER", 123, 127]]], ["Accordingly, the renewal equation is written asModeling methodswhere t in the right-hand side indicates the time since infection (or the so-called \"infection-age\").", [["right-hand", "ANATOMY", 78, 88], ["infection", "DISEASE", 119, 128], ["infection", "DISEASE", 148, 157], ["infection", "PROBLEM", 119, 128], ["right", "ANATOMY_MODIFIER", 78, 83], ["infection", "OBSERVATION", 119, 128]]], ["The likelihood to estimate u consisting of the parameters R 0 , n, and a t is derived asModeling methodswhere T is the latest time of observation (i.e., December 22 in our case study) and c T = (c 1 , c 2 , : : : , c T ).Uncertainty and sensitivity analysesWhile we specified unknown parameters as R 0 , n, and a t , it is expected that R 0 is correlated with initially immune fraction n and also a t .", [["c T", "GENE_OR_GENE_PRODUCT", 215, 218], ["our case study", "TEST", 168, 182], ["sensitivity analyses", "TEST", 237, 257]]], ["In the present study, n was estimated through uncertainty analysis, while a t was estimated as a step function governed by two parameters, a 1 and a 2 .", [["uncertainty analysis", "TEST", 46, 66]]], ["Here we use the Latin Hypercube sampling (LHS) method (Sanchez & Blower, 1997) in which a symmetric triangular distribution of n was assumed to be in the range from 0.0 to 0.7; the health survey of Rohingya population indicated that overall 30.8% of children had received no vaccinations (Guzek et al., 2017) , and the remaining 69.2% receives at least a single immunization, which is not necessarily against diphtheria, thus, vaccination coverage for diphtheria should be less than 69.2%.", [["diphtheria", "DISEASE", 409, 419], ["diphtheria", "DISEASE", 452, 462], ["children", "ORGANISM", 250, 258], ["children", "SPECIES", 250, 258], ["the Latin Hypercube sampling", "TREATMENT", 12, 40], ["vaccinations", "TREATMENT", 275, 287], ["a single immunization", "TREATMENT", 353, 374], ["diphtheria", "PROBLEM", 409, 419], ["vaccination coverage", "TREATMENT", 427, 447], ["diphtheria", "PROBLEM", 452, 462], ["symmetric", "OBSERVATION_MODIFIER", 90, 99], ["triangular", "OBSERVATION_MODIFIER", 100, 110], ["distribution", "OBSERVATION_MODIFIER", 111, 123], ["not necessarily", "UNCERTAINTY", 385, 400]]], ["In addition, we examined the sensitivity of R 0 to variations in the length of the serial interval.Ethical considerationsThe present study analyzed data that is publicly available.", [["The present study", "TEST", 121, 138], ["length", "OBSERVATION_MODIFIER", 69, 75]]], ["As such, the datasets used in our study were de-identified and fully anonymized in advance, and the analysis of publicly available data without identity information does not require ethical approval.", [["our study", "TEST", 30, 39], ["the analysis", "TEST", 96, 108], ["ethical approval", "TREATMENT", 182, 198]]], ["Figure 2 shows univariate distributions of estimated parameters R 0 and a t based on LHS (n = 1,000) of parameter n from 0 to 0.70 with the peak at 0.35. a 1 Reflects ascertainment by December 11, 2017, while a 2 shows the same on and after December 12.", [["univariate distributions", "TEST", 15, 39], ["LHS", "TEST", 85, 88]]], ["R 0 took the minimum and maximum estimates at 4.7 and 14.8, respectively, with the median estimate at 7.2.", [["the median estimate", "TEST", 79, 98]]], ["The distribution was skewed to the right with the mode at 6.7.", [["distribution", "OBSERVATION_MODIFIER", 4, 16], ["right", "ANATOMY_MODIFIER", 35, 40]]], ["Excluding lower and upper tails, 950 samples (95%) of R 0 (or what it can be assumed as the 95% tolerance intervals) were in the range of 5.0-12.3.", [["samples", "ANATOMY", 37, 44], ["lower", "ANATOMY_MODIFIER", 10, 15], ["upper tails", "ANATOMY", 20, 31]]], ["Distributions of a 1 and a 2 were also right skewed. a 1 Ranged from 0.007 to 0.021 with the median 0.010, while a 2 ranged from 0.003 to 0.011 with the median 0.005.", [["right", "ANATOMY_MODIFIER", 39, 44]]], ["Lower and upper 95% tolerance intervals of a 1 and a 2 were (0.007, 0.017) and (0.004, 0.009), respectively.", [["upper", "ANATOMY_MODIFIER", 10, 15]]], ["Figure 3 shows the distributions of two estimated parameters in two-dimensional spaces and also the comparison between observed and predicted epidemic curve.", [["distributions", "OBSERVATION_MODIFIER", 19, 32], ["two", "OBSERVATION_MODIFIER", 64, 67]]], ["(4), R 0 and n were positively correlated given an epidemic curve.", [["an epidemic curve", "PROBLEM", 48, 65]]], ["Similarly, R 0 was positively correlated with ascertainment rates, a 1 and a 2 .", [["R 0", "GENE_OR_GENE_PRODUCT", 11, 14], ["ascertainment rates", "TEST", 46, 65]]], ["While the ascertainment might have been lowered due to the stricter case definition, the small estimate of a 2 can also indicate that a substantial fraction of undiagnosed individuals existed and the susceptible fraction was then gradually depleted in the population.", [["individuals", "ORGANISM", 172, 183], ["undiagnosed individuals", "PROBLEM", 160, 183], ["the susceptible fraction", "PROBLEM", 196, 220], ["small", "OBSERVATION_MODIFIER", 89, 94], ["substantial", "OBSERVATION_MODIFIER", 136, 147], ["fraction", "OBSERVATION_MODIFIER", 148, 156], ["susceptible", "OBSERVATION_MODIFIER", 200, 211], ["fraction", "OBSERVATION_MODIFIER", 212, 220]]], ["The observed and predicted epidemic curves are compared in the right lower panel of Fig. 3 .", [["epidemic", "OBSERVATION_MODIFIER", 27, 35], ["curves", "OBSERVATION_MODIFIER", 36, 42], ["right", "ANATOMY_MODIFIER", 63, 68], ["lower", "ANATOMY_MODIFIER", 69, 74], ["Fig", "OBSERVATION", 84, 87]]], ["While the model is kept simple with four unknown parameters, the predicted epidemic curve overall captured the observed pattern.RESULTSSensitivity of R 0 to the variation in the serial interval is shown in Fig. 4 .", [["the predicted epidemic curve", "PROBLEM", 61, 89]]], ["We varied the CV of the serial interval distribution from 25% to 75%.", [["distribution", "OBSERVATION_MODIFIER", 40, 52]]], ["When the CV was 25%, the median and mode of R 0 from LHS were 9.4 and 8.2, respectively.", [["the CV", "TEST", 5, 11], ["LHS", "TEST", 53, 56]]], ["When the CV was 75%, the median and mode of R 0 were estimated to be 5.7 and 5.2, respectively.", [["the CV", "TEST", 5, 11]]], ["However, the variation in R 0 induced by the CV was smaller than the uncertainty associated with the initially immune fraction.DISCUSSIONThe present study estimated R 0 of diphtheria in the Rohingya refugee camp, explicitly accounting for case ascertainment and previously immune fraction.", [["diphtheria", "DISEASE", 172, 182], ["R 0", "GENE_OR_GENE_PRODUCT", 26, 29], ["The present study", "TEST", 137, 154], ["diphtheria", "PROBLEM", 172, 182], ["variation", "OBSERVATION_MODIFIER", 13, 22], ["smaller", "OBSERVATION_MODIFIER", 52, 59], ["immune fraction", "OBSERVATION", 111, 126]]], ["Since previously immune fraction n of the refugee population was not precisely known, uncertainty analysis of R 0 was conducted with an input parameter assumption for n employing the LHS method.", [["an input parameter assumption", "TREATMENT", 133, 162], ["the LHS method", "TREATMENT", 179, 193]]], ["R 0 ranged from 4.7 to 14.8 with the median estimate at 7.2.", [["the median estimate", "TEST", 33, 52]]], ["To our knowledge, the present study is the first to statistically estimate R 0 of diphtheria from epidemic data.", [["diphtheria", "DISEASE", 82, 92], ["the present study", "TEST", 18, 35], ["diphtheria", "PROBLEM", 82, 92]]], ["For the statistical estimation of R 0 , the renewal process model was employed, which has an advantage to handle the right-censored data during the course of an epidemic, compared with other available methods for completely observed data, e.g., Nishiura (2010) .", [["right", "ANATOMY_MODIFIER", 117, 122]]], ["Estimated median R 0 was broadly consistent with the value ranging from 6 to 7 as indicated by Anderson & May (1982) based on a static model for endemic data that uses the age-dependent incidence in the UK.", [["endemic data", "TEST", 145, 157]]], ["Assuming R 0 = 7, to control diphtheria by means of mass vaccination, the coverage greater than 86% must be satisfied.", [["diphtheria", "DISEASE", 29, 39], ["diphtheria", "PROBLEM", 29, 39], ["mass vaccination", "TREATMENT", 52, 68], ["the coverage", "TREATMENT", 70, 82], ["mass", "OBSERVATION", 52, 56]]], ["Since our study focused on uncertainty and sensitivity analyses, the exact estimate of R 0 cannot be pointed out.", [["our study", "TEST", 6, 15], ["sensitivity analyses", "TEST", 43, 63]]], ["While the mode of distribution for R 0 was 6.7, the validity of this value depends on the validity of our prior distribution of n, which was not supported by any published evidence of this refugee population.", [["this refugee population", "PROBLEM", 184, 207]]], ["Nevertheless, a Demographic and Health Survey data of the Rohingya population in Myanmar indicated a close value from 40% to 50% as the coverage of DTP (Ministry of Health and Sports, 2017).", [["DTP", "CHEMICAL", 148, 151], ["DTP", "PROBLEM", 148, 151]]], ["Ascertainment rates were jointly estimated only by using the epidemiological case data and the population size.", [["Ascertainment rates", "PROBLEM", 0, 19], ["size", "OBSERVATION_MODIFIER", 106, 110]]], ["Even without explicit estimate of the initially immune fraction, we have shown that an indication of the possible value of R 0 can be obtained through uncertainty analysis.", [["uncertainty analysis", "TEST", 151, 171]]], ["LHS appeared to be particularly useful in the setting of refugee camp in which the background health status is not well quantified (Helton & Davis, 2002; Nishiura et al., 2017) .", [["refugee camp", "TREATMENT", 57, 69]]], ["While Bayesian modeling has replaced LHS to some extent of uncertainty analysis as it can also offer posterior distributions of even uncertain parameters (Elderd, Dukic & Dwyer, 2006 ; Coelho, Code\u00e7o & Struchiner, 2008) , there could be an issue of identifiability when two or more parameters are evidently correlated, e.g., as anticipated between R 0 and n in our model (4).", [["uncertainty analysis", "TEST", 59, 79]]], ["In such an instance, we cannot be sure if the limited epidemic data with the Bayesian estimation method can offer identifiable distributions for all parameters, and then LHS can remain to act as a useful tool for uncertainty analysis.", [["uncertainty analysis", "TEST", 213, 233]]], ["The estimated small ascertainment rate during the epidemic is considered as reflecting the time-dependent diagnostic practice at a local level.", [["The estimated small ascertainment rate", "PROBLEM", 0, 38], ["small", "OBSERVATION_MODIFIER", 14, 19], ["ascertainment", "OBSERVATION", 20, 33]]], ["In fact, the small ascertainment rate can lead us to observing the low case fatality risk of diphtheria in the Cox's Bazar that has been estimated to be small (27/2,526 = 1%), although the right censoring would of course matter for the real-time interpretation Mizumoto et al., 2015) .", [["diphtheria", "DISEASE", 93, 103], ["the small ascertainment rate", "PROBLEM", 9, 37], ["diphtheria", "PROBLEM", 93, 103], ["small", "OBSERVATION_MODIFIER", 13, 18], ["diphtheria", "OBSERVATION", 93, 103], ["small", "OBSERVATION_MODIFIER", 153, 158], ["right", "ANATOMY_MODIFIER", 189, 194]]], ["Nevertheless, cases could have died in the community unnoticed with low specificity of the case definition, and this is endorsed as a possible reason for observing the small number of deaths by the World Health Organization (WHO) (2017d).", [["deaths", "DISEASE", 184, 190], ["small", "OBSERVATION_MODIFIER", 168, 173]]], ["A follow-up study in this regard should be conducted in the future.DISCUSSIONSeveral limitations must be noted.", [["A follow-up study", "TEST", 0, 17]]], ["First, our model rested on a homogeneous mixing assumption.", [["a homogeneous mixing assumption", "TREATMENT", 27, 58]]], ["No heterogeneous patterns of transmission, including contact patterns and age-dependency were taken into account due to shortage of information.", [["heterogeneous", "OBSERVATION_MODIFIER", 3, 16], ["patterns", "OBSERVATION_MODIFIER", 17, 25]]], ["In addition, the time-dependent heterogeneity, including the reduced transmission potential due to contact tracing and rapid hospitalization, was not explicitly taken into account due to insufficiency of the data.", [["contact tracing", "TEST", 99, 114], ["insufficiency of the data", "PROBLEM", 187, 212], ["dependent", "OBSERVATION_MODIFIER", 22, 31], ["heterogeneity", "OBSERVATION", 32, 45]]], ["If there were any additional indications or datasets that would allow explicit quantification of the effective reproduction number from December 12, that could give additional insights into the success of control measures.", [["control measures", "TREATMENT", 205, 221]]], ["Third, a little more realistic features of refugee population, such as the impact of migration on the epidemic were unfortunately discarded in the present study.", [["the present study", "TEST", 143, 160], ["little", "OBSERVATION_MODIFIER", 9, 15], ["more realistic", "OBSERVATION_MODIFIER", 16, 30], ["migration", "OBSERVATION_MODIFIER", 85, 94]]], ["Similarly, one could investigate how overcrowding and malnutrition in the deprived population would help enhance the spread of diphtheria, given sufficient data backup from epidemiological investigations.DISCUSSIONWhile these features need to be explicitly quantified in the future, we believe that our study adds an important piece of evidence to the literature on diphtheria.", [["malnutrition", "DISEASE", 54, 66], ["diphtheria", "DISEASE", 127, 137], ["diphtheria", "DISEASE", 366, 376], ["malnutrition", "PROBLEM", 54, 66], ["diphtheria", "PROBLEM", 127, 137], ["epidemiological investigations", "TEST", 173, 203], ["our study", "TEST", 299, 308], ["diphtheria", "PROBLEM", 366, 376], ["malnutrition", "OBSERVATION", 54, 66]]], ["The transmissibility of diphtheria in the refugee population was estimated to be consistent with that in an endemic setting and mass vaccination must satisfy at least the coverage of 86% to halt the major epidemic of diphtheria.CONCLUSIONThe present study estimated R 0 of diphtheria in the Rohingya refugee camp, explicitly accounting for case ascertainment and previously immune fraction.", [["diphtheria", "DISEASE", 24, 34], ["diphtheria", "DISEASE", 217, 227], ["diphtheria", "DISEASE", 273, 283], ["diphtheria", "ORGANISM", 24, 34], ["diphtheria", "PROBLEM", 24, 34], ["mass vaccination", "PROBLEM", 128, 144], ["diphtheria", "PROBLEM", 217, 227], ["The present study", "TEST", 238, 255], ["diphtheria", "PROBLEM", 273, 283], ["diphtheria", "OBSERVATION", 24, 34], ["consistent with", "UNCERTAINTY", 81, 96], ["mass", "OBSERVATION", 128, 132], ["diphtheria", "OBSERVATION", 217, 227]]], ["Since previously immune fraction n of the refugee population was not precisely known, uncertainty analysis of R 0 was conducted with an input parameter assumption for n employing the LHS.", [["an input parameter assumption", "TREATMENT", 133, 162]]], ["R 0 ranged from 4.7 to 14.8 with the median estimate at 7.2.", [["the median estimate", "TEST", 33, 52]]], ["LHS can offer probabilistic distribution of the outcome measure, and this method appeared to be particularly useful in the setting of refugee camp in which the background health status is poorly quantified.", [["refugee camp", "TREATMENT", 134, 146]]]], "9a13ccd6be3536af404c25e748c34eac997c5d16": [["Scientific RepoRts | 6:30926 | DOI: 10.1038/srep30926 CF patients may suffer from various gastrointestinal tract diseases, including the distal intestinal obstruction syndrome, meconium ileus of the newborn, intussusceptions, small bowel bacterial overgrowth, rectal prolapse, gastroparesis and gastroesophageal reflux 11, 23, 24 .", [["gastrointestinal tract", "ANATOMY", 90, 112], ["intestinal", "ANATOMY", 144, 154], ["bowel", "ANATOMY", 232, 237], ["rectal", "ANATOMY", 260, 266], ["gastroesophageal", "ANATOMY", 295, 311], ["gastrointestinal tract diseases", "DISEASE", 90, 121], ["intestinal obstruction syndrome", "DISEASE", 144, 175], ["meconium ileus of the newborn", "DISEASE", 177, 206], ["intussusceptions", "DISEASE", 208, 224], ["bowel bacterial overgrowth", "DISEASE", 232, 258], ["rectal prolapse", "DISEASE", 260, 275], ["gastroparesis", "DISEASE", 277, 290], ["gastroesophageal reflux", "DISEASE", 295, 318], ["patients", "ORGANISM", 57, 65], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 90, 112], ["intestinal", "ORGAN", 144, 154], ["rectal", "ORGAN", 260, 266], ["patients", "SPECIES", 57, 65], ["various gastrointestinal tract diseases", "PROBLEM", 82, 121], ["the distal intestinal obstruction syndrome", "PROBLEM", 133, 175], ["meconium ileus of the newborn", "PROBLEM", 177, 206], ["intussusceptions", "PROBLEM", 208, 224], ["small bowel bacterial overgrowth", "PROBLEM", 226, 258], ["rectal prolapse", "PROBLEM", 260, 275], ["gastroparesis", "PROBLEM", 277, 290], ["gastroesophageal reflux", "PROBLEM", 295, 318], ["gastrointestinal tract", "ANATOMY", 90, 112], ["distal", "ANATOMY_MODIFIER", 137, 143], ["intestinal", "ANATOMY", 144, 154], ["obstruction", "OBSERVATION", 155, 166], ["meconium ileus", "OBSERVATION", 177, 191], ["small", "OBSERVATION_MODIFIER", 226, 231], ["bowel", "ANATOMY", 232, 237], ["bacterial overgrowth", "OBSERVATION", 238, 258], ["rectal prolapse", "ANATOMY", 260, 275], ["gastroparesis", "OBSERVATION", 277, 290], ["gastroesophageal reflux", "ANATOMY", 295, 318]]], ["The majority of these diseases are is causally related to the malfunction of the CFTR protein in the epithelial cells of the gastrointestinal tract and pancreas resulting in enzyme insufficiency and thickening of gastrointestinal secretions [25] [26] [27] [28] .", [["epithelial cells", "ANATOMY", 101, 117], ["gastrointestinal tract", "ANATOMY", 125, 147], ["pancreas", "ANATOMY", 152, 160], ["gastrointestinal", "ANATOMY", 213, 229], ["CFTR", "GENE_OR_GENE_PRODUCT", 81, 85], ["epithelial cells", "CELL", 101, 117], ["gastrointestinal tract", "ORGAN", 125, 147], ["pancreas", "ORGAN", 152, 160], ["gastrointestinal", "ORGAN", 213, 229], ["25] [26] [27] [28]", "SIMPLE_CHEMICAL", 242, 260], ["CFTR protein", "PROTEIN", 81, 93], ["epithelial cells", "CELL_TYPE", 101, 117], ["these diseases", "PROBLEM", 16, 30], ["the CFTR protein", "TEST", 77, 93], ["enzyme insufficiency", "PROBLEM", 174, 194], ["thickening of gastrointestinal secretions", "PROBLEM", 199, 240], ["majority", "OBSERVATION_MODIFIER", 4, 12], ["diseases", "OBSERVATION", 22, 30], ["malfunction", "OBSERVATION", 62, 73], ["epithelial cells", "OBSERVATION", 101, 117], ["gastrointestinal tract", "ANATOMY", 125, 147], ["pancreas", "ANATOMY", 152, 160], ["enzyme insufficiency", "OBSERVATION", 174, 194], ["thickening", "OBSERVATION_MODIFIER", 199, 209], ["gastrointestinal", "ANATOMY", 213, 229], ["secretions", "OBSERVATION", 230, 240]]], ["However, given its crucial role in the control of motility, and exocrine and endocrine secretions in the tractus gastrointestionalis, it is conceivable that abnormalities in the ENS might also contribute to the pathogenesis of the gastrointestinal diseases found in CF.", [["exocrine", "ANATOMY", 64, 72], ["endocrine secretions", "ANATOMY", 77, 97], ["tractus gastrointestionalis", "ANATOMY", 105, 132], ["ENS", "ANATOMY", 178, 181], ["gastrointestinal", "ANATOMY", 231, 247], ["gastrointestinal diseases", "DISEASE", 231, 256], ["CF", "DISEASE", 266, 268], ["exocrine", "ORGAN", 64, 72], ["endocrine secretions", "MULTI-TISSUE_STRUCTURE", 77, 97], ["tractus gastrointestionalis", "ORGANISM", 105, 132], ["ENS", "ANATOMICAL_SYSTEM", 178, 181], ["gastrointestinal", "ORGAN", 231, 247], ["exocrine and endocrine secretions in the tractus gastrointestionalis", "PROBLEM", 64, 132], ["abnormalities in the ENS", "PROBLEM", 157, 181], ["the gastrointestinal diseases", "PROBLEM", 227, 256], ["tractus gastrointestionalis", "ANATOMY", 105, 132], ["gastrointestinal", "ANATOMY", 231, 247], ["diseases", "OBSERVATION", 248, 256]]], ["In this study, we aimed to investigate the distribution and expression of CFTR protein and mRNA in ganglion cells of the human ENS.", [["ganglion cells", "ANATOMY", 99, 113], ["ENS", "ANATOMY", 127, 130], ["CFTR", "GENE_OR_GENE_PRODUCT", 74, 78], ["ganglion cells", "CELL", 99, 113], ["human", "ORGANISM", 121, 126], ["ENS", "ANATOMICAL_SYSTEM", 127, 130], ["CFTR protein", "PROTEIN", 74, 86], ["mRNA", "RNA", 91, 95], ["ganglion cells", "CELL_TYPE", 99, 113], ["human", "SPECIES", 121, 126], ["human", "SPECIES", 121, 126], ["this study", "TEST", 3, 13], ["CFTR protein", "PROBLEM", 74, 86], ["mRNA in ganglion cells", "PROBLEM", 91, 113], ["ganglion cells", "OBSERVATION", 99, 113], ["human ENS", "ANATOMY", 121, 130]]], ["Widespread expression of CFTR was demonstrated in the ENS, which could provide an additional explanation for the gastrointestinal symptoms in CF.Materials and MethodsHuman Tissue Collection.", [["ENS", "ANATOMY", 54, 57], ["gastrointestinal", "ANATOMY", 113, 129], ["gastrointestinal symptoms", "DISEASE", 113, 138], ["CF", "DISEASE", 142, 144], ["CFTR", "GENE_OR_GENE_PRODUCT", 25, 29], ["ENS", "ANATOMICAL_SYSTEM", 54, 57], ["gastrointestinal", "ORGAN", 113, 129], ["CFTR", "PROTEIN", 25, 29], ["CFTR", "PROBLEM", 25, 29], ["the gastrointestinal symptoms in CF", "PROBLEM", 109, 144], ["MethodsHuman Tissue Collection", "TREATMENT", 159, 189], ["CFTR", "OBSERVATION", 25, 29], ["ENS", "ANATOMY", 54, 57], ["gastrointestinal", "ANATOMY", 113, 129], ["MethodsHuman Tissue", "OBSERVATION", 159, 178]]], ["Human tissue samples of gastrointestinal tracts were obtained from a total of 16 patients, 11 from patients undergoing surgery and 5 autopsy cases from the Peking University Third Hospital (Beijing, PR China) and Shantou Medical University Hospital (Shantou, PR China).", [["tissue samples", "ANATOMY", 6, 20], ["gastrointestinal tracts", "ANATOMY", 24, 47], ["Human", "ORGANISM", 0, 5], ["tissue samples", "CANCER", 6, 20], ["gastrointestinal tracts", "MULTI-TISSUE_STRUCTURE", 24, 47], ["patients", "ORGANISM", 81, 89], ["patients", "ORGANISM", 99, 107], ["Human", "SPECIES", 0, 5], ["patients", "SPECIES", 81, 89], ["patients", "SPECIES", 99, 107], ["Human", "SPECIES", 0, 5], ["Human tissue samples", "TEST", 0, 20], ["gastrointestinal tracts", "TEST", 24, 47], ["surgery", "TREATMENT", 119, 126], ["gastrointestinal tracts", "ANATOMY", 24, 47]]], ["None of the subjects was diagnosed with any disease of the nervous system or CF.", [["nervous system", "ANATOMY", 59, 73], ["disease of the nervous system", "DISEASE", 44, 73], ["CF", "DISEASE", 77, 79], ["subjects", "ORGANISM", 12, 20], ["nervous system", "ANATOMICAL_SYSTEM", 59, 73], ["any disease of the nervous system", "PROBLEM", 40, 73], ["CF", "PROBLEM", 77, 79], ["nervous system", "ANATOMY", 59, 73]]], ["All methods were carried out in accordance with the approved guidelines of the Institutional Animal Care and Use Committee Guide of Peking University.", [["All methods", "TREATMENT", 0, 11]]], ["All experimental protocols were approved by Peking University.", [["All experimental protocols", "TREATMENT", 0, 26]]], ["The study received local hospital ethics committee approval.", [["The study", "TEST", 0, 9]]], ["Informed consent was obtained from all patients.", [["patients", "ORGANISM", 39, 47], ["patients", "SPECIES", 39, 47]]], ["General information about these cases is listed in Table 1 .Materials and MethodsTissue Preparation.", [["MethodsTissue Preparation", "TREATMENT", 74, 99]]], ["The autopsied bodies were kept at 4 \u00b0C, and the autopsies were performed within 48 hours after death.", [["bodies", "ANATOMY", 14, 20], ["death", "DISEASE", 95, 100], ["The autopsied bodies", "TREATMENT", 0, 20], ["the autopsies", "TEST", 44, 57], ["death", "PROBLEM", 95, 100]]], ["For immunohistochemistry and in situ hybridization, samples were fixed in 4% formalin solution after removal for 24 hours and then embedded in paraffin blocks.", [["samples", "ANATOMY", 52, 59], ["formalin", "CHEMICAL", 77, 85], ["formalin", "CHEMICAL", 77, 85], ["paraffin", "CHEMICAL", 143, 151], ["formalin", "SIMPLE_CHEMICAL", 77, 85], ["immunohistochemistry", "TEST", 4, 24], ["samples", "TEST", 52, 59], ["4% formalin solution", "TREATMENT", 74, 94], ["removal", "TREATMENT", 101, 108], ["paraffin blocks", "OBSERVATION", 143, 158]]], ["For reverse transcription-polymerase chain reaction (RT-PCR), fresh tissue samples were immediately snap-frozen in liquid nitrogen and stored at \u2212 80 \u00b0C until use.", [["tissue samples", "ANATOMY", 68, 82], ["nitrogen", "CHEMICAL", 122, 130], ["tissue samples", "ORGANISM_SUBSTANCE", 68, 82], ["reverse transcription", "TREATMENT", 4, 25], ["polymerase chain reaction", "PROBLEM", 26, 51], ["RT-PCR", "TEST", 53, 59], ["fresh tissue samples", "TEST", 62, 82], ["snap", "TEST", 100, 104], ["liquid nitrogen", "TREATMENT", 115, 130]]], ["The segments evaluated in this study include the stomach, duodenum, jejunum, ileum, cecum, appendix, colon and rectum.", [["stomach", "ANATOMY", 49, 56], ["duodenum", "ANATOMY", 58, 66], ["jejunum", "ANATOMY", 68, 75], ["ileum", "ANATOMY", 77, 82], ["cecum", "ANATOMY", 84, 89], ["appendix", "ANATOMY", 91, 99], ["colon", "ANATOMY", 101, 106], ["rectum", "ANATOMY", 111, 117], ["stomach", "ORGAN", 49, 56], ["duodenum", "MULTI-TISSUE_STRUCTURE", 58, 66], ["jejunum", "MULTI-TISSUE_STRUCTURE", 68, 75], ["ileum", "MULTI-TISSUE_STRUCTURE", 77, 82], ["cecum", "MULTI-TISSUE_STRUCTURE", 84, 89], ["appendix", "MULTI-TISSUE_STRUCTURE", 91, 99], ["colon", "ORGAN", 101, 106], ["rectum", "ORGAN", 111, 117], ["this study", "TEST", 26, 36], ["the stomach, duodenum, jejunum, ileum, cecum, appendix, colon and rectum", "PROBLEM", 45, 117], ["segments", "ANATOMY_MODIFIER", 4, 12], ["stomach", "ANATOMY", 49, 56], ["duodenum", "ANATOMY", 58, 66], ["jejunum", "ANATOMY", 68, 75], ["ileum", "ANATOMY", 77, 82], ["cecum", "ANATOMY", 84, 89], ["appendix", "ANATOMY", 91, 99], ["colon", "ANATOMY", 101, 106], ["rectum", "ANATOMY", 111, 117]]], ["In each surgical case, the appropriate consent for the use of tissues was obtained.", [["tissues", "ANATOMY", 62, 69], ["tissues", "TISSUE", 62, 69]]], ["Samples were taken from macroscopically unaffected areas that were determined by visual inspection.", [["Samples", "ANATOMY", 0, 7], ["Samples", "TEST", 0, 7], ["macroscopically unaffected areas", "PROBLEM", 24, 56], ["visual inspection", "TEST", 81, 98]]], ["Immunohistochemistry localization.", [["Immunohistochemistry localization", "TEST", 0, 33]]], ["CFTR expression was localized, using immunohistochemistry on consecutive formalin-fixed paraffin-embedded tissue sections (4 \u03bcm) which preserve good morphology for neuron identification and CFTR protein expression as following: (1) The tissue sections were deparaffinized in xylene and rehydrated in gradient ethanol, incubated in 70% ammonia-ethanol at room temperature for 30 min to remove formalin deposition and then washed in 0.01 M phosphate-buffered saline (PBS).", [["tissue sections", "ANATOMY", 106, 121], ["\u03bcm", "ANATOMY", 125, 127], ["neuron", "ANATOMY", 164, 170], ["tissue sections", "ANATOMY", 236, 251], ["xylene", "CHEMICAL", 275, 281], ["ethanol", "CHEMICAL", 309, 316], ["ammonia", "CHEMICAL", 335, 342], ["ethanol", "CHEMICAL", 343, 350], ["formalin", "CHEMICAL", 392, 400], ["phosphate", "CHEMICAL", 438, 447], ["formalin", "CHEMICAL", 73, 81], ["paraffin", "CHEMICAL", 88, 96], ["xylene", "CHEMICAL", 275, 281], ["ethanol", "CHEMICAL", 309, 316], ["ammonia", "CHEMICAL", 335, 342], ["ethanol", "CHEMICAL", 343, 350], ["formalin", "CHEMICAL", 392, 400], ["phosphate", "CHEMICAL", 438, 447], ["CFTR", "GENE_OR_GENE_PRODUCT", 0, 4], ["tissue sections", "MULTI-TISSUE_STRUCTURE", 106, 121], ["neuron", "CELL", 164, 170], ["CFTR", "GENE_OR_GENE_PRODUCT", 190, 194], ["tissue sections", "MULTI-TISSUE_STRUCTURE", 236, 251], ["xylene", "SIMPLE_CHEMICAL", 275, 281], ["ethanol", "SIMPLE_CHEMICAL", 309, 316], ["ammonia", "SIMPLE_CHEMICAL", 335, 342], ["ethanol", "SIMPLE_CHEMICAL", 343, 350], ["formalin", "SIMPLE_CHEMICAL", 392, 400], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 438, 463], ["CFTR", "PROTEIN", 0, 4], ["CFTR", "PROTEIN", 190, 194], ["immunohistochemistry", "TEST", 37, 57], ["consecutive formalin", "TEST", 61, 81], ["fixed paraffin-embedded tissue sections", "TREATMENT", 82, 121], ["neuron identification", "TEST", 164, 185], ["The tissue sections", "TEST", 232, 251], ["xylene", "TREATMENT", 275, 281], ["gradient ethanol", "TREATMENT", 300, 316], ["formalin deposition", "TREATMENT", 392, 411], ["0.01 M phosphate", "TREATMENT", 431, 447], ["buffered saline (PBS", "TREATMENT", 448, 468], ["embedded tissue", "OBSERVATION_MODIFIER", 97, 112], ["good morphology", "OBSERVATION_MODIFIER", 144, 159]]], ["(2) Antigen retrieval was performed by heating the slides at 96 \u00b0C in a sodium citrate buffer (pH 6.0) for 15 min 29 .Materials and Methods(3) After cooling to room temperature, slides were rinsed in 0.01 M PBS, then again in 3% hydrogen peroxide incubation for 30 min to quench the endogenous peroxidase activity.", [["sodium citrate", "CHEMICAL", 72, 86], ["hydrogen peroxide", "CHEMICAL", 229, 246], ["sodium citrate", "CHEMICAL", 72, 86], ["hydrogen peroxide", "CHEMICAL", 229, 246], ["sodium citrate", "SIMPLE_CHEMICAL", 72, 86], ["hydrogen peroxide", "SIMPLE_CHEMICAL", 229, 246], ["peroxidase", "GENE_OR_GENE_PRODUCT", 294, 304], ["endogenous peroxidase", "PROTEIN", 283, 304], ["Antigen retrieval", "TREATMENT", 4, 21], ["a sodium citrate buffer", "TREATMENT", 70, 93], ["pH", "TEST", 95, 97], ["slides", "TEST", 178, 184], ["3% hydrogen peroxide incubation", "TREATMENT", 226, 257], ["peroxidase activity", "OBSERVATION", 294, 313]]], ["They were then washed with 0.01 M PBS 3 times for 3 min each.", [["0.01 M PBS", "TREATMENT", 27, 37]]], ["(4) Primary mouse anti-human monoclonal antibodies to CFTR (1:100; Zymed Laboratories, South San Francisco, CA, USA) and neurofilament (NF, 1:100; Dako, Copenhagen, Denmark) were added to 2 consecutive sections to identify CFTR-positive cells and ganglion cells, respectively, and incubated overnight at 4 \u00b0C. PBS was used in place of the primary antibody for the negative control sections.", [["sections", "ANATOMY", 202, 210], ["CFTR-positive cells", "ANATOMY", 223, 242], ["ganglion cells", "ANATOMY", 247, 261], ["sections", "ANATOMY", 381, 389], ["mouse", "ORGANISM", 12, 17], ["CFTR", "GENE_OR_GENE_PRODUCT", 54, 58], ["neurofilament", "GENE_OR_GENE_PRODUCT", 121, 134], ["CFTR", "GENE_OR_GENE_PRODUCT", 223, 227], ["cells", "CELL", 237, 242], ["ganglion cells", "CELL", 247, 261], ["Primary mouse anti-human monoclonal antibodies", "PROTEIN", 4, 50], ["CFTR", "PROTEIN", 54, 58], ["neurofilament", "PROTEIN", 121, 134], ["NF", "PROTEIN", 136, 138], ["CFTR", "PROTEIN", 223, 227], ["positive cells", "CELL_TYPE", 228, 242], ["ganglion cells", "CELL_TYPE", 247, 261], ["primary antibody", "PROTEIN", 339, 355], ["mouse", "SPECIES", 12, 17], ["mouse", "SPECIES", 12, 17], ["Primary mouse anti-human monoclonal antibodies", "TEST", 4, 50], ["CFTR", "TEST", 54, 58], ["CFTR", "TEST", 223, 227], ["ganglion cells", "TEST", 247, 261], ["PBS", "TEST", 310, 313], ["positive cells", "OBSERVATION", 228, 242], ["ganglion cells", "OBSERVATION", 247, 261]]], ["(5) Horseradish-peroxidase-conjugated anti-mouse/rabbit IgG (PV9000 immunohistochemistry kit; Zymed Laboratories) and horseradish-peroxidase conjugated anti-goat IgG (1:1000; Jackson, West Grove, PA, USA) were added and incubated at room temperature for 20 min as the secondary antibody.", [["Horseradish-peroxidase", "SIMPLE_CHEMICAL", 4, 26], ["rabbit", "ORGANISM", 49, 55], ["IgG", "GENE_OR_GENE_PRODUCT", 56, 59], ["Zymed", "GENE_OR_GENE_PRODUCT", 94, 99], ["horseradish-peroxidase", "SIMPLE_CHEMICAL", 118, 140], ["anti-goat IgG", "SIMPLE_CHEMICAL", 152, 165], ["Horseradish-peroxidase", "PROTEIN", 4, 26], ["conjugated anti-mouse", "PROTEIN", 27, 48], ["rabbit IgG", "PROTEIN", 49, 59], ["PV9000 immunohistochemistry kit", "PROTEIN", 61, 92], ["Zymed Laboratories", "PROTEIN", 94, 112], ["horseradish-peroxidase conjugated anti-goat IgG", "PROTEIN", 118, 165], ["secondary antibody", "PROTEIN", 268, 286], ["anti-mouse", "SPECIES", 38, 48], ["rabbit", "SPECIES", 49, 55], ["horseradish", "SPECIES", 118, 129], ["anti-goat", "SPECIES", 152, 161], ["rabbit", "SPECIES", 49, 55], ["Horseradish", "TEST", 4, 15], ["peroxidase", "TEST", 16, 26], ["conjugated anti-mouse/rabbit IgG", "TREATMENT", 27, 59], ["horseradish", "TEST", 118, 129], ["peroxidase conjugated anti-goat IgG", "TREATMENT", 130, 165]]], ["(6) After being washed in PBS, 3,3\u2032 -diaminobenzidine (DAB; Zymed Laboratories) was used to visualize antigen localization.", [["3,3\u2032 -diaminobenzidine", "CHEMICAL", 31, 53], ["3,3\u2032 -diaminobenzidine", "CHEMICAL", 31, 53], ["DAB", "CHEMICAL", 55, 58], ["3,3\u2032 -diaminobenzidine", "SIMPLE_CHEMICAL", 31, 53], ["DAB", "SIMPLE_CHEMICAL", 55, 58], ["Zymed", "GENE_OR_GENE_PRODUCT", 60, 65], ["PBS", "TEST", 26, 29]]], ["All slides were counterstained with hematoxylin.", [["hematoxylin", "CHEMICAL", 36, 47], ["hematoxylin", "SIMPLE_CHEMICAL", 36, 47], ["hematoxylin", "TREATMENT", 36, 47]]], ["The results of immune staining on neurofilament (NF) on adjacent sections were compared to examine whether the CFTR-containing cells were neurons.Materials and MethodsLaser-assisted microdissection, RNA extraction and nested RT-PCR.", [["sections", "ANATOMY", 65, 73], ["cells", "ANATOMY", 127, 132], ["neurons", "ANATOMY", 138, 145], ["neurofilament", "GENE_OR_GENE_PRODUCT", 34, 47], ["NF", "GENE_OR_GENE_PRODUCT", 49, 51], ["sections", "MULTI-TISSUE_STRUCTURE", 65, 73], ["CFTR", "GENE_OR_GENE_PRODUCT", 111, 115], ["cells", "CELL", 127, 132], ["neurons", "CELL", 138, 145], ["neurofilament", "PROTEIN", 34, 47], ["NF", "PROTEIN", 49, 51], ["CFTR", "PROTEIN", 111, 115], ["immune staining", "TEST", 15, 30], ["adjacent sections", "TEST", 56, 73], ["the CFTR", "TEST", 107, 115], ["Materials", "TREATMENT", 146, 155], ["MethodsLaser-assisted microdissection", "TREATMENT", 160, 197], ["RNA extraction", "TREATMENT", 199, 213], ["nested RT-PCR", "TEST", 218, 231]]], ["Because of the strong positive expression of CFTR in gastrointestinal tract epithelial cells, we performed a laser-assisted microdissection (LMD) to ensure the isolation of only gastrointestinal ganglion cells for RNA extraction followed by nested RT-PCR, to avoid possible contamination of nearby epithelial cells.", [["gastrointestinal tract epithelial cells", "ANATOMY", 53, 92], ["gastrointestinal ganglion cells", "ANATOMY", 178, 209], ["epithelial cells", "ANATOMY", 298, 314], ["CFTR", "GENE_OR_GENE_PRODUCT", 45, 49], ["gastrointestinal tract epithelial cells", "CELL", 53, 92], ["gastrointestinal ganglion cells", "CELL", 178, 209], ["epithelial cells", "CELL", 298, 314], ["CFTR", "PROTEIN", 45, 49], ["gastrointestinal tract epithelial cells", "CELL_TYPE", 53, 92], ["gastrointestinal ganglion cells", "CELL_TYPE", 178, 209], ["nearby epithelial cells", "CELL_TYPE", 291, 314], ["CFTR in gastrointestinal tract epithelial cells", "PROBLEM", 45, 92], ["a laser-assisted microdissection (LMD", "TREATMENT", 107, 144], ["gastrointestinal ganglion cells", "PROBLEM", 178, 209], ["RNA extraction", "TREATMENT", 214, 228], ["nested RT-PCR", "TREATMENT", 241, 254], ["contamination of nearby epithelial cells", "PROBLEM", 274, 314], ["gastrointestinal tract", "ANATOMY", 53, 75], ["epithelial cells", "OBSERVATION", 76, 92], ["gastrointestinal ganglion", "ANATOMY", 178, 203], ["nearby epithelial cells", "OBSERVATION", 291, 314]]], ["The frozen tissue samples of human gastrointestinal tract segments were sectioned (10 \u03bcm) and mounted on pretreated slides (LCM DNase-free, RNase-free, PEN-membrane slides, Leica Microsystems, Wetzlar, Germany).", [["tissue samples", "ANATOMY", 11, 25], ["gastrointestinal tract segments", "ANATOMY", 35, 66], ["tissue samples", "TISSUE", 11, 25], ["human", "ORGANISM", 29, 34], ["gastrointestinal tract segments", "MULTI-TISSUE_STRUCTURE", 35, 66], ["RNase", "GENE_OR_GENE_PRODUCT", 140, 145], ["DNase", "PROTEIN", 128, 133], ["RNase", "PROTEIN", 140, 145], ["human", "SPECIES", 29, 34], ["human", "SPECIES", 29, 34], ["The frozen tissue samples", "TEST", 0, 25], ["pretreated slides", "TEST", 105, 122], ["LCM DNase", "TEST", 124, 133], ["RNase", "TEST", 140, 145], ["frozen tissue", "OBSERVATION", 4, 17], ["human", "ANATOMY_MODIFIER", 29, 34], ["gastrointestinal tract", "ANATOMY", 35, 57], ["segments", "ANATOMY_MODIFIER", 58, 66]]], ["The slides were then quickly fixed in 70% ethanol for 1 min, rinsed in DEPC-treated water for 30 s, stained with DEPC-treated hematoxylin for 1 min, and rinsed in DEPC-treated water (pH 8.0) twice for 30 s each time.", [["ethanol", "CHEMICAL", 42, 49], ["DEPC", "CHEMICAL", 71, 75], ["DEPC", "CHEMICAL", 113, 117], ["DEPC", "CHEMICAL", 163, 167], ["ethanol", "CHEMICAL", 42, 49], ["DEPC", "CHEMICAL", 71, 75], ["DEPC", "CHEMICAL", 113, 117], ["hematoxylin", "CHEMICAL", 126, 137], ["DEPC", "CHEMICAL", 163, 167], ["ethanol", "SIMPLE_CHEMICAL", 42, 49], ["DEPC", "SIMPLE_CHEMICAL", 71, 75], ["DEPC", "SIMPLE_CHEMICAL", 113, 117], ["hematoxylin", "SIMPLE_CHEMICAL", 126, 137], ["DEPC", "SIMPLE_CHEMICAL", 163, 167], ["DEPC", "TREATMENT", 113, 117], ["hematoxylin", "TREATMENT", 126, 137], ["pH", "TEST", 183, 185]]], ["All of the chemicals were prepared with DEPC-treated water.", [["DEPC", "CHEMICAL", 40, 44], ["DEPC", "CHEMICAL", 40, 44], ["DEPC", "SIMPLE_CHEMICAL", 40, 44], ["DEPC", "TREATMENT", 40, 44]]], ["The ganglion cell groups were identified by their morphology, and were isolated from the frozen tissue sections using the Leica Microdissection System (Leica LMD 6000 B, Leica Microsystems).", [["ganglion cell", "ANATOMY", 4, 17], ["tissue sections", "ANATOMY", 96, 111], ["ganglion cell", "CELL", 4, 17], ["tissue sections", "MULTI-TISSUE_STRUCTURE", 96, 111], ["the Leica Microdissection System", "TREATMENT", 118, 150], ["ganglion cell groups", "OBSERVATION", 4, 24], ["frozen tissue", "OBSERVATION", 89, 102]]], ["The microdissected target ganglia were then collected in an Eppendorf tube.", [["ganglia", "ANATOMY", 26, 33], ["ganglia", "ORGAN", 26, 33], ["an Eppendorf tube", "TREATMENT", 57, 74], ["microdissected", "OBSERVATION_MODIFIER", 4, 18], ["target", "OBSERVATION_MODIFIER", 19, 25], ["ganglia", "ANATOMY", 26, 33], ["Eppendorf tube", "OBSERVATION", 60, 74]]], ["Smooth muscle cell groups were captured and used to exclude the expression of CFTR in smooth muscle cells.", [["Smooth muscle cell", "ANATOMY", 0, 18], ["smooth muscle cells", "ANATOMY", 86, 105], ["Smooth muscle cell", "CELL", 0, 18], ["CFTR", "GENE_OR_GENE_PRODUCT", 78, 82], ["smooth muscle cells", "CELL", 86, 105], ["CFTR", "PROTEIN", 78, 82], ["smooth muscle cells", "CELL_TYPE", 86, 105], ["CFTR in smooth muscle cells", "PROBLEM", 78, 105], ["muscle", "ANATOMY", 7, 13], ["cell", "OBSERVATION", 14, 18], ["CFTR", "OBSERVATION", 78, 82], ["smooth muscle cells", "OBSERVATION", 86, 105]]], ["Epithelial cell groups were also captured and used as positive controls.", [["Epithelial cell", "ANATOMY", 0, 15], ["Epithelial cell", "CELL", 0, 15], ["Epithelial cell groups", "PROBLEM", 0, 22]]], ["The procedure was performed in accordance with the manufacturer's instructions.", [["The procedure", "TREATMENT", 0, 13]]], ["RNA extraction was performed using the RNeasy Micro Kit (Qiagen, Cologne, Germany) to extract total RNA from the dissected ganglion cells.", [["ganglion cells", "ANATOMY", 123, 137], ["ganglion cells", "CELL", 123, 137], ["total RNA", "RNA", 94, 103], ["dissected ganglion cells", "CELL_TYPE", 113, 137], ["RNA extraction", "TREATMENT", 0, 14], ["the RNeasy Micro Kit", "TREATMENT", 35, 55], ["dissected ganglion cells", "OBSERVATION", 113, 137]]], ["The reverse transcription was carried out with the Super Script III cDNA Kit (Invitrogen, CA, USA) following the manufacturer's instructions.", [["Super Script III cDNA", "DNA", 51, 72], ["the manufacturer's instructions", "TREATMENT", 109, 140]]], ["Briefly, 5 \u03bcg of total RNA was extracted from the dissected tissue and reverse transcription reactions were performed using random primers at 55 \u00b0C for 60 min.Materials and MethodsThe sequences of the CFTR primers were obtained from the GenBank (acc.", [["tissue", "ANATOMY", 60, 66], ["tissue", "TISSUE", 60, 66], ["CFTR", "GENE_OR_GENE_PRODUCT", 201, 205], ["CFTR primers", "DNA", 201, 213], ["total RNA", "TREATMENT", 17, 26], ["reverse transcription reactions", "PROBLEM", 71, 102], ["random primers", "TREATMENT", 124, 138], ["Methods", "TREATMENT", 173, 180], ["The sequences of the CFTR primers", "TEST", 180, 213], ["dissected tissue", "ANATOMY", 50, 66]]], ["NM-031506).", [["NM-031506", "CHEMICAL", 0, 9], ["NM-031506", "CHEMICAL", 0, 9]]], ["Nested RT-PCR was used to ensure the specificity of the results as two pairs of primers were employed.", [["Nested RT-PCR", "TREATMENT", 0, 13]]], ["The primers for nested PCR were as follows: external 5\u2032 -CACTGCTGGTATGCTCTCCA-3\u2032 (sense), and 5\u2032 -AATGAATGGCATCGAAGAGG-3\u2032 (antisense); internal 5\u2032 -CACTGCTGGTATGCTCTCCA-3\u2032 (sense), and 5\u2032 -ACCGAAAGACAACAGCATCC-3\u2032 (antisense).", [["AATGAATGGCATCGAAGAGG-3", "GENE_OR_GENE_PRODUCT", 98, 120], ["AATGAATGGCATCGAAGAGG-3\u2032", "DNA", 98, 121], ["ACCGAAAGACAACAGCATCC-3\u2032", "DNA", 189, 212], ["nested PCR", "TEST", 16, 26], ["CACTGCTGGTATGCTCTCCA", "TEST", 57, 77], ["AATGAATGGCATCGAAGAGG", "TEST", 98, 118], ["CACTGCTGGTATGCTCTCCA", "TEST", 148, 168], ["ACCGAAAGACAACAGCATCC", "TEST", 189, 209]]], ["The PCR products span one intron.", [["PCR products", "DNA", 4, 16], ["intron", "DNA", 26, 32], ["The PCR products", "TREATMENT", 0, 16], ["span", "OBSERVATION_MODIFIER", 17, 21], ["one intron", "OBSERVATION", 22, 32]]], ["18S was amplified as an endogenous reference with the following primers: 5\u2032 -AAACGGCTACCACATCCAAG-3\u2032 (sense), and 5\u2032 -CCTCCAATGGATCCTCGTTA-3\u2032 (anti-sense).", [["18S", "GENE_OR_GENE_PRODUCT", 0, 3], ["18S", "DNA", 0, 3], ["AAACGGCTACCACATCCAAG", "TEST", 77, 97], ["CCTCCAATGGATCCTCGTTA", "TEST", 118, 138]]], ["The final amplifying products of CFTR and 18S were 179 bp and 155 bp.", [["CFTR", "GENE_OR_GENE_PRODUCT", 33, 37], ["18S", "GENE_OR_GENE_PRODUCT", 42, 45], ["CFTR", "PROTEIN", 33, 37], ["18S", "DNA", 42, 45], ["CFTR", "TEST", 33, 37], ["18S", "TEST", 42, 45], ["bp", "TEST", 55, 57], ["bp", "TEST", 66, 68]]], ["Nested PCR was performed with Taq Polymerase (NEB, Nebraska, US).", [["Taq Polymerase", "GENE_OR_GENE_PRODUCT", 30, 44], ["Taq Polymerase", "PROTEIN", 30, 44], ["Nested PCR", "TEST", 0, 10], ["Taq Polymerase", "TREATMENT", 30, 44]]], ["The first amplification with the external primers proceeded for 40 cycles of 30 s at 94 \u00b0C, 40 cycles of 30 s at 55 \u00b0C, and 40 cycles of 1 min at 72 \u00b0C. The final cycle was followed by an extension period of 10 min at 72 \u00b0C. The second amplification round with the internal primers proceeded in a manner identical to the first amplification round.Materials and MethodsPlasmid construction, sequence analysis and cRNA probe preparation.", [["The first amplification", "TREATMENT", 0, 23], ["the external primers", "TREATMENT", 29, 49], ["The second amplification round", "TREATMENT", 225, 255], ["the internal primers", "TREATMENT", 261, 281], ["MethodsPlasmid construction", "TREATMENT", 361, 388], ["sequence analysis", "TEST", 390, 407], ["cRNA probe preparation", "TREATMENT", 412, 434], ["round", "OBSERVATION_MODIFIER", 250, 255]]], ["To perform sequence analysis and generate the cRNA probe, we used a specifically designed CFTR RT-PCR product, as described before 17, 18, 30 .", [["CFTR", "GENE_OR_GENE_PRODUCT", 90, 94], ["cRNA probe", "DNA", 46, 56], ["sequence analysis", "TEST", 11, 28], ["CFTR RT-PCR product", "TREATMENT", 90, 109]]], ["Human brain tissue RNA extraction was carried out using oligo (dT) primers by a cDNA synthesis kit (#K1621, Fermentas; Lithuania).", [["brain tissue", "ANATOMY", 6, 18], ["Human", "ORGANISM", 0, 5], ["brain tissue", "TISSUE", 6, 18], ["Human", "SPECIES", 0, 5], ["Human", "SPECIES", 0, 5], ["Human brain tissue RNA extraction", "TREATMENT", 0, 33], ["oligo (dT) primers", "TREATMENT", 56, 74], ["a cDNA synthesis kit", "TEST", 78, 98], ["K1621", "TEST", 101, 106]]], ["The PCR was then performed with pairs of specific primers for nested RT-PCR.", [["The PCR", "TEST", 0, 7], ["specific primers", "TEST", 41, 57], ["nested RT-PCR", "TEST", 62, 75]]], ["They were encoded as follows: 5\u2032 -CCCTTCGGCGATGTT-3\u2032 , 5\u2032 -CAGGAAACCAAGTCCACAG-3\u2032 (external); and 5\u2032 -AGGAGGAACGCTCTATCG-3\u2032 , 5\u2032 -GCAGACGCCTGTAACAAC-3\u2032 (internal).", [["5\u2032 -CCCTTCGGCGATGTT-3\u2032 , 5\u2032", "CHEMICAL", 30, 57], ["AGGAGGAACGCTCTATCG-3\u2032 , 5\u2032", "CHEMICAL", 102, 128], ["CAGGAAACCAAGTCCACAG", "TEST", 59, 78], ["AGGAGGAACGCTCTATCG", "TEST", 102, 120], ["GCAGACGCCTGTAACAAC", "TEST", 130, 148]]], ["The final amplification product of CFTR was 328 bp and encompassed two splicing events.", [["CFTR", "GENE_OR_GENE_PRODUCT", 35, 39], ["CFTR", "PROTEIN", 35, 39], ["CFTR", "TEST", 35, 39], ["bp", "TEST", 48, 50], ["two splicing events", "PROBLEM", 67, 86]]], ["The first amplification of PCR was performed for 40 cycles of 1 min at 94 \u00b0C, 40 cycles of 30 s at 72 \u00b0C, and 40 cycles of 30 s at 52 \u00b0C; the second amplification round was for 40 cycles of 1 min at 94 \u00b0C, 40 cycles of 30 s at 72 \u00b0C, and 40 cycles of 30 s at 54 \u00b0C. In both reactions, the first PCR cycle was preceded by an incubation period of 10 min at 94 \u00b0C, and the final cycle was followed by an extension period of 5 min at 72 \u00b0C. Five \u03bcg of the product was separated on 2% agarose gel by electrophoresis, extracted from the gel using the Gel DNA Extraction kit (Tiangen Biotech, Beijing, China), and then subcloned into the pGM-T vector by T4 ligase (Tiangen Biotech).", [["agarose", "SIMPLE_CHEMICAL", 480, 487], ["DNA", "CELLULAR_COMPONENT", 549, 552], ["pGM-T", "GENE_OR_GENE_PRODUCT", 631, 636], ["T4 ligase", "GENE_OR_GENE_PRODUCT", 647, 656], ["pGM-T vector", "DNA", 631, 643], ["T4 ligase", "PROTEIN", 647, 656], ["Tiangen Biotech", "PROTEIN", 658, 673], ["PCR", "TEST", 27, 30], ["the first PCR cycle", "TEST", 285, 304], ["2% agarose gel", "TREATMENT", 477, 491], ["the gel", "TREATMENT", 527, 534], ["the Gel DNA Extraction", "TREATMENT", 541, 563], ["both", "OBSERVATION_MODIFIER", 269, 273], ["reactions", "OBSERVATION", 274, 283]]], ["The plasmid was then transfected into Escherichia coli XLl-Blue.", [["plasmid", "ANATOMY", 4, 11], ["Escherichia coli", "ORGANISM", 38, 54], ["Escherichia coli", "SPECIES", 38, 54], ["Escherichia coli", "SPECIES", 38, 54], ["The plasmid", "TREATMENT", 0, 11], ["Escherichia coli", "OBSERVATION", 38, 54], ["Blue", "OBSERVATION_MODIFIER", 59, 63]]], ["X-gal/ isopropyl-b-D-thiogalactopyranoside and ampicillin (100 \u03bcg/mL) double selections were performed.Materials and MethodsSequencing was carried out to determine the identity of the CFTR gene.", [["X-gal/ isopropyl-b-D-thiogalactopyranoside", "CHEMICAL", 0, 42], ["ampicillin", "CHEMICAL", 47, 57], ["isopropyl-b-D-thiogalactopyranoside", "CHEMICAL", 7, 42], ["ampicillin", "CHEMICAL", 47, 57], ["X-gal", "SIMPLE_CHEMICAL", 0, 5], ["isopropyl-b-D-thiogalactopyranoside", "SIMPLE_CHEMICAL", 7, 42], ["ampicillin", "SIMPLE_CHEMICAL", 47, 57], ["CFTR", "GENE_OR_GENE_PRODUCT", 184, 188], ["CFTR gene", "DNA", 184, 193], ["isopropyl", "TREATMENT", 7, 16], ["thiogalactopyranoside", "TREATMENT", 21, 42], ["ampicillin", "TREATMENT", 47, 57], ["double selections", "TREATMENT", 70, 87], ["MethodsSequencing", "TREATMENT", 117, 134]]], ["Plasmid, extracted from the positive clone, was linearized with either the SalI or NcoI restriction enzyme, and an in vitro transcription reaction was performed to generate the cRNA probe.", [["Plasmid", "ANATOMY", 0, 7], ["clone", "ANATOMY", 37, 42], ["clone", "CELL", 37, 42], ["SalI", "GENE_OR_GENE_PRODUCT", 75, 79], ["NcoI", "GENE_OR_GENE_PRODUCT", 83, 87], ["SalI", "DNA", 75, 79], ["NcoI restriction enzyme", "PROTEIN", 83, 106], ["cRNA probe", "DNA", 177, 187], ["Plasmid", "PROBLEM", 0, 7], ["the positive clone", "PROBLEM", 24, 42], ["the SalI or NcoI restriction enzyme", "TEST", 71, 106], ["an in vitro transcription reaction", "PROBLEM", 112, 146], ["positive clone", "OBSERVATION", 28, 42]]], ["Anti-sense cRNA probes were generated with Sp6 RNA polymerase, and sense probes were generated with T7 RNA polymerase.", [["Sp6", "GENE_OR_GENE_PRODUCT", 43, 46], ["Sp6 RNA polymerase", "RNA", 43, 61], ["T7 RNA polymerase", "PROTEIN", 100, 117], ["Anti-sense cRNA probes", "TREATMENT", 0, 22], ["Sp6 RNA polymerase", "TEST", 43, 61], ["sense probes", "TEST", 67, 79], ["T7 RNA polymerase", "PROBLEM", 100, 117]]], ["The probes were labeled with a Digoxigenin RNA Labeling Mix (Roche Molecular Biochemicals; Mannheim, Germany) for in situ hybridization.Materials and MethodsIn situ hybridization localization.", [["Digoxigenin", "SIMPLE_CHEMICAL", 31, 42], ["The probes", "TREATMENT", 0, 10], ["a Digoxigenin RNA", "TREATMENT", 29, 46]]], ["To determine the CFTR mRNA localization in human gastrointestinal ganglia, we performed in situ hybridization on consecutive formalin-fixed paraffin-embedded tissue sections (4 \u03bcm) with a specific cRNA anti-sense probe against the CFTR gene prepared as described above.", [["gastrointestinal ganglia", "ANATOMY", 49, 73], ["tissue sections", "ANATOMY", 158, 173], ["formalin", "CHEMICAL", 125, 133], ["paraffin", "CHEMICAL", 140, 148], ["CFTR", "GENE_OR_GENE_PRODUCT", 17, 21], ["human", "ORGANISM", 43, 48], ["gastrointestinal ganglia", "MULTI-TISSUE_STRUCTURE", 49, 73], ["tissue sections", "MULTI-TISSUE_STRUCTURE", 158, 173], ["CFTR", "GENE_OR_GENE_PRODUCT", 231, 235], ["CFTR mRNA", "RNA", 17, 26], ["CFTR gene", "DNA", 231, 240], ["human", "SPECIES", 43, 48], ["human", "SPECIES", 43, 48], ["the CFTR mRNA localization in human gastrointestinal ganglia", "PROBLEM", 13, 73], ["consecutive formalin", "TREATMENT", 113, 133], ["fixed paraffin-embedded tissue sections", "TREATMENT", 134, 173], ["a specific cRNA anti-sense probe", "TREATMENT", 186, 218], ["gastrointestinal ganglia", "ANATOMY", 49, 73], ["embedded tissue", "OBSERVATION_MODIFIER", 149, 164]]], ["All the solutions used were prepared with diethyl-pyrocarbonate (DEPC)-treated water to avoid mRNA degradation.", [["diethyl-pyrocarbonate", "CHEMICAL", 42, 63], ["DEPC", "CHEMICAL", 65, 69], ["diethyl-pyrocarbonate", "CHEMICAL", 42, 63], ["DEPC", "CHEMICAL", 65, 69], ["diethyl-pyrocarbonate", "SIMPLE_CHEMICAL", 42, 63], ["DEPC", "SIMPLE_CHEMICAL", 65, 69], ["water", "SIMPLE_CHEMICAL", 79, 84], ["All the solutions", "TREATMENT", 0, 17], ["diethyl-pyrocarbonate (DEPC)", "TREATMENT", 42, 70], ["mRNA degradation", "PROBLEM", 94, 110]]], ["The tissue sections were deparaffinized in xylene, rehydrated in gradient ethanol, incubated in 1 N HCl at room temperature for 10 min to increase permeability and washed in 0.01 M phosphate-buffered saline (PBS).", [["tissue sections", "ANATOMY", 4, 19], ["xylene", "CHEMICAL", 43, 49], ["ethanol", "CHEMICAL", 74, 81], ["1 N HCl", "CHEMICAL", 96, 103], ["phosphate", "CHEMICAL", 181, 190], ["xylene", "CHEMICAL", 43, 49], ["ethanol", "CHEMICAL", 74, 81], ["HCl", "CHEMICAL", 100, 103], ["phosphate", "CHEMICAL", 181, 190], ["tissue sections", "MULTI-TISSUE_STRUCTURE", 4, 19], ["xylene", "SIMPLE_CHEMICAL", 43, 49], ["ethanol", "SIMPLE_CHEMICAL", 74, 81], ["phosphate-buffered saline", "SIMPLE_CHEMICAL", 181, 206], ["The tissue sections", "TEST", 0, 19], ["xylene", "TREATMENT", 43, 49], ["gradient ethanol", "TREATMENT", 65, 81], ["0.01 M phosphate", "TREATMENT", 174, 190], ["buffered saline (PBS", "TREATMENT", 191, 211]]], ["The slides were heated to 96 \u00b0C in sodium citrate buffer (pH 6.0) for 15 min 29 .", [["sodium citrate", "CHEMICAL", 35, 49], ["sodium citrate", "CHEMICAL", 35, 49], ["sodium citrate", "SIMPLE_CHEMICAL", 35, 49], ["The slides", "TEST", 0, 10], ["sodium citrate buffer", "TREATMENT", 35, 56], ["pH", "TEST", 58, 60]]], ["After being cooled to room temperature, and rinsed in 0.01 M PBS, the slides were fixed in 4% paraformaldehyde for 10 min, washed and dehydrated in 90% ethanol for 15 s, and hybridized overnight at 45 \u00b0C with the specific digoxigenin-labeled CFTR cRNA probe.", [["ethanol", "CHEMICAL", 152, 159], ["paraformaldehyde", "CHEMICAL", 94, 110], ["ethanol", "CHEMICAL", 152, 159], ["paraformaldehyde", "SIMPLE_CHEMICAL", 94, 110], ["ethanol", "SIMPLE_CHEMICAL", 152, 159], ["digoxigenin", "SIMPLE_CHEMICAL", 222, 233], ["CFTR", "GENE_OR_GENE_PRODUCT", 242, 246], ["CFTR", "PROTEIN", 242, 246], ["the specific digoxigenin", "TREATMENT", 209, 233], ["CFTR cRNA probe", "TREATMENT", 242, 257]]], ["The slides were then washed three times, first with 2\u00d7 standard saline citrate (SSC) plus 50% formamid, then with 2\u00d7 SSC, and finally with 0.1\u00d7 SSC at 37 \u00b0C for 15 min each.", [["citrate", "CHEMICAL", 71, 78], ["formamid", "CHEMICAL", 94, 102], ["citrate", "CHEMICAL", 71, 78], ["saline citrate", "SIMPLE_CHEMICAL", 64, 78], ["formamid", "SIMPLE_CHEMICAL", 94, 102], ["The slides", "TREATMENT", 0, 10], ["2\u00d7 standard saline citrate (SSC)", "TREATMENT", 52, 84]]], ["After blocking with normal horse serum (1:100) at room temperature for 1 hour, the sections were incubated with an alkaline phosphatase-labeled anti-digoxigenin antibody (1:500; Roche Diagnostics, Pensberg, Germany) for 1 hour.", [["serum", "ANATOMY", 33, 38], ["sections", "ANATOMY", 83, 91], ["horse", "ORGANISM", 27, 32], ["serum", "ORGANISM_SUBSTANCE", 33, 38], ["anti-digoxigenin antibody", "SIMPLE_CHEMICAL", 144, 169], ["alkaline phosphatase", "PROTEIN", 115, 135], ["anti-digoxigenin antibody", "PROTEIN", 144, 169], ["horse", "SPECIES", 27, 32], ["horse", "SPECIES", 27, 32], ["the sections", "TEST", 79, 91], ["an alkaline phosphatase", "TEST", 112, 135], ["anti-digoxigenin antibody", "TEST", 144, 169]]], ["Nitro blue tetrazolium/5-bromo-4-choloro-3-indolyl phosphate (NBT/BCIP; Promega Corp., Madison, Wis.) was used to visualize the reaction staining, which resulted in a purple-blue signal.", [["Nitro blue tetrazolium", "CHEMICAL", 0, 22], ["5-bromo-4-choloro-3-indolyl phosphate", "CHEMICAL", 23, 60], ["NBT", "CHEMICAL", 62, 65], ["Nitro blue tetrazolium", "CHEMICAL", 0, 22], ["5-bromo-4-choloro-3-indolyl phosphate", "CHEMICAL", 23, 60], ["NBT", "CHEMICAL", 62, 65], ["BCIP", "CHEMICAL", 66, 70], ["Nitro blue tetrazolium", "SIMPLE_CHEMICAL", 0, 22], ["5-bromo-4-choloro-3-indolyl phosphate", "SIMPLE_CHEMICAL", 23, 60], ["NBT", "SIMPLE_CHEMICAL", 62, 65], ["Nitro blue tetrazolium", "TREATMENT", 0, 22], ["bromo", "TREATMENT", 25, 30], ["choloro", "TREATMENT", 33, 40], ["indolyl phosphate", "TREATMENT", 43, 60], ["the reaction staining", "PROBLEM", 124, 145], ["a purple-blue signal", "PROBLEM", 165, 185], ["purple", "OBSERVATION_MODIFIER", 167, 173], ["blue signal", "OBSERVATION", 174, 185]]], ["All slides were counterstained with methyl green.", [["methyl green", "CHEMICAL", 36, 48], ["methyl green", "CHEMICAL", 36, 48], ["methyl green", "SIMPLE_CHEMICAL", 36, 48]]], ["The slides were incubated with a corresponding sense probe or with hybridizing solutions only as negative controls.", [["hybridizing solutions", "TREATMENT", 67, 88]]], ["To identify the cell type that expressed CFTR mRNA, immunostaining with antibody to NF was performed on tissue sections consecutive to the ones on which CFTR in situ hybridization staining was performed.", [["cell", "ANATOMY", 16, 20], ["tissue sections", "ANATOMY", 104, 119], ["cell type", "CELL", 16, 25], ["CFTR", "GENE_OR_GENE_PRODUCT", 41, 45], ["NF", "GENE_OR_GENE_PRODUCT", 84, 86], ["tissue sections", "MULTI-TISSUE_STRUCTURE", 104, 119], ["CFTR", "GENE_OR_GENE_PRODUCT", 153, 157], ["CFTR mRNA", "RNA", 41, 50], ["NF", "PROTEIN", 84, 86], ["CFTR mRNA", "PROBLEM", 41, 50], ["immunostaining", "TEST", 52, 66], ["antibody to NF", "TEST", 72, 86], ["tissue sections", "TEST", 104, 119], ["CFTR in situ hybridization staining", "TEST", 153, 188]]], ["The NF immunostaining results were compared with the CFTR in situ hybridization results on consecutive sections to investigate whether CFTR mRNA positive cells were NF-positive neurons.CFTR expression in human enteric ganglia by IHC.The human enteric ganglia were identified based on their location and morphology.", [["sections", "ANATOMY", 103, 111], ["cells", "ANATOMY", 154, 159], ["NF-positive neurons", "ANATOMY", 165, 184], ["enteric ganglia", "ANATOMY", 210, 225], ["enteric ganglia", "ANATOMY", 243, 258], ["NF", "GENE_OR_GENE_PRODUCT", 4, 6], ["CFTR", "GENE_OR_GENE_PRODUCT", 135, 139], ["cells", "CELL", 154, 159], ["NF", "GENE_OR_GENE_PRODUCT", 165, 167], ["CFTR", "GENE_OR_GENE_PRODUCT", 185, 189], ["human", "ORGANISM", 204, 209], ["enteric ganglia", "MULTI-TISSUE_STRUCTURE", 210, 225], ["human", "ORGANISM", 237, 242], ["enteric ganglia", "ORGAN", 243, 258], ["CFTR mRNA", "RNA", 135, 144], ["NF-positive neurons", "CELL_TYPE", 165, 184], ["CFTR", "PROTEIN", 185, 189], ["human", "SPECIES", 204, 209], ["human", "SPECIES", 237, 242], ["human", "SPECIES", 204, 209], ["human", "SPECIES", 237, 242], ["The NF immunostaining", "TEST", 0, 21], ["consecutive sections", "TEST", 91, 111], ["CFTR mRNA positive cells", "PROBLEM", 135, 159], ["CFTR expression in human enteric ganglia", "PROBLEM", 185, 225], ["human", "ANATOMY_MODIFIER", 204, 209], ["enteric ganglia", "ANATOMY", 210, 225], ["IHC", "OBSERVATION", 229, 232], ["human", "ANATOMY_MODIFIER", 237, 242], ["enteric ganglia", "ANATOMY", 243, 258], ["morphology", "OBSERVATION_MODIFIER", 303, 313]]], ["They were composed of small cell groups of enteric neurons, glial cells and nerve fibers.", [["cell", "ANATOMY", 28, 32], ["enteric neurons", "ANATOMY", 43, 58], ["glial cells", "ANATOMY", 60, 71], ["nerve fibers", "ANATOMY", 76, 88], ["cell", "CELL", 28, 32], ["enteric neurons", "CELL", 43, 58], ["glial cells", "CELL", 60, 71], ["nerve fibers", "TISSUE", 76, 88], ["enteric neurons", "CELL_TYPE", 43, 58], ["glial cells", "CELL_TYPE", 60, 71], ["small cell groups of enteric neurons", "PROBLEM", 22, 58], ["nerve fibers", "PROBLEM", 76, 88], ["small cell groups", "OBSERVATION", 22, 39], ["enteric neurons", "ANATOMY", 43, 58], ["glial cells", "OBSERVATION", 60, 71], ["nerve fibers", "OBSERVATION", 76, 88]]], ["The number, shape, size and orientation of the neurons in each ganglion varied in the different gastrointestinal segments.CFTR expression in human enteric ganglia by IHC.CFTR immunoreactivity was detected in the cytoplasm and dendrites of all neurons of the human enteric ganglia by IHC, both in myenteric and submucosal plexus.", [["neurons", "ANATOMY", 47, 54], ["ganglion", "ANATOMY", 63, 71], ["gastrointestinal segments", "ANATOMY", 96, 121], ["enteric ganglia", "ANATOMY", 147, 162], ["cytoplasm", "ANATOMY", 212, 221], ["dendrites", "ANATOMY", 226, 235], ["neurons", "ANATOMY", 243, 250], ["enteric ganglia", "ANATOMY", 264, 279], ["myenteric", "ANATOMY", 296, 305], ["submucosal plexus", "ANATOMY", 310, 327], ["neurons", "CELL", 47, 54], ["ganglion", "TISSUE", 63, 71], ["gastrointestinal segments", "MULTI-TISSUE_STRUCTURE", 96, 121], ["CFTR", "GENE_OR_GENE_PRODUCT", 122, 126], ["human", "ORGANISM", 141, 146], ["enteric ganglia", "MULTI-TISSUE_STRUCTURE", 147, 162], ["CFTR", "GENE_OR_GENE_PRODUCT", 170, 174], ["cytoplasm", "ORGANISM_SUBSTANCE", 212, 221], ["dendrites", "CELLULAR_COMPONENT", 226, 235], ["neurons", "CELL", 243, 250], ["human", "ORGANISM", 258, 263], ["enteric ganglia", "ORGAN", 264, 279], ["myenteric", "MULTI-TISSUE_STRUCTURE", 296, 305], ["submucosal plexus", "MULTI-TISSUE_STRUCTURE", 310, 327], ["CFTR", "PROTEIN", 122, 126], ["CFTR", "PROTEIN", 170, 174], ["human", "SPECIES", 141, 146], ["human", "SPECIES", 258, 263], ["human", "SPECIES", 141, 146], ["human", "SPECIES", 258, 263], ["CFTR expression in human enteric ganglia", "PROBLEM", 122, 162], ["CFTR immunoreactivity", "TEST", 170, 191], ["number", "OBSERVATION_MODIFIER", 4, 10], ["shape", "OBSERVATION_MODIFIER", 12, 17], ["size", "OBSERVATION_MODIFIER", 19, 23], ["orientation", "OBSERVATION_MODIFIER", 28, 39], ["neurons", "ANATOMY", 47, 54], ["each ganglion", "ANATOMY_MODIFIER", 58, 71], ["different", "ANATOMY_MODIFIER", 86, 95], ["gastrointestinal segments", "ANATOMY", 96, 121], ["human", "ANATOMY_MODIFIER", 141, 146], ["enteric ganglia", "ANATOMY", 147, 162], ["IHC", "OBSERVATION", 166, 169], ["cytoplasm", "ANATOMY_MODIFIER", 212, 221], ["dendrites", "ANATOMY_MODIFIER", 226, 235], ["all neurons", "ANATOMY_MODIFIER", 239, 250], ["human enteric ganglia", "ANATOMY", 258, 279], ["IHC", "OBSERVATION", 283, 286], ["myenteric", "ANATOMY", 296, 305], ["submucosal plexus", "ANATOMY", 310, 327]]], ["Consecutive sections showed the presence of positive NF (neurofilament, specific neuronal cell marker) IHC signal in all CFTR-positive cells.", [["sections", "ANATOMY", 12, 20], ["neuronal cell", "ANATOMY", 81, 94], ["CFTR-positive cells", "ANATOMY", 121, 140], ["NF", "GENE_OR_GENE_PRODUCT", 53, 55], ["neurofilament", "GENE_OR_GENE_PRODUCT", 57, 70], ["neuronal cell", "CELL", 81, 94], ["CFTR", "GENE_OR_GENE_PRODUCT", 121, 125], ["positive NF", "PROTEIN", 44, 55], ["neurofilament", "PROTEIN", 57, 70], ["CFTR-positive cells", "CELL_LINE", 121, 140], ["Consecutive sections", "TEST", 0, 20], ["positive NF", "PROBLEM", 44, 55], ["IHC signal", "TEST", 103, 113], ["all CFTR", "TEST", 117, 125], ["positive NF", "OBSERVATION_MODIFIER", 44, 55], ["positive cells", "OBSERVATION", 126, 140]]], ["The smooth muscle cells and glial cells showed negative immunostaining for CFTR and NF.", [["smooth muscle cells", "ANATOMY", 4, 23], ["glial cells", "ANATOMY", 28, 39], ["smooth muscle cells", "CELL", 4, 23], ["glial cells", "CELL", 28, 39], ["CFTR", "GENE_OR_GENE_PRODUCT", 75, 79], ["NF", "GENE_OR_GENE_PRODUCT", 84, 86], ["smooth muscle cells", "CELL_TYPE", 4, 23], ["glial cells", "CELL_TYPE", 28, 39], ["CFTR", "PROTEIN", 75, 79], ["NF", "PROTEIN", 84, 86], ["glial cells", "TEST", 28, 39], ["CFTR", "PROBLEM", 75, 79], ["NF", "PROBLEM", 84, 86], ["smooth muscle cells", "OBSERVATION", 4, 23], ["glial cells", "OBSERVATION", 28, 39]]], ["The specificity of IHC was established in parallel control experiments.", [["IHC", "TEST", 19, 22]]], ["In the positive control, strong CFTR-positive signals were detected in human gastric epithelium.", [["gastric epithelium", "ANATOMY", 77, 95], ["CFTR", "GENE_OR_GENE_PRODUCT", 32, 36], ["human", "ORGANISM", 71, 76], ["gastric epithelium", "TISSUE", 77, 95], ["CFTR", "PROTEIN", 32, 36], ["human", "SPECIES", 71, 76], ["human", "SPECIES", 71, 76], ["human", "ANATOMY_MODIFIER", 71, 76], ["gastric", "ANATOMY", 77, 84], ["epithelium", "ANATOMY_MODIFIER", 85, 95]]], ["In the negative controls, no specific signal was observed.", [["negative", "OBSERVATION", 7, 15]]], ["In all segments of the tractus gastrointestinalis, the expression and distribution of CFTR were similar (Fig. 1) .", [["tractus gastrointestinalis", "ANATOMY", 23, 49], ["tractus gastrointestinalis", "ORGANISM", 23, 49], ["CFTR", "GENE_OR_GENE_PRODUCT", 86, 90], ["CFTR", "PROTEIN", 86, 90], ["all", "ANATOMY_MODIFIER", 3, 6], ["segments", "ANATOMY_MODIFIER", 7, 15], ["tractus gastrointestinalis", "ANATOMY", 23, 49], ["expression", "OBSERVATION_MODIFIER", 55, 65], ["distribution", "OBSERVATION_MODIFIER", 70, 82]]], ["No obvious differences were observed either among the different segments of the gastrointestinal tract of each case, or among the different cases.CFTR expression in human enteric ganglia by IHC.CFTR mRNA expression in human gastrointestinal ganglia by ISH.", [["gastrointestinal tract", "ANATOMY", 80, 102], ["enteric ganglia", "ANATOMY", 171, 186], ["gastrointestinal ganglia", "ANATOMY", 224, 248], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 80, 102], ["CFTR", "GENE_OR_GENE_PRODUCT", 146, 150], ["human", "ORGANISM", 165, 170], ["enteric ganglia", "MULTI-TISSUE_STRUCTURE", 171, 186], ["CFTR", "GENE_OR_GENE_PRODUCT", 194, 198], ["human", "ORGANISM", 218, 223], ["gastrointestinal ganglia", "MULTI-TISSUE_STRUCTURE", 224, 248], ["CFTR", "PROTEIN", 146, 150], ["CFTR mRNA", "RNA", 194, 203], ["human", "SPECIES", 165, 170], ["human", "SPECIES", 218, 223], ["human", "SPECIES", 165, 170], ["human", "SPECIES", 218, 223], ["obvious differences", "PROBLEM", 3, 22], ["CFTR expression in human enteric ganglia", "PROBLEM", 146, 186], ["CFTR mRNA expression in human gastrointestinal ganglia", "PROBLEM", 194, 248], ["obvious", "OBSERVATION_MODIFIER", 3, 10], ["differences", "OBSERVATION", 11, 22], ["gastrointestinal tract", "ANATOMY", 80, 102], ["human", "ANATOMY_MODIFIER", 165, 170], ["enteric ganglia", "ANATOMY", 171, 186], ["IHC", "OBSERVATION", 190, 193], ["gastrointestinal ganglia", "ANATOMY", 224, 248]]], ["CFTR mRNA expression was detected and localized by in situ hybridization.", [["CFTR", "GENE_OR_GENE_PRODUCT", 0, 4], ["CFTR mRNA", "RNA", 0, 9], ["CFTR mRNA expression", "PROBLEM", 0, 20]]], ["Positive CFTR mRNA anti-sense signals were found in the cytoplasm and dendrites of all neurons of the enteric ganglia.", [["cytoplasm", "ANATOMY", 56, 65], ["dendrites", "ANATOMY", 70, 79], ["neurons", "ANATOMY", 87, 94], ["enteric ganglia", "ANATOMY", 102, 117], ["CFTR", "GENE_OR_GENE_PRODUCT", 9, 13], ["cytoplasm", "ORGANISM_SUBSTANCE", 56, 65], ["dendrites", "CELLULAR_COMPONENT", 70, 79], ["neurons", "CELL", 87, 94], ["enteric", "ANATOMICAL_SYSTEM", 102, 109], ["ganglia", "ORGAN", 110, 117], ["CFTR mRNA", "RNA", 9, 18], ["mRNA anti-sense signals", "TEST", 14, 37], ["cytoplasm", "ANATOMY_MODIFIER", 56, 65], ["dendrites", "ANATOMY_MODIFIER", 70, 79], ["all neurons", "ANATOMY_MODIFIER", 83, 94], ["enteric ganglia", "ANATOMY", 102, 117]]], ["Positive signals were detected in all of the gastrointestinal segments examined.", [["gastrointestinal segments", "ANATOMY", 45, 70], ["gastrointestinal segments", "MULTI-TISSUE_STRUCTURE", 45, 70], ["gastrointestinal segments", "ANATOMY", 45, 70]]], ["The distribution pattern was identical to that of CFTR protein as detected by IHC.", [["CFTR", "GENE_OR_GENE_PRODUCT", 50, 54], ["CFTR protein", "PROTEIN", 50, 62], ["CFTR protein", "PROBLEM", 50, 62]]], ["In some cases nuclei also showed positive hybridization signals.", [["nuclei", "ANATOMY", 14, 20], ["nuclei", "CELLULAR_COMPONENT", 14, 20], ["positive hybridization signals", "PROBLEM", 33, 63], ["positive", "OBSERVATION", 33, 41], ["hybridization signals", "OBSERVATION", 42, 63]]], ["No signal was observed in either smooth muscle cells or glial cells.", [["smooth muscle cells", "ANATOMY", 33, 52], ["glial cells", "ANATOMY", 56, 67], ["smooth muscle cells", "CELL", 33, 52], ["glial cells", "CELL", 56, 67], ["smooth muscle cells", "CELL_TYPE", 33, 52], ["glial cells", "CELL_TYPE", 56, 67], ["smooth muscle", "ANATOMY", 33, 46], ["cells", "OBSERVATION", 47, 52], ["glial cells", "OBSERVATION", 56, 67]]], ["IHC with antibody to NF on consecutive sections confirmed that the CFTR mRNA positive cells were indeed neurons.", [["sections", "ANATOMY", 39, 47], ["cells", "ANATOMY", 86, 91], ["neurons", "ANATOMY", 104, 111], ["antibody to NF", "GENE_OR_GENE_PRODUCT", 9, 23], ["CFTR", "GENE_OR_GENE_PRODUCT", 67, 71], ["neurons", "CELL", 104, 111], ["NF", "PROTEIN", 21, 23], ["CFTR mRNA", "RNA", 67, 76], ["IHC", "TEST", 0, 3], ["consecutive sections", "TEST", 27, 47], ["the CFTR mRNA", "TEST", 63, 76], ["positive cells", "OBSERVATION", 77, 91]]], ["In gastric epithelium, which was used as positive control, strong CFTR mRNA signals were detected.", [["gastric epithelium", "ANATOMY", 3, 21], ["gastric epithelium", "TISSUE", 3, 21], ["CFTR", "GENE_OR_GENE_PRODUCT", 66, 70], ["CFTR mRNA", "RNA", 66, 75], ["strong CFTR mRNA signals", "PROBLEM", 59, 83], ["gastric epithelium", "ANATOMY", 3, 21]]], ["In the negative controls, no specific signal was observed when the specific probe was replaced by the CFTR sense probe or hybridization solution.", [["CFTR", "GENE_OR_GENE_PRODUCT", 102, 106], ["CFTR sense probe", "DNA", 102, 118], ["the CFTR sense probe", "TREATMENT", 98, 118], ["hybridization solution", "TREATMENT", 122, 144], ["negative", "OBSERVATION", 7, 15]]], ["The expression and distribution of CFTR mRNA displayed the same pattern among the various segments of the gastrointestinal tracts studied (Fig. 1 ).Localization and detection of CFTR mRNA in ganglion cells by LMD-assisted nested RT-PCR.As CFTR is known to be extensively expressed in the epithelium throughout the gastrointestinal tract, we performed LMD to carefully isolate enteric ganglia without epithelial cells (Fig. 2) .", [["gastrointestinal tracts", "ANATOMY", 106, 129], ["ganglion cells", "ANATOMY", 191, 205], ["epithelium", "ANATOMY", 288, 298], ["gastrointestinal tract", "ANATOMY", 314, 336], ["enteric ganglia", "ANATOMY", 376, 391], ["epithelial cells", "ANATOMY", 400, 416], ["CFTR", "GENE_OR_GENE_PRODUCT", 35, 39], ["gastrointestinal tracts", "MULTI-TISSUE_STRUCTURE", 106, 129], ["CFTR", "GENE_OR_GENE_PRODUCT", 178, 182], ["ganglion cells", "CELL", 191, 205], ["CFTR", "GENE_OR_GENE_PRODUCT", 239, 243], ["epithelium", "TISSUE", 288, 298], ["gastrointestinal tract", "ORGAN", 314, 336], ["enteric ganglia", "CELL", 376, 391], ["epithelial cells", "CELL", 400, 416], ["CFTR mRNA", "RNA", 35, 44], ["CFTR mRNA", "RNA", 178, 187], ["ganglion cells", "CELL_TYPE", 191, 205], ["CFTR", "PROTEIN", 239, 243], ["epithelial cells", "CELL_TYPE", 400, 416], ["CFTR mRNA", "TEST", 35, 44], ["Localization", "TEST", 148, 160], ["CFTR mRNA in ganglion cells", "PROBLEM", 178, 205], ["LMD", "TEST", 209, 212], ["assisted nested RT-PCR", "TREATMENT", 213, 235], ["epithelial cells", "PROBLEM", 400, 416], ["CFTR mRNA", "OBSERVATION", 35, 44], ["various", "ANATOMY_MODIFIER", 82, 89], ["segments", "ANATOMY_MODIFIER", 90, 98], ["gastrointestinal tracts", "ANATOMY", 106, 129], ["CFTR mRNA", "OBSERVATION", 178, 187], ["ganglion cells", "OBSERVATION", 191, 205], ["epithelium", "ANATOMY_MODIFIER", 288, 298], ["gastrointestinal tract", "ANATOMY", 314, 336], ["enteric ganglia", "ANATOMY", 376, 391], ["without", "UNCERTAINTY", 392, 399], ["epithelial cells", "OBSERVATION", 400, 416]]], ["Following isolation of the ganglion cells, nested RT-PCR was performed.", [["ganglion cells", "ANATOMY", 27, 41], ["ganglion cells", "CELL", 27, 41], ["ganglion cells", "CELL_TYPE", 27, 41], ["the ganglion cells", "TEST", 23, 41], ["nested RT-PCR", "TEST", 43, 56], ["ganglion cells", "ANATOMY", 27, 41]]], ["The CFTR product of 179 bp was identified by agarose gel electrophoresis (Fig. 2 ).", [["CFTR", "GENE_OR_GENE_PRODUCT", 4, 8], ["agarose", "SIMPLE_CHEMICAL", 45, 52], ["CFTR product", "PROTEIN", 4, 16], ["The CFTR product", "TEST", 0, 16], ["bp", "TEST", 24, 26], ["agarose gel electrophoresis", "TEST", 45, 72]]], ["In addition, NF mRNA was successfully amplified confirming that ganglionic neurons had indeed been captured by LMD, whereas lack of CK mRNA amplification indicated that solely ganglion cells had been isolated.Localization and detection of CFTR mRNA in ganglion cells by LMD-assisted nested RT-PCR.Smooth muscle cells were captured to exclude the expression of CFTR and showed a much weaker positive PCR product.", [["ganglionic neurons", "ANATOMY", 64, 82], ["ganglion cells", "ANATOMY", 176, 190], ["ganglion cells", "ANATOMY", 252, 266], ["Smooth muscle cells", "ANATOMY", 297, 316], ["NF", "GENE_OR_GENE_PRODUCT", 13, 15], ["ganglionic neurons", "CELL", 64, 82], ["CK", "GENE_OR_GENE_PRODUCT", 132, 134], ["ganglion cells", "CELL", 176, 190], ["CFTR", "GENE_OR_GENE_PRODUCT", 239, 243], ["ganglion cells", "CELL", 252, 266], ["Smooth muscle cells", "CELL", 297, 316], ["CFTR", "GENE_OR_GENE_PRODUCT", 360, 364], ["NF mRNA", "RNA", 13, 20], ["ganglionic neurons", "CELL_TYPE", 64, 82], ["CK mRNA", "RNA", 132, 139], ["ganglion cells", "CELL_TYPE", 176, 190], ["CFTR mRNA", "RNA", 239, 248], ["ganglion cells", "CELL_TYPE", 252, 266], ["Smooth muscle cells", "CELL_TYPE", 297, 316], ["CFTR", "PROTEIN", 360, 364], ["ganglionic neurons", "PROBLEM", 64, 82], ["CK mRNA amplification", "TEST", 132, 153], ["solely ganglion cells", "PROBLEM", 169, 190], ["Localization", "TEST", 209, 221], ["CFTR mRNA in ganglion cells", "PROBLEM", 239, 266], ["LMD", "TEST", 270, 273], ["assisted nested RT-PCR", "TREATMENT", 274, 296], ["the expression of CFTR", "PROBLEM", 342, 364], ["a much weaker positive PCR product", "PROBLEM", 376, 410], ["ganglion cells", "OBSERVATION", 176, 190], ["CFTR mRNA", "OBSERVATION", 239, 248], ["ganglion cells", "OBSERVATION", 252, 266], ["muscle cells", "OBSERVATION", 304, 316]]], ["Colon epithelial tissue was used as positive control and showed a PCR product of the expected size.", [["Colon epithelial tissue", "ANATOMY", 0, 23], ["Colon epithelial tissue", "TISSUE", 0, 23], ["Colon epithelial tissue", "PROBLEM", 0, 23], ["a PCR", "TEST", 64, 69], ["epithelial tissue", "ANATOMY", 6, 23], ["size", "OBSERVATION_MODIFIER", 94, 98]]], ["In the negative control no amplification signal was detected.", [["amplification signal", "PROBLEM", 27, 47]]], ["Sequence analysis was in 100% agreement with the human CFTR mRNA sequence as encoded by the NCBI.DiscussionIn this study we demonstrated CFTR expression in human enteric ganglia, which could offer a better understanding of the functions of CFTR in the normal physiology of the ENS, as well as in CF patients.DiscussionOriginally the epithelial cell was regarded as the only cell type expressing CFTR.", [["enteric ganglia", "ANATOMY", 162, 177], ["ENS", "ANATOMY", 277, 280], ["epithelial cell", "ANATOMY", 333, 348], ["cell", "ANATOMY", 374, 378], ["CF", "DISEASE", 296, 298], ["human", "ORGANISM", 49, 54], ["CFTR", "GENE_OR_GENE_PRODUCT", 55, 59], ["CFTR", "GENE_OR_GENE_PRODUCT", 137, 141], ["human", "ORGANISM", 156, 161], ["enteric ganglia", "MULTI-TISSUE_STRUCTURE", 162, 177], ["CFTR", "GENE_OR_GENE_PRODUCT", 240, 244], ["ENS", "ANATOMICAL_SYSTEM", 277, 280], ["patients", "ORGANISM", 299, 307], ["epithelial cell", "CELL", 333, 348], ["cell type", "CELL", 374, 383], ["CFTR", "GENE_OR_GENE_PRODUCT", 395, 399], ["human CFTR mRNA sequence", "RNA", 49, 73], ["NCBI", "DNA", 92, 96], ["CFTR", "PROTEIN", 137, 141], ["CFTR", "PROTEIN", 240, 244], ["epithelial cell", "CELL_TYPE", 333, 348], ["CFTR", "PROTEIN", 395, 399], ["human", "SPECIES", 49, 54], ["human", "SPECIES", 156, 161], ["patients", "SPECIES", 299, 307], ["human", "SPECIES", 49, 54], ["human", "SPECIES", 156, 161], ["Sequence analysis", "TEST", 0, 17], ["the human CFTR mRNA sequence", "TEST", 45, 73], ["this study", "TEST", 110, 120], ["CFTR expression in human enteric ganglia", "PROBLEM", 137, 177], ["the epithelial cell", "PROBLEM", 329, 348], ["enteric ganglia", "ANATOMY", 162, 177], ["epithelial cell", "OBSERVATION", 333, 348]]], ["The CFTR gene with its gene product was identified in 1989 and its expression was detected in the epithelial cells of those organs most severely affected in CF, including the lungs, intestines, kidney, pancreas and liver 25, [31] [32] [33] .", [["epithelial cells", "ANATOMY", 98, 114], ["organs", "ANATOMY", 124, 130], ["CF", "ANATOMY", 157, 159], ["lungs", "ANATOMY", 175, 180], ["intestines", "ANATOMY", 182, 192], ["kidney", "ANATOMY", 194, 200], ["pancreas", "ANATOMY", 202, 210], ["liver", "ANATOMY", 215, 220], ["CFTR", "GENE_OR_GENE_PRODUCT", 4, 8], ["epithelial cells", "CELL", 98, 114], ["organs", "ORGAN", 124, 130], ["lungs", "ORGAN", 175, 180], ["intestines", "ORGAN", 182, 192], ["kidney", "ORGAN", 194, 200], ["pancreas", "ORGAN", 202, 210], ["liver", "ORGAN", 215, 220], ["CFTR gene", "DNA", 4, 13], ["epithelial cells", "CELL_TYPE", 98, 114], ["epithelial cells", "OBSERVATION", 98, 114], ["CF", "OBSERVATION", 157, 159], ["lungs", "ANATOMY", 175, 180], ["intestines", "ANATOMY", 182, 192], ["kidney", "ANATOMY", 194, 200], ["pancreas", "ANATOMY", 202, 210], ["liver", "ANATOMY", 215, 220]]], ["In the tractus gastrointestinalis CFTR was found localized to the mucosal epithelial cells of the stomach, duodenum, jejunum, ileum and colon, with crypt cells expressing more CFTR than villus cells 34, 35 .", [["tractus gastrointestinalis", "ANATOMY", 7, 33], ["mucosal epithelial cells", "ANATOMY", 66, 90], ["stomach", "ANATOMY", 98, 105], ["duodenum", "ANATOMY", 107, 115], ["jejunum", "ANATOMY", 117, 124], ["ileum", "ANATOMY", 126, 131], ["colon", "ANATOMY", 136, 141], ["crypt cells", "ANATOMY", 148, 159], ["villus cells", "ANATOMY", 186, 198], ["tractus gastrointestinalis", "ORGANISM", 7, 33], ["CFTR", "GENE_OR_GENE_PRODUCT", 34, 38], ["mucosal epithelial cells", "CELL", 66, 90], ["stomach", "ORGAN", 98, 105], ["duodenum", "MULTI-TISSUE_STRUCTURE", 107, 115], ["jejunum", "MULTI-TISSUE_STRUCTURE", 117, 124], ["ileum", "MULTI-TISSUE_STRUCTURE", 126, 131], ["colon", "ORGAN", 136, 141], ["crypt cells", "CELL", 148, 159], ["CFTR", "GENE_OR_GENE_PRODUCT", 176, 180], ["villus cells", "CELL", 186, 198], ["CFTR", "PROTEIN", 34, 38], ["mucosal epithelial cells", "CELL_TYPE", 66, 90], ["crypt cells", "CELL_TYPE", 148, 159], ["CFTR", "PROTEIN", 176, 180], ["villus cells", "CELL_TYPE", 186, 198], ["tractus gastrointestinalis", "SPECIES", 7, 33], ["crypt cells", "PROBLEM", 148, 159], ["villus cells", "TEST", 186, 198], ["tractus", "ANATOMY_MODIFIER", 7, 14], ["mucosal", "ANATOMY_MODIFIER", 66, 73], ["epithelial cells", "OBSERVATION", 74, 90], ["stomach", "ANATOMY", 98, 105], ["duodenum", "ANATOMY", 107, 115], ["jejunum", "ANATOMY", 117, 124], ["ileum", "ANATOMY", 126, 131], ["colon", "ANATOMY", 136, 141], ["crypt cells", "OBSERVATION", 148, 159]]], ["However, in the years following the discovery of CFTR several other cell types were found to express CFTR, such as fibroblasts, neutrophils, lymphocytes, macrophages, and mast cells 36, 37 .", [["cell", "ANATOMY", 68, 72], ["fibroblasts", "ANATOMY", 115, 126], ["neutrophils", "ANATOMY", 128, 139], ["lymphocytes", "ANATOMY", 141, 152], ["macrophages", "ANATOMY", 154, 165], ["mast cells", "ANATOMY", 171, 181], ["CFTR", "GENE_OR_GENE_PRODUCT", 49, 53], ["cell", "CELL", 68, 72], ["CFTR", "GENE_OR_GENE_PRODUCT", 101, 105], ["fibroblasts", "CELL", 115, 126], ["neutrophils", "CELL", 128, 139], ["lymphocytes", "CELL", 141, 152], ["macrophages", "CELL", 154, 165], ["mast cells", "CELL", 171, 181], ["CFTR", "PROTEIN", 49, 53], ["CFTR", "PROTEIN", 101, 105], ["fibroblasts", "CELL_TYPE", 115, 126], ["neutrophils", "CELL_TYPE", 128, 139], ["lymphocytes", "CELL_TYPE", 141, 152], ["macrophages", "CELL_TYPE", 154, 165], ["mast cells", "CELL_TYPE", 171, 181], ["CFTR several other cell types", "PROBLEM", 49, 78], ["CFTR", "TEST", 101, 105], ["neutrophils", "TEST", 128, 139], ["lymphocytes", "TEST", 141, 152], ["macrophages", "TEST", 154, 165], ["mast cells", "TEST", 171, 181], ["lymphocytes", "ANATOMY", 141, 152], ["macrophages", "ANATOMY", 154, 165], ["mast cells", "OBSERVATION", 171, 181]]], ["In respect to the human nervous system, CFTR expression was detected in the hypothalamus 15 .", [["nervous system", "ANATOMY", 24, 38], ["hypothalamus", "ANATOMY", 76, 88], ["human", "ORGANISM", 18, 23], ["nervous system", "ANATOMICAL_SYSTEM", 24, 38], ["CFTR", "GENE_OR_GENE_PRODUCT", 40, 44], ["CFTR", "PROTEIN", 40, 44], ["human", "SPECIES", 18, 23], ["human", "SPECIES", 18, 23], ["CFTR expression", "PROBLEM", 40, 55], ["human nervous", "ANATOMY", 18, 31], ["hypothalamus", "ANATOMY", 76, 88]]], ["Yet recent studies have demonstrated a more widespread expression of CFTR in both the central and peripheral nervous system, including various regions of the brain, as well as spinal, cerebellum, sympathetic ganglia, paracervical ganglia and trigeminal ganglion 17 patients with CF might be directly related to the loss of CFTR 40 .", [["peripheral nervous system", "ANATOMY", 98, 123], ["brain", "ANATOMY", 158, 163], ["spinal", "ANATOMY", 176, 182], ["cerebellum", "ANATOMY", 184, 194], ["sympathetic ganglia", "ANATOMY", 196, 215], ["paracervical ganglia", "ANATOMY", 217, 237], ["trigeminal ganglion", "ANATOMY", 242, 261], ["CF", "DISEASE", 279, 281], ["CFTR", "GENE_OR_GENE_PRODUCT", 69, 73], ["central", "ANATOMICAL_SYSTEM", 86, 93], ["peripheral nervous system", "ANATOMICAL_SYSTEM", 98, 123], ["brain", "ORGAN", 158, 163], ["spinal", "ORGAN", 176, 182], ["cerebellum", "MULTI-TISSUE_STRUCTURE", 184, 194], ["sympathetic ganglia", "MULTI-TISSUE_STRUCTURE", 196, 215], ["paracervical ganglia", "MULTI-TISSUE_STRUCTURE", 217, 237], ["trigeminal ganglion", "MULTI-TISSUE_STRUCTURE", 242, 261], ["patients", "ORGANISM", 265, 273], ["CFTR", "GENE_OR_GENE_PRODUCT", 323, 327], ["CFTR", "PROTEIN", 69, 73], ["CFTR 40", "PROTEIN", 323, 330], ["patients", "SPECIES", 265, 273], ["recent studies", "TEST", 4, 18], ["CFTR in both the central and peripheral nervous system", "PROBLEM", 69, 123], ["spinal, cerebellum, sympathetic ganglia, paracervical ganglia and trigeminal ganglion", "PROBLEM", 176, 261], ["CF", "PROBLEM", 279, 281], ["the loss of CFTR", "PROBLEM", 311, 327], ["widespread", "OBSERVATION_MODIFIER", 44, 54], ["expression", "OBSERVATION", 55, 65], ["CFTR", "OBSERVATION", 69, 73], ["both", "ANATOMY_MODIFIER", 77, 81], ["central", "ANATOMY_MODIFIER", 86, 93], ["peripheral", "ANATOMY_MODIFIER", 98, 108], ["nervous system", "ANATOMY", 109, 123], ["various", "ANATOMY_MODIFIER", 135, 142], ["regions", "ANATOMY_MODIFIER", 143, 150], ["brain", "ANATOMY", 158, 163], ["spinal", "ANATOMY", 176, 182], ["cerebellum", "ANATOMY", 184, 194], ["sympathetic ganglia", "ANATOMY", 196, 215], ["paracervical ganglia", "ANATOMY", 217, 237], ["trigeminal ganglion", "ANATOMY", 242, 261]]], ["In the present study we investigated CFTR expression in the ganglia of the ENS in various segments of the human gastrointestinal tract, including the stomach, duodenum, jejunum, ileum, cecum, appendix, colon and rectum.", [["ganglia", "ANATOMY", 60, 67], ["ENS", "ANATOMY", 75, 78], ["gastrointestinal tract", "ANATOMY", 112, 134], ["stomach", "ANATOMY", 150, 157], ["duodenum", "ANATOMY", 159, 167], ["jejunum", "ANATOMY", 169, 176], ["ileum", "ANATOMY", 178, 183], ["cecum", "ANATOMY", 185, 190], ["appendix", "ANATOMY", 192, 200], ["colon", "ANATOMY", 202, 207], ["rectum", "ANATOMY", 212, 218], ["CFTR", "GENE_OR_GENE_PRODUCT", 37, 41], ["ganglia", "ORGAN", 60, 67], ["ENS", "ANATOMICAL_SYSTEM", 75, 78], ["human", "ORGANISM", 106, 111], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 112, 134], ["stomach", "ORGAN", 150, 157], ["duodenum", "MULTI-TISSUE_STRUCTURE", 159, 167], ["jejunum", "MULTI-TISSUE_STRUCTURE", 169, 176], ["ileum", "MULTI-TISSUE_STRUCTURE", 178, 183], ["cecum", "MULTI-TISSUE_STRUCTURE", 185, 190], ["appendix", "MULTI-TISSUE_STRUCTURE", 192, 200], ["colon", "ORGAN", 202, 207], ["rectum", "ORGAN", 212, 218], ["CFTR", "PROTEIN", 37, 41], ["human", "SPECIES", 106, 111], ["human", "SPECIES", 106, 111], ["the present study", "TEST", 3, 20], ["CFTR expression", "PROBLEM", 37, 52], ["the stomach, duodenum, jejunum, ileum, cecum, appendix, colon and rectum", "PROBLEM", 146, 218], ["ganglia", "ANATOMY_MODIFIER", 60, 67], ["ENS", "ANATOMY_MODIFIER", 75, 78], ["various segments", "ANATOMY_MODIFIER", 82, 98], ["human", "ANATOMY_MODIFIER", 106, 111], ["gastrointestinal tract", "ANATOMY", 112, 134], ["stomach", "ANATOMY", 150, 157], ["duodenum", "ANATOMY", 159, 167], ["jejunum", "ANATOMY", 169, 176], ["ileum", "ANATOMY", 178, 183], ["cecum", "ANATOMY", 185, 190], ["appendix", "ANATOMY", 192, 200], ["colon", "ANATOMY", 202, 207], ["rectum", "ANATOMY", 212, 218]]], ["The results of IHC, ISH and RT-PCR, all convincingly demonstrate the presence of CFTR mRNA and protein in both the myenteric and submucosal plexuses.", [["myenteric", "ANATOMY", 115, 124], ["submucosal plexuses", "ANATOMY", 129, 148], ["CFTR", "GENE_OR_GENE_PRODUCT", 81, 85], ["myenteric", "MULTI-TISSUE_STRUCTURE", 115, 124], ["submucosal plexuses", "MULTI-TISSUE_STRUCTURE", 129, 148], ["CFTR mRNA", "RNA", 81, 90], ["IHC", "TEST", 15, 18], ["ISH", "TEST", 20, 23], ["RT-PCR", "TEST", 28, 34], ["CFTR mRNA", "PROBLEM", 81, 90], ["CFTR mRNA", "OBSERVATION", 81, 90], ["both", "ANATOMY_MODIFIER", 106, 110], ["myenteric", "ANATOMY", 115, 124], ["submucosal plexuses", "ANATOMY", 129, 148]]], ["Immunohistochemistry with antibodies to CFTR and NF and in situ hybridization with a CFTR mRNA anti-sense probe on consecutive sections demonstrated that the cells expressing CFTR were NF-positive neurons.", [["sections", "ANATOMY", 127, 135], ["cells", "ANATOMY", 158, 163], ["NF-positive neurons", "ANATOMY", 185, 204], ["CFTR", "GENE_OR_GENE_PRODUCT", 40, 44], ["NF", "GENE_OR_GENE_PRODUCT", 49, 51], ["CFTR", "GENE_OR_GENE_PRODUCT", 85, 89], ["cells", "CELL", 158, 163], ["CFTR", "GENE_OR_GENE_PRODUCT", 175, 179], ["NF", "GENE_OR_GENE_PRODUCT", 185, 187], ["CFTR", "PROTEIN", 40, 44], ["NF", "PROTEIN", 49, 51], ["CFTR mRNA", "RNA", 85, 94], ["CFTR", "PROTEIN", 175, 179], ["NF", "PROTEIN", 185, 187], ["Immunohistochemistry", "TEST", 0, 20], ["antibodies", "TEST", 26, 36], ["CFTR", "TEST", 40, 44], ["NF", "TEST", 49, 51], ["a CFTR mRNA anti-sense probe", "TREATMENT", 83, 111], ["consecutive sections", "TEST", 115, 135], ["positive neurons", "OBSERVATION", 188, 204]]], ["As the enteric ganglia are in close proximity to the mucosal epithelial cells, which abundantly express CFTR, LMD was performed prior to RT-PCR to isolate only neurons.", [["enteric ganglia", "ANATOMY", 7, 22], ["mucosal epithelial cells", "ANATOMY", 53, 77], ["neurons", "ANATOMY", 160, 167], ["enteric ganglia", "ORGAN", 7, 22], ["mucosal epithelial cells", "CELL", 53, 77], ["CFTR", "GENE_OR_GENE_PRODUCT", 104, 108], ["neurons", "CELL", 160, 167], ["mucosal epithelial cells", "CELL_TYPE", 53, 77], ["CFTR", "PROTEIN", 104, 108], ["RT-PCR", "TEST", 137, 143], ["enteric ganglia", "ANATOMY", 7, 22], ["mucosal", "ANATOMY", 53, 60], ["epithelial cells", "OBSERVATION", 61, 77]]], ["Successful amplification of NF mRNA and lack of amplification of CK mRNA confirmed that neurons were captured, but not epithelial cells.DiscussionThe extensive expression of CFTR in both the central nervous system and the peripheral nervous system including the ENS suggests that this protein may play a role in the normal functioning of the nervous system.", [["neurons", "ANATOMY", 88, 95], ["epithelial cells", "ANATOMY", 119, 135], ["central nervous system", "ANATOMY", 191, 213], ["peripheral nervous system", "ANATOMY", 222, 247], ["ENS", "ANATOMY", 262, 265], ["nervous system", "ANATOMY", 342, 356], ["NF", "GENE_OR_GENE_PRODUCT", 28, 30], ["CK", "GENE_OR_GENE_PRODUCT", 65, 67], ["neurons", "CELL", 88, 95], ["epithelial cells", "CELL", 119, 135], ["CFTR", "GENE_OR_GENE_PRODUCT", 174, 178], ["central nervous system", "ANATOMICAL_SYSTEM", 191, 213], ["peripheral nervous system", "ANATOMICAL_SYSTEM", 222, 247], ["ENS", "ANATOMICAL_SYSTEM", 262, 265], ["nervous system", "ANATOMICAL_SYSTEM", 342, 356], ["NF mRNA", "RNA", 28, 35], ["CK mRNA", "RNA", 65, 72], ["epithelial cells", "CELL_TYPE", 119, 135], ["CFTR", "PROTEIN", 174, 178], ["NF mRNA", "TREATMENT", 28, 35], ["amplification of CK mRNA", "TEST", 48, 72], ["epithelial cells", "PROBLEM", 119, 135], ["CFTR", "PROBLEM", 174, 178], ["epithelial cells", "OBSERVATION", 119, 135], ["CFTR", "OBSERVATION", 174, 178], ["central", "ANATOMY_MODIFIER", 191, 198], ["nervous system", "ANATOMY", 199, 213], ["peripheral", "ANATOMY_MODIFIER", 222, 232], ["nervous system", "ANATOMY", 233, 247], ["normal", "OBSERVATION", 316, 322], ["nervous system", "ANATOMY", 342, 356]]], ["CFTR might be involved in neuronal physiology through several mechanisms, as discussed previously by Guo et al. 17, 18 , with the most important ones being the following: maintenance of the steady-state of intracellular electrolytes 41 , regulation of membrane recycling [42] [43] [44] [45] [46] [47] , modulation of membrane traffic 48, 49 , governing the efflux of gluthatione 50, 51 , regulation of neuropeptide secretion 15 , and functioning as a neuromodulator and cell signaling molecule.", [["neuronal", "ANATOMY", 26, 34], ["intracellular", "ANATOMY", 206, 219], ["membrane", "ANATOMY", 252, 260], ["membrane", "ANATOMY", 317, 325], ["cell", "ANATOMY", 470, 474], ["[42] [43] [44] [45] [46] [47]", "CHEMICAL", 271, 300], ["gluthatione", "CHEMICAL", 367, 378], ["gluthatione", "CHEMICAL", 367, 378], ["CFTR", "GENE_OR_GENE_PRODUCT", 0, 4], ["neuronal", "CELL", 26, 34], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 206, 219], ["membrane", "CELLULAR_COMPONENT", 252, 260], ["[42] [43] [44] [45] [46] [47]", "SIMPLE_CHEMICAL", 271, 300], ["membrane", "CELLULAR_COMPONENT", 317, 325], ["gluthatione 50", "SIMPLE_CHEMICAL", 367, 381], ["neuropeptide secretion 15", "GENE_OR_GENE_PRODUCT", 402, 427], ["cell", "CELL", 470, 474], ["CFTR", "PROTEIN", 0, 4], ["neuropeptide secretion 15", "PROTEIN", 402, 427], ["cell signaling molecule", "PROTEIN", 470, 493], ["intracellular electrolytes", "TEST", 206, 232], ["membrane recycling", "TEST", 252, 270], ["membrane traffic", "TEST", 317, 333], ["gluthatione", "TEST", 367, 378], ["neuropeptide secretion", "TEST", 402, 424], ["cell signaling molecule", "PROBLEM", 470, 493]]], ["Consequently, mutation of CFTR could theoretically lead to neuronal dysfunctioning.DiscussionThe ENS constitutes together with the parasympathetic and sympathetic nervous systems the autonomous nervous system.", [["neuronal", "ANATOMY", 59, 67], ["ENS", "ANATOMY", 97, 100], ["sympathetic nervous systems", "ANATOMY", 151, 178], ["nervous system", "ANATOMY", 194, 208], ["neuronal dysfunctioning", "DISEASE", 59, 82], ["CFTR", "GENE_OR_GENE_PRODUCT", 26, 30], ["neuronal", "CELL", 59, 67], ["ENS", "ANATOMICAL_SYSTEM", 97, 100], ["parasympathetic", "ANATOMICAL_SYSTEM", 131, 146], ["sympathetic nervous systems", "ANATOMICAL_SYSTEM", 151, 178], ["nervous system", "ANATOMICAL_SYSTEM", 194, 208], ["CFTR", "PROTEIN", 26, 30], ["mutation of CFTR", "PROBLEM", 14, 30], ["neuronal dysfunctioning", "PROBLEM", 59, 82], ["the parasympathetic and sympathetic nervous systems", "PROBLEM", 127, 178], ["neuronal dysfunctioning", "OBSERVATION", 59, 82], ["sympathetic nervous", "ANATOMY", 151, 170], ["autonomous nervous", "OBSERVATION", 183, 201]]], ["Autonomous neuropathy appears to exist in patients with CF 52 , as illustrated by decreased cardiovascular sensitivity to \u03b2 -adrenergic stimulation 12, 53 and abnormal \u03b1 -adrenergic and cholinergic regulation of the pupils 53, 54 .", [["cardiovascular", "ANATOMY", 92, 106], ["neuropathy", "DISEASE", 11, 21], ["patients", "ORGANISM", 42, 50], ["\u03b2 -adrenergic", "GENE_OR_GENE_PRODUCT", 122, 135], ["\u03b1 -adrenergic", "GENE_OR_GENE_PRODUCT", 168, 181], ["\u03b2", "PROTEIN", 122, 123], ["patients", "SPECIES", 42, 50], ["Autonomous neuropathy", "PROBLEM", 0, 21], ["CF", "PROBLEM", 56, 58], ["decreased cardiovascular sensitivity", "PROBLEM", 82, 118], ["\u03b2", "TEST", 122, 123], ["adrenergic stimulation", "TEST", 125, 147], ["abnormal \u03b1 -adrenergic", "PROBLEM", 159, 181], ["neuropathy", "OBSERVATION", 11, 21]]], ["Whether autonomic dysfunction of the gastrointestinal tract frequently occurs in CF patients is not clear, as symptoms might be non-specific and accurate tests to determine abnormalities are not readily available 52 .", [["gastrointestinal tract", "ANATOMY", 37, 59], ["autonomic dysfunction of the gastrointestinal tract", "DISEASE", 8, 59], ["CF", "DISEASE", 81, 83], ["gastrointestinal tract", "ORGAN", 37, 59], ["patients", "ORGANISM", 84, 92], ["patients", "SPECIES", 84, 92], ["autonomic dysfunction of the gastrointestinal tract", "PROBLEM", 8, 59], ["symptoms", "PROBLEM", 110, 118], ["accurate tests", "TEST", 145, 159], ["dysfunction", "OBSERVATION", 18, 29], ["gastrointestinal tract", "ANATOMY", 37, 59]]], ["The main etiological factors of autonomic neuropathy in CF are considered to be metabolic and nutritional 52 .", [["autonomic neuropathy", "DISEASE", 32, 52], ["CF", "DISEASE", 56, 58], ["autonomic neuropathy in CF", "PROBLEM", 32, 58], ["main", "OBSERVATION_MODIFIER", 4, 8], ["autonomic neuropathy", "OBSERVATION", 32, 52]]], ["Given the expression of CFTR in the ENS together with the previously established CFTR expression in the sympathetic ganglia and paracervical ganglia, it is conceivable that malfunction of CFTR in the ganglionic neurons also contributes to the occurrence of autonomic neuropathy in CF.DiscussionGastrointestinal manifestations are frequently observed in CF patients and include delayed gastric emptying, gastritis, distal intestinal obstruction syndrome, meconium ileus of the newborn, intussusceptions, fibrosing colonopathy, and rectal prolapse, among others 8, 10, 11, 23, 24, 28, [55] [56] [57] .", [["ENS", "ANATOMY", 36, 39], ["sympathetic ganglia", "ANATOMY", 104, 123], ["paracervical ganglia", "ANATOMY", 128, 148], ["ganglionic neurons", "ANATOMY", 200, 218], ["Gastrointestinal", "ANATOMY", 294, 310], ["gastric", "ANATOMY", 385, 392], ["intestinal", "ANATOMY", 421, 431], ["rectal", "ANATOMY", 530, 536], ["autonomic neuropathy", "DISEASE", 257, 277], ["CF", "DISEASE", 281, 283], ["CF", "DISEASE", 353, 355], ["delayed gastric emptying", "DISEASE", 377, 401], ["gastritis", "DISEASE", 403, 412], ["intestinal obstruction syndrome", "DISEASE", 421, 452], ["meconium ileus of the newborn", "DISEASE", 454, 483], ["intussusceptions", "DISEASE", 485, 501], ["fibrosing colonopathy", "DISEASE", 503, 524], ["rectal prolapse", "DISEASE", 530, 545], ["CFTR", "GENE_OR_GENE_PRODUCT", 24, 28], ["ENS", "ANATOMICAL_SYSTEM", 36, 39], ["CFTR", "GENE_OR_GENE_PRODUCT", 81, 85], ["sympathetic ganglia", "MULTI-TISSUE_STRUCTURE", 104, 123], ["paracervical ganglia", "MULTI-TISSUE_STRUCTURE", 128, 148], ["CFTR", "GENE_OR_GENE_PRODUCT", 188, 192], ["ganglionic neurons", "CELL", 200, 218], ["patients", "ORGANISM", 356, 364], ["gastric", "ORGAN", 385, 392], ["intestinal", "ORGAN", 421, 431], ["rectal", "ORGAN", 530, 536], ["CFTR", "PROTEIN", 24, 28], ["CFTR", "PROTEIN", 81, 85], ["CFTR", "PROTEIN", 188, 192], ["ganglionic neurons", "CELL_TYPE", 200, 218], ["patients", "SPECIES", 356, 364], ["the previously established CFTR expression in the sympathetic ganglia and paracervical ganglia", "PROBLEM", 54, 148], ["malfunction of CFTR in the ganglionic neurons", "PROBLEM", 173, 218], ["autonomic neuropathy in CF", "PROBLEM", 257, 283], ["Gastrointestinal manifestations", "PROBLEM", 294, 325], ["delayed gastric emptying", "PROBLEM", 377, 401], ["gastritis", "PROBLEM", 403, 412], ["distal intestinal obstruction syndrome", "PROBLEM", 414, 452], ["meconium ileus of the newborn", "PROBLEM", 454, 483], ["intussusceptions", "PROBLEM", 485, 501], ["fibrosing colonopathy", "PROBLEM", 503, 524], ["rectal prolapse", "PROBLEM", 530, 545], ["sympathetic ganglia", "ANATOMY", 104, 123], ["paracervical ganglia", "ANATOMY", 128, 148], ["ganglionic neurons", "ANATOMY", 200, 218], ["autonomic neuropathy", "OBSERVATION", 257, 277], ["gastric", "ANATOMY", 385, 392], ["emptying", "OBSERVATION", 393, 401], ["gastritis", "OBSERVATION", 403, 412], ["distal", "ANATOMY_MODIFIER", 414, 420], ["intestinal", "ANATOMY", 421, 431], ["obstruction syndrome", "OBSERVATION", 432, 452], ["meconium ileus", "OBSERVATION", 454, 468], ["newborn", "ANATOMY", 476, 483], ["fibrosing colonopathy", "OBSERVATION", 503, 524], ["rectal prolapse", "ANATOMY", 530, 545]]], ["Some of these manifestations have a direct causal relation to the malfunction of the CFTR in epithelial cells of gastrointestinal tract and pancreas, such as the distal intestinal obstruction syndrome and meconium ileus, whereas others, such as fibrosing colonopathy and gastritis, are regarded as secondary complications of the disease or its therapy 24 .", [["epithelial cells", "ANATOMY", 93, 109], ["gastrointestinal tract", "ANATOMY", 113, 135], ["pancreas", "ANATOMY", 140, 148], ["intestinal", "ANATOMY", 169, 179], ["intestinal obstruction syndrome", "DISEASE", 169, 200], ["meconium ileus", "DISEASE", 205, 219], ["fibrosing colonopathy", "DISEASE", 245, 266], ["gastritis", "DISEASE", 271, 280], ["CFTR", "GENE_OR_GENE_PRODUCT", 85, 89], ["epithelial cells", "CELL", 93, 109], ["gastrointestinal tract", "ORGAN", 113, 135], ["pancreas", "ORGAN", 140, 148], ["intestinal", "ORGAN", 169, 179], ["gastritis", "PATHOLOGICAL_FORMATION", 271, 280], ["CFTR", "PROTEIN", 85, 89], ["epithelial cells", "CELL_TYPE", 93, 109], ["these manifestations", "PROBLEM", 8, 28], ["the distal intestinal obstruction syndrome", "PROBLEM", 158, 200], ["meconium ileus", "PROBLEM", 205, 219], ["fibrosing colonopathy", "PROBLEM", 245, 266], ["gastritis", "PROBLEM", 271, 280], ["secondary complications", "PROBLEM", 298, 321], ["the disease", "PROBLEM", 325, 336], ["its therapy", "TREATMENT", 340, 351], ["malfunction", "OBSERVATION", 66, 77], ["CFTR", "OBSERVATION", 85, 89], ["epithelial cells", "OBSERVATION", 93, 109], ["gastrointestinal tract", "ANATOMY", 113, 135], ["pancreas", "ANATOMY", 140, 148], ["distal", "ANATOMY_MODIFIER", 162, 168], ["intestinal", "ANATOMY", 169, 179], ["obstruction syndrome", "OBSERVATION", 180, 200], ["meconium ileus", "OBSERVATION", 205, 219], ["fibrosing", "OBSERVATION_MODIFIER", 245, 254], ["gastritis", "OBSERVATION", 271, 280], ["disease", "OBSERVATION", 329, 336]]], ["As CFTR is responsible for anion transport 58, 59 , its dysfunction causes abnormal water and electrolyte secretion resulting not only in thick and adherent fluids in the intestines but also in the development of mucous and acidic enzyme secretions in the pancreas causing destruction of pancreatic tissue with ensuing exocrine pancreatic insufficiency leading on its turn to malabsorption in the gastrointestinal tract 57, 60 .", [["fluids", "ANATOMY", 157, 163], ["intestines", "ANATOMY", 171, 181], ["mucous", "ANATOMY", 213, 219], ["pancreas", "ANATOMY", 256, 264], ["pancreatic tissue", "ANATOMY", 288, 305], ["exocrine pancreatic", "ANATOMY", 319, 338], ["gastrointestinal tract", "ANATOMY", 397, 419], ["destruction of pancreatic tissue", "DISEASE", 273, 305], ["exocrine pancreatic insufficiency", "DISEASE", 319, 352], ["malabsorption", "DISEASE", 376, 389], ["CFTR", "GENE_OR_GENE_PRODUCT", 3, 7], ["anion", "SIMPLE_CHEMICAL", 27, 32], ["water", "SIMPLE_CHEMICAL", 84, 89], ["electrolyte", "SIMPLE_CHEMICAL", 94, 105], ["intestines", "ORGAN", 171, 181], ["mucous", "ORGANISM_SUBDIVISION", 213, 219], ["pancreas", "ORGAN", 256, 264], ["pancreatic tissue", "TISSUE", 288, 305], ["exocrine pancreatic", "MULTI-TISSUE_STRUCTURE", 319, 338], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 397, 419], ["CFTR", "PROTEIN", 3, 7], ["anion transport", "TEST", 27, 42], ["its dysfunction", "PROBLEM", 52, 67], ["abnormal water and electrolyte secretion", "PROBLEM", 75, 115], ["thick and adherent fluids in the intestines", "PROBLEM", 138, 181], ["mucous and acidic enzyme secretions in the pancreas", "PROBLEM", 213, 264], ["destruction of pancreatic tissue", "PROBLEM", 273, 305], ["ensuing exocrine pancreatic insufficiency", "PROBLEM", 311, 352], ["malabsorption in the gastrointestinal tract", "PROBLEM", 376, 419], ["adherent", "OBSERVATION_MODIFIER", 148, 156], ["fluids", "OBSERVATION", 157, 163], ["intestines", "ANATOMY", 171, 181], ["mucous", "OBSERVATION", 213, 219], ["acidic enzyme secretions", "OBSERVATION", 224, 248], ["pancreas", "ANATOMY", 256, 264], ["destruction", "OBSERVATION", 273, 284], ["pancreatic tissue", "ANATOMY", 288, 305], ["exocrine", "ANATOMY_MODIFIER", 319, 327], ["pancreatic", "ANATOMY", 328, 338], ["insufficiency", "OBSERVATION", 339, 352], ["malabsorption", "OBSERVATION", 376, 389], ["gastrointestinal tract", "ANATOMY", 397, 419]]], ["In light of the regulatory role of the ENS in motility, water and electrolyte flow and endocrine secretions in the gastrointestinal tract 21 , it appears, however, not unlikely that ENS abnormalities caused by dysfunctional CFTR may also play a role in the pathogenesis of gastrointestinal diseases in CF.DiscussionIn this context, it is of interest to note that immaturity of the myenteric plexus appeared to be the main etiological factor in newborns with meconium ileus without CF 61, 62 .", [["ENS", "ANATOMY", 39, 42], ["endocrine secretions", "ANATOMY", 87, 107], ["gastrointestinal tract", "ANATOMY", 115, 137], ["gastrointestinal", "ANATOMY", 273, 289], ["myenteric plexus", "ANATOMY", 381, 397], ["ENS abnormalities", "DISEASE", 182, 199], ["gastrointestinal diseases", "DISEASE", 273, 298], ["CF", "DISEASE", 302, 304], ["immaturity of the myenteric plexus", "DISEASE", 363, 397], ["meconium ileus", "DISEASE", 458, 472], ["ENS", "ANATOMICAL_SYSTEM", 39, 42], ["water", "SIMPLE_CHEMICAL", 56, 61], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 115, 137], ["ENS", "ANATOMICAL_SYSTEM", 182, 185], ["CFTR", "GENE_OR_GENE_PRODUCT", 224, 228], ["gastrointestinal", "ORGAN", 273, 289], ["myenteric plexus", "MULTI-TISSUE_STRUCTURE", 381, 397], ["newborns", "ORGANISM", 444, 452], ["CFTR", "PROTEIN", 224, 228], ["electrolyte flow", "TEST", 66, 82], ["endocrine secretions in the gastrointestinal tract", "PROBLEM", 87, 137], ["ENS abnormalities", "PROBLEM", 182, 199], ["dysfunctional CFTR", "PROBLEM", 210, 228], ["gastrointestinal diseases in CF", "PROBLEM", 273, 304], ["immaturity of the myenteric plexus", "PROBLEM", 363, 397], ["meconium ileus", "PROBLEM", 458, 472], ["CF", "PROBLEM", 481, 483], ["gastrointestinal tract", "ANATOMY", 115, 137], ["not unlikely", "UNCERTAINTY", 164, 176], ["gastrointestinal", "ANATOMY", 273, 289], ["diseases", "OBSERVATION", 290, 298], ["myenteric plexus", "ANATOMY", 381, 397], ["meconium", "OBSERVATION_MODIFIER", 458, 466], ["ileus", "OBSERVATION", 467, 472]]], ["In addition, myenteric ganglionitis, aganglionosis, and neuronal dysplasia have all been found in CF patients with distal intestinal obstruction syndrome and meconium ileus [63] [64] [65] .", [["myenteric ganglionitis", "ANATOMY", 13, 35], ["neuronal dysplasia", "ANATOMY", 56, 74], ["intestinal", "ANATOMY", 122, 132], ["myenteric ganglionitis", "DISEASE", 13, 35], ["aganglionosis", "DISEASE", 37, 50], ["neuronal dysplasia", "DISEASE", 56, 74], ["CF", "DISEASE", 98, 100], ["intestinal obstruction syndrome", "DISEASE", 122, 153], ["meconium ileus", "DISEASE", 158, 172], ["myenteric ganglionitis", "CANCER", 13, 35], ["neuronal dysplasia", "PATHOLOGICAL_FORMATION", 56, 74], ["patients", "ORGANISM", 101, 109], ["intestinal", "ORGAN", 122, 132], ["patients", "SPECIES", 101, 109], ["myenteric ganglionitis", "PROBLEM", 13, 35], ["aganglionosis", "PROBLEM", 37, 50], ["neuronal dysplasia", "PROBLEM", 56, 74], ["distal intestinal obstruction syndrome", "PROBLEM", 115, 153], ["meconium ileus", "PROBLEM", 158, 172], ["myenteric ganglionitis", "OBSERVATION", 13, 35], ["aganglionosis", "OBSERVATION", 37, 50], ["neuronal dysplasia", "OBSERVATION", 56, 74], ["distal", "ANATOMY_MODIFIER", 115, 121], ["intestinal", "ANATOMY", 122, 132], ["obstruction", "OBSERVATION", 133, 144], ["meconium ileus", "OBSERVATION", 158, 172]]], ["These findings support the assumption that abnormalities of enteric ganglia might induce dysfunction of the gastrointestinal tract.DiscussionIn conclusion, our study provides evidence of CFTR expression in the neurons of the ENS.", [["enteric ganglia", "ANATOMY", 60, 75], ["gastrointestinal tract", "ANATOMY", 108, 130], ["neurons", "ANATOMY", 210, 217], ["ENS", "ANATOMY", 225, 228], ["dysfunction of the gastrointestinal tract", "DISEASE", 89, 130], ["enteric ganglia", "ORGAN", 60, 75], ["gastrointestinal tract", "ORGAN", 108, 130], ["CFTR", "GENE_OR_GENE_PRODUCT", 187, 191], ["neurons", "CELL", 210, 217], ["ENS", "ANATOMICAL_SYSTEM", 225, 228], ["CFTR", "PROTEIN", 187, 191], ["abnormalities of enteric ganglia", "PROBLEM", 43, 75], ["dysfunction of the gastrointestinal tract", "PROBLEM", 89, 130], ["our study", "TEST", 156, 165], ["CFTR expression", "PROBLEM", 187, 202], ["enteric ganglia", "ANATOMY", 60, 75], ["gastrointestinal tract", "ANATOMY", 108, 130], ["ENS", "ANATOMY", 225, 228]]], ["Widespread distribution of CFTR in enteric ganglia throughout the gastrointestinal tract suggests that this protein might exert a role in maintaining the normal structure and physiological functions of enteric ganglion cells.", [["enteric ganglia", "ANATOMY", 35, 50], ["gastrointestinal tract", "ANATOMY", 66, 88], ["enteric ganglion cells", "ANATOMY", 202, 224], ["CFTR", "GENE_OR_GENE_PRODUCT", 27, 31], ["enteric ganglia", "ORGAN", 35, 50], ["gastrointestinal tract", "ORGAN", 66, 88], ["enteric ganglion cells", "CELL", 202, 224], ["CFTR", "PROTEIN", 27, 31], ["enteric ganglion cells", "CELL_TYPE", 202, 224], ["CFTR in enteric ganglia throughout the gastrointestinal tract", "PROBLEM", 27, 88], ["this protein", "PROBLEM", 103, 115], ["distribution", "OBSERVATION_MODIFIER", 11, 23], ["CFTR", "OBSERVATION", 27, 31], ["enteric ganglia", "ANATOMY", 35, 50], ["gastrointestinal tract", "ANATOMY", 66, 88], ["normal structure", "OBSERVATION", 154, 170], ["enteric ganglion cells", "OBSERVATION", 202, 224]]], ["In addition, the presence of dysfunctional CFTR in the ENS may have adverse effects on the gastrointestinal tract.", [["ENS", "ANATOMY", 55, 58], ["gastrointestinal tract", "ANATOMY", 91, 113], ["adverse effects on the gastrointestinal tract", "DISEASE", 68, 113], ["CFTR", "GENE_OR_GENE_PRODUCT", 43, 47], ["ENS", "ANATOMICAL_SYSTEM", 55, 58], ["gastrointestinal tract", "ORGANISM_SUBDIVISION", 91, 113], ["CFTR", "PROTEIN", 43, 47], ["dysfunctional CFTR in the ENS", "PROBLEM", 29, 58], ["adverse effects on the gastrointestinal tract", "PROBLEM", 68, 113], ["dysfunctional CFTR", "OBSERVATION", 29, 47], ["gastrointestinal tract", "ANATOMY", 91, 113]]], ["Further research is required to clarify the exact function of CFTR in the ENS and the implications of dysfunctional CFTR in the enteric ganglia for patients with CF.", [["ENS", "ANATOMY", 74, 77], ["enteric ganglia", "ANATOMY", 128, 143], ["CF", "DISEASE", 162, 164], ["CFTR", "GENE_OR_GENE_PRODUCT", 62, 66], ["ENS", "ANATOMICAL_SYSTEM", 74, 77], ["CFTR", "GENE_OR_GENE_PRODUCT", 116, 120], ["enteric ganglia", "ORGAN", 128, 143], ["patients", "ORGANISM", 148, 156], ["CFTR", "PROTEIN", 62, 66], ["CFTR", "PROTEIN", 116, 120], ["patients", "SPECIES", 148, 156], ["dysfunctional CFTR in the enteric ganglia", "PROBLEM", 102, 143], ["dysfunctional CFTR", "OBSERVATION", 102, 120], ["enteric ganglia", "ANATOMY", 128, 143]]]], "PMC6481985": [["Search questionDo children with croup (patient group) when treated with nebulised adrenaline (intervention) develop re-emergence of stridor, worse than the initial baseline presentation (comparison) as defined by changes in symptoms score (outcome)?Search strategySecondary sources: the Cochrane library was searched in September 2018 with the terms Croup and Adrenaline OR Epinephrine.", [["croup", "DISEASE", 32, 37], ["adrenaline", "CHEMICAL", 82, 92], ["stridor", "DISEASE", 132, 139], ["Adrenaline", "CHEMICAL", 360, 370], ["Epinephrine", "CHEMICAL", 374, 385], ["adrenaline", "CHEMICAL", 82, 92], ["Adrenaline", "CHEMICAL", 360, 370], ["Epinephrine", "CHEMICAL", 374, 385], ["children", "ORGANISM", 18, 26], ["patient", "ORGANISM", 39, 46], ["adrenaline", "SIMPLE_CHEMICAL", 82, 92], ["Adrenaline", "SIMPLE_CHEMICAL", 360, 370], ["Epinephrine", "SIMPLE_CHEMICAL", 374, 385], ["children", "SPECIES", 18, 26], ["patient", "SPECIES", 39, 46], ["nebulised adrenaline (intervention", "TREATMENT", 72, 106], ["stridor", "PROBLEM", 132, 139], ["changes in symptoms score", "PROBLEM", 213, 238], ["Adrenaline", "TREATMENT", 360, 370], ["Epinephrine", "TREATMENT", 374, 385], ["stridor", "OBSERVATION", 132, 139]]], ["The review included eight studies.", [["eight studies", "TEST", 20, 33]]], ["Primary sources: MEDLINE was searched via PubMed using following terms Croup OR Laryngitis AND Adrenaline OR Epinephrine OR rebound stridor.", [["Adrenaline", "CHEMICAL", 95, 105], ["Epinephrine", "CHEMICAL", 109, 120], ["stridor", "DISEASE", 132, 139], ["Adrenaline", "CHEMICAL", 95, 105], ["Epinephrine", "CHEMICAL", 109, 120], ["Adrenaline", "SIMPLE_CHEMICAL", 95, 105], ["Epinephrine", "SIMPLE_CHEMICAL", 109, 120], ["Laryngitis", "PROBLEM", 80, 90], ["Adrenaline", "TREATMENT", 95, 105], ["Epinephrine", "TREATMENT", 109, 120], ["rebound stridor", "PROBLEM", 124, 139], ["Laryngitis", "OBSERVATION", 80, 90], ["rebound", "OBSERVATION_MODIFIER", 124, 131], ["stridor", "OBSERVATION", 132, 139]]], ["Inclusion criteria were that studies included children between the ages of 0 and 18 years.", [["children", "ORGANISM", 46, 54], ["children", "SPECIES", 46, 54]]], ["A further two studies [12, 13] were considered relevant, in addition to the eight studies included in the Cochrane review.", [["A further two studies", "TEST", 0, 21], ["the eight studies", "TEST", 72, 89]]], ["Summaries of the papers are presented in the table 1.DiscussionThe management of children with croup has had several controversies over the decades.", [["croup", "DISEASE", 95, 100], ["children", "ORGANISM", 81, 89], ["children", "SPECIES", 81, 89]]], ["In 1988, a review by Couriel [21] emphasised the lack of high-quality studies to aid management.", [["aid management", "TREATMENT", 81, 95]]], ["Nebulised adrenaline was advocated only in children with impending airway obstruction, due to the transient improvement and possibility of rebound.", [["airway", "ANATOMY", 67, 73], ["adrenaline", "CHEMICAL", 10, 20], ["airway obstruction", "DISEASE", 67, 85], ["adrenaline", "CHEMICAL", 10, 20], ["adrenaline", "SIMPLE_CHEMICAL", 10, 20], ["children", "ORGANISM", 43, 51], ["airway obstruction", "PATHOLOGICAL_FORMATION", 67, 85], ["children", "SPECIES", 43, 51], ["Nebulised adrenaline", "TREATMENT", 0, 20], ["impending airway obstruction", "PROBLEM", 57, 85], ["rebound", "PROBLEM", 139, 146], ["airway", "ANATOMY", 67, 73], ["obstruction", "OBSERVATION", 74, 85], ["transient", "OBSERVATION_MODIFIER", 98, 107], ["improvement", "OBSERVATION", 108, 119], ["rebound", "OBSERVATION", 139, 146]]], ["The benefit of steroids in the management was not clearly established at that time and hence most early studies compared treatments of nebulised adrenaline with placebo or racemic adrenaline versusl-adrenaline.DiscussionLenny and Milner [8] proposed the possibility of rebound phenomenon in children with acute viral croup treated with a nebulised \u03b1-adrenergic stimulant.", [["steroids", "CHEMICAL", 15, 23], ["adrenaline", "CHEMICAL", 145, 155], ["adrenaline", "CHEMICAL", 180, 190], ["versusl-adrenaline", "CHEMICAL", 191, 209], ["acute viral croup", "DISEASE", 305, 322], ["steroids", "CHEMICAL", 15, 23], ["adrenaline", "CHEMICAL", 145, 155], ["adrenaline", "CHEMICAL", 180, 190], ["adrenaline", "CHEMICAL", 199, 209], ["steroids", "SIMPLE_CHEMICAL", 15, 23], ["adrenaline", "SIMPLE_CHEMICAL", 145, 155], ["placebo", "SIMPLE_CHEMICAL", 161, 168], ["adrenaline versusl-adrenaline", "SIMPLE_CHEMICAL", 180, 209], ["children", "ORGANISM", 291, 299], ["children", "SPECIES", 291, 299], ["steroids", "TREATMENT", 15, 23], ["nebulised adrenaline", "TREATMENT", 135, 155], ["placebo", "TREATMENT", 161, 168], ["racemic adrenaline", "TREATMENT", 172, 190], ["adrenaline", "TREATMENT", 199, 209], ["rebound phenomenon", "PROBLEM", 269, 287], ["acute viral croup", "PROBLEM", 305, 322], ["a nebulised \u03b1-adrenergic stimulant", "TREATMENT", 336, 370], ["acute", "OBSERVATION_MODIFIER", 305, 310], ["viral", "OBSERVATION", 311, 316]]], ["The authors studied the total airway resistance before and after administration of nebulised phenylephrine in eight children.", [["airway", "ANATOMY", 30, 36], ["phenylephrine", "CHEMICAL", 93, 106], ["phenylephrine", "CHEMICAL", 93, 106], ["airway", "MULTI-TISSUE_STRUCTURE", 30, 36], ["phenylephrine", "SIMPLE_CHEMICAL", 93, 106], ["children", "ORGANISM", 116, 124], ["children", "SPECIES", 116, 124], ["nebulised phenylephrine", "TREATMENT", 83, 106], ["total", "OBSERVATION_MODIFIER", 24, 29], ["airway resistance", "OBSERVATION", 30, 47]]], ["Prior to nebulisation, two drops of 0.05% xylometazoline were instilled in each nostril to ensure full nasal patency and children were sedated with 80 mg\u00b7kg\u22121 chloral hydrate.", [["nasal", "ANATOMY", 103, 108], ["xylometazoline", "CHEMICAL", 42, 56], ["chloral hydrate", "CHEMICAL", 159, 174], ["xylometazoline", "CHEMICAL", 42, 56], ["chloral hydrate", "CHEMICAL", 159, 174], ["xylometazoline", "SIMPLE_CHEMICAL", 42, 56], ["nostril", "ORGANISM_SUBDIVISION", 80, 87], ["nasal", "ORGANISM_SUBDIVISION", 103, 108], ["children", "ORGANISM", 121, 129], ["chloral hydrate", "SIMPLE_CHEMICAL", 159, 174], ["children", "SPECIES", 121, 129], ["nebulisation", "TREATMENT", 9, 21], ["two drops", "TREATMENT", 23, 32], ["0.05% xylometazoline", "TREATMENT", 36, 56], ["sedated", "TREATMENT", 135, 142], ["1 chloral hydrate", "TREATMENT", 157, 174], ["nasal", "ANATOMY", 103, 108], ["patency", "OBSERVATION", 109, 116]]], ["Seven out of eight children who were treated with nebulised phenylephrine showed improvement clinically and in terms of airway resistance.", [["airway", "ANATOMY", 120, 126], ["phenylephrine", "CHEMICAL", 60, 73], ["phenylephrine", "CHEMICAL", 60, 73], ["children", "ORGANISM", 19, 27], ["phenylephrine", "SIMPLE_CHEMICAL", 60, 73], ["airway", "MULTI-TISSUE_STRUCTURE", 120, 126], ["children", "SPECIES", 19, 27], ["nebulised phenylephrine", "TREATMENT", 50, 73], ["airway resistance", "PROBLEM", 120, 137], ["airway resistance", "OBSERVATION", 120, 137]]], ["One child who did not show improvement was later was diagnosed with acute epiglottitis.", [["epiglottitis", "DISEASE", 74, 86], ["child", "ORGANISM", 4, 9], ["acute epiglottitis", "PROBLEM", 68, 86], ["acute", "OBSERVATION_MODIFIER", 68, 73], ["epiglottitis", "OBSERVATION", 74, 86]]], ["The authors reported that improvement was transient and the airway resistance returned to pre-treatment levels within 30 min, which was hypothesised as a possible rebound phenomenon.DiscussionOver the following 40 years, the 10 studies identified here are very reassuring in that rebound does not exist and that although symptoms may return after the use of nebulised adrenaline, no study has reported the symptoms as being worse than baseline.", [["airway", "ANATOMY", 60, 66], ["adrenaline", "CHEMICAL", 368, 378], ["adrenaline", "CHEMICAL", 368, 378], ["airway", "MULTI-TISSUE_STRUCTURE", 60, 66], ["adrenaline", "SIMPLE_CHEMICAL", 368, 378], ["the airway resistance", "PROBLEM", 56, 77], ["pre-treatment levels", "TEST", 90, 110], ["rebound phenomenon", "PROBLEM", 163, 181], ["the 10 studies", "TEST", 221, 235], ["symptoms", "PROBLEM", 321, 329], ["nebulised adrenaline", "TREATMENT", 358, 378], ["the symptoms", "PROBLEM", 402, 414], ["transient", "OBSERVATION_MODIFIER", 42, 51], ["airway", "ANATOMY", 60, 66], ["resistance", "OBSERVATION", 67, 77], ["possible", "UNCERTAINTY", 154, 162], ["rebound phenomenon", "OBSERVATION", 163, 181]]], ["If steroids are used as well then, as their effect starts to impact the upper airway at 2 h post-administration, this reduces any re-emergence of symptoms post-adrenaline as that effect wears off after 1\u20132 h.DiscussionA small underpowered study from 1973 by Gardneret al. [20], reported before the advent of the widespread use of steroids, was a retrospective review and this, not surprisingly, failed to substantiate a decrease in either hospitalisation or symptoms resulting from treatment with nebulised adrenaline.", [["upper airway", "ANATOMY", 72, 84], ["steroids", "CHEMICAL", 3, 11], ["post-adrenaline", "CHEMICAL", 155, 170], ["steroids", "CHEMICAL", 330, 338], ["adrenaline", "CHEMICAL", 507, 517], ["steroids", "CHEMICAL", 3, 11], ["post-adrenaline", "CHEMICAL", 155, 170], ["steroids", "CHEMICAL", 330, 338], ["adrenaline", "CHEMICAL", 507, 517], ["steroids", "SIMPLE_CHEMICAL", 3, 11], ["upper airway", "MULTI-TISSUE_STRUCTURE", 72, 84], ["post-adrenaline", "SIMPLE_CHEMICAL", 155, 170], ["steroids", "SIMPLE_CHEMICAL", 330, 338], ["adrenaline", "SIMPLE_CHEMICAL", 507, 517], ["steroids", "TREATMENT", 3, 11], ["symptoms", "PROBLEM", 146, 154], ["steroids", "TREATMENT", 330, 338], ["symptoms", "PROBLEM", 458, 466], ["treatment", "TREATMENT", 482, 491], ["nebulised adrenaline", "TREATMENT", 497, 517], ["upper", "ANATOMY_MODIFIER", 72, 77], ["airway", "ANATOMY", 78, 84], ["decrease", "OBSERVATION_MODIFIER", 420, 428]]], ["They did, however, acknowledge that adrenaline may be of therapeutic value in some patients with croup depending on the aetiological agent but may simply be the addition of moisture to the airways.DiscussionThree small studies [17\u201319], involving 48 children in total, showed significant initial improvement using nebulised adrenaline compared to placebo with some return of symptoms but no rebound reported.", [["airways", "ANATOMY", 189, 196], ["adrenaline", "CHEMICAL", 36, 46], ["croup", "DISEASE", 97, 102], ["adrenaline", "CHEMICAL", 323, 333], ["adrenaline", "CHEMICAL", 36, 46], ["adrenaline", "CHEMICAL", 323, 333], ["adrenaline", "SIMPLE_CHEMICAL", 36, 46], ["patients", "ORGANISM", 83, 91], ["airways", "MULTI-TISSUE_STRUCTURE", 189, 196], ["children", "ORGANISM", 249, 257], ["adrenaline", "SIMPLE_CHEMICAL", 323, 333], ["patients", "SPECIES", 83, 91], ["children", "SPECIES", 249, 257], ["adrenaline", "TREATMENT", 36, 46], ["croup", "PROBLEM", 97, 102], ["nebulised adrenaline", "TREATMENT", 313, 333], ["placebo", "TREATMENT", 346, 353], ["symptoms", "PROBLEM", 374, 382], ["rebound", "PROBLEM", 390, 397], ["airways", "ANATOMY", 189, 196], ["significant", "OBSERVATION_MODIFIER", 275, 286], ["no", "UNCERTAINTY", 387, 389], ["rebound", "OBSERVATION", 390, 397]]], ["The following studies started using steroids in their design and recruited larger numbers but in children with more severe croup.", [["steroids", "CHEMICAL", 36, 44], ["croup", "DISEASE", 123, 128], ["steroids", "CHEMICAL", 36, 44], ["children", "ORGANISM", 97, 105], ["children", "SPECIES", 97, 105], ["The following studies", "TEST", 0, 21], ["steroids", "TREATMENT", 36, 44], ["more severe croup", "PROBLEM", 111, 128], ["larger", "OBSERVATION_MODIFIER", 75, 81], ["severe", "OBSERVATION_MODIFIER", 116, 122], ["croup", "OBSERVATION", 123, 128]]], ["No rebound of symptoms is described and an effect of the steroids reducing any re-emergence of symptoms is becoming clearer [7, 15, 16] (see table 1).DiscussionKristjanssonet al. [14] reported re-emergence of symptoms in 35% of children receiving nebulised adrenaline and in 25% of children receiving placebo.", [["steroids", "CHEMICAL", 57, 65], ["adrenaline", "CHEMICAL", 257, 267], ["steroids", "CHEMICAL", 57, 65], ["adrenaline", "CHEMICAL", 257, 267], ["children", "ORGANISM", 228, 236], ["adrenaline", "SIMPLE_CHEMICAL", 257, 267], ["children", "ORGANISM", 282, 290], ["children", "SPECIES", 228, 236], ["children", "SPECIES", 282, 290], ["rebound of symptoms", "PROBLEM", 3, 22], ["the steroids", "TREATMENT", 53, 65], ["symptoms", "PROBLEM", 95, 103], ["symptoms", "PROBLEM", 209, 217], ["nebulised adrenaline", "TREATMENT", 247, 267], ["placebo", "TREATMENT", 301, 308], ["rebound", "OBSERVATION", 3, 10], ["symptoms", "OBSERVATION", 14, 22]]], ["No steroids were used.", [["steroids", "CHEMICAL", 3, 11], ["steroids", "CHEMICAL", 3, 11], ["steroids", "SIMPLE_CHEMICAL", 3, 11], ["steroids", "TREATMENT", 3, 11], ["steroids", "OBSERVATION", 3, 11]]], ["They posited that it is not likely that the phenomenon is related to adrenaline only, but rather to ongoing inflammation and oedema in the airway.", [["airway", "ANATOMY", 139, 145], ["adrenaline", "CHEMICAL", 69, 79], ["inflammation", "DISEASE", 108, 120], ["oedema", "DISEASE", 125, 131], ["adrenaline", "CHEMICAL", 69, 79], ["adrenaline", "SIMPLE_CHEMICAL", 69, 79], ["airway", "MULTI-TISSUE_STRUCTURE", 139, 145], ["the phenomenon", "PROBLEM", 40, 54], ["adrenaline", "TREATMENT", 69, 79], ["ongoing inflammation", "PROBLEM", 100, 120], ["oedema in the airway", "PROBLEM", 125, 145], ["not likely", "UNCERTAINTY", 24, 34], ["phenomenon", "OBSERVATION", 44, 54], ["inflammation", "OBSERVATION", 108, 120], ["oedema", "OBSERVATION", 125, 131], ["airway", "ANATOMY", 139, 145]]], ["They concluded that nebulised adrenaline is effective for the treatment of acute mild to moderately severe croup and that it should be used as a first line treatment [14].", [["adrenaline", "CHEMICAL", 30, 40], ["croup", "DISEASE", 107, 112], ["adrenaline", "CHEMICAL", 30, 40], ["adrenaline", "SIMPLE_CHEMICAL", 30, 40], ["nebulised adrenaline", "TREATMENT", 20, 40], ["acute mild to moderately severe croup", "PROBLEM", 75, 112], ["a first line treatment", "TREATMENT", 143, 165], ["acute", "OBSERVATION_MODIFIER", 75, 80], ["mild", "OBSERVATION_MODIFIER", 81, 85], ["moderately", "OBSERVATION_MODIFIER", 89, 99], ["severe", "OBSERVATION_MODIFIER", 100, 106], ["croup", "OBSERVATION", 107, 112]]], ["This has not been taken up universally, but it is now standard practice in some countries to use steroids and nebulised adrenaline in the emergency department, watch the patients for 2 h and then discharge home if well enough [2].", [["steroids", "CHEMICAL", 97, 105], ["adrenaline", "CHEMICAL", 120, 130], ["steroids", "CHEMICAL", 97, 105], ["adrenaline", "CHEMICAL", 120, 130], ["steroids", "SIMPLE_CHEMICAL", 97, 105], ["adrenaline", "SIMPLE_CHEMICAL", 120, 130], ["patients", "ORGANISM", 170, 178], ["patients", "SPECIES", 170, 178], ["steroids", "TREATMENT", 97, 105], ["nebulised adrenaline", "TREATMENT", 110, 130]]], ["The final two studies both used steroids and nebulised adrenaline, showing clearly a good response to the treatment with no rebound or indeed any major re-emergence of symptoms [12, 13].DiscussionThe data presented here are reassuring in that re-emergence of symptoms may occur but is no worse than baseline.", [["steroids", "CHEMICAL", 32, 40], ["adrenaline", "CHEMICAL", 55, 65], ["steroids", "CHEMICAL", 32, 40], ["adrenaline", "CHEMICAL", 55, 65], ["steroids", "SIMPLE_CHEMICAL", 32, 40], ["adrenaline", "SIMPLE_CHEMICAL", 55, 65], ["The final two studies", "TEST", 0, 21], ["steroids", "TREATMENT", 32, 40], ["nebulised adrenaline", "TREATMENT", 45, 65], ["the treatment", "TREATMENT", 102, 115], ["rebound", "PROBLEM", 124, 131], ["symptoms", "PROBLEM", 168, 176], ["symptoms", "PROBLEM", 259, 267], ["no", "UNCERTAINTY", 285, 287], ["worse", "OBSERVATION_MODIFIER", 288, 293]]], ["The re-emergence of symptoms is less marked in studies when children received concurrent steroids.DiscussionSo, in answer to the proposed question: \u201cDo children with croup (patient group) when treated with nebulised adrenaline (intervention) develop re-emergence of stridor, worse than initial baseline presentation (comparison) as defined by changes in symptoms score (outcome)?\u201d", [["steroids", "CHEMICAL", 89, 97], ["croup", "DISEASE", 166, 171], ["adrenaline", "CHEMICAL", 216, 226], ["stridor", "DISEASE", 266, 273], ["steroids", "CHEMICAL", 89, 97], ["adrenaline", "CHEMICAL", 216, 226], ["children", "ORGANISM", 60, 68], ["children", "ORGANISM", 152, 160], ["patient", "ORGANISM", 173, 180], ["adrenaline", "SIMPLE_CHEMICAL", 216, 226], ["children", "SPECIES", 60, 68], ["children", "SPECIES", 152, 160], ["patient", "SPECIES", 173, 180], ["symptoms", "PROBLEM", 20, 28], ["concurrent steroids", "TREATMENT", 78, 97], ["nebulised adrenaline (intervention", "TREATMENT", 206, 240], ["stridor", "PROBLEM", 266, 273], ["changes in symptoms score", "PROBLEM", 343, 368], ["less marked", "OBSERVATION_MODIFIER", 32, 43], ["stridor", "OBSERVATION", 266, 273]]], ["Or \u201cRebound stridor in children with croup after nebulised adrenaline: does it really exist?\u201d", [["stridor", "DISEASE", 12, 19], ["croup", "DISEASE", 37, 42], ["adrenaline", "CHEMICAL", 59, 69], ["adrenaline", "CHEMICAL", 59, 69], ["children", "ORGANISM", 23, 31], ["adrenaline", "SIMPLE_CHEMICAL", 59, 69], ["children", "SPECIES", 23, 31], ["Rebound stridor", "PROBLEM", 4, 19], ["nebulised adrenaline", "TREATMENT", 49, 69], ["Rebound", "OBSERVATION_MODIFIER", 4, 11], ["stridor", "OBSERVATION", 12, 19]]]], "PMC7499662": [["IntroductionAfrica\u2019s prisons are a long-standing concern of human rights defenders.", [["human", "ORGANISM", 60, 65], ["human", "SPECIES", 60, 65], ["human", "SPECIES", 60, 65]]], ["Overcrowding, poor nutrition, illness, disease, and rights violations, to name a few concerns, characterize Africa\u2019s prisons.", [["Overcrowding", "DISEASE", 0, 12], ["illness", "DISEASE", 30, 37], ["illness", "PROBLEM", 30, 37], ["disease", "PROBLEM", 39, 46], ["poor nutrition", "OBSERVATION", 14, 28]]], ["The possibility that a highly infectious virus for which there is no vaccine becomes prevalent in Africa\u2019s prisons is a scenario almost too disastrous to contemplate.", [["a highly infectious virus", "PROBLEM", 21, 46], ["vaccine", "PROBLEM", 69, 76], ["highly", "OBSERVATION_MODIFIER", 23, 29], ["infectious", "OBSERVATION", 30, 40], ["no", "UNCERTAINTY", 66, 68]]], ["Many are familiar with the devastation that AIDS brought to Africa\u2019s prisons and with underlying health conditions such as HIV/AIDS, tuberculosis (TB) and general poor nutrition, COVID-19 does conjure up images of an unprecedented prisons health crisis, as both the infection rate (the proportion of people infected) and the infection fatality rate (the proportion of infected persons who die) may be higher in prisons than that which may occur among the general population outside prison.IntroductionThis essay reviews the situation regarding prisons and COVID-19 in southern and east Africa.", [["AIDS", "DISEASE", 44, 48], ["HIV/AIDS", "DISEASE", 123, 131], ["tuberculosis", "DISEASE", 133, 145], ["TB", "DISEASE", 147, 149], ["infection", "DISEASE", 266, 275], ["infection", "DISEASE", 325, 334], ["people", "ORGANISM", 300, 306], ["persons", "ORGANISM", 377, 384], ["HIV", "SPECIES", 123, 126], ["people", "SPECIES", 300, 306], ["persons", "SPECIES", 377, 384], ["HIV", "SPECIES", 123, 126], ["underlying health conditions", "PROBLEM", 86, 114], ["HIV/AIDS", "PROBLEM", 123, 131], ["tuberculosis", "PROBLEM", 133, 145], ["TB", "PROBLEM", 147, 149], ["COVID", "TEST", 179, 184], ["the infection rate", "PROBLEM", 262, 280], ["the infection fatality rate", "PROBLEM", 321, 348], ["COVID", "TREATMENT", 556, 561], ["tuberculosis", "OBSERVATION", 133, 145], ["infection", "OBSERVATION", 266, 275]]], ["There are many gaps in the information, which does point to long-standing issues on data reliability and accessibility.", [["long-standing issues", "PROBLEM", 60, 80], ["many", "OBSERVATION_MODIFIER", 10, 14], ["gaps", "OBSERVATION", 15, 19]]], ["This followed by a short description of COVID-19 in Africa and how different states have responded, imposing more or less severe restrictive measures.Overview of the numbersSouthern and east Africa consist of 24 internationally recognized countries1 and have a combined prison population of some 655,000 people.2 The average national prison population size for these countries is some 30,000, with the average prison holding 533 prisoners.", [["people", "ORGANISM", 304, 310], ["people", "SPECIES", 304, 310], ["COVID", "TEST", 40, 45], ["less severe restrictive measures", "PROBLEM", 117, 149], ["severe", "OBSERVATION_MODIFIER", 122, 128], ["restrictive", "OBSERVATION", 129, 140], ["average", "OBSERVATION_MODIFIER", 317, 324], ["size", "OBSERVATION_MODIFIER", 352, 356]]], ["There are, however, significant outliers with island states like the Comoros having 225 prisoners in three prisons and, at the other end of the spectrum, South Africa with some 235 prisons holding close on 160,000 prisoners at an average size of 657 prisoners per facility.", [["significant", "OBSERVATION_MODIFIER", 20, 31], ["outliers", "OBSERVATION", 32, 40]]], ["Firstly, it indicates the efficiency and effectiveness of the criminal justice system, with a low percentage indicating that there is good reason for pre-trial detention and that individuals do not remain in pretrial detention for an excessive time.", [["pre-trial detention", "PROBLEM", 150, 169], ["efficiency", "OBSERVATION_MODIFIER", 26, 36]]], ["Secondly, a high percentage of pretrial detainees not only reflects inefficiency and ineffectiveness, but also results in more contact between the prison population and the outside world, because of remand prisoners\u2019 appearances in court and visits to them in prison, and this contact is relevant to the COVID-19 discussion.", [["ineffectiveness", "PROBLEM", 85, 100]]], ["The average for all 24 countries is 31 per cent, meaning that nearly one-third of bed spaces in prisons are occupied by people presumed to be innocent.", [["people", "ORGANISM", 120, 126], ["people", "SPECIES", 120, 126]]], ["In Uganda and Zambia prisons are occupied at 319 per cent and 303 per cent respectively, meaning three people are using the space originally designed for one person.Overview of the numbersColonial-era laws as well as colonial-era modalities of policing have also shaped to some extent the profile of that segment of the population coming into (regular) contact with the criminal justice system.", [["people", "ORGANISM", 103, 109], ["people", "SPECIES", 103, 109], ["person", "SPECIES", 158, 164], ["some extent", "OBSERVATION_MODIFIER", 273, 284]]], ["It is in particular in anglophone states of southern and east Africa that a myriad of laws dating back to the previous century give the police wide discretion in arresting people for poorly defined offences such as loitering or being a rogue and vagabond (Muntingh 2015; Muntingh and Petersen 2015).", [["people", "ORGANISM", 172, 178], ["people", "SPECIES", 172, 178]]], ["These petty and outdated offences remain an affront to human dignity and perceptions of fairness, and need to be removed from statutes (ACHPR, Principles on the Decriminalisation of Petty Offences in Africa).", [["human", "ORGANISM", 55, 60], ["human", "SPECIES", 55, 60], ["human", "SPECIES", 55, 60], ["ACHPR", "TREATMENT", 136, 141]]], ["Nonetheless, their continuous enforcement plays an important role in determining who is imprisoned.Conditions of detentionWhile there is much variation in the conditions of imprisonment in these countries, it can generally be concluded that there is significant room for improvement and, in some instances, prison systems are not able to meet even the most basic standards of humane detention with reference to accommodation, nutrition and health care.", [["much", "OBSERVATION_MODIFIER", 137, 141], ["variation", "OBSERVATION_MODIFIER", 142, 151]]], ["In some states prisoners are provided with only one meal per day of the most basic nature, resulting in malnutrition; illness and infectious diseases are common in the prison population; and prisoners are forced to sleep in cells filled to two or three times their capacity with the most rudimentary toilet facilities, and with limited capacity to maintain and keep ablution facilities sanitary.", [["cells", "ANATOMY", 224, 229], ["malnutrition", "DISEASE", 104, 116], ["illness", "DISEASE", 118, 125], ["infectious diseases", "DISEASE", 130, 149], ["cells", "CELL", 224, 229], ["malnutrition", "PROBLEM", 104, 116], ["illness", "PROBLEM", 118, 125], ["infectious diseases", "PROBLEM", 130, 149], ["malnutrition", "OBSERVATION", 104, 116]]], ["These conditions worsen health outcomes.Conditions of detentionPoor conditions of detention and structural problems in African criminal justice systems are well documented and a number of efforts have been made at international and regional levels to enable, encourage and support prison and criminal justice reform.", [["structural problems", "PROBLEM", 96, 115]]], ["The African Commission on Human and Peoples\u2019 Rights (ACHPR) not only appointed two special mechanisms3 on the issue, but also adopted four soft law instruments to support reform.4 Despite these efforts as well as general efforts to improve conditions of detention, the situation has not improved markedly.", [["Human", "ORGANISM", 26, 31], ["Human", "SPECIES", 26, 31], ["improved", "OBSERVATION_MODIFIER", 287, 295], ["markedly", "OBSERVATION_MODIFIER", 296, 304]]], ["There are a few countries in east and southern Africa that have been able to effectively maintain and replace (if not expand) prison infrastructure, such as South Africa and Botswana.", [["few", "OBSERVATION_MODIFIER", 12, 15]]], ["But in most instances, the same infrastructure built by Britain, Portugal and France as colonial powers more than 50 years ago remains in use and it is simply not possible to meet the minimum standards of humane detention (UN Standard Minimum Rules for the Treatment of Prisoners 2015).", [["humane detention", "TREATMENT", 205, 221], ["most instances", "OBSERVATION_MODIFIER", 7, 21]]], ["In many instances sentenced and unsentenced prisoners are not segregated, as is required by Rule 11(b) of the 2015 UN Standard Minimum Rules, and this has implications for controlling infectious diseases.Conditions of detentionNot only have post-independence governments largely failed to invest in criminal justice and prison reform; they have also failed to see prisons from a public health perspective and give recognition to the inescapable fact that prisons are vectors for disease.COVID-19 comes to AfricaThe first COVID-19 case in Africa was reported from Egypt (BBC News 2020) and the second from Algeria (WHO Africa 2020).", [["infectious diseases", "DISEASE", 184, 203], ["controlling infectious diseases", "PROBLEM", 172, 203], ["disease", "PROBLEM", 479, 486], ["COVID", "TEST", 487, 492]]], ["COVID-19 came to Africa through various entry points and most likely travel hubs like Johannesburg and Nairobi, from where it moved quickly to even the island states of the region, such as Seychelles (14 March 2020), Madagascar (20 March) and Comoros (15 April).", [["COVID", "TEST", 0, 5], ["Madagascar", "TREATMENT", 217, 227], ["Comoros", "TREATMENT", 243, 250], ["most likely", "UNCERTAINTY", 57, 68]]], ["The South African government is currently predicting the peak of infection in South Africa to occur in September or October 2020.", [["infection", "DISEASE", 65, 74], ["infection", "PROBLEM", 65, 74], ["infection", "OBSERVATION", 65, 74]]], ["Approximately 550 natural deaths are recorded in South African prisons each year (Independent Online 2019), which equates to a death rate of 333 per 100,000.", [["deaths", "DISEASE", 26, 32], ["death", "DISEASE", 127, 132], ["a death rate", "TEST", 125, 137]]], ["This is likely to rise if there is widespread infection coupled with a higher fatality rate than in the general population in relation to the virus.Lack of data and releasesThe COVID-19 pandemic and subsequent government responses again demonstrate the importance of reliable and up to date data on the prison population, and any confined population (such as police and immigration detainees).", [["infection", "DISEASE", 46, 55], ["widespread infection", "PROBLEM", 35, 55], ["a higher fatality rate", "PROBLEM", 69, 91], ["the virus", "PROBLEM", 138, 147], ["The COVID", "TEST", 173, 182], ["likely to", "UNCERTAINTY", 8, 17], ["widespread", "OBSERVATION_MODIFIER", 35, 45], ["infection", "OBSERVATION", 46, 55], ["virus", "OBSERVATION", 142, 147]]], ["This not only concerns data on the health of prisoners, as well as more general data concerning the profile of prisoners, the reasons for their custody and so forth, but above all, if this information is available in the public domain those with an interest in prisoners\u2019 rights can make informed contributions to governments and other stakeholders.Lack of data and releasesWhen the World Health Organization (WHO) recommended the release of prisoners to address overcrowding (WHO 2020) and this call was further supported by the UN Subcommittee on Prevention of Torture (SPT) in its public advice to National Preventive Mechanisms (NPMs) (UN SPT 2020: para 9(b)), it seemed in principle like an admirable idea, but reality demanded a more cautious approach, in Africa at least.", [["Torture (SPT)", "PROBLEM", 563, 576]]], ["Firstly, cognizance should be had for public safety and that it cannot merely be a case of opening the prison gates indiscriminately, not least because the person concerned may currently be infected.", [["person", "SPECIES", 156, 162], ["infected", "OBSERVATION", 190, 198]]], ["This means that there need to be clear criteria for eligibility, a confirmed and contactable address, and presumably consent from the household in which the person is intending to reside.", [["person", "SPECIES", 157, 163]]], ["Following from this, it must also be asked: how many people need to be released in order to have a protective impact for those that remain behind?", [["people", "ORGANISM", 53, 59], ["people", "SPECIES", 53, 59]]], ["Secondly, in some instances, especially when an infection has not been recorded at a particular prison, it may in fact be a better option not to release prisoners since their basic needs are at least met in prison (this is assuming that basic nutritional and health requirements are complied with).", [["infection", "DISEASE", 48, 57], ["an infection", "PROBLEM", 45, 57], ["infection", "OBSERVATION", 48, 57]]], ["They may not be welcome at their normal place of residence, or they may indeed have no place to go to, or their return may place additional socioeconomic strain on an already marginal household.", [["additional socioeconomic strain", "PROBLEM", 129, 160]]], ["With large-scale loss of income in the formal and informal sectors, and the absence of state-provided socioeconomic support, the large-scale release of prisoners may require a re-think in the African context.Lack of data and releasesRegardless of this, a number of southern and east African countries announced the release of prisoners to \u2018ease congestion\u2019, but the intended impact would be symbolic rather than real.", [["congestion", "DISEASE", 345, 355], ["socioeconomic support", "TREATMENT", 102, 123], ["congestion", "PROBLEM", 345, 355], ["large", "OBSERVATION_MODIFIER", 5, 10], ["-scale", "OBSERVATION_MODIFIER", 10, 16], ["loss", "OBSERVATION_MODIFIER", 17, 21], ["congestion", "OBSERVATION", 345, 355]]], ["In the case of South Africa, the releases would constitute 12 per cent of the total prison population.", [["the total prison population", "TREATMENT", 74, 101]]], ["The releases should also be seen against the background of normal releases when prisoners are released conditionally (for example, parole) or on expiry of sentence.", [["normal", "OBSERVATION", 59, 65]]], ["These figures are not in the public domain and it is therefore not known if the releases will have any meaningful and sustained impact on prison congestion.High turnover of peopleMuch as we would like to think that prisons are isolated from society, they are not.", [["congestion", "DISEASE", 145, 155], ["prison congestion", "PROBLEM", 138, 155], ["congestion", "OBSERVATION", 145, 155]]], ["Family and friends visiting prisoners are in many ways the lifeblood of the prison, bringing not only human interaction and contact with the outside world but also resources such as cash, food, bedding, toiletries and so forth.", [["human", "ORGANISM", 102, 107], ["human", "SPECIES", 102, 107], ["human", "SPECIES", 102, 107]]], ["It is predominantly the poor who find themselves in prisons, but since the state cannot provide all the resources, prisoners are dependent on outside support (when they have such support) to make life in prison more bearable.", [["predominantly", "OBSERVATION_MODIFIER", 6, 19]]], ["This has obvious implications for virus transmission.Restrictions on access to prisonsOf the 24 countries surveyed in southern and east Africa, only two could be confirmed as not having declared a state of disaster or emergency or lockdown: Malawi and Tanzania (New Frame 2020).", [["virus transmission", "PROBLEM", 34, 52], ["obvious implications for", "UNCERTAINTY", 9, 33], ["virus", "OBSERVATION", 34, 39]]], ["This was then to a greater or lesser degree supported by a lockdown or curfew (terminology differs from one state to another).", [["lesser degree", "OBSERVATION_MODIFIER", 30, 43]]], ["While it must be appreciated that governments have an obligation to protect their citizens against public health threats, it must also be noted that the states surveyed have by and large shown a particular enthusiasm to restrict civil and political liberties and, further, to limit access to prisons.How did oversight agencies perform?The guidelines from WHO made it clear that the \u2018COVID-19 outbreak must not be used as a justification for objecting to external inspection of prisons and other places of detention by independent international or national bodies whose mandate is to prevent torture and other cruel, inhuman or degrading treatment or punishment\u2019 (WHO 2020).", [["the \u2018COVID", "TREATMENT", 378, 388], ["external inspection", "TEST", 454, 473]]], ["Moreover, this also prevented visits under the OPCAT, to which South Africa is a party, since the JICS forms part of the National Preventive Mechanism (NPM), the South African Human Rights Commission (SAHRC), as designated by South Africa in June 2019.", [["Human", "ORGANISM", 176, 181], ["Human", "SPECIES", 176, 181]]], ["It then appears that a major victim of COVID-19 was transparency of the prison system.How did oversight agencies perform?South Africa\u2019s neighbour, Mozambique, declared a state of emergency on 30 March (All Africa 2020c), but technically also a state of disaster in terms of a threat to public health or a natural disaster, and so which should be distinguished from martial law.", [["COVID", "TEST", 39, 44]]], ["The impact of restrictions imposed is less severe, and essentially, gatherings of more than 20 people are prohibited, including in prisons.", [["people", "ORGANISM", 95, 101], ["people", "SPECIES", 95, 101], ["less", "OBSERVATION_MODIFIER", 38, 42], ["severe", "OBSERVATION_MODIFIER", 43, 49]]], ["Moreover, no restrictions, save for family members, are placed on who visits prisons and lawyers and the NPM is free to conduct visits and even training programmes are continuing as long as groups remain under the 20-person ceiling (T. Lorizzo, Director: REFORMAR, based in Maputo, Mozambique, interview with the author, 6 May 2020).", [["NPM", "GENE_OR_GENE_PRODUCT", 105, 108], ["person", "SPECIES", 217, 223], ["no", "UNCERTAINTY", 10, 12]]], ["Visits by the NPM are, however, not taking place since the donors that would have supported the NPM\u2019s visits to places of detention (and planning was reportedly well under way) placed all funding on hold due to the COVID-19 pandemic.ConclusionCOVID-19 has again highlighted the long-standing problems in Africa\u2019s prisons, and these were noted above.", [["NPM", "GENE_OR_GENE_PRODUCT", 14, 17], ["donors", "ORGANISM", 59, 65], ["NPM", "GENE_OR_GENE_PRODUCT", 96, 99], ["the COVID", "TEST", 211, 220], ["pandemic", "PROBLEM", 224, 232], ["ConclusionCOVID", "TEST", 233, 248], ["the long-standing problems", "PROBLEM", 274, 300]]], ["It is necessary to look beyond COVID-19 and pose questions about long-term solutions.ConclusionPeople should also not find themselves unnecessarily in prison and that means that reforms in law, policy and practice are needed, as has been advocated by many, including the African Commission on Human and Peoples\u2019 Rights.", [["People", "ORGANISM", 95, 101], ["Human", "ORGANISM", 293, 298], ["People", "SPECIES", 95, 101], ["Human", "SPECIES", 293, 298], ["long-term solutions", "TREATMENT", 65, 84]]], ["Pretrial detention is very often the default position without any real exploration of conditional release mechanisms such as warning and bail.", [["Pretrial detention", "PROBLEM", 0, 18]]], ["Monetary bail is frequently set at amounts that are simply not affordable (such as equivalent to a year\u2019s income) that can only be regarded as punishing people for being poor.ConclusionThe statutes of many African states still contain colonial-era offences (such as rogue and vagabond) and in a more recent development, the creation of new petty offences, frequently under municipal by-laws, for which people are arrested and end up in custody.", [["people", "ORGANISM", 153, 159], ["people", "ORGANISM", 402, 408], ["people", "SPECIES", 153, 159], ["people", "SPECIES", 402, 408]]], ["Placing people in custody for petty offences is not only disproportionate, it places their health at risk and holds significant adverse socioeconomic consequences.", [["people", "ORGANISM", 8, 14], ["people", "SPECIES", 8, 14], ["significant adverse socioeconomic consequences", "PROBLEM", 116, 162]]], ["There are only a few African states where these measures are used on any significant scale.ConclusionPublic health threats such as COVID-19 or tuberculosis (TB) will always have particular significance in the prison environment, but also pose a particular threat to public health when prisons are poorly managed and resourced.", [["COVID-19", "CHEMICAL", 131, 139], ["tuberculosis", "DISEASE", 143, 155], ["TB", "DISEASE", 157, 159], ["COVID-19", "SPECIES", 131, 139], ["COVID", "TEST", 131, 136], ["tuberculosis", "PROBLEM", 143, 155], ["few", "OBSERVATION_MODIFIER", 17, 20], ["African", "OBSERVATION_MODIFIER", 21, 28], ["tuberculosis", "OBSERVATION", 143, 155]]], ["In the end, the old dictum stands: Good prison health is good public health.FundingThis work was supported by the Open Society Foundation (Human Rights Initiative) and the Sigrid Rausing Trust.", [["Human", "ORGANISM", 139, 144], ["Human", "SPECIES", 139, 144]]]]}